<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Direct‐acting antivirals for chronic hepatitis C - Jakobsen, JC - 2017 | Cochrane Library</title> <meta content="Direct‐acting antivirals for chronic hepatitis C - Jakobsen, JC - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012143.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Direct‐acting antivirals for chronic hepatitis C - Jakobsen, JC - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012143.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012143.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Direct‐acting antivirals for chronic hepatitis C" name="citation_title"/> <meta content="Janus C Jakobsen" name="citation_author"/> <meta content="jcj@ctu.dk" name="citation_author_email"/> <meta content="Emil Eik Nielsen" name="citation_author"/> <meta content="Department 7812, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Joshua Feinberg" name="citation_author"/> <meta content="Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Kiran Kumar Katakam" name="citation_author"/> <meta content="Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Kristina Fobian" name="citation_author"/> <meta content="Department 7812, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Goran Hauser" name="citation_author"/> <meta content="Clinical Hospital Centre Rijeka" name="citation_author_institution"/> <meta content="Goran Poropat" name="citation_author"/> <meta content="Clinical Hospital Centre Rijeka" name="citation_author_institution"/> <meta content="Snezana Djurisic" name="citation_author"/> <meta content="Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Karl Heinz Weiss" name="citation_author"/> <meta content="Heidelberg University Hospital" name="citation_author_institution"/> <meta content="Milica Bjelakovic" name="citation_author"/> <meta content="University of Nis" name="citation_author_institution"/> <meta content="Goran Bjelakovic" name="citation_author"/> <meta content="Medical Faculty, University of Nis" name="citation_author_institution"/> <meta content="Sarah Louise Klingenberg" name="citation_author"/> <meta content="Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Jian Ping Liu" name="citation_author"/> <meta content="Beijing University of Chinese Medicine" name="citation_author_institution"/> <meta content="Dimitrinka Nikolova" name="citation_author"/> <meta content="Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Ronald L Koretz" name="citation_author"/> <meta content="Christian Gluud" name="citation_author"/> <meta content="Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD012143.pub3" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/09/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012143.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012143.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012143.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antiviral Agents [adverse effects, *therapeutic use]; Cause of Death; Hepacivirus [drug effects]; Hepatitis C, Chronic [complications, *drug therapy, mortality]; Nucleic Acid Synthesis Inhibitors [adverse effects, therapeutic use]; Placebos [therapeutic use]; Protease Inhibitors [adverse effects, therapeutic use]; Randomized Controlled Trials as Topic; Safety‐Based Drug Withdrawals; Simeprevir [adverse effects, therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012143.pub3&amp;doi=10.1002/14651858.CD012143.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012143.pub3&amp;doi=10.1002/14651858.CD012143.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012143.pub3&amp;doi=10.1002/14651858.CD012143.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012143.pub3&amp;doi=10.1002/14651858.CD012143.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012143.pub3&amp;doi=10.1002/14651858.CD012143.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012143.pub3&amp;doi=10.1002/14651858.CD012143.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012143.pub3&amp;doi=10.1002/14651858.CD012143.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012143.pub3&amp;doi=10.1002/14651858.CD012143.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012143.pub3&amp;doi=10.1002/14651858.CD012143.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012143.pub3&amp;doi=10.1002/14651858.CD012143.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012143.pub3&amp;doi=10.1002/14651858.CD012143.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012143.pub3&amp;doi=10.1002/14651858.CD012143.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012143.pub3&amp;doi=10.1002/14651858.CD012143.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012143.pub3&amp;doi=10.1002/14651858.CD012143.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012143.pub3&amp;doi=10.1002/14651858.CD012143.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012143.pub3&amp;doi=10.1002/14651858.CD012143.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012143.pub3&amp;doi=10.1002/14651858.CD012143.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012143.pub3&amp;doi=10.1002/14651858.CD012143.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012143.pub3&amp;doi=10.1002/14651858.CD012143.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012143.pub3&amp;doi=10.1002/14651858.CD012143.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012143.pub3&amp;doi=10.1002/14651858.CD012143.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012143.pub3&amp;doi=10.1002/14651858.CD012143.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012143.pub3&amp;doi=10.1002/14651858.CD012143.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="k5rEBE5b";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012143\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012143\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012143\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012143\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ms","hr","fr","de","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012143.pub3",title:"Direct\\u2010acting antivirals for chronic hepatitis C",firstPublishedDate:"Sep 18, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Hepato‐Biliary Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=k5rEBE5b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012143.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012143.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012143.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012143.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012143.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012143.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012143.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012143.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012143.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012143.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6780 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012143.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/full#CD012143-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/full#CD012143-sec-0148"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/full#CD012143-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/full#CD012143-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/full#CD012143-sec-0039"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/full#CD012143-sec-0040"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/full#CD012143-sec-0084"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/full#CD012143-sec-0140"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/appendices#CD012143-sec-0153"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/table_n/CD012143StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/table_n/CD012143StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Direct‐acting antivirals for chronic hepatitis C</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/information#CD012143-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Janus C Jakobsen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/information#CD012143-cr-0003">Emil Eik Nielsen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/information#CD012143-cr-0004">Joshua Feinberg</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/information#CD012143-cr-0005">Kiran Kumar Katakam</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/information#CD012143-cr-0006">Kristina Fobian</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/information#CD012143-cr-0007">Goran Hauser</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/information#CD012143-cr-0008">Goran Poropat</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/information#CD012143-cr-0009">Snezana Djurisic</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/information#CD012143-cr-0010">Karl Heinz Weiss</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/information#CD012143-cr-0011">Milica Bjelakovic</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/information#CD012143-cr-0012">Goran Bjelakovic</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/information#CD012143-cr-0013">Sarah Louise Klingenberg</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/information#CD012143-cr-0014">Jian Ping Liu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/information#CD012143-cr-0015">Dimitrinka Nikolova</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/information#CD012143-cr-0016">Ronald L Koretz</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012143.pub3/information#CD012143-cr-0017">Christian Gluud</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/information/en#CD012143-sec-0167">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 September 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012143.pub3">https://doi.org/10.1002/14651858.CD012143.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012143-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012143-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012143-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012143-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012143-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012143-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012143-abs-0001" lang="en"> <section id="CD012143-sec-0001"> <h3 class="title" id="CD012143-sec-0001">Background</h3> <p>Millions of people worldwide suffer from hepatitis C, which can lead to severe liver disease, liver cancer, and death. Direct‐acting antivirals (DAAs), e.g. sofosbuvir, are relatively new and expensive interventions for chronic hepatitis C, and preliminary results suggest that DAAs may eradicate hepatitis C virus (HCV) from the blood (sustained virological response). Sustained virological response (SVR) is used by investigators and regulatory agencies as a surrogate outcome for morbidity and mortality, based solely on observational evidence. However, there have been no randomised trials that have validated that usage. </p> </section> <section id="CD012143-sec-0002"> <h3 class="title" id="CD012143-sec-0002">Objectives</h3> <p>To assess the benefits and harms of DAAs in people with chronic HCV.</p> </section> <section id="CD012143-sec-0003"> <h3 class="title" id="CD012143-sec-0003">Search methods</h3> <p>We searched for all published and unpublished trials in The Cochrane Hepato‐Biliary Group Controlled Trials Register, CENTRAL, MEDLINE, Embase, Science Citation Index Expanded, LILACS, and BIOSIS; the Chinese Biomedical Literature Database (CBM), China Network Knowledge Information (CNKI), the Chinese Science Journal Database (VIP), Google Scholar, The Turning Research into Practice (TRIP) Database, <a href="https://www.clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a>, European Medicines Agency (EMA) (<a href="http://www.ema.europa.eu/ema/" target="_blank">www.ema.europa.eu/ema/</a>), WHO International Clinical Trials Registry Platform (<a href="http://www.who.int/ictrp" target="_blank">www.who.int/ictrp</a>), the Food and Drug Administration (FDA) (<a href="http://www.fda.gov/" target="_blank">www.fda.gov</a>), and pharmaceutical company sources for ongoing or unpublished trials. Searches were last run in October 2016. </p> </section> <section id="CD012143-sec-0004"> <h3 class="title" id="CD012143-sec-0004">Selection criteria</h3> <p>Randomised clinical trials comparing DAAs versus no intervention or placebo, alone or with co‐interventions, in adults with chronic HCV. We included trials irrespective of publication type, publication status, and language. </p> </section> <section id="CD012143-sec-0005"> <h3 class="title" id="CD012143-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane. Our primary outcomes were hepatitis C‐related morbidity, serious adverse events, and health‐related quality of life. Our secondary outcomes were all‐cause mortality, ascites, variceal bleeding, hepato‐renal syndrome, hepatic encephalopathy, hepatocellular carcinoma, non‐serious adverse events (each reported separately), and SVR. We systematically assessed risks of bias, performed Trial Sequential Analysis, and followed an eight‐step procedure to assess thresholds for statistical and clinical significance. We evaluated the overall quality of the evidence, using GRADE. </p> </section> <section id="CD012143-sec-0006"> <h3 class="title" id="CD012143-sec-0006">Main results</h3> <p>We included a total of 138 trials randomising a total of 25,232 participants. The trials were generally short‐term trials and designed primarily to assess the effect of treatment on SVR. The trials evaluated 51 different DAAs. Of these, 128 trials employed matching placebo in the control group. All included trials were at high risk of bias. Eighty‐four trials involved DAAs on the market or under development (13,466 participants). Fifty‐seven trials administered DAAs that were discontinued or withdrawn from the market. Study populations were treatment‐naive in 95 trials, had been exposed to treatment in 17 trials, and comprised both treatment‐naive and treatment‐experienced individuals in 24 trials. The HCV genotypes were genotype 1 (119 trials), genotype 2 (eight trials), genotype 3 (six trials), genotype 4 (nine trials), and genotype 6 (one trial). We identified two ongoing trials. </p> <p>We could not reliably determine the effect of DAAs on the market or under development on our primary outcome of hepatitis C‐related morbidity or all‐cause mortality. There were no data on hepatitis C‐related morbidity and only limited data on mortality from 11 trials (DAA 15/2377 (0.63%) versus control 1/617 (0.16%); OR 3.72, 95% CI 0.53 to 26.18, very low‐quality evidence). We did not perform Trial Sequential Analysis on this outcome. </p> <p>There is very low quality evidence that DAAs on the market or under development do not influence serious adverse events (DAA 5.2% versus control 5.6%; OR 0.93, 95% CI 0.75 to 1.15 , 15,817 participants, 43 trials). The Trial Sequential Analysis showed that there was sufficient information to rule out that DAAs reduce the relative risk of a serious adverse event by 20% when compared with placebo. The only DAA that showed a lower risk of serious adverse events when meta‐analysed separately was simeprevir (OR 0.62, 95% CI 0.45 to 0.86). However, Trial Sequential Analysis showed that there was not enough information to confirm or reject a relative risk reduction of 20%, and when one trial with an extreme result was excluded, the meta‐analysis result showed no evidence of a difference. </p> <p>DAAs on the market or under development may reduce the risk of no SVR from 54.1% in untreated people to 23.8% in people treated with DAA (RR 0.44, 95% CI 0.37 to 0.52, 6886 participants, 32 trials, low quality evidence). Trial Sequential Analysis confirmed this meta‐analysis result. </p> <p>Only 1/84 trials on the market or under development assessed the effects of DAAs on health‐related quality of life (SF‐36 mental score and SF‐36 physical score). </p> <p>There was insufficient evidence from trials on withdrawn or discontinued DAAs to determine their effect on hepatitis C‐related morbidity and all‐cause mortality (OR 0.64, 95% CI 0.23 to 1.79; 5 trials, very low‐quality evidence). However, these DAAs seemed to increase the risk of serious adverse events (OR 1.45, 95% CI 1.22 to 1.73; 29 trials, very low‐quality evidence). Trial Sequential Analysis confirmed this meta‐analysis result. </p> <p>None of the 138 trials provided useful data to assess the effects of DAAs on the remaining secondary outcomes (ascites, variceal bleeding, hepato‐renal syndrome, hepatic encephalopathy, and hepatocellular carcinoma). </p> </section> <section id="CD012143-sec-0007"> <h3 class="title" id="CD012143-sec-0007">Authors' conclusions</h3> <p>The evidence for our main outcomes of interest come from short‐term trials, and we are unable to determine the effect of long‐term treatment with DAAs. The rates of hepatitis C morbidity and mortality observed in the trials are relatively low and we are uncertain as to how DAAs affect this outcome. Overall, there is very low quality evidence that DAAs on the market or under development do not influence serious adverse events. There is insufficient evidence to judge if DAAs have beneficial or harmful effects on other clinical outcomes for chronic HCV. Simeprevir may have beneficial effects on risk of serious adverse event. In all remaining analyses, we could neither confirm nor reject that DAAs had any clinical effects. DAAs may reduce the number of people with detectable virus in their blood, but we do not have sufficient evidence from randomised trials that enables us to understand how SVR affects long‐term clinical outcomes. SVR is still an outcome that needs proper validation in randomised clinical trials. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012143-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012143-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012143-abs-0011">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012143-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012143-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012143-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012143-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012143-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012143-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012143-abs-0005" lang="en"> <h3>Direct‐acting antivirals for chronic hepatitis C</h3> <p><b>Background</b> <br/> Millions of people worldwide suffer from hepatitis C, which can lead to severe liver disease, liver cancer, and death. Numerous previous interferon‐based interventions have been used for hepatitis C, but none of these interventions have proven effective on patient‐centred outcomes and their use was associated with serious side‐effects. DAAs are relatively new but expensive interventions for hepatitis C, and preliminary results have shown that DAAs seem to eradicate hepatitis C virus from the blood (sustained virological response) much more frequently. In addition, these agents do appear to create much less serious adverse‐effects. In this Cochrane Review, we assessed the evidence on the clinical effects of DAAs for hepatitis C. </p> <p><b>Study characteristics</b> <br/> We included 138 randomised clinical trials. All included trials were at high risk of bias. The 138 trials used 51 different DAAs. Of these, 84 trials assessed DAAs on the market or under development; 57 trials were on DAAs withdrawn from development or the market. Trials were conducted from 2004 to 2016. The trials were from all over the world including 34 different countries. We included 17 trials where all the participants had previously been treated for hepatitis C (treatment‐experienced) before being included in the trial. There were 95 trials that included only participants who had not been previously treated for hepatitis C (treatment‐naive). The intervention periods ranged from one day to 48 weeks with an average of 14 weeks. The combined intervention period and follow‐up period ranged from one day to 120 weeks with an average of 34 weeks. </p> <p><b>Key results</b> <br/> We could not reliably determine the effect of DAAs on hepatitis C‐related morbidity or death from any cause. There were no data on hepatitis C‐related morbidity and very few deaths occurred over the course of the trials (15 deaths/2377 direct‐acting antiviral participants (0.63%) versus 1 death/617 control participants (0.16%), very low quality evidence). Based on very low quality evidence, 5.2% people treated with DAAs had one or more serious adverse events versus 5.6% participants who were untreated during the observation period. When analysed separately, simeprevir was the only direct‐acting antiviral that showed evidence of a beneficial effect when assessing risk of a serious adverse event. Our analyses, however, showed that the validity of this result is questionable and that 'play of chance' might be the cause for the difference. There was not enough information to determine if there was any effect of DAAs on other clinically relevant outcomes. Our results confirm that DAAs seem to reduce the number of people who have the hepatitis C virus in their blood from 54.1% in untreated people to 23.8% in those who were treated. Because the loss of detectable hepatitis C virus in the blood stream is only a blood test, the studies could not tell what this result means in the long term. </p> <p><b>Quality of the evidence</b> <br/> Due to several limitations (e.g. lack of blinding, lack of relevant data, missing data, no published protocol) we assessed the quality of the evidence in this review as very low or low quality. First, all trials and outcome results were at high risk of bias, which means that our results presumably overestimate the beneficial effects of DAAs and underestimate any potential harmful effects. Second, there were limited data on most of our clinical outcomes, that is, there were only relevant clinical data for meta‐analyses on all‐cause mortality and serious adverse events, and for these, data were sparse. There are no long‐term trials that have assessed whether or not DAA treatment improves morbidity or mortality. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012143-sec-0148" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012143-sec-0148"></div> <h3 class="title" id="CD012143-sec-0149">Implications for practice</h3> <section id="CD012143-sec-0149"> <p>Most trials were designed to measure the short‐term effect of direct‐acting antiviral (DAA) treatment on virological response in adults with chronic hepatitis C, the majority of whom had not been treated previously. Rates of hepatitis C morbidity and mortality observed in the trials are low and we are uncertain as to how DAAs affect this outcome (very low quality evidence). Considered as one overall intervention, there is very low quality evidence that DAAs on the market or under development do not seem to influence the risk of serious adverse events. There is insufficient evidence to judge if DAAs have beneficial or harmful effects on other clinical outcomes for chronic HCV. DAAs may reduce the number of people with detectable virus in their blood, but we do not have sufficient evidence from randomised trials that enables us to understand how sustained virological response affects long‐term clinical outcomes. We are unable to determine effects of long‐term treatment from randomised evidence. All the trials and all of the outcome results were at high risk of bias, so there are risks that our results overestimate benefits and underestimate harms. </p> <p>When analysed separately, simeprevir was the only DAA that showed evidence of an effect when assessing the risk of a serious adverse event, but this result was at high risk of bias and high risk of random errors. Withdrawn DAAs seemed to increase the risk of serious adverse events. Further evidence of long‐term clinical benefit of DAAs on hepatitis C virus‐related morbidity and mortality is needed to determine the efficacy of this treatment with greater certainty. </p> </section> <h3 class="title" id="CD012143-sec-0150">Implications for research</h3> <section id="CD012143-sec-0150"> <p>Randomised clinical trials assessing the clinical effects of DAAs are needed. Such trials should be conducted with low risk of bias, low risk of design errors, and low risk of random errors. Future trials ought to focus their assessments on patient‐centred clinical outcomes. </p> <p>Future randomised clinical trials ought to avoid the negative aspects we noted in the first 138 randomised clinical trials conducted on DAAs versus placebo or no intervention: </p> <p> <ol id="CD012143-list-0016"> <li> <p>many of the trials employed skewed randomisation, so that more participants were randomised to DAA compared with placebo or no intervention. This reduces the power for the trials and makes it more difficult to assess rare outcomes such as clinical outcomes and serious adverse events; </p> </li> <li> <p>most of the trials used as primary outcome a surrogate outcome, that is, sustained virological response. This outcome has not been subject to validation from randomised evidence; </p> </li> <li> <p>most of the trials were at high risk of for‐profit bias;</p> </li> <li> <p>most of the trials were extremely short term, with trial intervention durations below 48 weeks and a follow‐up period below 38 weeks; </p> </li> <li> <p>too many of the trials had problems with randomisation and too short follow‐up periods;</p> </li> <li> <p>many of the trials used co‐interventions that were not equally distributed among the participants in the experimental and control groups; </p> </li> <li> <p>lack of trials assessing the effects of DAAs on quality of life;</p> </li> <li> <p>many of the trials used multiple intervention arms making it hard or impossible to assess intervention effects properly; and </p> </li> <li> <p>many of the trials reported adverse events in a way that it was hard or impossible to assess their severity. </p> </li> </ol> </p> <p>Future trials ought to be designed according to the SPIRIT guidelines (<a href="./references#CD012143-bbs2-0286" title="ChanAW , TetzlaffJM , AltmanDG , LaupacisA , GøtzschePC , Krleža‐JerićK , et al. SPIRIT 2013 Statement: defining standard protocol items for clinical trials. Annals of Internal Medicine2013;158(3):200‐7. ">Chan 2013</a>) and reported according to the CONSORT guidelines (<a href="./references#CD012143-bbs2-0360" title="SchulzKF , AltmanDG , MoherD . CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Annals of Internal Medicine2010;152(11):726‐32. ">Schultz 2010</a>). Threats to the validity of the evidence ought to be accounted for (<a href="./references#CD012143-bbs2-0304" title="GarattiniS , JakobsenJC , WetterslevJ , BerteleV , BanziR , RathA , et al. Evidence‐based clinical practice: overview of threats to the validity of evidence and how to minimise them. European Journal of Internal Medicine2016;32:13‐21. ">Garattini 2016</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012143-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012143-sec-0029"></div> <div class="table" id="CD012143-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Direct‐acting antivirals versus control</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Direct‐acting antivirals versus control</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with chronic hepatitis C<br/> <b>Setting:</b> any setting<br/> <b>Intervention:</b> direct‐acting antivirals on the market or under development<br/> <b>Comparison:</b> placebo or no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> <p><b>(TSA‐adjusted CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or no intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with direct‐acting antivirals</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality at maximum follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000<br/> (1 to 42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 3.72<br/> (0.53 to 26.18) </p> <p>(‐)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2996<br/> (11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It was not possible to perform Trial Sequential Analysis because of limited data and too few events </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of participants with one or more serious adverse event at maximum follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 per 1000<br/> (49 to 55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.93<br/> (0.75 to 1.15) </p> <p>(TSA CI 0.71 to 1.33)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15,817<br/> (43 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial Sequential Analysis showed that the boundary for futility was crossed. This leads us to conclude that any possible intervention effect, if any, is less than 20% </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of participants with no sustained virological response at maximum follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>541 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>238 per 1000<br/> (200 to 281) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.44<br/> (0.37 to 0.52) </p> <p>(TSA CI 0.42 to 0.55)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6886<br/> (32 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial Sequential Analysis showed that the boundary for benefit was crossed. This indicates that DAAs seem to decrease the risk of no sustained virological response by at least 20% if risk of bias and other threats to the validity can be disregarded </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the observed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>DAA</b> : direct‐acting antivirals; <b>OR:</b> odds ratio; <b>RCTs</b> : randomised clinical trials; <b>RR:</b> risk ratio; <b>TSA</b>: Trial Sequential Analysis </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded two levels because of very serious risk of bias in the included trials (see <a href="./full#CD012143-fig-0001">Figure 1</a>) and two levels due to very serious imprecision (none of the TSA boundaries are crossed, so the information size is too low).<br/> <sup>2</sup>Downgraded two levels due to very serious risk of bias in the included trials (see <a href="./full#CD012143-fig-0001">Figure 1</a>) and one level due to serious indirectness (the components of this composite outcome consisted of events with very different degrees of severity, which limits the interpretability of this outcome result).<br/> <sup>3</sup>Downgraded two levels because of very serious risk of bias in the included trials (<a href="./full#CD012143-fig-0001">Figure 1</a>). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="figure" id="CD012143-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="original image" data-id="CD012143-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <div class="table" id="CD012143-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Direct‐acting antivirals withdrawn from the market versus control</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Direct‐acting antivirals withdrawn from the market versus control</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with chronic hepatitis C<br/> <b>Setting:</b> any setting<br/> <b>Intervention:</b> direct‐acting antivirals withdrawn from the market<br/> <b>Comparison:</b> placebo or no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> <p><b>(TSA‐adjusted CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or no intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with direct‐acting antivirals</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality</p> <p>at maximum follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000<br/> (2 to 12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.64<br/> (0.23 to 1.79) </p> <p>(‐)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3045<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It was not possible to perform Trial Sequential Analysis because of limited data and too few events </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of participants with one or more serious adverse event at maximum follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>75 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>108 per 1000<br/> (91 to 129) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.45<br/> (1.22 to 1.73) </p> <p>(TSA 1.16 to 1.82)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9229<br/> (29 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial Sequential Analysis showed that the boundary for harm was crossed. This shows that there is firm evidence that withdrawn DAAs increase the risk of a serious adverse event by at least 20% </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of participants with no sustained virological response at maximum follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>586 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>356 per 1000<br/> (322 to 404) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.61 (0.55, 0.69)</p> <p>(TSA CI 0.42 to 0.55)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9075<br/> (21 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial Sequential Analysis not performed</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the observed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>DAA</b> : direct‐acting antivirals; <b>OR:</b> odds ratio; <b>RCTs</b> : randomised clinical trials; <b>RR:</b> risk ratio; <b>TSA</b>: Trial Sequential Analysis </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded two levels because of very serious risk of bias in the included trials (see <a href="./full#CD012143-fig-0001">Figure 1</a>) and two levels due to very serious imprecision (none of the TSA boundaries are crossed so the information size is too low).<br/> <sup>2</sup>Downgraded two levels because of very serious risk of bias in the included trials (see <a href="./full#CD012143-fig-0001">Figure 1</a>) and one level due to serious indirectness (the components of this composite outcome consisted of events with very different degrees of severity which limits the interpretability of this outcome result).<br/> <sup>3</sup>Downgraded two levels because of very serious risk of bias in the included trials (<a href="./full#CD012143-fig-0001">Figure 1</a>). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012143-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012143-sec-0030"></div> <section id="CD012143-sec-0031"> <h3 class="title" id="CD012143-sec-0031">Description of the condition</h3> <p>The hepatitis C virus (HCV) was discovered in 1989 and has since become recognised as the leading cause of cirrhosis and hepatocellular carcinoma (<a href="./references#CD012143-bbs2-0288" title="ChooQL , KuoG , WeinerAJ , OverbyLR , BradleyDW , HoughtonM . Isolation of a cDNA clone derived from a blood‐borne non‐A, non‐B viral hepatitis genome. Science1989;244(4902):359‐62. ">Choo 1989</a>). Worldwide, an estimated 700,000 deaths per year can be related to HCV liver diseases and more than 115 million individuals are infected. This corresponds to a global prevalence of 1.6% (<a href="./references#CD012143-bbs2-0375" title="WHO . Hepatitis C Fact sheet N°164. www.who.int/mediacentre/factsheets/fs164/en/ 2015 (accessed 2 March 2016). ">WHO 2014</a>; <a href="./references#CD012143-bbs2-0341" title="GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age‐sex specific all‐cause and cause‐specific mortality for 240 causes of death, 1990‐2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet2015;385(9963):117‐71. ">MCDC 2015</a>). Mother to child transmission of HCV has become a leading cause of paediatric infection of HCV, and up to half of the children infected with HCV acquired the HCV infection in utero (<a href="./references#CD012143-bbs2-0345" title="MokJ , PembreyL , TovoPA , NewellML , European Paediatric Hepatitis C Virus Network. When does mother to child transmission of hepatitis C virus occur?. Archives of Disease in Childhood. Fetal and Neonatal Edition2005;90(2):156‐60. ">Mok 2005</a>). In the USA, an estimated 50% of individuals with chronic HCV infection are unaware of their diagnosis (<a href="./references#CD012143-bbs2-0364" title="SpradlingPR , RuppL , MoormanAC , LuM , TeshaleEH , GordonSC , et al. Chronic Hepatitis Cohort Study Investigators. Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence. Clinical Infectious Diseases2012;55(8):1047‐55. ">Spradling 2012</a>). Failure to identify infected individuals has been considered to be a major bottleneck to successful control of HCV (<a href="./references#CD012143-bbs2-0364" title="SpradlingPR , RuppL , MoormanAC , LuM , TeshaleEH , GordonSC , et al. Chronic Hepatitis Cohort Study Investigators. Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence. Clinical Infectious Diseases2012;55(8):1047‐55. ">Spradling 2012</a>). Screening asymptomatic individuals who may have an increased likelihood of being infected with HCV could become an important step toward improving the detection and, ultimately, treatment of HCV‐infected people (<a href="./references#CD012143-bbs2-0364" title="SpradlingPR , RuppL , MoormanAC , LuM , TeshaleEH , GordonSC , et al. Chronic Hepatitis Cohort Study Investigators. Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence. Clinical Infectious Diseases2012;55(8):1047‐55. ">Spradling 2012</a>). </p> <p>HCV is a member of the family <i>Flaviviridae</i> belonging to the <i>Hepacivirus</i> genus, and is an enveloped single‐stranded positive‐sense ribonucleic acid (RNA) virus (<a href="./references#CD012143-bbs2-0359" title="ScheelTK , RiceCM . Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nature Medicine2013;19(7):837‐49. ">Scheel 2013</a>; <a href="./references#CD012143-bbs2-0295" title="DubuissonJ , CossetFL . Virology and cell biology of the hepatitis C virus life cycle: an update. Journal of Hepatology2014;61(1 Suppl):S3‐S13. ">Dubuisson 2014</a>). The genome of HCV contains one open reading frame encoding a poly‐protein (<a href="./references#CD012143-bbs2-0359" title="ScheelTK , RiceCM . Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nature Medicine2013;19(7):837‐49. ">Scheel 2013</a>; <a href="./references#CD012143-bbs2-0295" title="DubuissonJ , CossetFL . Virology and cell biology of the hepatitis C virus life cycle: an update. Journal of Hepatology2014;61(1 Suppl):S3‐S13. ">Dubuisson 2014</a>). This poly‐protein is processed by host and viral proteins to yield the structural (core, glycoproteins E1 and E2, and protein P7) and the nonstructural proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) (<a href="./references#CD012143-bbs2-0359" title="ScheelTK , RiceCM . Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nature Medicine2013;19(7):837‐49. ">Scheel 2013</a>; <a href="./references#CD012143-bbs2-0295" title="DubuissonJ , CossetFL . Virology and cell biology of the hepatitis C virus life cycle: an update. Journal of Hepatology2014;61(1 Suppl):S3‐S13. ">Dubuisson 2014</a>). </p> <p>Classification of HCV is based on phylogeny (i.e. history of evolution) and sequence diversity, dividing HCV into seven major genotypes (<a href="./references#CD012143-bbs2-0359" title="ScheelTK , RiceCM . Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nature Medicine2013;19(7):837‐49. ">Scheel 2013</a>; <a href="./references#CD012143-bbs2-0342" title="MessinaJP , HumphreysI , FlaxmanA , BrownA , CookeGS , PybusOG , et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology2015;61(1):77‐87. ">Messina 2015</a>). The geographical distribution and the prevalence of the seven genotypes varies (<a href="./references#CD012143-bbs2-0359" title="ScheelTK , RiceCM . Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nature Medicine2013;19(7):837‐49. ">Scheel 2013</a>; <a href="./references#CD012143-bbs2-0342" title="MessinaJP , HumphreysI , FlaxmanA , BrownA , CookeGS , PybusOG , et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology2015;61(1):77‐87. ">Messina 2015</a>). Genotype 1 is highly prevalent, accounting for 46% of all HCV infections globally (<a href="./references#CD012143-bbs2-0359" title="ScheelTK , RiceCM . Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nature Medicine2013;19(7):837‐49. ">Scheel 2013</a>; <a href="./references#CD012143-bbs2-0342" title="MessinaJP , HumphreysI , FlaxmanA , BrownA , CookeGS , PybusOG , et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology2015;61(1):77‐87. ">Messina 2015</a>). Genotype 2 has been found to dominate in West Africa, genotype 3 in South Asia and parts of Scandinavia, genotype 4 in Central and North Africa, genotype 5 in South Africa, and genotype 6 and 7 in South East Asia (<a href="./references#CD012143-bbs2-0359" title="ScheelTK , RiceCM . Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nature Medicine2013;19(7):837‐49. ">Scheel 2013</a>; <a href="./references#CD012143-bbs2-0307" title="GowerE , EstesC , BlachS , Razavi‐ShearerK , RazaviH . Global epidemiology and genotype distribution of the hepatitis C virus infection. Journal of Hepatology2014;61(1):45‐57. ">Gowan 2014</a>; <a href="./references#CD012143-bbs2-0342" title="MessinaJP , HumphreysI , FlaxmanA , BrownA , CookeGS , PybusOG , et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology2015;61(1):77‐87. ">Messina 2015</a>). It has been shown that the interleukin−28 beta (IL‐28B) subunit gene in the host is dramatically associated with both sustained virological response to pegylated interferon α (peg‐IFNα) and ribavirin (RBV) and spontaneous viral clearance in the absence of therapy (<a href="./references#CD012143-bbs2-0282" title="BergerCT , KimAY . IL28B polymorphisms as a pre‐treatment predictor of response to HCV treatment. Infectious Disease Clinics of North America2012;26(4):863‐77. [DOI: 10.1016/j.idc.2012.08.010] ">Berger 2012</a>). </p> <p>HCV is primarily transmitted parenterally through exposure to contaminated blood (e.g. in people who inject drugs) (<a href="./references#CD012143-bbs2-0285" title="Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV‐related chronic disease. MMWR. Recommendations and Reports: Morbidity and Mortality Weekly Report1998;47(RR‐19):1‐39. ">CDCP 1998</a>). The signs and symptoms of HCV have been found to be largely similar across genotypes, but genotype 3 is associated with higher risks of hepatic steatosis and progressive liver disease (<a href="./references#CD012143-bbs2-0359" title="ScheelTK , RiceCM . Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nature Medicine2013;19(7):837‐49. ">Scheel 2013</a>). An infection with HCV is often asymptomatic and if the disease does not progress further to cirrhosis or give rise to cancer, it may not result in harmful events for infected people (<a href="./references#CD012143-bbs2-0335" title="KoretzRL , LinKW , IoannidisJP , LenzerJ . Is widespread screening for hepatitis C justified?. BMJ (Clinical Research Ed.)2015;350:g7809. ">Koretz 2015</a>). Approximately 20% of infected people have self‐limited acute hepatitis (<a href="./references#CD012143-bbs2-0335" title="KoretzRL , LinKW , IoannidisJP , LenzerJ . Is widespread screening for hepatitis C justified?. BMJ (Clinical Research Ed.)2015;350:g7809. ">Koretz 2015</a>), but in the remaining 80%, the virus is not cleared, which leads to a chronic HCV infection (<a href="./references#CD012143-bbs2-0375" title="WHO . Hepatitis C Fact sheet N°164. www.who.int/mediacentre/factsheets/fs164/en/ 2015 (accessed 2 March 2016). ">WHO 2014</a>). A systematic review of 111 studies analysing the natural history of HCV infection, found that the prevalence of cirrhosis 20 years after HCV infection was 16% (<a href="./references#CD012143-bbs2-0367" title="TheinHH , YiQ , DoreGJ , KrahnMD . Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection: a meta‐analysis and meta‐regression.. Hepatology2008;48(2):418. ">Thein 2008</a>). Other studies have reported that further progression into cirrhosis occurred in approximately 20% of HCV people but the prevalence could be even higher (<a href="./references#CD012143-bbs2-0292" title="ConteducaV , SansonnoD , RussiS , PavoneF , DammaccoF . Therapy of chronic hepatitis C virus infection in the era of direct‐acting and host‐targeting antiviral agents. Journal of Infection2014;68(1):1‐20. ">Conteduca 2014</a>; <a href="./references#CD012143-bbs2-0335" title="KoretzRL , LinKW , IoannidisJP , LenzerJ . Is widespread screening for hepatitis C justified?. BMJ (Clinical Research Ed.)2015;350:g7809. ">Koretz 2015</a>; <a href="./references#CD012143-bbs2-0371" title="WandelerG , DufourJF , BruggmannP , RauchA . Hepatitis C: a changing epidemic. Swiss Medical Weekly2015;145:w14093. ">Wandeler 2015</a>). Studies have shown varying results, but approximately 10% to 20% of the people with chronic HCV infection progress to end‐stage disease (i.e., decompensated cirrhosis or hepatocellular carcinoma, not just histologic cirrhosis), which corresponds to 8% to16% of all people who are infected with HCV (<a href="./references#CD012143-bbs2-0335" title="KoretzRL , LinKW , IoannidisJP , LenzerJ . Is widespread screening for hepatitis C justified?. BMJ (Clinical Research Ed.)2015;350:g7809. ">Koretz 2015</a>). </p> <p>Before the appearance of DAAs, the recommended standard of care for HCV infection consisted of peg‐IFN α plus RBV (<a href="./references#CD012143-bbs2-0340" title="MannsMP , WedemeyerH , CornbergM . Treating viral hepatitis C: efficacy, side effects, and complications. Gut2006;55(9):1350‐9. ">Manns 2006</a>; <a href="./references#CD012143-bbs2-0283" title="BrokJ , GluudLL , GluudC . Ribavirin monotherapy for chronic hepatitis C. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD005527.pub2] ">Brok 2009</a>; <a href="./references#CD012143-bbs2-0284" title="BrokJ , GluudLL , GluudC . Ribavirin plus interferon versus interferon for chronic hepatitis C. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD005445.pub2] ">Brok 2010</a>; <a href="./references#CD012143-bbs2-0321" title="HauserG , AwadT , BrokJ , ThorlundK , ŠtimacD , MabroukM , et al. Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD005441.pub3] ">Hauser 2014</a>). Several mechanisms of action of RBV have so far been suggested; one of the proposed mechanisms is a direct effect against the HCV RNA‐dependent RNA polymerase (<a href="./references#CD012143-bbs2-0290" title="ClarkV , NelsonDR . The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C. Liver International2012;32(1):103‐7. ">Clark 2012</a>). However, given the lack of a clear understanding of the RBV mechanism, it is considered challenging to confidently classify RBV as a DAA (<a href="./references#CD012143-bbs2-0290" title="ClarkV , NelsonDR . The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C. Liver International2012;32(1):103‐7. ">Clark 2012</a>). </p> <p>Treatment with peg‐IFNα plus RBV, compared with other antiviral drugs, has been shown to increase the rates of sustained virological response (SVR) defined as aviraemia 24 weeks after antiviral therapy (<a href="./references#CD012143-bbs2-0300" title="ErmisF , Senocak TasciE . New treatment strategies for hepatitis C infection. World Journal of Hepatology2015;7(17):2100‐9. ">Ermis 2015</a>). Treatment with peg‐IFNα plus RBV is associated with serious adverse events, often leading to discontinuation of the treatment, and the effects on clinically‐relevant outcomes remain unclear (<a href="./references#CD012143-bbs2-0284" title="BrokJ , GluudLL , GluudC . Ribavirin plus interferon versus interferon for chronic hepatitis C. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD005445.pub2] ">Brok 2010</a>; <a href="./references#CD012143-bbs2-0334" title="KoretzRL , PleguezueloM , ArvanitiV , BarreraBP , CiriaR , GurusamyKS , et al. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD003617.pub2] ">Koretz 2013</a>; <a href="./references#CD012143-bbs2-0321" title="HauserG , AwadT , BrokJ , ThorlundK , ŠtimacD , MabroukM , et al. Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD005441.pub3] ">Hauser 2014</a>; <a href="./references#CD012143-bbs2-0335" title="KoretzRL , LinKW , IoannidisJP , LenzerJ . Is widespread screening for hepatitis C justified?. BMJ (Clinical Research Ed.)2015;350:g7809. ">Koretz 2015</a>; <a href="./references#CD012143-bbs2-0355" title="RighiE , LonderoA , CarneluttiA , BaccaraniU , BassettiM . Impact of new treatment options for hepatitis C virus infection in liver transplantation. World Journal of Gastroenterology2015;21(38):10760‐75. ">Righi 2015</a>). The many serious adverse events associated with IFNα plus RBV treatment has encouraged the development of new interventions, such as DAAs (<a href="./references#CD012143-bbs2-0300" title="ErmisF , Senocak TasciE . New treatment strategies for hepatitis C infection. World Journal of Hepatology2015;7(17):2100‐9. ">Ermis 2015</a>). </p> <p>Several observational studies have shown that achieving sustained virologic response in hepatitis C seems to be associated with improved clinical outcomes (<a href="./references#CD012143-bbs2-0363" title="Smith‐PalmerJ , CerriK , ValentineW . Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infectious Diseases2015;15(19). ">Smith‐Palmer 2015</a>). However, the SVR is a blood test and, as such, is a surrogate outcome. Since the SVR has been used universally as the primary outcome in hepatitis C treatment trials, it will be necessary to consider it in this review. </p> <p>Surrogate outcomes may or may not reflect ultimate clinical outcomes and they need to be validated. Such validations cannot be accomplished only by observational evidence (<a href="./references#CD012143-bbs2-0289" title="CianiO , BuyseM , DrummondM , RasiG , SaadED , TaylorRS . Time to review the role of surrogate end points in health policy: state of the art and the way forward. Value Health2017;20(3):487‐95. ">Ciani 2017</a>; <a href="./references#CD012143-bbs2-0302" title="FlemingTR , DeMetsDL . Surrogate end points in clinical trials: Are we being misled?. Annals of Internal Medicine 1996, 125(7):605‐613.. ">Flemming 1996</a>; <a href="./references#CD012143-bbs2-0303" title="FlemingTR , PowersJH . Biomarkers and surrogate endpoints in clinical trials. Statistics in medicine 2012, 31(25):2973‐2984.. ">Flemming 2012</a>; <a href="./references#CD012143-bbs2-0305" title="GluudC , BrokJ , GongY , KoretzRL . Hepatology may have problems with putative surrogate outcome measures. Journal of Hepatology2007;46(4):734‐42. ">Gluud 2007</a>; <a href="./references#CD012143-bbs2-0332" title="KempR , PrasadV . Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?. BMC Medicine 2017, 15(1):134.. ">Kemp 2017</a>). Validation consists of showing that the creation of surrogate outcomes ultimately results in comparable improvements in clinical outcomes. Thus, validation requires the performance of randomised clinical trials showing that the people who obtain SVRs also have a decreased risk of hepatis C‐related complications. Simply showing an association or a correlation between short‐term measures and long‐term clinical events does not validate a surrogate outcome. For example, people who develop SVRs have underlying characteristics that would predict that they would have better long‐term outcomes even if no treatment was provided (<a href="./references#CD012143-bbs2-0335" title="KoretzRL , LinKW , IoannidisJP , LenzerJ . Is widespread screening for hepatitis C justified?. BMJ (Clinical Research Ed.)2015;350:g7809. ">Koretz 2015</a>). Thus, if an observational study shows that people treated with DAAs who obtain SVRs had better outcomes than untreated (or unsuccessfully treated) people who do not obtain SVR, the explanation for the association may simply be that the SVR identified the inherently stronger population who both responded and had fewer clinical events because of their inherently better status (<a href="./references#CD012143-bbs2-0289" title="CianiO , BuyseM , DrummondM , RasiG , SaadED , TaylorRS . Time to review the role of surrogate end points in health policy: state of the art and the way forward. Value Health2017;20(3):487‐95. ">Ciani 2017</a>; <a href="./references#CD012143-bbs2-0302" title="FlemingTR , DeMetsDL . Surrogate end points in clinical trials: Are we being misled?. Annals of Internal Medicine 1996, 125(7):605‐613.. ">Flemming 1996</a>; <a href="./references#CD012143-bbs2-0303" title="FlemingTR , PowersJH . Biomarkers and surrogate endpoints in clinical trials. Statistics in medicine 2012, 31(25):2973‐2984.. ">Flemming 2012</a>; <a href="./references#CD012143-bbs2-0305" title="GluudC , BrokJ , GongY , KoretzRL . Hepatology may have problems with putative surrogate outcome measures. Journal of Hepatology2007;46(4):734‐42. ">Gluud 2007</a>; <a href="./references#CD012143-bbs2-0335" title="KoretzRL , LinKW , IoannidisJP , LenzerJ . Is widespread screening for hepatitis C justified?. BMJ (Clinical Research Ed.)2015;350:g7809. ">Koretz 2015</a>). As indicated by <a href="./references#CD012143-bbs2-0302" title="FlemingTR , DeMetsDL . Surrogate end points in clinical trials: Are we being misled?. Annals of Internal Medicine 1996, 125(7):605‐613.. ">Flemming 1996</a>: "While the effect of an intervention on a biomarker does provide direct evidence regarding biological activity, such evidence could be unreliable regarding effects on true clinical efficacy measures even when the biomarker is strongly correlated with these clinical efficacy measures in natural history observations." "A correlate does not a surrogate make" (<a href="./references#CD012143-bbs2-0302" title="FlemingTR , DeMetsDL . Surrogate end points in clinical trials: Are we being misled?. Annals of Internal Medicine 1996, 125(7):605‐613.. ">Flemming 1996</a>). In one clinical scenario (re‐treating patients with interferon monotherapy), the SVR did fail to validate: while the treated patients did have more SVRs, they also had more morbidity and may also have had a higher all‐cause mortality (<a href="./references#CD012143-bbs2-0334" title="KoretzRL , PleguezueloM , ArvanitiV , BarreraBP , CiriaR , GurusamyKS , et al. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD003617.pub2] ">Koretz 2013</a>). </p> <p>SVRs achieved with DAAs are not necessarily universal cures. A retrospective cohort study (<a href="./references#CD012143-bbs2-0298" title="El‐SeragHB , KanwalF , RichardsonP , KramerJ . Risk of hepatocellular carcinoma after sustained virological response in veterans with hepatitis C virus infection. Hepatology2016;64(1):130‐7. ">El‐Serag 2016</a>) recently showed that the risk of hepatocellular carcinoma after obtaining SVR remains relatively high at 0.33% per year. Older age and presence of cirrhosis at the time of sustained virological response are associated with a high enough risk to warrant surveillance (<a href="./references#CD012143-bbs2-0298" title="El‐SeragHB , KanwalF , RichardsonP , KramerJ . Risk of hepatocellular carcinoma after sustained virological response in veterans with hepatitis C virus infection. Hepatology2016;64(1):130‐7. ">El‐Serag 2016</a>). <a href="./references#CD012143-bbs2-0352" title="ReigM , MarinoZ , PerelloC , InarrairaeguiM , RibeiroA , LensS , et al. Unexpected high rate of early tumor recurrence in patients with HCV‐related HCC undergoing interferon‐free therapy. J Hepatol. 2016;65(4):719‐26.. ">Reig 2016</a> has in a small observational study shown an unexpected high rate and pattern of tumour recurrence coinciding with SVR, and the authors hypothesise that disruption of immune surveillance may facilitate the emergence of metastatic clones (<a href="./references#CD012143-bbs2-0352" title="ReigM , MarinoZ , PerelloC , InarrairaeguiM , RibeiroA , LensS , et al. Unexpected high rate of early tumor recurrence in patients with HCV‐related HCC undergoing interferon‐free therapy. J Hepatol. 2016;65(4):719‐26.. ">Reig 2016</a>; <a href="./references#CD012143-bbs2-0353" title="ReigM , BoixL , MarinoZ , TorresF , FornsX , BruixJ . Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure?. Semin Liver Dis. 2017;37(2):109‐18.. ">Reig 2017</a>). Case reports of hepatitis B reactivation have led to labelling changes for the DAAs (<a href="./references#CD012143-bbs2-0372" title="WangC , JiD , ChenJ , ShaoQ , LiB , LiuJ , WuV , WongA , WangY , ZhangX , LuL , Wong C. TsangS , ZhanfZ , SunJ , HouJ , ChenG , LauG . Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct‐acting antiviral agents. Clin Gastroenterol Hepatol 2017; 15:132‐6. ">Wang 2017</a>). Although SVR is widely accepted by regulatory bodies as a surrogate for long‐term benefit, the results from observational studies are not definitive and validation from randomised evidence has not been confirmed (<a href="./references#CD012143-bbs2-0304" title="GarattiniS , JakobsenJC , WetterslevJ , BerteleV , BanziR , RathA , et al. Evidence‐based clinical practice: overview of threats to the validity of evidence and how to minimise them. European Journal of Internal Medicine2016;32:13‐21. ">Garattini 2016</a>; <a href="./references#CD012143-bbs2-0305" title="GluudC , BrokJ , GongY , KoretzRL . Hepatology may have problems with putative surrogate outcome measures. Journal of Hepatology2007;46(4):734‐42. ">Gluud 2007</a>; <a href="./references#CD012143-bbs2-0335" title="KoretzRL , LinKW , IoannidisJP , LenzerJ . Is widespread screening for hepatitis C justified?. BMJ (Clinical Research Ed.)2015;350:g7809. ">Koretz 2015</a>). </p> </section> <section id="CD012143-sec-0032"> <h3 class="title" id="CD012143-sec-0032">Description of the intervention</h3> <p>Direct‐acting antivirals (DAAs) are molecules that target specific nonstructural proteins of the virus, resulting in disruption of viral replication and thereby infection (<a href="./references#CD012143-bbs2-0351" title="PoordadF , DieterichD . Treating hepatitis C: current standard of care and emerging direct‐acting antiviral agents. Journal of Viral Hepatitis2012;19(7):449‐64. ">Poordad 2012</a>; <a href="./references#CD012143-bbs2-0349" title="PockrosPJ . Direct‐acting antivirals for the treatment of hepatitis C virus infection. www.uptodate.com/contents/direct‐acting‐antivirals‐for‐the‐treatment‐of‐hepatitis‐c‐virus‐infection?source=search_result&amp;search=Direct‐acting+antivirals+for+the+treatment+of+hepatitis+C+virus+infection&amp;selectedTitle=1˜150 2015 (accessed 2 March 2016). ">Pockros 2015</a>). There are four classes of DAAs, defined by their mechanism of action and therapeutic target: nonstructural proteins 3/4A (NS3/4A), protease inhibitors (PIs), NS5B nucleoside polymerase inhibitors (NPIs), NS5B non‐nucleoside polymerase inhibitors (NNPIs), and NS5A inhibitors (<a href="./references#CD012143-bbs2-0351" title="PoordadF , DieterichD . Treating hepatitis C: current standard of care and emerging direct‐acting antiviral agents. Journal of Viral Hepatitis2012;19(7):449‐64. ">Poordad 2012</a>; <a href="./references#CD012143-bbs2-0349" title="PockrosPJ . Direct‐acting antivirals for the treatment of hepatitis C virus infection. www.uptodate.com/contents/direct‐acting‐antivirals‐for‐the‐treatment‐of‐hepatitis‐c‐virus‐infection?source=search_result&amp;search=Direct‐acting+antivirals+for+the+treatment+of+hepatitis+C+virus+infection&amp;selectedTitle=1˜150 2015 (accessed 2 March 2016). ">Pockros 2015</a>). <a href="#CD012143-tbl-0003">Table 1</a> presents an overview of the different DAAs we have been able to identify. </p> <div class="table" id="CD012143-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">List of direct‐acting antivirals</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b> Direct‐acting antiviral agents (DAAs)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>NS3/NS4A inhibitors</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>NS5B inhibitors</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>NS5A inhibitors</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NPI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NNPI</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACH‐2684</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALS2200/VX135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ABT‐072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACH‐2928</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asunaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BILB1941</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Beclabuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Daclatasvir</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GS0938/PSI352938</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BI201127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elbasvir</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Celuprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GS6620</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dasabuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK2336805</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Danoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GS9851(PSI7851)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Deleobuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ledipasvir</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Faldaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IDX184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Filibuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MK‐8408</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grazoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INX189/BMS986094</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK2878175/GSK175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Odalasvir</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GS9256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mericitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IDX375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ombitasvir</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GS9857</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MK‐3682</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MK‐3281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PPI461</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IDX320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sofosbuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nesbuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ravidasvir</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Narlaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VX‐135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radalbuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Samatasvir</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paritaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Setrobuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Velpatasvir</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PHX1766</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tegobuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Simperevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TMC‐647055</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sovaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VCH‐759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VCH‐916</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vaniprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VX222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vedroprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>The table presents a list of 58 direct‐acting antiviral agents (DAAs). We have listed the DAAs according to the DAA class they belong to (see <a href="#CD012143-sec-0030">Background</a> section). When a DAA has not been assigned a generic or brand name, we have presented it with its experimental compound number prefix. </p> </div> </div> <section id="CD012143-sec-0033"> <h4 class="title">Inhibitors of the NS3/4A protease</h4> <section id="CD012143-sec-0034"> <h5 class="title">DAA first‐generation protease inhibitors</h5> <p>The NS3/NS4A protease inhibitors, telaprevir and boceprevir, were approved for chronic genotype 1 HCV infection in 2011. It was shown that treating with a protease inhibitor combined with peg‐IFNα plus RBV resulted in sustained virological response reaching 68% to 75% in treatment‐naive (i.e. previously untreated) HCV patients and 59% to 88% in treatment‐experienced patients (i.e. previously‐treated HCV patients) (<a href="./references#CD012143-bbs2-0359" title="ScheelTK , RiceCM . Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nature Medicine2013;19(7):837‐49. ">Scheel 2013</a>; <a href="./references#CD012143-bbs2-0355" title="RighiE , LonderoA , CarneluttiA , BaccaraniU , BassettiM . Impact of new treatment options for hepatitis C virus infection in liver transplantation. World Journal of Gastroenterology2015;21(38):10760‐75. ">Righi 2015</a>). Considerable drawbacks to the treatment with telaprevir or boceprevir include a rapid occurrence of viral resistance (<a href="./references#CD012143-bbs2-0292" title="ConteducaV , SansonnoD , RussiS , PavoneF , DammaccoF . Therapy of chronic hepatitis C virus infection in the era of direct‐acting and host‐targeting antiviral agents. Journal of Infection2014;68(1):1‐20. ">Conteduca 2014</a>), a long treatment duration (24 to 48 weeks), and an apparent increase in serious adverse events (<a href="./references#CD012143-bbs2-0359" title="ScheelTK , RiceCM . Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nature Medicine2013;19(7):837‐49. ">Scheel 2013</a>; <a href="./references#CD012143-bbs2-0292" title="ConteducaV , SansonnoD , RussiS , PavoneF , DammaccoF . Therapy of chronic hepatitis C virus infection in the era of direct‐acting and host‐targeting antiviral agents. Journal of Infection2014;68(1):1‐20. ">Conteduca 2014</a>; <a href="./references#CD012143-bbs2-0355" title="RighiE , LonderoA , CarneluttiA , BaccaraniU , BassettiM . Impact of new treatment options for hepatitis C virus infection in liver transplantation. World Journal of Gastroenterology2015;21(38):10760‐75. ">Righi 2015</a>). For these reasons, and due to the development of second‐generation protease inhibitors, telaprevir was removed from the market and boceprevir is no longer a recommended intervention (<a href="./references#CD012143-bbs2-0355" title="RighiE , LonderoA , CarneluttiA , BaccaraniU , BassettiM . Impact of new treatment options for hepatitis C virus infection in liver transplantation. World Journal of Gastroenterology2015;21(38):10760‐75. ">Righi 2015</a>). </p> </section> <section id="CD012143-sec-0035"> <h5 class="title">DAA second‐generation protease inhibitors</h5> <p>The NS3/NS4A protease inhibitors, simeprevir and paritaprevir, are characterised by a theoretically high potency, have a low barrier to development of resistance (selection of resistant viruses), and there is cross‐resistance (drug‐drug interaction) among the different NS3/NS4A protease inhibitors (<a href="./references#CD012143-bbs2-0356" title="RocheB , CoillyA , Roque‐AfonsoAM , SamuelD . Interferon‐free hepatitis C treatment before and after liver transplantation: the role of HCV drug resistance. Viruses2015;7(9):5155‐68. ">Roche 2015</a>). Simeprevir was approved for administration in combination with peg‐IFNα/RBV in 2013 (<a href="./references#CD012143-bbs2-0300" title="ErmisF , Senocak TasciE . New treatment strategies for hepatitis C infection. World Journal of Hepatology2015;7(17):2100‐9. ">Ermis 2015</a>). Simeprevir has been used against HCV genotypes 1, 2, 5, and 6 and it is generally associated with tolerable adverse effects (<a href="./references#CD012143-bbs2-0292" title="ConteducaV , SansonnoD , RussiS , PavoneF , DammaccoF . Therapy of chronic hepatitis C virus infection in the era of direct‐acting and host‐targeting antiviral agents. Journal of Infection2014;68(1):1‐20. ">Conteduca 2014</a>; <a href="./references#CD012143-bbs2-0300" title="ErmisF , Senocak TasciE . New treatment strategies for hepatitis C infection. World Journal of Hepatology2015;7(17):2100‐9. ">Ermis 2015</a>). The recommended treatment period with simeprevir is approximately 24 weeks. Paritaprevir is often administered in combination with low‐dose ritonavir (an antiretroviral protease inhibitor of HIV/AIDS) aiming for a pharmacologic boosting effect (<a href="./references#CD012143-bbs2-0349" title="PockrosPJ . Direct‐acting antivirals for the treatment of hepatitis C virus infection. www.uptodate.com/contents/direct‐acting‐antivirals‐for‐the‐treatment‐of‐hepatitis‐c‐virus‐infection?source=search_result&amp;search=Direct‐acting+antivirals+for+the+treatment+of+hepatitis+C+virus+infection&amp;selectedTitle=1˜150 2015 (accessed 2 March 2016). ">Pockros 2015</a>). Paritaprevir and ritonavir are also available in combination with ombitasvir (an NS5A inhibitor, see below) and are usually administered with the NNPI dasabuvir (see below) (<a href="./references#CD012143-bbs2-0349" title="PockrosPJ . Direct‐acting antivirals for the treatment of hepatitis C virus infection. www.uptodate.com/contents/direct‐acting‐antivirals‐for‐the‐treatment‐of‐hepatitis‐c‐virus‐infection?source=search_result&amp;search=Direct‐acting+antivirals+for+the+treatment+of+hepatitis+C+virus+infection&amp;selectedTitle=1˜150 2015 (accessed 2 March 2016). ">Pockros 2015</a>). </p> </section> </section> <section id="CD012143-sec-0036"> <h4 class="title">DAA NS5B polymerase inhibitors and NS5A inhibitors</h4> <p>The NS5B polymerase inhibitors have been used against several HCV genotypes; they share a high theoretical potency and have high theoretical barrier to resistance due to the active site in NS5B, which is highly conserved across HCV genotypes (<a href="./references#CD012143-bbs2-0292" title="ConteducaV , SansonnoD , RussiS , PavoneF , DammaccoF . Therapy of chronic hepatitis C virus infection in the era of direct‐acting and host‐targeting antiviral agents. Journal of Infection2014;68(1):1‐20. ">Conteduca 2014</a>; <a href="./references#CD012143-bbs2-0300" title="ErmisF , Senocak TasciE . New treatment strategies for hepatitis C infection. World Journal of Hepatology2015;7(17):2100‐9. ">Ermis 2015</a>; <a href="./references#CD012143-bbs2-0355" title="RighiE , LonderoA , CarneluttiA , BaccaraniU , BassettiM . Impact of new treatment options for hepatitis C virus infection in liver transplantation. World Journal of Gastroenterology2015;21(38):10760‐75. ">Righi 2015</a>). The NS5B polymerase inhibitors can be divided into two groups: NPIs and NNPIs. The first NPI approved in 2013 was sofosbuvir and it is apparently well‐tolerated (<a href="./references#CD012143-bbs2-0355" title="RighiE , LonderoA , CarneluttiA , BaccaraniU , BassettiM . Impact of new treatment options for hepatitis C virus infection in liver transplantation. World Journal of Gastroenterology2015;21(38):10760‐75. ">Righi 2015</a>; <a href="./references#CD012143-bbs2-0356" title="RocheB , CoillyA , Roque‐AfonsoAM , SamuelD . Interferon‐free hepatitis C treatment before and after liver transplantation: the role of HCV drug resistance. Viruses2015;7(9):5155‐68. ">Roche 2015</a>). Sofosbuvir is administered once daily for 12 weeks in combination with other drugs for HCV and has a limited cross‐resistance interaction profile compared with previous DAAs (<a href="./references#CD012143-bbs2-0355" title="RighiE , LonderoA , CarneluttiA , BaccaraniU , BassettiM . Impact of new treatment options for hepatitis C virus infection in liver transplantation. World Journal of Gastroenterology2015;21(38):10760‐75. ">Righi 2015</a>; <a href="./references#CD012143-bbs2-0356" title="RocheB , CoillyA , Roque‐AfonsoAM , SamuelD . Interferon‐free hepatitis C treatment before and after liver transplantation: the role of HCV drug resistance. Viruses2015;7(9):5155‐68. ">Roche 2015</a>). NNPIs, for example dasabuvir, interact with areas on the NS5B polymerase that are less critical for viral survival. Thus, the NNPIs have the lowest theoretical barrier to resistance amongst the NS5B polymerase inhibitors (<a href="./references#CD012143-bbs2-0356" title="RocheB , CoillyA , Roque‐AfonsoAM , SamuelD . Interferon‐free hepatitis C treatment before and after liver transplantation: the role of HCV drug resistance. Viruses2015;7(9):5155‐68. ">Roche 2015</a>). </p> <p>Due to the theoretical low resistance barrier, NS5A inhibitors are administered with appropriate combination partners as well as protease inhibitors (<a href="./references#CD012143-bbs2-0292" title="ConteducaV , SansonnoD , RussiS , PavoneF , DammaccoF . Therapy of chronic hepatitis C virus infection in the era of direct‐acting and host‐targeting antiviral agents. Journal of Infection2014;68(1):1‐20. ">Conteduca 2014</a>). Daclatasvir, ledipasvir, and ombitasvir are all NS5A inhibitors, and in 2014 in the European Union (EU) and in 2015 in the USA, daclatasvir was approved for use in combination with other DAAs (<a href="./references#CD012143-bbs2-0355" title="RighiE , LonderoA , CarneluttiA , BaccaraniU , BassettiM . Impact of new treatment options for hepatitis C virus infection in liver transplantation. World Journal of Gastroenterology2015;21(38):10760‐75. ">Righi 2015</a>; <a href="http://www.fda.gov/" target="_blank">www.fda.gov</a>). </p> <p>The high cost and limited availability of DAA treatment remain as critical issues, especially in low‐income countries, despite the lack of documented benefit of DAAs on patient‐centred outcomes. The costs associated with DAA treatment is highly variable, but as an example, the drug cost of a 12‐week course of treatment with sofosbuvir amounts to GBP 34,983 (excluding value‐added tax (VAT)) (<a href="./references#CD012143-bbs2-0348" title="NICE . Sofosbuvir for treating chronic hepatitis C. www.nice.org.uk/guidance/ta330/chapter/2‐The‐technology 2015 (accessed 2 March 2016). ">NICE 2015b</a>), and with the addition of peg‐IFNα plus RBV to the treatment, approximately GBP 40,000 are added to the costs (excluding VAT and monitoring costs) for a 24‐week treatment course (<a href="./references#CD012143-bbs2-0347" title="NICE . Interferon alfa (pegylated and non‐pegylated) and ribavirin for the treatment of chronic hepatitis C. www.nice.org.uk/guidance/ta75NICE.org 2015 (accessed 2 March 2016). ">NICE 2015a</a>). Harvoni (ledipasvir/sofosbuvir) is the second most prescribed drug in the global market accounting for revenue of USD 9 billion <b>(</b><a href="./references#CD012143-bbs2-0301" title="Engeneering &amp; Biotechnology News. FiercePharma, annual Reports, company websites, SEC Filings and press releases2017. ">FiercePharma 2017</a>)<b>.</b> </p> </section> </section> <section id="CD012143-sec-0037"> <h3 class="title" id="CD012143-sec-0037">How the intervention might work</h3> <p>DAAs are molecules that target specific nonstructural HCV‐encoded proteins and hence attempt to disrupt viral replication and infection (<a href="./references#CD012143-bbs2-0349" title="PockrosPJ . Direct‐acting antivirals for the treatment of hepatitis C virus infection. www.uptodate.com/contents/direct‐acting‐antivirals‐for‐the‐treatment‐of‐hepatitis‐c‐virus‐infection?source=search_result&amp;search=Direct‐acting+antivirals+for+the+treatment+of+hepatitis+C+virus+infection&amp;selectedTitle=1˜150 2015 (accessed 2 March 2016). ">Pockros 2015</a>). The effects of DAAs theoretically depend on the HCV genotype and subtype (<a href="./references#CD012143-bbs2-0349" title="PockrosPJ . Direct‐acting antivirals for the treatment of hepatitis C virus infection. www.uptodate.com/contents/direct‐acting‐antivirals‐for‐the‐treatment‐of‐hepatitis‐c‐virus‐infection?source=search_result&amp;search=Direct‐acting+antivirals+for+the+treatment+of+hepatitis+C+virus+infection&amp;selectedTitle=1˜150 2015 (accessed 2 March 2016). ">Pockros 2015</a>). </p> </section> <section id="CD012143-sec-0038"> <h3 class="title" id="CD012143-sec-0038">Why it is important to do this review</h3> <p>Previously published randomised clinical trials assessing the effects of DAAs have primarily focused on assessing sustained virological response as an outcome (aviraemia 24 weeks after antiviral therapy) (<a href="./references#CD012143-bbs2-0126" title="EversonGT , GordonSC , JacobsonI , KauffmanRS , McNairL , MuirA , et al. PROVE 1: subgroup analysis of a phase 2 study of telaprevir with peginterferon alfa‐2a and ribavirin in treatment‐naive subjects with hepatitis C. Hepatology International2009;3:167. MannsM , MuirA , AddaN , JacobsonI , AfdhalN , HeathcoteJ , et al. Telaprevir in hepatitis C genotype‐1‐infected patients with prior non‐response, viral breakthrough or relapse to peginterferonalfa‐2A/B and ribavirin therapy: SVR results of the PROVE3 study. Journal of Hepatology2009;50(Suppl 1):S379. McHutchinsonJG , MannsMP , MuirAJ , TerraultNA , JacobsonIM , AfdhalNH , et al. Telaprevir for previously treated chronic HCV infection. New England Journal of Medicine2010;362(14):1292‐303. McHutchinsonJG , ShiffmanML , TerraultN , MannsMP , DiBiscegliAM , JacobsonIM , et al. Interim results of PROVE 3: a randomized, controlled, phase 2b study of telaprevir (TVR) with peginterferon‐alfa‐2a (P) and/or ribavirin (R) in subjects with hepatitis C genotype 1 who failed to achieve an SVR with a prior course of PR therapy. Hepatology International2009;3(1):25. McHutchisonJG , MannsMP , MuirA , TerraultN , JacobsonIM , AfdhalNH , et al. PROVE3 final results and 1‐year durability of SVR with telaprevir‐based regimen in hepatitis C genotype 1‐infected patients with prior non‐response, viral breakthrough or relapse to peginterferon‐alfa‐2a/b and ribavirin therapy. Hepatology2009;50(4 Suppl):334A‐5A. McHutchisonJG , ShiffmanML , TerraultN , MannsMP , DiBisceglieAM , JacobsonIM , et al. A phase 2b study of telaprevir with peginterferon‐alfa‐2a and ribavirin in hepatitis C genotype 1 null and partial responders and relapsers following a prior course of peginterferon‐alfa‐2a/b and ribavirin therapy: PROVE3 interim results. Hepatology2008;48(4 Suppl):269A‐70A. ">McHutchison 2010</a>; <a href="./references#CD012143-bbs2-0279" title="BaconBR , GordonSC , LawitzE , MarcellinP , VierlingJM , ZeuzemS , et al. Boceprevir for previously treated chronic HCV genotype 1 infection. New England Journal of Medicine2011;364(13):1207‐17. ">Bacon 2011</a>; <a href="./references#CD012143-bbs2-0327" title="JacobsonIM , McHutchisonJG , DusheikoG , DiBisceglieAM , ReddyKR , BzowejNH , et al. Telaprevir for previously untreated chronic hepatitis C virus infection. New England Journal of Medicine2011;364(25):2405‐16. ">Jacobson 2011</a>; <a href="./references#CD012143-bbs2-0350" title="PoordadF , McConeJJr , BaconBR , BrunoS , MannsMP , SulkowskiMS , et al. SPRINT‐2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. New England Journal of Medicine2011;364(13):1195‐206. ">Poordad 2011</a>; <a href="./references#CD012143-bbs2-0338" title="LawitzE , MangiaA , WylesD , Rodriguez‐TorresM , HassaneinT , GordonSC , et al. Sofosbuvir for previously untreated chronic hepatitis C infection. New England Journal of Medicine2013;368(20):1878‐87. ">Lawitz 2013</a>; <a href="./references#CD012143-bbs2-0278" title="AfdhalN , ZeuzemS , KwoP , ChojkierM , GitlinN , PuotiM , et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. New England Journal of Medicine2014;370(20):1889‐98. ">Afdhal 2014</a>; <a href="./references#CD012143-bbs2-0377" title="WylesDL , RuanePJ , SulkowskiMS , DieterichD , LuetkemeyerA , MorganTR , et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV‐1. New England Journal of Medicine2015;373(8):714‐25. ">Wyles 2015</a>). As examples, treatment with sofosbuvir has shown the proportion of participants with sustained virological response above 85% when combined with peg‐IFNα plus RBV or RBV alone (<a href="./references#CD012143-bbs2-0355" title="RighiE , LonderoA , CarneluttiA , BaccaraniU , BassettiM . Impact of new treatment options for hepatitis C virus infection in liver transplantation. World Journal of Gastroenterology2015;21(38):10760‐75. ">Righi 2015</a>); a study assessing the use of daclatasvir in combination with peg‐IFNα plus RBV in treatment‐naive genotype 1 patients has shown sustained virological responses in 90% of the HCV patients (<a href="./references#CD012143-bbs2-0300" title="ErmisF , Senocak TasciE . New treatment strategies for hepatitis C infection. World Journal of Hepatology2015;7(17):2100‐9. ">Ermis 2015</a>); and ledipasvir in combination with sofosbuvir has, in a randomised clinical trial, shown sustained virological responses between 93% and 99% of the HCV patients (<a href="./references#CD012143-bbs2-0355" title="RighiE , LonderoA , CarneluttiA , BaccaraniU , BassettiM . Impact of new treatment options for hepatitis C virus infection in liver transplantation. World Journal of Gastroenterology2015;21(38):10760‐75. ">Righi 2015</a>). Many other trials have similarly shown that DAAs seem to increase the proportion of participants with sustained virological response (<a href="./references#CD012143-bbs2-0126" title="EversonGT , GordonSC , JacobsonI , KauffmanRS , McNairL , MuirA , et al. PROVE 1: subgroup analysis of a phase 2 study of telaprevir with peginterferon alfa‐2a and ribavirin in treatment‐naive subjects with hepatitis C. Hepatology International2009;3:167. MannsM , MuirA , AddaN , JacobsonI , AfdhalN , HeathcoteJ , et al. Telaprevir in hepatitis C genotype‐1‐infected patients with prior non‐response, viral breakthrough or relapse to peginterferonalfa‐2A/B and ribavirin therapy: SVR results of the PROVE3 study. Journal of Hepatology2009;50(Suppl 1):S379. McHutchinsonJG , MannsMP , MuirAJ , TerraultNA , JacobsonIM , AfdhalNH , et al. Telaprevir for previously treated chronic HCV infection. New England Journal of Medicine2010;362(14):1292‐303. McHutchinsonJG , ShiffmanML , TerraultN , MannsMP , DiBiscegliAM , JacobsonIM , et al. Interim results of PROVE 3: a randomized, controlled, phase 2b study of telaprevir (TVR) with peginterferon‐alfa‐2a (P) and/or ribavirin (R) in subjects with hepatitis C genotype 1 who failed to achieve an SVR with a prior course of PR therapy. Hepatology International2009;3(1):25. McHutchisonJG , MannsMP , MuirA , TerraultN , JacobsonIM , AfdhalNH , et al. PROVE3 final results and 1‐year durability of SVR with telaprevir‐based regimen in hepatitis C genotype 1‐infected patients with prior non‐response, viral breakthrough or relapse to peginterferon‐alfa‐2a/b and ribavirin therapy. Hepatology2009;50(4 Suppl):334A‐5A. McHutchisonJG , ShiffmanML , TerraultN , MannsMP , DiBisceglieAM , JacobsonIM , et al. A phase 2b study of telaprevir with peginterferon‐alfa‐2a and ribavirin in hepatitis C genotype 1 null and partial responders and relapsers following a prior course of peginterferon‐alfa‐2a/b and ribavirin therapy: PROVE3 interim results. Hepatology2008;48(4 Suppl):269A‐70A. ">McHutchison 2010</a>; <a href="./references#CD012143-bbs2-0279" title="BaconBR , GordonSC , LawitzE , MarcellinP , VierlingJM , ZeuzemS , et al. Boceprevir for previously treated chronic HCV genotype 1 infection. New England Journal of Medicine2011;364(13):1207‐17. ">Bacon 2011</a>; <a href="./references#CD012143-bbs2-0327" title="JacobsonIM , McHutchisonJG , DusheikoG , DiBisceglieAM , ReddyKR , BzowejNH , et al. Telaprevir for previously untreated chronic hepatitis C virus infection. New England Journal of Medicine2011;364(25):2405‐16. ">Jacobson 2011</a>; <a href="./references#CD012143-bbs2-0350" title="PoordadF , McConeJJr , BaconBR , BrunoS , MannsMP , SulkowskiMS , et al. SPRINT‐2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. New England Journal of Medicine2011;364(13):1195‐206. ">Poordad 2011</a>; <a href="./references#CD012143-bbs2-0338" title="LawitzE , MangiaA , WylesD , Rodriguez‐TorresM , HassaneinT , GordonSC , et al. Sofosbuvir for previously untreated chronic hepatitis C infection. New England Journal of Medicine2013;368(20):1878‐87. ">Lawitz 2013</a>; <a href="./references#CD012143-bbs2-0278" title="AfdhalN , ZeuzemS , KwoP , ChojkierM , GitlinN , PuotiM , et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. New England Journal of Medicine2014;370(20):1889‐98. ">Afdhal 2014</a>; <a href="./references#CD012143-bbs2-0377" title="WylesDL , RuanePJ , SulkowskiMS , DieterichD , LuetkemeyerA , MorganTR , et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV‐1. New England Journal of Medicine2015;373(8):714‐25. ">Wyles 2015)</a>. Observational studies have noted associations between SVRs and increased survival and fewer liver‐related complications. Such associations have been attributed to stabilisation, or even reversal, of fibrosis and attributed to the removal of the hepatitis C virus (<a href="./references#CD012143-bbs2-0296" title="European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C. Journal of Hepatology2015;63(1):199‐236. ">EASL 2015</a>). However, association cannot establish causation. As we have described in <a href="#CD012143-sec-0031">Description of the condition</a>, a relationship between the SVR and a favourable clinical outcome has not been confirmed from randomised evidence. The clinical effects of DAAs are unclear and have been questioned (<a href="./references#CD012143-bbs2-0335" title="KoretzRL , LinKW , IoannidisJP , LenzerJ . Is widespread screening for hepatitis C justified?. BMJ (Clinical Research Ed.)2015;350:g7809. ">Koretz 2015</a>). No systematic review, taking into account the risks of systematic, design, or random errors, has previously been conducted (<a href="./references#CD012143-bbs2-0373" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial Sequential Analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. ">Wetterslev 2008</a>; <a href="./references#CD012143-bbs2-0374" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology2009;9:86. ">Wetterslev 2009</a>; <a href="./references#CD012143-bbs2-0323" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.Cochrane.org. ">Higgins 2011a</a>; <a href="./references#CD012143-bbs2-0328" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14(1):120. ">Jakobsen 2014a</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012143-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012143-sec-0039"></div> <p>To assess the benefits and harms of DAAs in people with chronic HCV.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012143-sec-0040" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012143-sec-0040"></div> <section id="CD012143-sec-0041"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012143-sec-0042"> <h4 class="title">Types of studies</h4> <p>Randomised clinical trials irrespective of publication type, publication status, and language. If, during the selection of trials, we identified any observational studies (i.e. case series; cohort studies, or quasi‐randomised studies) reporting validly on adverse events of DAAs, we planned to consider these data separately, but we did not specifically search for observational studies for inclusion in this review. </p> </section> <section id="CD012143-sec-0043"> <h4 class="title">Types of participants</h4> <p>Adults diagnosed with chronic HCV (as defined by trialists), regardless of sex, ethnicity, occupation, country of residence, and duration of infection. Both treatment‐naive and treatment‐experienced participants were included. </p> <p>Trial participants could</p> <p> <ol id="CD012143-list-0001"> <li> <p>have been treatment‐naive or treatment‐experienced or both;</p> </li> <li> <p>have had any comorbidity to HCV, such as HIV, hepatitis B, alcoholism, and with any other specific comorbid diagnosis; and </p> </li> <li> <p>have been pregnant women with chronic HCV and adults with chronic HCV who use and inject drugs. </p> </li> </ol> </p> </section> <section id="CD012143-sec-0044"> <h4 class="title">Types of interventions</h4> <p>Any of the four classes of DAA drugs (<a href="#CD012143-sec-0032">Description of the intervention;</a><a href="#CD012143-tbl-0003">Table 1</a>). </p> <section id="CD012143-sec-0045"> <h5 class="title">Experimental intervention</h5> <p>Any of the four classes of DAA drugs administered singly, combined with another DAA, or combined with other medical co‐interventions (<a href="#CD012143-sec-0032">Description of the intervention;</a><a href="#CD012143-tbl-0003">Table 1</a>). </p> </section> <section id="CD012143-sec-0046"> <h5 class="title">Control intervention</h5> <p> <ol id="CD012143-list-0002"> <li> <p>No intervention or placebo.</p> </li> <li> <p>Any medical intervention (except for DAAs) or any combination of medical interventions.</p> </li> </ol> </p> </section> </section> <section id="CD012143-sec-0047"> <h4 class="title">Types of outcome measures</h4> <section id="CD012143-sec-0048"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD012143-list-0003"> <li> <p>Hepatitis C‐related morbidity (diagnosed after randomisation) or all‐cause mortality. Hepatitis C‐related morbidity was defined as the proportion of participants with either: cirrhosis, ascites, variceal bleeding, hepato‐renal syndrome, hepatic encephalopathy, or hepatocellular carcinoma. </p> </li> <li> <p>Proportion of participants with one or more serious adverse events. We defined a serious adverse event as any untoward medical occurrence that resulted in death, was life‐threatening, required hospitalisation or prolongation of existing hospitalisation, or resulted in persistent or significant disability or incapacity (<a href="./references#CD012143-bbs2-0326" title="International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR &amp; ICH Guidelines. Vol. 1, Philadelphia (PA): Barnett International/PAREXEL, 1997. ">ICH‐GCP 1997</a>). </p> </li> <li> <p>Health‐related quality of life (any valid continuous outcome scale used by the trialists).</p> </li> </ol> </p> </section> <section id="CD012143-sec-0049"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD012143-list-0004"> <li> <p>All‐cause mortality.</p> </li> <li> <p>Proportion of participants with ascites (as defined by trialists).</p> </li> <li> <p>Proportion of participants with variceal bleeding (as defined by trialists).</p> </li> <li> <p>Proportion of participants with hepato‐renal syndrome (as defined by trialists).</p> </li> <li> <p>Proportion of participants with hepatocellular carcinoma (as defined by trialists).</p> </li> <li> <p>Proportion of participants with hepatic encephalopathy (as defined by trialists).</p> </li> <li> <p>Proportion of participants with non‐serious adverse events (any other adverse event not included in the definition of serious adverse events (see <a href="#CD012143-sec-0048">Primary outcomes</a>)). We planned to assess each non‐serious adverse event separately. </p> </li> <li> <p>Proportion of participants without sustained virological response (as defined by trialists). Usually, this is the number of participants with detectable HCV RNA (i.e. above a lower limit of detection) in the serum by a sensitive polymerase chain reaction (PCR)‐based assay or by a transcription‐mediated amplification testing, 12 or 24 weeks after the end of treatment. </p> </li> </ol> </p> <section id="CD012143-sec-0050"> <h6 class="title">Exploratory outcomes</h6> <p> <ol id="CD012143-list-0005"> <li> <p>Proportion of participants with liver transplantation after randomisation.</p> </li> <li> <p>Proportion of participants without histological improvement (as defined by trialists).</p> </li> <li> <p>Proportion of participants without significant reductions in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) serum levels (as defined by trialists). </p> </li> </ol> </p> <p>We only assessed all outcomes at 'maximum follow‐up'. We planned to use sensitivity analysis to assess how the different follow‐up periods affected our results if we had found that the time from randomisation to maximum follow‐ up differed significantly between the included trials. </p> </section> </section> </section> </section> <section id="CD012143-sec-0051"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012143-sec-0052"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Hepato‐Biliary Controlled Trials Register (<a href="./references#CD012143-bbs2-0306" title="GluudC , NikolovaD , KlingenbergSL . Cochrane Hepato‐Biliary Group. About Cochrane (Cochrane Review Groups (CRGs)) 2016, Issue 2. Art. No.: LIVER Vol. http://hbg.cochrane.org. ">Gluud 2015</a>), Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, MEDLINE (OvidSP), Embase (OvidSP), Science Citation Expanded (Web of Science), LILACS (Bireme), and BIOSIS (Web of Science) in order to identify relevant trials. We also searched the Chinese Biomedical Literature Database (CBM), China Network Knowledge Information (CNKI), the Chinese Science Journal Database (VIP), and the Wanfang Database. Search strategies, including the time spans of the searches, are provided in <a href="./appendices#CD012143-sec-0154">Appendix 1</a>. Searches were last run in October 2016. </p> </section> <section id="CD012143-sec-0053"> <h4 class="title">Searching other resources</h4> <p>We searched the bibliographic references of identified randomised clinical trials and review articles in order to find randomised clinical trials not identified by the electronic searches and handsearches. We contacted the principal authors of the identified randomised clinical trials to inquire about additional randomised clinical trials that they might know. </p> <p>We also searched Google Scholar, The Turning Research into Practice (TRIP) Database, and on‐line trials registries such as <a href="https://www.clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a>, European Medicines Agency (EMA) (<a href="http://www.ema.europa.eu/ema/" target="_blank">www.ema.europa.eu/ema/</a>), WHO International Clinical Trial Registry Platform (<a href="http://www.who.int/ictrp" target="_blank">www.who.int/ictrp</a>), the Food and Drug Administration (FDA) (<a href="http://www.fda.gov/" target="_blank">www.fda.gov</a>), as well as pharmaceutical company sources for ongoing or unpublished trials. </p> <p>Additionally, we handsearched Hepatology, New England Journal of Medicine, JAMA, BMJ, PLoS Medicine, and Annals of Internal Medicine for relevant trials. </p> <p>We also searched for unpublished and grey literature trials.</p> </section> </section> <section id="CD012143-sec-0054"> <h3 class="title" id="CD012143-sec-0054">Data collection and analysis</h3> <p>We performed the review following the recommendations of Cochrane (<a href="./references#CD012143-bbs2-0323" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.Cochrane.org. ">Higgins 2011a</a>) and the Cochrane Hepato‐Biliary Module (<a href="./references#CD012143-bbs2-0306" title="GluudC , NikolovaD , KlingenbergSL . Cochrane Hepato‐Biliary Group. About Cochrane (Cochrane Review Groups (CRGs)) 2016, Issue 2. Art. No.: LIVER Vol. http://hbg.cochrane.org. ">Gluud 2015</a>). We performed the analyses using Review Manager 5 (<a href="./references#CD012143-bbs2-0354" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>), STATA 14 (<a href="http://www.stata.com/" target="_blank">www.stata.com</a>), and Trial Sequential Analysis (<a href="./references#CD012143-bbs2-0369" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 2 March 2016). ">Thorlund 2011</a>; <a href="./references#CD012143-bbs2-0370" title="Copenhagen Trial Unit. TSA ‐ Trial Sequential Analysis. Version 0.9 Beta. Copenhagen: Copenhagen Trial Unit, 2011. ">TSA 2011</a>). </p> <section id="CD012143-sec-0055"> <h4 class="title">Selection of studies</h4> <p>Fourteen review authors (EN, JF, KF, KK, GH, GP, SD, KW, MB, GB, SK, JP, DN, RK) independently and in pairs assessed all identified articles. If a trial was identified as relevant by one author, but not by another, the authors discussed the reasoning behind their decision. If they still disagreed, JCJ served as arbitrator. </p> </section> <section id="CD012143-sec-0056"> <h4 class="title">Data extraction and management</h4> <p>Twelve review authors (EN, JF, KF, KK, GH, GP, SD, KW, MB, GB, SK, DN) independently and in pairs extracted and validated data. We used data extraction forms that were designed for the purpose. The twelve authors discussed any disagreement concerning the extracted data. If the authors still disagreed, JCJ served as arbitrator. In case of relevant data not being available, we contacted the trial authors. </p> </section> <section id="CD012143-sec-0057"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The review authors, working in pairs, independently assessed the risk of bias of each included trial according to the recommendations in the<i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012143-bbs2-0324" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>) and the Cochrane Hepato‐Biliary Module (<a href="./references#CD012143-bbs2-0306" title="GluudC , NikolovaD , KlingenbergSL . Cochrane Hepato‐Biliary Group. About Cochrane (Cochrane Review Groups (CRGs)) 2016, Issue 2. Art. No.: LIVER Vol. http://hbg.cochrane.org. ">Gluud 2015</a>). We used the following definitions in the assessment of risk of bias (<a href="./references#CD012143-bbs2-0361" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Journal of the American Medical Association1995;273(5):408‐12. ">Schulz 1995</a>; <a href="./references#CD012143-bbs2-0343" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet1998;352(9128):609‐13. ">Moher 1998</a>; <a href="./references#CD012143-bbs2-0333" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine2001;135(11):982‐9. ">Kjaergard 2001</a>; <a href="./references#CD012143-bbs2-0376" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ (Clinical Research Ed.)2008;366:601‐5. ">Wood 2008</a>; <a href="./references#CD012143-bbs2-0323" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.Cochrane.org. ">Higgins 2011a</a>; <a href="./references#CD012143-bbs2-0339" title="LundhA , SismondoS , LexchinJ , BusuiocOA , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2] ">Lundh 2012</a>; <a href="./references#CD012143-bbs2-0357" title="SavovićJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429‐38. ">Savović 2012a</a>; <a href="./references#CD012143-bbs2-0358" title="SavovićJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment2012;16(35):1‐82. ">Savović 2012b</a>): </p> <section id="CD012143-sec-0058"> <h5 class="title">Allocation sequence generation</h5> <p> <ol id="CD012143-list-0006"> <li> <p>Low risk of bias: sequence generation was achieved using computer random‐number generation or a random‐number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice were adequate if performed by an independent person not otherwise involved in the trial. </p> </li> <li> <p>Unclear risk of bias: the method of sequence generation was not specified.</p> </li> <li> <p>High risk of bias: the sequence generation method was not random or only quasi‐randomised.</p> </li> </ol> </p> </section> <section id="CD012143-sec-0059"> <h5 class="title">Allocation concealment</h5> <p> <ol id="CD012143-list-0007"> <li> <p>Low risk of bias: the allocation sequence was described as unknown to the investigators. Hence, the participants' allocations could not have been foreseen in advance of, or during, enrolment. Allocation was controlled by a central and independent randomisation unit, an on‐site locked computer, identical looking numbered sealed opaque envelopes, drug bottles or containers prepared by an independent pharmacist, or an independent investigator. </p> </li> <li> <p>Unclear risk of bias: it was unclear if the allocation was hidden or if the block size was relatively small and fixed so that intervention allocations may have been foreseen in advance of, or during, enrolment. </p> </li> <li> <p>High risk of bias: the allocation sequence was likely to be known to the investigators who assigned the participants. </p> </li> </ol> </p> </section> <section id="CD012143-sec-0060"> <h5 class="title">Blinding of participants and treatment providers</h5> <p> <ol id="CD012143-list-0008"> <li> <p>Low risk of bias: it was described that both participants and treatment providers were blinded to treatment allocation. </p> </li> <li> <p>Unclear risk of bias: it was unclear whether participants and treatment providers were blinded, or the extent of blinding was insufficiently described. </p> </li> <li> <p>High risk of bias: no blinding or incomplete blinding of participants and treatment providers was performed. </p> </li> </ol> </p> </section> <section id="CD012143-sec-0061"> <h5 class="title">Blinding of outcome assessment</h5> <p> <ol id="CD012143-list-0009"> <li> <p>Low risk of bias: it was mentioned that outcome assessors were blinded and this was described. </p> </li> <li> <p>Unclear risk of bias: it was not mentioned whether the outcome assessors were blinded, or the extent of blinding was insufficiently described. </p> </li> <li> <p>High risk of bias: no blinding or incomplete blinding of outcome assessors was performed.</p> </li> </ol> </p> </section> <section id="CD012143-sec-0062"> <h5 class="title">Incomplete outcome data</h5> <p> <ol id="CD012143-list-0010"> <li> <p>Low risk of bias: missing data were unlikely to make intervention effects depart from plausible values. This could either be: 1. there were no drop‐outs or withdrawals; or 2. the numbers and reasons for the withdrawals and drop‐outs for all outcomes were clearly stated and could be described as being similar in both groups, and the trial handled missing data appropriately in an intention‐to‐treat analysis using proper methods (e.g. multiple imputations). Generally, the trial was judged to be at a low risk of bias due to incomplete outcome data if drop‐outs were less than 5%. However, the 5% cut‐off was not definitive. </p> </li> <li> <p>Unclear risk of bias: there was insufficient information to assess whether missing data were likely to induce bias on the results. </p> </li> <li> <p>High risk of bias: the results were likely to be biased due to missing data either because the pattern of drop‐outs could be described as being different in the two intervention groups or the trial used improper methods in dealing with the missing data (e.g. last observation carried forward). </p> </li> </ol> </p> </section> <section id="CD012143-sec-0063"> <h5 class="title">Selective outcome reporting</h5> <p> <ol id="CD012143-list-0011"> <li> <p>Low risk of bias: a protocol was published before randomisation began and all outcome results were reported adequately. </p> </li> <li> <p>Unclear risk of bias: no protocol was published.</p> </li> <li> <p>High risk of bias: the outcomes in the protocol were not reported on.</p> </li> </ol> </p> </section> <section id="CD012143-sec-0064"> <h5 class="title">Vested‐interest bias</h5> <p> <ol id="CD012143-list-0012"> <li> <p>Low risk of bias: it was described that the trial was not sponsored by any pharmaceutical company, any person, or any group with a financial or other interest in a certain result of the trial. </p> </li> <li> <p>Unclear risk of bias: it was unclear how the trial was sponsored.</p> </li> <li> <p>High risk of bias: the trial was sponsored by a pharmaceutical company, a person, or a group with a certain financial or other interest in a given result of the trial. </p> </li> </ol> </p> </section> <section id="CD012143-sec-0065"> <h5 class="title">Other bias</h5> <p> <ol id="CD012143-list-0013"> <li> <p>Low risk of bias: the trial appeared to be free of other bias domains that could put it at risk of bias. </p> </li> <li> <p>Unclear risk of bias: the trial may or may not have been free of other domains that could put it at risk of bias. </p> </li> <li> <p>High risk of bias: there were other factors in the trial that could put it at risk of bias. </p> </li> </ol> </p> </section> <section id="CD012143-sec-0066"> <h5 class="title">Overall risk of bias</h5> <p>We judged trials to be at an 'overall low risk of bias' if they were assessed as 'low risk of bias' in all the above domains. We judged trials to be at an 'overall high risk of bias' if they were assessed as having unclear risk of bias or high risk of bias in one or more of the above domains. </p> <p>We assessed the domains 'Blinding of outcome assessment', 'Incomplete outcome data', and 'Selective outcome reporting' for each outcome result. Thus, we assessed the bias risk for each outcome result in addition to the overall bias risk for each trial. </p> </section> </section> <section id="CD012143-sec-0067"> <h4 class="title">Measures of treatment effect</h4> <section id="CD012143-sec-0068"> <h5 class="title">Dichotomous outcomes</h5> <p>We planned to present risk ratios (RR) with 95% confidence intervals (CI) for dichotomous outcomes. However, since we found several trials with zero events, we handled this according to <a href="./references#CD012143-bbs2-0366" title="SweetingMJ , SuttonAJ , LambertPC . What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data. Statistics in Medicine2004;23(9):1351‐75. ">Sweeting 2004</a>, and used odds ratios (OR) instead. </p> </section> <section id="CD012143-sec-0069"> <h5 class="title">Continuous outcomes</h5> <p>We included both follow‐up scores and change scores in the analyses. We used follow‐up scores in the analyses in the case when both were reported. We presented the mean differences (MD) and the standardised mean differences (SMD) with 95% CI for continuous outcomes. </p> </section> </section> <section id="CD012143-sec-0070"> <h4 class="title">Unit of analysis issues</h4> <p>For cross‐over trials, we only included participants from the first treatment period in the trial. We avoided counting data more than once from participants in control arms of trials with multiple experimental intervention arms by dividing the sample size and number of participants experiencing the event by the number of eligible treatment arms used.. There were no other unit of analysis issues. </p> </section> <section id="CD012143-sec-0071"> <h4 class="title">Dealing with missing data</h4> <section id="CD012143-sec-0072"> <h5 class="title">Dichotomous outcomes</h5> <p>If the trialists used proper methodology (e.g. multiple imputation) to deal with missing data, we used these data in our primary analysis. We did not impute missing values for any outcomes in our primary analysis. In two of our sensitivity analyses (see below), we imputed missing data (<a href="./references#CD012143-bbs2-0328" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14(1):120. ">Jakobsen 2014a</a>). </p> </section> <section id="CD012143-sec-0073"> <h5 class="title">Continuous outcomes</h5> <p>If trialists used proper methodology (e.g. multiple imputation) to deal with missing data, we used these data in our primary analysis (<a href="./references#CD012143-bbs2-0328" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14(1):120. ">Jakobsen 2014a</a>). We primarily used follow‐up scores. If only change‐from‐baseline values were reported, we analysed change scores together with follow‐up scores (<a href="./references#CD012143-bbs2-0325" title="HigginsJPT , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011c</a>). If standard deviations (SDs) were not reported, we calculated these using data from the trial if possible. We did not impute missing values for any outcomes in our primary analysis (<a href="./references#CD012143-bbs2-0328" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14(1):120. ">Jakobsen 2014a</a>). </p> </section> <section id="CD012143-sec-0074"> <h5 class="title">Sensitivity analyses</h5> <p>To assess the potential impact of the missing data for dichotomous outcomes, we performed the two following sensitivity analyses (<a href="./references#CD012143-bbs2-0328" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14(1):120. ">Jakobsen 2014a</a>). </p> <p> <ol id="CD012143-list-0014"> <li> <p>'Best‐worst‐case' scenario: we assumed that all participants lost to follow‐up in the experimental group had survived, had no serious adverse event, and had no morbidity (for all dichotomous outcomes); and all those participants with missing outcomes in the control group had not survived, had a serious adverse event, and had morbidity (for all dichotomous outcomes). </p> </li> <li> <p>'Worst‐best‐case' scenario: we assumed that all participants lost to follow‐up in the experimental group had not survived, had a serious adverse event, and had morbidity (for all dichotomous outcomes); and that all those participants lost to follow‐up in the control group had survived, had no serious adverse event, and had no morbidity (for all dichotomous outcomes). </p> </li> </ol> </p> </section> </section> <section id="CD012143-sec-0075"> <h4 class="title">Assessment of heterogeneity</h4> <p>We primarily inspected forest plots visually in order to assess if there were signs of statistical heterogeneity (<a href="./references#CD012143-bbs2-0328" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14(1):120. ">Jakobsen 2014a</a>). We also assessed the presence of statistical heterogeneity using the Chi² test with significance set at P value &lt; 0.10 and measured the quantities of heterogeneity using the I² statistic (<a href="./references#CD012143-bbs2-0322" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>; <a href="./references#CD012143-bbs2-0294" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). </p> </section> <section id="CD012143-sec-0076"> <h4 class="title">Assessment of reporting biases</h4> <p>We primarily inspected funnel plots visually in order to assess if there were signs of reporting bias if 10 or more trials were included (<a href="./references#CD012143-bbs2-0328" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14(1):120. ">Jakobsen 2014a</a>). Using the asymmetry of the funnel plot, we assessed the risk of bias. For dichotomous outcomes we also assessed if there were signs of asymmetry with the Harbord test if τ<sup>2</sup> was less than 0.1 and with the Rücker test if τ<sup>2</sup> was more than 0.1 (<a href="./references#CD012143-bbs2-0320" title="HarbordRM , EggerM , SterneJA . A modified test for small‐study effects in meta‐analyses of controlled trials with binary endpoints. Statistics in Medicine2006;25(20):3443‐57. ">Harbord 2006</a>; <a href="./references#CD012143-bbs2-0365" title="SterneJAC , EggerM , MoherD (editors) . Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Sterne 2011</a>). For continuous outcomes we used the regression asymmetry test (<a href="./references#CD012143-bbs2-0297" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple graphical test. BMJ (Clinical Research Ed.)1997;315(7109):629‐34. ">Egger 1997</a>). </p> </section> <section id="CD012143-sec-0077"> <h4 class="title">Data synthesis</h4> <p>We based our primary conclusions on the results of the primary outcomes with low risk of bias. Our primary analyses were based on trials assessing the effects of DAAs on the market and trials using similar medical co‐interventions in both the experimental and control group. </p> <section id="CD012143-sec-0078"> <h5 class="title">Meta‐analysis</h5> <p>We undertook this meta‐analysis according to the recommendations stated in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012143-bbs2-0294" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). We used the statistical software Review Manager 5 provided by Cochrane to analyse data (<a href="./references#CD012143-bbs2-0354" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). When we observed unbalanced data, a large number of zero events, and rare incidences of events in the control group, we excluded trial results with zero events in both groups (<a href="./references#CD012143-bbs2-0294" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). We then used reciprocal zero cell correction and fixed meta‐analysis in STATA 14 (<a href="http://www.stata.com/" target="_blank">www.stata.com</a>) and the following subgroup analyses were based on the inverse variance method (<a href="./references#CD012143-bbs2-0366" title="SweetingMJ , SuttonAJ , LambertPC . What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data. Statistics in Medicine2004;23(9):1351‐75. ">Sweeting 2004</a>; <a href="./references#CD012143-bbs2-0294" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). </p> </section> <section id="CD012143-sec-0079"> <h5 class="title">Assessment of significance</h5> <p>We assessed our intervention effects with both random‐effects meta‐analysis and fixed‐effect meta‐analysis (<a href="./references#CD012143-bbs2-0328" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14(1):120. ">Jakobsen 2014a</a>). We used the more conservative point estimate of the two (<a href="./references#CD012143-bbs2-0328" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14(1):120. ">Jakobsen 2014a</a>). The more conservative point estimate was the estimate closest to zero effect. If the two estimates were equal, we used the estimate with the widest CI. Our analyses showed that multiple trials had zero and rare events. In these cases we used fixed‐effect meta‐analysis (<a href="./references#CD012143-bbs2-0366" title="SweetingMJ , SuttonAJ , LambertPC . What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data. Statistics in Medicine2004;23(9):1351‐75. ">Sweeting 2004</a>). We assessed three primary outcomes; therefore, we considered a P value of 0.025 or less as statistically significant on the primary outcomes (<a href="./references#CD012143-bbs2-0328" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14(1):120. ">Jakobsen 2014a</a>; <a href="./references#CD012143-bbs2-0329" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . The thresholds for statistical and clinical significance ‐ a five‐step procedure for evaluation of intervention effects in randomised clinical trials. BMC Medical Research Methodology2014;14:34. ">Jakobsen 2014b</a>; <a href="./references#CD012143-bbs2-0330" title="JakobsenJC , WetterslevJ , LangeT , GluudC . Viewpoint: taking into account risks of random errors when analysing multiple outcomes in systematic reviews [editorial]. Cochrane Database of Systematic Reviews2016, issue 3:10.1002/14651858.ED000111. [DOI: 10.1002/14651858.ED000111] ">Jakobsen 2016a</a>). We assessed eight secondary outcomes; therefore, we considered a P value of 0.011 or less as statistically significant on the secondary outcomes (<a href="./references#CD012143-bbs2-0328" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14(1):120. ">Jakobsen 2014a</a>; <a href="./references#CD012143-bbs2-0329" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . The thresholds for statistical and clinical significance ‐ a five‐step procedure for evaluation of intervention effects in randomised clinical trials. BMC Medical Research Methodology2014;14:34. ">Jakobsen 2014b</a>; <a href="./references#CD012143-bbs2-0330" title="JakobsenJC , WetterslevJ , LangeT , GluudC . Viewpoint: taking into account risks of random errors when analysing multiple outcomes in systematic reviews [editorial]. Cochrane Database of Systematic Reviews2016, issue 3:10.1002/14651858.ED000111. [DOI: 10.1002/14651858.ED000111] ">Jakobsen 2016a</a>). We used an eight‐step procedure to assess if the thresholds for statistical significance and clinical significance were crossed (<a href="./references#CD012143-bbs2-0328" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14(1):120. ">Jakobsen 2014a</a>). </p> </section> <section id="CD012143-sec-0080"> <h5 class="title">Trial Sequential Analysis</h5> <p>Traditional meta‐analysis runs the risk of random errors due to sparse data and repetitive testing of accumulating data when updating reviews. Therefore, we performed Trial Sequential Analysis (<a href="./references#CD012143-bbs2-0373" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial Sequential Analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. ">Wetterslev 2008</a>; <a href="./references#CD012143-bbs2-0374" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology2009;9:86. ">Wetterslev 2009</a>; <a href="./references#CD012143-bbs2-0284" title="BrokJ , GluudLL , GluudC . Ribavirin plus interferon versus interferon for chronic hepatitis C. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD005445.pub2] ">Brok 2010</a>; <a href="./references#CD012143-bbs2-0328" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14(1):120. ">Jakobsen 2014a</a>) on the outcomes in order to calculate the required information size and assessed the eventual breach of the cumulative Z‐curve of the relevant trial sequential monitoring boundaries for benefit, harm, or futility (<a href="./references#CD012143-bbs2-0373" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial Sequential Analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. ">Wetterslev 2008</a>; <a href="./references#CD012143-bbs2-0374" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology2009;9:86. ">Wetterslev 2009</a>; <a href="./references#CD012143-bbs2-0284" title="BrokJ , GluudLL , GluudC . Ribavirin plus interferon versus interferon for chronic hepatitis C. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD005445.pub2] ">Brok 2010</a>; <a href="./references#CD012143-bbs2-0328" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14(1):120. ">Jakobsen 2014a</a>). Thereby, we wished to control the risks of type I errors and type II errors. A more detailed description of Trial Sequential Analysis can be found at <a href="http://www.ctu.dk/tsa" target="_blank">www.ctu.dk/tsa</a> (<a href="./references#CD012143-bbs2-0369" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 2 March 2016). ">Thorlund 2011</a>; <a href="./references#CD012143-bbs2-0370" title="Copenhagen Trial Unit. TSA ‐ Trial Sequential Analysis. Version 0.9 Beta. Copenhagen: Copenhagen Trial Unit, 2011. ">TSA 2011</a>). </p> <p>For dichotomous outcomes, we estimated the required information size based on the proportion of participants with an outcome in the control group, a relative risk reduction of 20%, an alpha of 2.5% and 1.1% depending on primary or secondary outcome, a beta of 20%, and the observed diversity in the trials in the meta‐analysis (<a href="./references#CD012143-bbs2-0328" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14(1):120. ">Jakobsen 2014a</a>). For continuous outcomes, we estimated the required information size based on the SD observed in the control group of trials with low risk of bias, a minimal relevant difference of 50% of this observed SD, an alpha of 2.5% and 1.1% depending on primary or secondary outcome, a beta of 20%, and the observed diversity in the trials in the meta‐analysis (<a href="./references#CD012143-bbs2-0328" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14(1):120. ">Jakobsen 2014a</a>). </p> </section> <section id="CD012143-sec-0081"> <h5 class="title">'Summary of findings' table</h5> <p>We created 'Summary of findings' tables on three of our outcomes (all‐cause mortality, serious adverse events, and no sustained virological response) using GRADEpro Guideline Development Tool (<a href="http://www.gradepro.org" target="_blank">www.gradepro.org</a>). We chose these three outcomes because we consider these outcomes to be the important outcomes for decision makers; all‐cause mortality and serious adverse events because of the obvious clinical relevance of these outcomes, and no sustained virological because of the focus on this surrogate outcome in hepatitis C intervention research (see <a href="#CD012143-sec-0031">Description of the condition</a> and <a href="#CD012143-sec-0147">Agreements and disagreements with other studies or reviews</a>). The GRADE approach appraises the quality of a body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. The quality of a body of evidence considers within‐study risk of bias, indirectness of the evidence, heterogeneity of the data, imprecision of effect estimates (wide CIs) (<a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011949/full#CD011949-bbs2-0043" target="_blank">Jakobsen 2014</a>), and risk of publication bias (<a href="./references#CD012143-bbs2-0280" title="BalshemH , HelfandM , SchunemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401‐6. [PUBMED: 21208779] ">Balshem 2011</a>; <a href="./references#CD012143-bbs2-0308" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383‐94. [PUBMED: 21195583] ">Guyatt 2011a</a>; <a href="./references#CD012143-bbs2-0309" title="GuyattGH , OxmanAD , KunzR , AtkinsD , BrozekJ , VistG , et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology2011;64(4):395‐400. [PUBMED: 21194891] ">Guyatt 2011b</a>; <a href="./references#CD012143-bbs2-0310" title="GuyattGH , OxmanAD , VistG , KunzR , BrozekJ , Alonso‐CoelloP , et al. GRADE guidelines: 4. Rating the quality of evidence‐‐study limitations (risk of bias). Journal of Clinical Epidemiology2011;64(4):407‐15. [PUBMED: 21247734] ">Guyatt 2011c</a>; <a href="./references#CD012143-bbs2-0311" title="GuyattGH , OxmanAD , MontoriV , VistG , KunzR , BrozekJ , et al. GRADE guidelines: 5. Rating the quality of evidence‐‐publication bias. Journal of Clinical Epidemiology2011;64(12):1277‐82. [PUBMED: 21802904] ">Guyatt 2011d</a>; <a href="./references#CD012143-bbs2-0312" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso‐CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence‐‐imprecision. Journal of Clinical Epidemiology2011;64(12):1283‐93. [PUBMED: 21839614] ">Guyatt 2011e</a>; <a href="./references#CD012143-bbs2-0313" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 7. Rating the quality of evidence‐‐inconsistency. Journal of Clinical Epidemiology2011;64(12):1294‐302. [PUBMED: 21803546] ">Guyatt 2011f</a>; <a href="./references#CD012143-bbs2-0314" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 8. Rating the quality of evidence‐‐indirectness. Journal of Clinical Epidemiology2011;64(12):1303‐10. [PUBMED: 21802903] ">Guyatt 2011g</a>; <a href="./references#CD012143-bbs2-0315" title="GuyattGH , OxmanAD , SultanS , GlasziouP , AklEA , Alonso‐CoelloP , et al. GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology2011;64(12):1311‐6. [PUBMED: 21802902] ">Guyatt 2011h</a>; <a href="./references#CD012143-bbs2-0316" title="GuyattG , OxmanAD , SultanS , BrozekJ , GlasziouP , Alonso‐CoelloP , et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology2013;66(2):151‐7. [PUBMED: 22542023] ">Guyatt 2013a</a>; <a href="./references#CD012143-bbs2-0317" title="GuyattGH , OxmanAD , SantessoN , HelfandM , VistG , KunzR , et al. GRADE guidelines: 12. Preparing summary of findings tables‐binary outcomes. Journal of Clinical Epidemiology2013;66(2):158‐72. [PUBMED: 22609141] ">Guyatt 2013b</a>; <a href="./references#CD012143-bbs2-0318" title="GuyattGH , ThorlundK , OxmanAD , WalterSD , PatrickD , FurukawaTA , et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles‐continuous outcomes. Journal of Clinical Epidemiology2013;66(2):173‐83. [PUBMED: 23116689] ">Guyatt 2013c</a>; <a href="./references#CD012143-bbs2-0346" title="MustafaRA , SantessoN , BrozekJ , AklEA , WalterSD , NormanG , et al. The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses. Journal of Clinical Epidemiology2013;66(7):736‐42; quiz 742.e1‐5. [PUBMED: 23623694] ">Mustafa 2013</a>). </p> </section> </section> <section id="CD012143-sec-0082"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned a large number of subgroup analyses (see below). We did not specify in detail how exactly we would compare the subgroups, but we chose to use the formal test for subgroup difference (<a href="./references#CD012143-bbs2-0294" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>) to assess if there was evidence of a difference between subgroups. and if the formal test for subgroup differences (<a href="./references#CD012143-bbs2-0294" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>) showed evidence of a difference then we assessed each subgroup separately and reported each subgroup meta‐analysis result. We chose to use the formal test for subgroup difference (<a href="./references#CD012143-bbs2-0294" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>) to limit the number of comparisons and hence problems with multiplicity. The large number of comparisons increases the risks of type I errors and type II errors (<a href="./references#CD012143-bbs2-0328" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14(1):120. ">Jakobsen 2014a</a>; <a href="./references#CD012143-bbs2-0330" title="JakobsenJC , WetterslevJ , LangeT , GluudC . Viewpoint: taking into account risks of random errors when analysing multiple outcomes in systematic reviews [editorial]. Cochrane Database of Systematic Reviews2016, issue 3:10.1002/14651858.ED000111. [DOI: 10.1002/14651858.ED000111] ">Jakobsen 2016a</a>). </p> <p> <ol id="CD012143-list-0015"> <li> <p>Trials with overall low risk of bias compared to trials with overall high risk of bias. </p> </li> <li> <p>Trials randomising HCV participants following the different combinations of DAAs assessed.</p> </li> <li> <p>Trials randomising HCV participants with and without HIV infection.</p> </li> <li> <p>Trials randomising HCV participants with and without HIV infection, hepatitis B, alcoholism, severe fibrosis, cirrhosis, mixed group, or any other specific comorbid diagnosis. </p> </li> <li> <p>Trials randomising HCV participants specifically according to the different HCV genotypes (both comparing the effects of different drug combination on the same genotype and the effects each specific drug combination on each genotype). </p> </li> <li> <p>Trials randomising HCV participants specifically according to the different IL28 genotypes (both comparing the effects of different drug combination on the same IL 28 genotype and the effects each specific drug combination on each IL28 genotype). </p> </li> <li> <p>Trials randomising HCV participants from Asian compared to non‐Asian regions (<a href="./references#CD012143-bbs2-0368" title="ThomasDL , ThioCL , MartinMP , QiY , GeD , O'HuiginC , et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature2009;461(7265):798–801. ">Thomas 2009</a>). </p> </li> <li> <p>Trials randomising HCV participants according to specific races or ethnicities (<a href="./references#CD012143-bbs2-0368" title="ThomasDL , ThioCL , MartinMP , QiY , GeD , O'HuiginC , et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature2009;461(7265):798–801. ">Thomas 2009</a>). </p> </li> <li> <p>Trials that are stopped early (not reaching the planned sample size) compared to trials that are not stopped early. </p> </li> <li> <p>Trials randomising treatment‐naive participants compared to previously‐treated patients.</p> </li> <li> <p>Trials assessing the effects of DAAs combined with IFN compared to trials assessing the effects of DAAs combined with no IFN. </p> </li> <li> <p>Trials assessing the effects of DAAs combined with RBV compared to trials assessing the effects of DAAs combined with no RBV. </p> </li> <li> <p>Trials randomising HCV participants with and without chronic kidney disease (as defined by trialists). </p> </li> <li> <p>Trials randomising HCV participants with and without mixed cryoglobulinaemia (as defined by trialists). </p> </li> </ol> </p> </section> <section id="CD012143-sec-0083"> <h4 class="title">Sensitivity analysis</h4> <p>Please see above under <a href="#CD012143-sec-0071">Dealing with missing data</a>. Furthermore, we intended to use sensitivity analyses whenever we wanted to assess robustness of our findings (<a href="./references#CD012143-bbs2-0328" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14(1):120. ">Jakobsen 2014a</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012143-sec-0084" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012143-sec-0084"></div> <section id="CD012143-sec-0085"> <h3 class="title">Description of studies</h3> <p>We assessed all trials according to the <i>Cochrane Handbook of Stystematic Reviews of Interventions</i> (<a href="./references#CD012143-bbs2-0362" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011</a>), and the protocol for this review <a href="./references#CD012143-bbs2-0331" title="JakobsenJC , NielsenEE , FeinbergJ , FobianK , KatakamKK , HauserG , et al. Direct‐acting antivirals for chronic hepatitis C. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD012143] ">Jakobsen 2016b</a>. Characteristics of each trial can be found in <a href="./references#CD012143-sec-0173" title="">Characteristics of included studies</a>; <a href="./references#CD012143-sec-0174" title="">Characteristics of excluded studies</a>; and <a href="./references#CD012143-sec-0175" title="">Characteristics of ongoing studies</a>. </p> <section id="CD012143-sec-0086"> <h4 class="title">Results of the search</h4> <p>We identified a total of 9358 potentially relevant references through searching the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, Science Citation Expanded, LILACS, BIOSIS, Chinese Biomedical Literature Database (CBM), China Network Knowledge Information (CNKI), the Chinese Science Journal Database (VIP), and the Wanfang Database. Additionally, 229 unpublished records were identified through United States Food and Drug Administration, clinical trials registers of the USA and Europe, and company websites. We excluded 2857 reference duplicates. Accordingly, 6730 were screened, and 6312 records were excluded based on titles and abstracts. We assessed 419 published/unpublished full‐text papers for eligibility. Of these we excluded 68 references because of the inclusion criteria and exclusion criteria. Reasons for exclusion are listed in the <a href="./references#CD012143-sec-0174" title="">Characteristics of excluded studies</a> table. We included 351 references reporting results of 138 trials. Additionally two trials were ongoing trials. The study flow chart can be seen in <a href="#CD012143-fig-0002">Figure 2</a> (<a href="./references#CD012143-bbs2-0344" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta‐Analyses: The PRISMA Statement.. PLoS Medicine2009;6(7):e1000097. [DOI: 10.1371/journal.pmed1000097] ">Moher 2009</a>). </p> <div class="figure" id="CD012143-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD012143-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD012143-sec-0087"> <h4 class="title">Included studies</h4> <p>We included 351 references on 138 trials (<a href="#CD012143-fig-0002">Figure 2</a>). The trials were conducted between 2004 and 2016. Only 85 of these trials assessed DAAs on the market or under development. Fifty‐seven trials were on withdrawn DAAs. The trials were from 34 different countries located in six continents: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czech Republic, Denmark, France, Germany, India, Ireland, Israel, Italy, Japan, Korea, Lithuania, Mexico, Moldova, Netherlands, New Zealand, Poland, Puerto Rico, Romania, Russia, South Korea, Spain, Sweden, Taiwan, Thailand, UK, USA. For further details on included studies see <a href="./references#CD012143-sec-0173" title="">Characteristics of included studies</a>. </p> <section id="CD012143-sec-0088"> <h5 class="title">Participants</h5> <p>A total of 25,232 participants were randomised in 138 trials (two trials did not report the number of randomised participants). A total of 13,466 participants were randomised in the 84 trials assessing DAAs on the market or under development. The number of participants in each trial ranged from 10 to 1097 (average 182 participants). </p> <p>We included 17 trials where the participants were treatment‐experienced, 95 trials where the participants were treatment‐naive, 24 trials where the participants were mixed (both treatment‐naive and treatment‐experienced), and five trials where it was unclear whether the participants were treatment‐experienced or treatment‐naive. </p> <p>We included participants with different HCV genotypes: HCV genotype 1 (119 trials), HCV genotype 2 (eight trials), HCV genotype 3 (six trials), HCV genotype 4 (nine trials), and HCV genotype 6 (one trial). Twelve trials did not specify which HCV genotypes they assessed. </p> <p>We included three trials where HIV was an inclusion criteria, 102 where HIV was an exclusion criteria, one trial with both HIV and non‐HIV participants, and 35 trials where it was unclear if HIV was an inclusion/exclusion criteria. </p> <p>Two trials included only participants with diagnosed cirrhosis, 44 trials included both participants with and without cirrhosis, 67 trials did not include participants with cirrhosis or advanced liver disease, and in 25 trials it was unclear wether participants with cirrhosis or advanced liver disease were included. </p> </section> <section id="CD012143-sec-0089"> <h5 class="title">Experimental interventions</h5> <p>Eighty‐four trials were on DAAs on the market or under development. Fifty‐seven trials were on withdrawn (or discontinued) DAAs. The intervention period ranged from one day to 48 weeks with an average of 14 weeks. The follow‐up in the included trials ranged from one day to 120 weeks with an average of 34 weeks. The 138 trials used 51 different DAAs: ACH‐2064 (n = 1); alisporivir (n = 1); ALS‐2200 (n = 1); asunaprevir (n = 3); balapiravir (n = 2); beclabuvir (n = 2); BILB‐1941 (n = 1); BILN‐2061 (n = 1); BIT‐25 (n = 1); boceprevir (n = 12); ciluprevir (n = 2); daclatasvir (n = 6); danoprevir (n = 5); deleobuvir (n = 2); faldaprevir (n = 8); filibuvir (n = 2); grazoprevir (n = 2); GS‐6620 (n = 1); GS‐9256 (n = 2); GS‐9451 (n = 2); GS‐9669 (n = 1); GS‐9851 (n = 1); GS‐9857 (n = 1); GSK2336805 (n = 2); GSK2878175 (n = 1); HCV‐796 (n = 1); IDX‐184 (n = 2); INX‐09189 (n = 1); ledispasvir (n = 1); mericitabine (n = 6); mixed (n = 13); narlaprevir (n = 2); nesbuvir (n = 2); odalasavir (n = 1); ombitasvir (n = 1); paritaprevir (n = 1); PHX1766 (n = 1); PPI‐461 (n = 1); PSI‐352938 (n = 1); samatasvir (n = 1); setrobuvir (n = 2); simeprevir (n = 11); sofosbuvir (n = 6); sovaprevir (n = 2); tegobuvir (n = 2); telaprevir (n = 10); valopicitabine (n = 1); vaniprevir (n = 5); VCH‐759 (n = 1); VCH‐916 (n = 1); velpatasvir (n = 1); VX‐222 (n = 1). </p> </section> <section id="CD012143-sec-0090"> <h5 class="title">Control interventions and co‐interventions</h5> <p>We included 128 trials where the control group received a matching placebo and 13 trials where the control group did not receive placebo. We included 46 trials where neither intervention group (DAA and control) received RBV nor IFN; 79 trials where both groups received RBV and IFN; two trials where both groups received IFN and no RBV; five trials where both groups received RBV and no IFN; three trials where only the control group received IFN and RBV; two trials where only the control group received RBV; and one trial where only the experimental group received RBV and IFN. We included three trials where an additional DAA (different from the experimental type of DAA) was given as co‐intervention in both the experimental and control group. </p> </section> <section id="CD012143-sec-0091"> <h5 class="title">Funding</h5> <p>One trial was not funded by someone with a financial interest in a certain result of the trial (<a href="./references#CD012143-bbs2-0127" title="MostafaI , HassanM , IbrahimAM , KhalafallaO , EssawyF , AbdelazemA , et al. Pilot study to determine the efficacy and safety of combining boceprevir with peginterferon alfa 2B and ribavirin in treatment naive patients with genotype 4 chronic hepatitis C infection. Hepatology International2015;9(1 Suppl):S259. ">Mostafa 2015</a>). In the remaining 140 trials it was either not reported, in sufficient detail, how the trial was funded or the trial was financially supported by someone with a financial interest in a certain result of the trial (<a href="./full#CD012143-fig-0001">Figure 1</a>). </p> </section> </section> <section id="CD012143-sec-0092"> <h4 class="title">Excluded studies</h4> <p>We excluded 68 studies. Of these, 38 studies had a control group receiving an intervention beyond our inclusion and exclusion criteria (33 studies had DAA as control intervention, five studies had no control group); seven studies did not use DAA as intervention; 12 studies were not randomised; seven studies were comments; and four studies used healthy participants. <a href="./references#CD012143-sec-0174" title="">Characteristics of excluded studies</a> table presents a summary of the reasons for the exclusions. </p> </section> </section> <section id="CD012143-sec-0093"> <h3 class="title">Risk of bias in included studies</h3> <section id="CD012143-sec-0094"> <h4 class="title">Allocation</h4> <p>We assessed the generation of the allocation sequence generation as low risk of bias in 37/138 trials. The remaining trials were described as being randomised but they did not describe the method used for allocation sequence generation in sufficient detail, resulting in an 'uncertain risk of bias' (<a href="./full#CD012143-fig-0001">Figure 1</a>). </p> <p>We assessed the methodology used for allocation concealment as low risk of bias in 38/138 trials. The methodology used for allocation concealment was unclear or we assessed it as high risk of bias in the remaining trials (<a href="./full#CD012143-fig-0001">Figure 1</a>). </p> </section> <section id="CD012143-sec-0095"> <h4 class="title">Blinding</h4> <p>We assessed the blinding of participants and personnel as low risk of bias in 28/138 trials. The remaining trials either did not describe the blinding of participants and personnel in sufficient detail (unclear) or we assessed the methodology as high risk of bias (<a href="./full#CD012143-fig-0001">Figure 1</a>). </p> <p>We assessed the blinding of outcome assessors as low risk of bias in 14/138 trials. The methods for blinding of outcome assessors for the remaining trials were either not described in sufficient detail (unclear) or we assessed them as high risk of bias (<a href="./full#CD012143-fig-0001">Figure 1</a>). </p> </section> <section id="CD012143-sec-0096"> <h4 class="title">Incomplete outcome data</h4> <p>We assessed trials' handling of incomplete outcome data as low risk of bias in 49/138 trials. The remaining trials either did not describe how they handled incomplete outcome data (unclear) or we assessed the methodology as high risk of bias (<a href="./full#CD012143-fig-0001">Figure 1</a>). </p> </section> <section id="CD012143-sec-0097"> <h4 class="title">Selective reporting</h4> <p>We assessed selective outcome reporting as low risk of bias in 49/138 trials. The remaining trials either did not register or publish a protocol with predefined outcomes before the randomisation began or the methodology was assessed as high risk of bias (<a href="./full#CD012143-fig-0001">Figure 1</a>). </p> </section> <section id="CD012143-sec-0098"> <h4 class="title">Other potential sources of bias</h4> <p>We assessed the vested‐interest domain as low risk of bias in one trial (<a href="./references#CD012143-bbs2-0127" title="MostafaI , HassanM , IbrahimAM , KhalafallaO , EssawyF , AbdelazemA , et al. Pilot study to determine the efficacy and safety of combining boceprevir with peginterferon alfa 2B and ribavirin in treatment naive patients with genotype 4 chronic hepatitis C infection. Hepatology International2015;9(1 Suppl):S259. ">Mostafa 2015</a>) and high risk of bias in the remaining 140 trials; either because the funding or financial interests were not reported in sufficient detail or because the trial was financially supported by someone with a financial interest in a certain result of the trial. </p> <section id="CD012143-sec-0099"> <h5 class="title">Overall risk of bias</h5> <p>Based on our predefined 'Risk of bias' assessment, we considered all 138 trials at high risk of bias. Many trials were judged to have unclear risk of bias in several domains, and additional information could not be obtained from the trial authors. Only four trials had low risk of bias in 7/8 domains (<a href="./references#CD012143-bbs2-0206" title="ChenYC , MoreiraS , IpeD , KulkarniR , PasseS , ZhuY , et al. The effect of host il28b genotype and mericitabine (MCB; RG7128) dose on early viral kinetics following administration of MCB plus pegifn alpha‐2a plus ribavirin (P/R) in patients with chronic hepatitis C (CHC). Hepatology2011;54(Suppl S1):553A. JensenDM , WedemeyerH , HerringRW , FerenciP , MaMM , ZeuzemS , et al. High rates of early viral response, promising safety profile and lack of resistance‐related breakthrough in HCV GT 1/4 patients treated with RG7128 plus PegIFN alfa‐2a (40KD)/RBV: planned week 12 interim analysis from the PROPEL study. Hepatology2010;52(Suppl S1):360A. WedemeyerH , JensenD , HerringR , FerenciP , MaMM , ZeuzemS , et al. Efficacy and safety of mericitabine (MCB) in combination with Peg‐Ifn alpha‐2A/RBV in G1/4 treatment naive HCV patients: final analysis from the PROPEL study. Journal of Hepatology2012;56(Suppl S2):S481‐2. WedemeyerH , JensenD , HerringR , FerenciP , MaMM , ZeuzemS , et al. PROPEL: a randomized trial of mericitabine plus peginterferon alpha‐2a/ribavirin therapy in treatment‐naive HCV genotype 1/4 patients. Hepatology2013;58(2):524‐37. ">Wedemeyer 2013</a>; <a href="./references#CD012143-bbs2-0049" title="FeldJJ , KowdleyKV , CoakleyE , SigalS , NelsonD , CrawfordD , et al. Sapphire I: Phase 3 placebo‐controlled study of interferon‐free, 12‐week regimen of ABT‐450/R/ABT‐267, ABT‐333, and ribavirin in 631 treatment‐naive adults with hepatitis Cvirus genotype 1. Journal of Hepatology2014;60(1 Suppl 1):S25. FeldJJ , KowdleyKV , CoakleyE , SigalS , NelsonDR , CrawfordD , et al. Treatment of HCV with ABT‐450/r‐ombitasvir and dasabuvir with ribavirin. New England Journal of Medicine2014;370(17):1594‐603. KowdleyKV , FeldJJ , CoakleyE , SigalS , NelsonDR , CrawfordD , et al. Sapphire I: Phase 3 placebo‐controlled study of interferon‐free, 12‐week regimen of ABT‐450/R/ABT‐267, ABT‐333, and ribavirin in 631 treatment‐naive adults with hepatitis C virus genotype 1. Gastroenterology2014;146(5 Suppl 1):S912‐S3. ">Feld 2014</a>; <a href="./references#CD012143-bbs2-0210" title="LiuY , LarsenL , BourliereM , BaranR , JudayT . Ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin (RBV) has mild impact on health‐related quality of life (HRQoL) compared with placebo during 12‐week treatment in treatment‐experienced adults with chronic hepatitis C (CHC). Journal of Hepatology2015;62(Suppl S2):S661. ZeuzemS , JacobsonIM , BaykalT , MarinhoRT , PoordadF , BourliereM , et al. Retreatment of HCV with ABT‐450/r‐ombitasvir and dasabuvir with ribavirin. New England Journal of Medicine2014;370(17):1604‐14. ">Zeuzem 2014a</a>; <a href="./references#CD012143-bbs2-0029" title="ArduinoJM , WangY , BrownDD , KhawajaS , MartinezE , ButtertonJR , et al. C‐EDGE TN: Impact of 12‐week oral regimen of grazoprevir (GZR, MK‐5172)/Elbasvir (EBR, MK‐8742) on patient‐reported outcomes (PROs) in treatment‐naive patients with chronic hepatitis C virus (HCV) genotype (GT) 1, 4, or 6 infection. Hepatology2015;62(Suppl S1):565A‐566A. ZeuzemS , GhalibR , ReddyK , PockrosPJ , Ben AriZIV , ZhaoYUE , et al. Grazoprevir‐elbasvir combination therapy for treatment‐naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Annals of Internal Medicine2015;163(1):1‐13. ZeuzemS , GhalibR , ReddyKR , PockrosPJ , AriZB , ZhaoY , et al. The phase 3 C‐EDGE treatment‐naive (TN) study of a 12‐week oral regimen of grazoprevir (GZR, mk‐5172)/ elbasvir (EBR, mk‐8742) in patients with chronic HCV genotype (GT) 1, 4, or 6 infection. Journal of Hepatology2015;62(Suppl S2):S213. ">C‐EDGE TN 2015</a>. The latter four trials were at high risk of bias in the vested‐interest bias risk domain (<a href="./full#CD012143-fig-0001">Figure 1</a>). Additional information can be found in the 'Risk of bias' summary (<a href="./full#CD012143-fig-0001">Figure 1</a>). </p> </section> </section> </section> <section id="CD012143-sec-0100"> <h3 class="title" id="CD012143-sec-0100">Effects of interventions</h3> <p>See: <a href="./full#CD012143-tbl-0001"><b>Summary of findings for the main comparison</b> Direct‐acting antivirals versus control</a>; <a href="./full#CD012143-tbl-0002"><b>Summary of findings 2</b> Direct‐acting antivirals withdrawn from the market versus control</a> </p> <section id="CD012143-sec-0101"> <h4 class="title">Analyses of trials assessing the effects of DAAs on the market or under development</h4> <section id="CD012143-sec-0102"> <h5 class="title">Hepatitis C‐related morbidity or all‐cause mortality</h5> <p>When analysing the composite outcome hepatitis C‐related morbidity or all‐cause mortality, all events were deaths only. </p> <section id="CD012143-sec-0103"> <h6 class="title">Meta‐analysis</h6> <p>Eleven trials with a total of 2996 participants provided useful data on all‐cause mortality. A total of 15/2377 (0.63%) participants died in the DAA groups versus 1/617 (0.16%) participants who died in the control groups during the observation period. Because of the unbalanced data, the large number of zero events, and the rare incidence of events in the control group, we used reciprocal zero cell correction and fixed‐effect meta‐analysis (STATA 14; <a href="http://www.stata.com/" target="_blank">www.stata.com</a>) (<a href="./references#CD012143-bbs2-0366" title="SweetingMJ , SuttonAJ , LambertPC . What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data. Statistics in Medicine2004;23(9):1351‐75. ">Sweeting 2004</a>). The extracted data can be found in the standard results section, but the meta‐analysis results can be found in the STATA forest plots. Meta‐analysis showed no evidence of a difference when assessing risk of all‐cause mortality (OR 3.72, 95% CI 0.53 to 26.18, P = 0.19; I² = 0%, 11 trials, very low‐quality evidence, <a href="./references#CD012143-fig-0008" title="">Analysis 1.1</a>). </p> </section> <section id="CD012143-sec-0104"> <h6 class="title">Heterogeneity</h6> <p>Neither visual inspection of the forest plots nor tests for statistical heterogeneity (I² = 0%, P = 0.99) indicated significant heterogeneity. </p> </section> <section id="CD012143-sec-0105"> <h6 class="title">Risk of bias and sensitivity analyses</h6> <p>The risk of bias of this outcome result was assessed as high risk of bias.</p> </section> <section id="CD012143-sec-0106"> <h6 class="title">Additional analyses</h6> <p>Due to the total lack of data on hepatitis C‐related morbidity and the low number of events on all‐cause mortality, we did not perform additional analysis including Trial Sequential Analysis, Bayes factor, funnel plots, or subgroup analysis. </p> </section> </section> <section id="CD012143-sec-0107"> <h5 class="title">Serious adverse events</h5> <section id="CD012143-sec-0108"> <h6 class="title">Meta‐analysis</h6> <p>Forty‐three trials with a total of 15,817 participants reported results on serious adverse events. A total of 376/13,574 (2.77%) participants in the DAA groups had one or more serious adverse events versus a total of 125/2243 (5.57%) participants in the control groups during the observation period (<a href="#CD012143-tbl-0004">Table 2</a>). Because of the unbalanced data, the large number of zero events, and the rare incidence of events in the control groups, we used reciprocal zero cell correction and fixed‐effect meta‐analysis (STATA 14; <a href="http://www.stata.com/" target="_blank">www.stata.com</a>) (<a href="./references#CD012143-bbs2-0366" title="SweetingMJ , SuttonAJ , LambertPC . What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data. Statistics in Medicine2004;23(9):1351‐75. ">Sweeting 2004</a>; <a href="./references#CD012143-bbs2-0294" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). The extracted data can be found in the <a href="./references#CD012143-sec-0152" title="">Data and analyses</a> section, but the meta‐analysis is performed in STATA (figure not shown). The meta‐analysis showed no evidence of a difference between the two intervention groups (OR 0.93, 95% CI 0.75 to 1.15, P = 0.52, I² = 0%; 43 trials, very low‐quality evidence, <a href="./references#CD012143-fig-0026" title="">Analysis 2.1</a>). </p> <div class="table" id="CD012143-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Serious adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Experimental intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Type and number of serious adverse events (experimental group)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Proportion of participants with a serious adverse event (experimental group)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Type and number of serious adverse events (control group)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Proportion of participants with a serious adverse event (control group)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0024" title="BronowickiJP , PolS , ThuluvathP , LarreyD , MartorellCT , RustgiVK , et al. Asunaprevir (ASV; BMS‐650032), an NS3 protease inhibitor, in combination with peginterferon and ribavirin in treatment‐naive patients with genotype 1 chronic hepatitis C infection. Journal of Hepatology2012;56(Suppl 2):S431‐2. BronowickiJP , PolS , ThuluvathPJ , LarreyD , MartorellCT , RustgiVK , et al. BMS‐650032, an NS3 inhibitor, in combination with peginterferon alpha‐2a and ribavirin in treatment‐naive subjects with genotype 1 chronic hepatitis C infection. Journal of Hepatology2011;54:S472. BronowickiJP , PolS , ThuluvathPJ , LarreyD , MartorellCT , RustgiVK , et al. Randomized study of asunaprevir plus pegylated interferon‐alpha and ribavirin for previously untreated genotype 1 chronic hepatitis C. Antiviral Therapy2013;18(7):885‐93. ">Bronowicki 2013a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asunaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 abdominal pain, 1 lung neoplasm malignant, 1 cytolytic hepatitis, and 2 unspecified events </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 out of 36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0027" title="BronowickiJ‐P , RatziuV , GadanoA , Thuluvath PaulJ , BessoneF , Martorell ClaudiaT , et al. Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C. Journal of Hepatology2014;61(6):1220‐7. BronowickiJP , PolS , ThuluvathP , LarreyD , MartorellCT , RustgiVK , et al. Asunaprevir (ASV; BMS‐650032), an NS3 protease inhibitor, in combination with peginterferon and ribavirin in treatment‐naive patients with genotype 1 chronic hepatitis C infection. Journal of Hepatology2012;56(Suppl 2):S431‐S2. BronowickiJP , RatziuV , GadanoA , ThuluvathPJ , BessoneF , MartorellCT , et al. Asunaprevir with peginterferon‐alfa and ribavirin in treatment‐naive patients with genotype‐1 or ‐4 chronic hepatitis C: SVR24 results from a randomized phase 2B study (AI447016). Journal of Hepatology2013;58:S571‐2. ">Bronowicki 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asunaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 deaths and 14 unspecified events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 out of 177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 unspecified events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 out of 61</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0130" title="NelsonDR , ZeuzemS , AndreoneP , FerenciP , HerringR , JensenDM , et al. Balapiravir plus peginterferon alfa‐2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. Annals of Hepatology2012;11(1):15‐31. ">Nelson 2012a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Balapiravir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Many events but only a few were specified: 3 deaths, 10 haematological, 10 infection, 8 eye disorders </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 out of 432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Many events but not all were specified: 2 infections, 1 death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 out of 72</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0201" title="McPheeF , FalkP , FracassoP , LemmJ , LiuM , KirkM , et al. Characterization of viral escape in HCV genotype 1‐infected patients treated with BMS‐791325 and pegylated interferon‐ALFA and ribavirin. Journal of Hepatology2012;56(Suppl S2):S473. TatumH , ThuluvathP , LawitzE , MartorellCT , DemiccoM , CohenS , et al. A phase 2A study of BMS‐791325, an NS5B polymerase inhibitor, with peginterferon alfa‐2A and ribavirin in treatment‐naive patients with genotype 1 chronic hepatitis C infection. Journal of Hepatology2012;56(Suppl S2):S460. TatumH , ThuluvathPJ , LawitzE , MartorellC , DemiccoM , CohenS , et al. A randomized, placebo‐controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1. Journal of Viral Hepatitis2015;22(8):658‐64. TatumHA , ThuluvathPJ , LawitzE , MartorellC , CohenSM , RustgiVK , et al. Safety and efficacy of BMS‐791325, a non‐nucleoside NS5B polymerase inhibitor, combined with peginterferon alfa‐2a and ribavirin in treatment‐naive patients infected with hepatitis C virus genotype 1. Hepatology2013;58(S1):759A‐60A. ">Tatum 2015a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Beclabuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 constipation, 1 febrile neutropenia, 1 leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 serotonin syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0016" title="BaconBR , BrunoS , SchiffER , KwoPY , ButiM , PediconeL , et al. Predictors of sustained virologic response (SVR) among poor interferon (IFN) responders when boceprevir (BOC) is added to peginterferon alfa‐2b/ribavirin (PR). Hepatology2011;54(S1):376A‐7A. BaconBR , GordonSC , LawitzE , MarcellinP , VierlingJM , ZeuzemS , et al. Boceprevir for previously treated chronic HCV genotype 1 infection. New England Journal of Medicine2011;364(13):1207‐17. BaconBR , GordonSC , LawitzE , MarcellinP , VierlingJM , ZeuzemS , et al. HCV RESPOND‐2 final results: high sustained virologic response among genotype 1 previous non‐responders and relapsers to peginterferon/ribavirin when re‐treated with boceprevir plus PEGINTRON (peginterferon alfa‐2b)/ribavirin. Hepatology2010;52(Suppl S1):430A. BarnardRJ , HoweJA , OgertRA , ZeuzemS , PoordadF , GordonSC , et al. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology2013;444(1‐2):329‐36. BognarFA , HuKQ , ThompsonS , PediconeL , WahlJ , LinSG . Boceprevir (BOC) plus peginterferon alfa‐2b/ ribavirin (PR) in the treatment of chronic hepatitis C virus genotype‐1 (HCV‐G1) infected Asian patients in the SPRINT‐1, SPRINT‐2 and RESPOND‐2 trials. Journal of Gastroenterology and Hepatology2012;27(Suppl 4):161. BrassC , BarnardRJO , HoweJA , OgertRA , RalstonR , BoparaiN , et al. Sustained virologic response and boceprevir resistance‐associated variants observed in patients infected with HCV genotpype Ia/Ib when treated with boceprevir plus peginterferon alfa‐2b/ribavirin. Journal of Hepatology2011;54(Suppl 1):S471‐2. BrunoS , VierlingJM , EstebanR , NybergLM , TannoH , AlbrechtJK , et al. Boceprevir in addition to standard of care enhanced SVR in hepatitis C virus (HCV) genotype‐1 with advanced fibrosis/cirrhosis: subgroup analysis of sprint‐2 and respond‐2 studies. Journal of Hepatology2011;54(Suppl 1):S4‐5. BrunoS , VierlingJM , EstebanR , NybergLM , TannoH , GoodmanZ , et al. Efficacy and safety of boceprevir plus peginterferon‐ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. Journal of Hepatology2013;58(3):479‐87. ChhatwalJ , FerranteSA , BrassC , ElKhouryAC , BurroughsM , BaconB , et al. Cost‐effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. Value in Health2013;16(6):973‐86. ChhatwalJ , FerranteSA , DasbachEJ , ElKhouryA , BurroughsM , BaconB , et al. Projecting the long‐term clinical impact of boceprevir in patients with chronic hepatitis C genotype‐1 who failed prior treatment with peginterferon/ribavirin. Journal of Hepatology2011;54:S164. ChhatwalJ , FerranteSA , DasbachEJ , KhouryA , BrassCA , BurroughsM , et al. Cost‐effectiveness of boceprevir use in patients with chronic hepatitis C genotype‐1 who failed prior treatment with peginterferon/ribavirin. Hepatology2011;54(4 (Suppl)):801A‐2A. ChhatwalJ , LundbergJ , FerranteS , ElKhourhyAC , OksanenA , ElbashaEH . Cost‐effectiveness of boceprevir in the treatment of chronic Hepatitis C genotype 1 in Sweden. Journal of Hepatology2012;56(Suppl 2):S386‐7. GordonSC , SulkowskiMS , JacobsonIM , VierlingJM , DavisGL , AfdhalNH , et al. Reasons for screen failure in 2 phase III studies of boceprevir with peginterferon/ribavirin in patients with chronic HCV genotype 1 infection (sprint‐2 and respond‐2). Hepatology2011;54(Suppl S1):848A‐9A. LenzO , FeveryB , VijgenL , VerbeeckJ , PeetersM , BeumontM , et al. TMC435 in combination with peginterferon alpha‐2A/ribavirin in treatment‐naïve patients infected with HCV genotype 1: virology analysis of the PILLAR study. Hepatology2011;54(4 (Suppl)):985A. MarcellinP , VierlingJM , AlricL , PirisiM , TranA , AlbrechtJK , et al. Efficacy among North American and European HCV genotype‐1 treatment‐naive and previous non‐responders and relapsers to peginterferon/ribavirin when treated with boceprevir plus peginterferon alfa‐2b/ribavirin. Journal of Hepatology2011;54(Suppl 1):S184. SulkowskiMS , BaconBR , GordonSC , LawitzE , MarcellinP , VierlingJM , et al. Boceprevir combined with peginterferon alfa‐2b/ribavirin for previous treatment failure patients with hepatitis C virus genotype 1: RESPOND‐2 final results. Journal of the International Association of Physicians in AIDS Care2011;10(3):198. ZeuzemS , VierlingJM , EstebanR , GibasAL , PolS , BoparaiN , et al. Predictors of sustained virologic response among genotype 1 previous non‐responders and relapsers to peginterferon/ribavirin when re‐treated with boceprevir plus peginterferon alfa‐2b/ribavirin. Journal of Hepatology2011;54(Suppl 1):S198‐9. ">Bacon 2011a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 anaemia, 1 angina pectoris, 1 atrial fibrillation, 1 coronary artery disease, 1 myocardial infarction, 1 myopericarditis, 2 abdominal pain, 1 constipation, 1 diarrhoea, 1 gastritis, 1 irritable bowel syndrome, 1 oesophageal varices haemorrhage, 1 pancreatitis acute, 1 pancreatitis necrotising, 1 peptic ulcer, 1 asthenia, 3 chest pain, 1 oedema peripheral, 1 pyrexia, 1 cholecystitis, 3 appendicitis, 1 bronchopneumonia, 1 catheter site infection, 1 gastroenteritis viral, 1 pneumonia, 1 lower limb fracture, 1 overdose, 1 decreased appetite, 1 dehydration, 1 hyperglycaemia, 1 back pain, 2 intervertebral disc protrusion, 1 pain in extremity, 1 hepatic neoplasm malignant, 1 hepatic encephalopathy, 1 sciatica, 1 syncope, 1 bipolar disorder, 1 completed suicide, 4 depression, 2 homicidal ideation, 5 suicidal ideation, 2 dyspnoea, 1 pleuritic pain, 1 pneumothorax, 1 abdominal hernia repair, 1 deep vein thrombosis, 1 phlebitis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 out of 323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 chest pain, 1 cholelithiasis, 1 gastroenteritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 out of 80</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0052" title="FlammS , LawitzE , JacobsonI , RubinR , BourliereM , HezodeC , et al. High sustained virologic response (SVR) among genotype 1 previous non‐responders and relapsers to peginterferon/ribavirin when re‐treated with boceprevir (BOC) plus peginterferon alfa‐2A/ribavirin. Journal of Hepatology2011;54(Suppl 1):S541‐2. FlammSL , LawitzE , JacobsonI , BourliereM , HezodeC , VierlingJM , et al. Boceprevir with peginterferon alfa‐2a‐ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clinical Gastroenterology and Hepatology2013;11(1):81‐7. HoweJA , OgertRA , BarnardRJ , HazudaD , PediconeL , BrassCA . Analysis of sustained viral response and boceprevir resistance following combination treatment with boceprevir plus peginterferon alfa‐2A/ribavirin in HCV genotype 1 prior relapsers and non‐responders. Hepatology2011;54(S1):443A. ">Flamm 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 coronary artery disease, 1 diarrhoea, 1 asthenia, 1 pyrexia, 2 pneumonia, 2 syncope, 1 suicidal ideation, 1 deep vein thrombosis, 1 neutropenia, 1 thrombocytopenia, 1 cardiac failure, 1 upper gastrointestinal haemorrhage , 1 multi‐organ failure, 1 bronchitis, 1 cellulitis, 1 chlamydia infection, 1 influenza, 1 pneumonia staphylococcal, 1 staphylococcal bacteraemia, 1 staphylococcal infection, 1 urosepsis, 1 gun shot wound, 2 hyponatraemia, 1 lethargy, 1 subarachnoid haemorrhage, 1 mental status changes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 out of 134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 chest pain, 1 intervertebral disc protrusion, 1 abnormal behaviour, 1 irritability, 1 osteotomy, 1 foreign body, 1 neuralgia, 1 anxiety, 1 renal colic </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 out of 67</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0080" title="IsakovV , NikitinI , ChulanovV , OgurtsovP , LukyanovaE , LongJ , et al. Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in Russia. World Journal of Hepatology2016;8(6):331‐9. ">Isakov 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 neutropenia, 1 intestinal obstruction, 1 osteomyelitis chronic, 1 pneumonia, 1 diabetic ketoacidosis, 1 intervertebral disc protrusion, 1 transient ischaemic attack </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 out of 159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 neutropenia, 1 general disorders, 1 accidental overdose, 1 prostatitis, 2 hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 out of 78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0086" title="KwoP , LawitzE , McConeJ , SchiffE , VierlingJ , PoundD , et al. HCV Sprint‐1 final results: SVR 24 from a phase 2 study of boceprevir plus pegintron (peginterferon ALFA‐2B)/ribavirin in treatment‐naive subjects with genotype‐1 chronic hepatitis C. Journal of Hepatology2009;50(Suppl 1):S4. KwoPJ , LawitzEJ , McConeJ , SchiffER , VierlingJM , PoundD , et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa‐2b and ribavirin in treatment‐naive patients with genotype 1 hepatitis C infection (SPRINT‐1): an open‐label, randomised, multicentre phase 2 trial. Lancet2010;376(9742):705‐16. OgertRA , HoweJA , VierlingJM , KwoPY , LawitzEJ , McConeJ , et al. Resistance‐associated amino acid variants associated with boceprevir plus pegylated interferon‐alpha2b and ribavirin in patients with chronic hepatitis C in the SPRINT‐1 trial. Antiviral Therapy2013;18(3):387‐97. PoordadF , VierlingJM , EstebanR , KwoPY , LongJ , ChaudhriEI , et al. Hemogloblin decline during lead‐in phase as an early predictor of anemia after the addition of boceprevir: a retrospective analysis of HCV SPRINT‐1. Hepatology2010;52(Suppl S1):770A. VierlingJM , KwoPY , LawitzE , McConeJ , SchiffER , PoundD , et al. Frequencies of resistance‐associated amino acid variants following combination treatment with boceprevir plus PEGINTRON (peginterferon alfa‐2b)/ribavirin in patients with chronic hepatitis C (CHC), genotype 1 (G1). Hepatology2010;52(Suppl S1):702A. ">Kwo 2010a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 abdominal pain, 2 asthenia, 2 pyrexia, 2 pneumonia, 1 decreased appetite, 1 dehydration, 2 depression, 2 homicidal ideation, 3 suicidal ideation, 1 dyspnoea, 1 deep vein thrombosis, 3 nausea, 1 vomiting, 3 neutropenia, 1 multi‐organ failure, 2 cellulitis, 2 abdominal pain upper, 1 headache, 1 suicide attempt, 1 accidental overdose, 1 fall, 1 pulmonary embolism, 1 gastroenteritis, 1 erysipelas, 1 panic attack, 1 fatigue, 1 supraventricular tachycardia, 3 pancreatitis, 1 cerebrovascular accident, 1 hypoaesthesia, 1 anxiety, 1 retinal ischaemia, 1 neuropathy peripheral, 1 aggression, 1 scotoma, 1 hypovolaemia, 1 vulval abscess, 1 retinopathy, 1 inguinal hernia, 1 cervix carcinoma, 1 pericarditis, 1 paranoia, 1 neutrophil count decreased, 1 paraesthesia, 1 peritoneal haemorrhage, 1 deafness unilateral, 1 periodontal disease, 1 corneal infection, 1 pneumonia streptococcal, 1 drug toxicity, 1 blood amylase increased, 1 lipase increased, 1 basal cell carcinoma, 1 renal cell carcinoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 out of 527</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 suicidal ideation, 1 breast cancer, 1 parathyroid tumour benign, 1 muscle spasms, 1 rib fracture, 1 contusion, 1 inguinal hernia, 1 diplopia, 1 staphylococcal sepsis, 1 animal bite, 1 hand fracture, 1 third nerve paralysis, 1 alcoholism, 1 dependence </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 out of 104</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0154" title="PearlmanBL , EhlebenC . Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor. Hepatology2014;59(1):71‐7. WangAS , PfeifferRM , MorganTR , O'BrienTR . Re: Pearlman and Ehleben ‐ hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor. Hepatology2014;59(6):2423–4. ">Pearlman 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0164" title="AlbrechtJ , VierlingJ , KwoP , LawitzE , McConeJ , SchiffE . Frequencies of resistance‐associated amino acid variants (RAV) following treatment with boceprevir (BOC) plus peginterferon alfa‐2b and ribavirin (P/R). Hepatology International2011;5(1):261‐2. BarnardRJO , PediconeLD , ChaudhriE , TongX , QiuP , BrassCA . Frequencies of resistance‐associated amino acid variants following combination treatment with boceprevir (BOC) plus Pegintron (peglnterferon alfa‐2b) and ribavirin (P/R) in patients with chronic hepatitis C (CHC), genotype 1 (G1). Journal of the International Association of Physicians in AIDS Care2011;10(3):199‐200. BronowickiJ , McConeJ , BaconBR , BrunoS , MannsMP , SulkowskiMS , et al. Response‐guided therapy (RGT) with boceprevir (BOC) + peginterferon alfa‐2b/ribavirin (P/R) for treatment‐naive patients with hepatitis C virus (HCV) genotype (G) 1 was similar to a 48‐wk fixed‐duration regimen with BOC + P/R in SPRINT‐2. Hepatology2010;52(Suppl S1):881A. CharltonM . Boceprevir (Victrelis) for HCV: V is for victory and very complex. Hepatology2011;54(5):1882‐6. MannsMP , MarkovaAA , SerranoBC , CornbergM . Phase III results of boceprevir in treatment naive patients with chronic hepatitis C genotype 1. Liver International2012;32(Suppl 1):27‐31. MannsMP , McConeJ , DavisM , ShiffmanML , RossaroL , BourliereM , et al. Safety benefits of response‐guided therapy with boceprevir (BOC) plus peginterferon alfa‐2B/ribavirin (PR) in previously untreated patients with HCV genotype 1 infection. Hepatology2011;54(4 Suppl):813A. McConeJ , JacobsonIM , BaconBR , PediconeL , GotetiVS , BurroughsM , et al. Treatment‐naive black patients treated with boceprevir combined with peginterferon alfa‐2b + ribavirin: results from HCV sprint‐2. Hepatology2011;54(4 Suppl):822A‐3A. PoordadF , McConeJ , BaconBR , BrunoS , MannsMP , SulkowskiMS , et al. Boceprevir (BOC) combined with peginterferon alfa‐2b/ribavirin (P/R) for treatment‐naive patients with hepatitis C virus (HCV) genotype (G) 1: SPRINT‐2 final results. Hepatology2010;52(Suppl S1):402A. PoordadF , McConeJ , BaconBR , BrunoS , MannsMP , SulkowskiMS , et al. Boceprevir for untreated chronic HCV genotype 1 infection. New England Journal of Medicine2011;364(13):1195‐206. ReddyKR , BrunoS , RossaroL , RavendhranN , PaulyMP , BoparaiN , et al. Predictors of sustained virologic response among treatment‐naive patients with hepatitis C virus genotype 1 when treated with boceprevir (BOC) plus peginterferon alfa‐2B/ribavirin (PR). Journal of Hepatology2011;54(Suppl 1):S190. SulkowskiMS , BaconBR , GordonSC , LawitzE , MarcellinP , VierlingJM , et al. Boceprevir combined with peginterferon alfa‐2b/ribavirin for previous treatment failure patients with hepatitis C virus genotype 1: RESPOND‐2 final results. Journal of the International Association of Physicians in AIDS Care2011;10(3):197‐8. SulkowskiMS , PoordadF , MannsMP , BronowickiJP , RajenderRK , HarrisonSA , et al. Anemia during treatment with peginterferon alfa‐2b/ribavirin and boceprevir: analysis from the serine protease inhibitor therapy 2 (SPRINT‐2) trial. Hepatology2013;57(3):974‐84. ">Poordad 2011a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 anaemia, 1 atrial fibrillation, 1 coronary artery disease, 2 abdominal pain, 1 gastritis, 1 pancreatitis acute, 5 chest pain, 4 pyrexia, 1 cholecystitis, 4 pneumonia, 1 overdose, 1 dehydration, 1 back pain, 1 intervertebral disc protrusion, 5 syncope, 1 completed suicide, 2 depression, 4 suicidal ideation, 1 dyspnoea, 1 nausea, 2 vomiting, 3 neutropenia, 3 thrombocytopenia, 2 bronchitis, 3 cellulitis, 1 staphylococcal infection, 1 hyponatraemia, 1 pancytopenia, 1 breast cancer, 1 malaise, 1 pneumonia pneumococcal, 1 haemoptysis, 1 road traffic accident, 1 suicide attempt, 1 pruritus, 1 rash erythematous, 1 dizziness, 2 pulmonary embolism, 1 haemorrhoids, 4 gastroenteritis, 1 general physical health deterioration, 1 hypertensive crisis, 1 colon cancer, 1 drug abuse, 2 hypokalaemia, 2 chest discomfort, 1 fatigue, 1 perirectal abscess, 1 acute myocardial infarction, 1 gastrointestinal haemorrhage, 1 aplasia pure red cell, 2 leukopenia, 1 atrial flutter, 1 cardiac arrest, 1 hypertrophic cardiomyopathy, 1 tachycardia, 1 deafness, 1 conjunctivitis, 1 optic neuropathy, 1 papilledema, 1 abdominal pain lower, 1 colonic polyp, 1 gastroesophageal reflux disease, 1 hematemesis, 1 haemorrhoidal haemorrhage, 1 Mallory‐weiss syndrome, 1 umbilical hernia, 1 sarcoidosis, 1 abscess, 1 abscess limb, 1 bacteraemia, 1 epiglottitis, 1 infected bites, 1 injection site infection, 1 scrotal abscess, 1 tracheobronchitis, 1 post procedural complication, 1 transfusion reaction, 1 vascular pseudoaneurysm, 1 wound dehiscence, 1 flank pain, 1 groin pain, 1 musculoskeletal chest pain, 1 bladder cancer, 1 pancreatic carcinoma, 1 prostate cancer, 1 carotid artery stenosis, 1 cerebral ischaemia, 1 motor neurone disease, 1 muscle spasticity, 1 affective disorder, 1 alcohol abuse, 1 anxiety, 1 psychiatric decompensation, 1 scrotal pain, 2 cough, 1 pleural fibrosis, 1 alcohol use, 1 laryngeal operation, 1 accelerated hypertension, 1 arterial thrombosis limb, 2 hypotension </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87 out of 734</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 myocardial infarction, 1 abdominal pain, 2 pyrexia, 1 cholecystitis, 1 appendicitis, 1 pneumonia, 1 hepatic neoplasm malignant, 1 completed suicide, 1 depression, 1 suicidal ideation, 1 pneumothorax, 2 cholelithiasis, 1 nausea, 1 vomiting, 1 cellulitis, 1 breast cancer, 1 colitis, 1 upper respiratory tract infection, 1 suicide attempt, 2 death, 1 accidental overdose, 1 dizziness, 1 loss of consciousness, 1 cholecystitis acute, 1 sinusitis, 2 pancreatitis, 1 leukocytosis, 1 cardiac arrest, 1 cardio‐respiratory arrest, 1 hypothyroidism, 1 cholelithiasis obstructive, 1 atypical mycobacterial infection, 1 diverticulitis, 1 enterocolitis infectious, 1 alcohol poisoning, 1 spinal fracture, 1 white blood cell count decreased, 1 lung adenocarcinoma, 1 prostate cancer, 1 hypoaesthesia, 1 affective disorder, 1 bipolar disorder, 1 drug dependence, 1 intentional self‐injury, 1 personality disorder, 1 glomerulonephritis minimal lesion, 1 renal tubular necrosis, 1 physical assault, 1 cholecystectomy, 1 skin neoplasm excision </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 out of 363</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0184" title="SilvaMO , TreitelM , GrahamDJ , CurryS , FronteraMJ , McMonagleP , et al. Antiviral activity of boceprevir monotherapy in treatment‐naive subjects with chronic hepatitis C genotype 2/3. Journal of Hepatology2013;59(1):31‐7. ">Silva 2013a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 atrial fibrillation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0196" title="ShermanKE , RockstrohJK , DieterichDT , SorianoV , GirardPM , McCallisterS , et al. Telaprevir combination with peginterferon alfa‐2A/ribavirin in HCV/HIV coinfected patients: 24‐week treatment interim analysis. Hepatology2011;54(4 Suppl):1431A‐2A. SulkowskiMS , ShermanKE , DieterichDT , BsharatM , MahnkeL , RockstrohJK , et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Annals of Internal Medicine2013;159(2):86‐96. SulkowskiMS , ShermanKE , SorianoV , RockstrohJ , DieterichDT , GirardPM , et al. Telaprevir in combination with peginterferon alfa‐2a/ribavirin in HCV/HIV co‐infected patients: SVR24 final study results. Hepatology2012;56(S1):219A. ">Sulkowski 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 anaemia, 2 pneumonia, 1 syncope, 1 depression, 1 deep vein thrombosis, 1 lymphadenopathy, 1 renal failure acute, 2 pulmonary embolism, 1 arthralgia, 1 sinusitis, 1 urinary tract infection, 1 lung infection pseudomonal, 1 pelvic inflammatory disease, 1 pulmonary hypertension, 1 suicide attempt </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 out of 64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 anaemia, 1 overdose, 1 cholelithiasis, 1 abdominal pain upper, 1 meniscus lesion, 1 pancreatitis, 1 post procedural infection, 1 renal failure, 1 cholecystectomy, 1 vulval abscess, 1 ventricular fibrillation, 1 ligament rupture, 1 lactic acidosis, 1 respiratory failure </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 out of 34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0042" title="DoreGJ , LawitzE , HezodeC , ShafranSD , RamjiA , TatumHA , et al. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. Gastroenterology2015;148(2):355‐66. ">Dore 2015a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daclatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 hepatic neoplasm malignant, 1 rectal ulcer haemorrhage, 1 gastrointestinal inflammation, 1 adhesion, 1 biliary colic, 1 hyperbilirubinaemia, 1 appendiceal abscess, 1 tonsil cancer </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 out of 196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 abdominal pain upper, 1 epicondylitis, 1 conversion disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 out of 100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0031" title="HezodeC , HirschfieldGM , GhesquiereW , SievertW , Rodriguez‐TorresM , ShafranS , et al. BMS‐790052, a NS5A replication complex inhibitor, combined with peginterferon alfa‐2a and ribavirin in treatment‐naive HCV‐genotype 1 or 4 patients: phase 2b AI444010 study interim week 12 results. Hepatology2011;54(S1):474A‐5A. HezodeC , HirschfieldGM , GhesquiereW , SievertW , Rodriguez‐TorresM , ShafranS , et al. Daclatasvir (BMS‐790052), a NS5A replication complex inhibitor, combined with peginterferon‐alfa‐2a and ribavirin in treatment‐naive HCV genotype 1 or 4 subjects: phase 2b AI444010 study interim week 24 results. Hepatology International2012;6(1):167. HezodeC , HirschfieldGM , GhesquiereW , SievertW , Rodriguez‐TorresM , ShafranSD , et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment‐naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut2015;64(6):948‐56. ">COMMAND‐1 2015a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daclatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 abdominal pain, 1 gastritis, 1 chest pain, 2 pneumonia, 1 overdose, 1 syncope, 2 depression, 2 suicidal ideation, 1 dyspnoea, 1 bronchitis, 1 peritonitis, 1 rash generalised, 1 febrile neutropenia, 1 aplastic anaemia, 1 auricular perichondritis, 2 gastric ulcer haemorrhage, 1 death, 1 bile duct stone, 1 clostridium difficile, 1 furuncle, 1 carbuncle, 1 oral herpes, 1 accidental overdose, 2 falls, 1 bursitis, 1 rhabdomyolysis, 1 muscle spasms, 1 costochondritis, 1 dizziness, 1 loss of consciousness, 1 adjustment disorder, 1 hypomania, 1 mental disorder, 1 substance‐induced psychotic disorder, 1 schizophrenia, paranoid type </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 out of 317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 anaemia, 1 atrial fibrillation, 1 pneumonia, 1 pyelonephritis, 1 haemoglobin decreased, 1 epistaxis, 1 electrocardiogram change, 1 neutrophil count decreased, 1 myalgia, 1 aphasia, 1 paraesthesia </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 out of 78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0081" title="IzumiN , AsahinaY , YokosukaO , ImazekiF , KawadaN , TamoriA , et al. Combination therapy of treatment‐naive and nonresponder patients with HCV genotype 1 infection with BMS‐790052, an NS5A replication complex inhibitor, in combination with peginterferon alfa‐2a and ribavirin. Hepatology2011;54(S1):1439A‐40A. IzumiN , YokosukaO , KawadaN , OsakiY , YamamotoK , SataM , et al. Daclatasvir combined with peginterferon alfa‐2a and ribavirin in Japanese patients infected with hepatitis C genotype 1. Antiviral Therapy2014;19(5):501‐10. McPheeF , HernandezD , ZhouN , YuF , UelandJ , MonikowskiA , et al. Virological escape in HCV genotype‐1‐infected patients receiving daclatasvir plus ribavirin and peginterferon alfa‐2a or alfa‐2b. Antiviral Therapy2014;19(5):479‐90. SuzukiF , ChayamaK , KawakamiY , ToyotaJ , KarinoY , MochidaS , et al. BMS‐790052, AN NS5A replication complex inhibitor, in combination with peginterferon alpha‐2B and ribavirin in Japanese treatment naive and nonresponder patients with chronic HCV genotype 1 infection. Hepatology2011;54(S1):1441A. SuzukiF , ChayamaK , KawakamiY , ToyotaJ , KarinoY , MochidaS , et al. Daclatasvir (BMS‐790052), an NS5A replication complex inhibitor, in combination with peginterferon alpha‐2b and ribavirin in Japanese treatment‐naive and nonresponder patients with chronic HCV genotype 1 infection. Hepatology International2012;6(1):161‐2. SuzukiF , ToyotaJ , IkedaK , ChayamaK , MochidaS , HayashiN , et al. A randomized trial of daclatasvir with peginterferon alfa‐2b and ribavirin for HCV genotype 1 infection. Antiviral Therapy2014;19(5):491‐9. ">Izumi 2014a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daclatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 pancreatitis acute, 1 back pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 out of 34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0161" title="PolS , GhalibRH , RustgiVK , MartorellC , EversonGT , TatumHA , et al. Daclatasvir for previously untreated chronic hepatitis C genotype‐1 infection: a randomised, parallel‐group, double‐blind, placebo‐controlled, dose‐finding, phase 2a trial. Lancet Infectious Diseases2012;12(9):671‐7. ">Pol 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daclatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 chest pain, 2 syncope, 1 bronchitis, 1 epistaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 out of 36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0035" title="EversonG , CooperC , HezodeC , ShiffmanML , YoshidaE , Beltran‐JaramilloT , et al. Dauphine: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha‐2a/ribavirin in HCV genotypes 1 or 4. Liver International2015;35(1):108‐19. EversonG , CooperC , HezodeC , ShiffmanML , YoshidaE , Beltran‐JaramilloT , et al. Rapid and sustained achievement of undetectable HCV RNA during treatment with ritonavir‐boosted danoprevir/peg‐ifna‐2a/RBV in HCV genotype 1 or 4 patients: dauphine week 12 interim analysis. Journal of Hepatology2012;56(Suppl 2):S466. HezodeC , ShiffmanML , CooperC , EversonGT , MarcellinP , Rodriguez‐TorresM , et al. Ritonavir‐boosted danoprevir plus peg‐IFNalpha‐2a/ribavirin (P/R) demonstrates up to 100% SVR24 with 12 or 24 weeks of total treatment in treatment‐naive patients with HCV genotype 4 infection in the DAUPHINE study. Hepatology2012;56(S1):557A. LePogamS , NavarroM , BuL , VoulgariA , IllnickaM , YanJM , et al. Low rate of on‐treatment resistance to danoprevir boosted by ritonavir (DNVR) combined with Peg‐IFNa‐2a/ribavirin: 12 week interim analysis from Dauphine study. Journal of Hepatology2012;56(Suppl 2):S472. ">Dauphine 2015a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Danoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 unspecified SAEs and 2 deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 out of 373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 unspecified SAE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 44</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0054" title="ForestierN , LarreyD , GuyaderD , MarcellinP , RouzierR , PatatA , et al. Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN‐191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study. Journal of Hepatology2011;54(6):1130‐6. ForestierN , LarreyDG , GuyaderD , MarcellinP , RouzierR , PatatAA , et al. Treatment of chronic hepatitis C virus (HCV) genotype 1 patients with the NS3/4A protease inhibitor ITMN‐191 leads to rapid reductions in plasma HCV RNA: results of a phase 1b multiple ascending dose (MAD) study. Hepatology2008;48(4 (Suppl)):1132A. MoucariR , ForestierN , LarreyD , GuyaderD , CouzigouP , BenhamouY , et al. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut2010;59(12):1694‐8. ">Forestier 2011a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Danoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 benign paroxysmal vertigo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0056" title="ForestierN , LarreyD , MarcellinP , BenhamouY , GuyaderD , BradfordW , et al. Antiviral activity and safety of ITMN‐191 in combination with peginterferon alfa‐2a and ribavirin in patients with chronic hepatitis C virus (HCV). Journal of Hepatology2009;50(Suppl 1):S35. ForestierN , LarreyD , MarcellinP , GuyaderD , PatatA , RouzierR , et al. Antiviral activity of danoprevir (ITMN‐191/RG7227) in combination with pegylated interferon alpha‐2a and ribavirin in patients with hepatitis C. Journal of Infectious Diseases2011;204(4):601‐8. ">Forestier 2011b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Danoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 gastroenteritis viral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0068" title="GaneE , RouzierR , StedmanC , Wiercinska‐DrapaloA , HorbanA , ChangL , et al. Ritonavir boosting of low dose RG7227/ITMN‐191, HCV NS3/4 a protease inhibitor, results in robust reduction in HCV RNA at lower exposures than provided by unboosted regimens. Journal of Hepatology2010;52(Suppl 1):S16‐7. GaneEJ , RouzierR , StedmanC , Wiercinska‐DrapaloA , HorbanA , ChangL , et al. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG‐IFN alpha‐2a/RBV in hepatitis C patients. Journal of Hepatology2011;55(5):972‐9. MorcosPN , ChangL , KulkarniR , GiraudonM , ShulmanN , BrennanBJ , et al. A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail. European Journal of Clinical Pharmacology2013;69(11):1939‐49. ">Gane 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Danoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 altered mood</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0015" title="MarcellinP , CooperC , BalartL , LarreyD , BoxT , YoshidaE , et al. Randomized controlled trial of danoprevir plus peginterferon alfa‐2a and ribavirin in treatment‐naïve patients with hepatitis C virus genotype 1 infection. Gastroenterology2013;145:790‐800. MarcellinP , CooperC , BalartLA , LarreyDG , BoxTD , YoshidaE , et al. High sustained virological response rates with response‐guided danoprevir plus peginterferon alfa‐2a (40KD) and ribavirin in treatment‐naive, HCV genotype 1 patients: ATLAS study final results. Journal of Hepatology2012;56(Suppl S2):S472. TerraultN , CooperC , BalartLA , LarreyDG , BoxTD , YoshidaE , et al. High sustained virologic response (SVR24) rates with response‐guided danoprevir (DNV; RG7227) plus pegIfn alpha‐2A (40KD) and ribavirin (P/R) in treatment‐naive HCV genotype 1 (G1) patients: results from the ATLAS study. Hepatology2011;54(S1):398A‐9A. TerraultN , CooperC , BalartLA , LarreyDG , BoxTD , YoshidaEM , et al. Phase II randomised, partially‐blind, parallel‐group study of oral danoprevir (RG7227) with PegIFNα‐2a (Pegasys) plus ribavirin (Copegus) in treatment‐naive genotype 1 patients with CHC: results of planned week 12 interim analysis of the ATLAS study. Hepatology2010;52(Suppl S1):335A. ">ATLAS 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Danoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 SAEs but not specified, 1 death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 out of 194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 SAEs but not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 out of 31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0094" title="LagaceL , CartierM , LaflammeG , LawetzC , MarquisM Triki I , et al. Genotypic and phenotypic analysis of the NS5B polymerase region from viral isolates of HCV chronically infected patients treated with BI 207127 for 5‐days monotherapy. Hepatology2010;52(Suppl S1):1205A‐6A. LarreyD , LohseAW , TrepoC , BronowickiJP , ArastehK , BourliereM , et al. Antiviral effect, safety, and pharmacokinetics of five‐day oral administration of deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis C. Antimicrobial Agents and Chemotherapy2013;57(10):4727‐35. LarreyDG , BenhamouY , LohseAW , TrepoC , MoellekenC , BronowickiJ , et al. BI 207127 is a potent HCV RNA polymerase inhibitor during 5 days monotherapy in patients with chronic hepatitis C. Hepatology2009;50(4):1044A. ">Larrey 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deleobuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 drug eruption</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0093" title="LarreyD , LohseA , DeLedinghenV , TrepoC , GerlachT , ZarskiJP , et al. 4 week therapy with the non‐nucleosidic polymerase inhibitor BI207127 in combination with peginterferon‐alfa2A and ribavirin in treatment naive and treatment experienced chronic HCV GT1 patients. Journal of Hepatology2010;52(Suppl S1):S466. LarreyD , LohseAW , DeLedinghenV , TrepoC , GerlachT , ZarskiJP , et al. Rapid and strong antiviral activity of the non‐nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. Journal of Hepatology2012;57(1):39‐46. ">Larrey 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deleobuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 syncope, 1 rash maculo‐papular, 1 umbilical hernia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 out of 49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0190" title="AsselahT , JensenDM , FosterG , SulkowskiM , OuzanD , MoranoL , et al. Faldaprevir plus pegylated interferon/ribavirin did not increase anaemia compared with pegylated interferon/ribavirin in HCV genotype‐1, treatment‐naive patients: pooled analysis of phase III studies. Gastroenterology2014;146(5 (Suppl 1)):S‐977. AsselahT , JensenDM , FosterG , SulkowskiM , OuzanD , MoranoL , et al. Virological response in treatment‐naive patients with chronic HCV genotype‐1 infection receiving faldaprevir plus pegylated interferon alpha‐2a and ribavirin is unaffected by ribavirin dose reduction. Gastroenterology2014;146(5 (Suppl 1)):S975‐6. BergerK , SarrazinC , FerenciP , JensenDM , JacobsonIM , SternJO , et al. NS3 Q80K did not impact efficacy or treatment‐emergent resistance patterns in HCV genotype 1‐infected patients receiving faldaprevir + peginterferon/ribavirin in three phase III trials. Journal of Hepatology2014;60(1):S497. FerenciP , DieterichD , ZeuzemS , MantryP , SarrazinC , CrespoJ , et al. Early stopping rules for faldaprevir plus pegylated interferon alpha‐2a and ribavirin in treatment‐naive patients: exploratory study of pooled data from phase III trials. Journal of Hepatology2014;60(1 (Suppl 1)):S452‐3. FosterGR , CooperC , DieterichD , FerenciP , CrespoJ , DiagoM , et al. Pharmacokinetic‐response analysis of faldaprevir in treatment‐naive patients with chronic HCV genotype‐1 infection: a pooled analysis of two phase III trials. Journal of Hepatology2014;60(1 (Suppl 1)):S454‐5. JensenDM , AsselahT , DieterichDT , FosterGR , SulkowskiMS , ZeuzemS , et al. A pooled analysis of two randomized, double‐blind placebo‐controlled phase III trials (STARTVerso1&amp;2) of faldaprevir plus pegylated interferon alfa‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C genotype‐1 infection. Hepatology2013;58(Suppl 1):734A‐5A. JensenDM , FosterG , FerenciP , CooperC , DieterichDT , SulkowskiM , et al. Faldaprevir plus pegylated interferon alfa‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C genotype‐1 infection: a pooled analysis of two randomized, double‐blind placebo‐controlled phase iii trials (STARTVerso1&amp;2). Gastroenterology2014;146(5 (Suppl 1)):S974. YoshidaEM , AsselahT , MorenoC , MaevskayaMV , KaoJH , CrespoJ , et al. Subgroup analyses and baseline predictors of response with faldaprevir plus pegylated interferon alfa‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C genotype‐1 infection: a pooled analysis of STARTVerso1 and 2. Hepatology2013;58(4 Suppl):751A‐2A. ZeuzemS , JensenDM , CarvalhoA , DiagoM , FeinmanSV , KowdleyKV , et al. No effect of faldaprevir on renal function in treatment‐naive patients with chronic HCV genotype‐1 infection: pooled data from two phase III trials. Journal of Hepatology2014;60(1 (Suppl 1)):S451. ">STARTverso‐2 2014a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faldaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 anaemia, 1 angina pectoris, 2 diarrhoea, 1 oesophageal varices haemorrhage, 1 cholecystitis, 2 pneumonia, 1 dehydration, 1 back pain, 1 intervertebral disc protrusion, 1 bipolar disorder, 1 depression, 1 suicidal ideation, 1 dyspnoea, 2 nausea, 3 vomiting, 2 neutropenia, 1 thrombocytopenia, 1 cellulitis, 1 mental status changes, 1 pancytopenia, 1 breast cancer, 1 malaise, 2 rash, 2 sepsis, 1 suicide attempt, 1 renal failure acute, 1 rash maculo‐papular, 1 accidental overdose, 1 muscle spasm, 1 tibia fracture, 1 contusion, 1 pulmonary embolism, 2 abortion spontaneous, 1 hypokalaemia, 1 subcutaneous abscess, 1 acute myocardial infarction, 1 pancreatitis, 1 umbilical hernia, 1 diverticulitis, 1 cerebral ischaemia, 1 drug dependence, 1 personality disorder, 1 epidermolysis, 1 ascites, 1 duodenal ulcer haemorrhage, 1 large intestine perforation, 1 hepatic cirrhosis, 2 hepatic failure, 1 hypersensitivity, 1 infective chondritis, 1 vulval abscess, 1 fibula fracture, 1 jaw fracture, 1 ligament sprain, 1 hypocalcaemia, 1 hyponatraemia, 1 hepatocellular carcinoma, 1 papillary thyroid cancer </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 out of 525</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 2 depression, 1 suicidal ideation, 1 bile duct stone, 1 subcutaneous abscess, 1 optic ischaemic neuropathy, 1 laceration, 1 mental status change </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 out of 132</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0188" title="AsselahT , JensenDM , FosterG , SulkowskiM , OuzanD , MoranoL , et al. Faldaprevir plus pegylated interferon/ribavirin did not increase anaemia compared with pegylated interferon/ribavirin in HCV genotype‐1, treatment‐naive patients: pooled analysis of phase III studies. Gastroenterology2014;146(5 Suppl 1):S‐977. AsselahT , JensenDM , FosterG , SulkowskiM , OuzanD , MoranoL , et al. Virological response in treatment‐naive patients with chronic HCV genotype‐1 infection receiving faldaprevir plus pegylated interferon alpha‐2a and ribavirin is unaffected by ribavirin dose reduction. Gastroenterology2014;146(5 Suppl 1):S975‐6. BergerK , SarrazinC , FerenciP , JensenDM , JacobsonIM , SternJO , et al. NS3 Q80K did not impact efficacy or treatment‐emergent resistance patterns in HCV genotype 1‐infected patients receiving faldaprevir + peginterferon/ribavirin in three phase III trials. Journal of Hepatology2014;60(1 Suppl S):S497. FerenciP , AsselahT , FosterGR , ZeuzemS , SarrazinC , MorenoC , et al. Faldaprevir plus pegylated interferon alfa‐2A and ribavirin in chronic HCV genotype‐1 treatment‐naive patients: final results from STARTVerso1, a randomised, double‐blind, placebo‐controlled phase III trial. Journal of Gastroenterology and Hepatology2013;28(Suppl 2):157‐8. FerenciP , AsselahT , FosterGR , ZeuzemS , SarrazinC , MorenoC , et al. STARTVerso1: a randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype‐1 infection. Journal of Hepatology2015;62(6):1246‐55. FerenciP , DieterichD , ZeuzemS , MantryP , SarrazinC , CrespoJ , et al. Early stopping rules for faldaprevir plus pegylated interferon alpha‐2a and ribavirin in treatment‐naive patients: exploratory study of pooled data from phase III trials. Journal of Hepatology2014;60(1 Suppl 1):S452‐S3. FosterGR , CooperC , DieterichD , FerenciP , CrespoJ , DiagoM , et al. Pharmacokinetic‐response analysis of faldaprevir in treatment‐naive patients with chronic HCV genotype‐1 infection: a pooled analysis of two phase III trials. Journal of Hepatology2014;60(1 Suppl 1):S454‐5. JensenDM , AsselahT , DieterichDT , FosterGR , SulkowskiMS , ZeuzemS , et al. A pooled analysis of two randomized, double‐blind placebo‐controlled phase III trials (STARTVerso1 &amp; 2) of faldaprevir plus pegylated interferon alfa‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C genotype‐1 infection. Hepatology2013;58(Suppl 1):734A‐5A. JensenDM , FosterG , FerenciP , CooperC , DieterichDT , SulkowskiM , et al. Faldaprevir plus pegylated interferon alfa‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C genotype‐1 infection: a pooled analysis of two randomized, double‐blind placebo‐controlled phase III trials (STARTVerso 1 &amp; 2). Gastroenterology2014;146(5 Suppl 1):S974. MorenoC , FerenciP , AsselahT , FosterG , ZeuzemS , SarrazinC , et al. Faldaprevir plus pegylated interferon alfa‐2a and ribavirin in chronic HCV genotype‐1 treatment‐naive patients: final results from STARTVerso1: a randomized, double‐blind, placebo‐controlled, phase 3 trial. American Journal of Gastroenterology2013;108(Suppl 1):S145. YoshidaEM , AsselahT , MorenoC , MaevskayaMV , KaoJH , CrespoJ , et al. Subgroup analyses and baseline predictors of response with faldaprevir plus pegylated interferon alfa‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C genotype‐1 infection: a pooled analysis of STARTVerso1 and 2. Hepatology2013;58(Suppl S1):751A‐2A. ZeuzemS , JensenDM , CarvalhoA , DiagoM , FeinmanSV , KowdleyKV , et al. No effect of faldaprevir on renal function in treatment‐naive patients with chronic HCV genotype‐1 infection: pooled data from two phase III trials. Journal of Hepatology2014;60(1 Suppl S):S451. ">STARTVerso‐1 2015a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faldaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 anaemia, 1 atrial fibrillation, 1 myocardial infarction, 1 asthenia, 1 chest pain, 1 pyrexia, 1 bronchopneumonia, 1 pneumonia, 1 sciatica, 2 vomiting, 1 thrombocytopenia, 1 pancytopenia, 1 headache, 2 rash, 1 drug eruption, 1 dizziness, 1 haemorrhoids, 1 psychotic disorder, 1 urinary tract infection, 1 diabetes mellitus, 1 parapsoriasis, 1 pancreatitis, 1 histiocytosis haematophagic, 1 cerebrovascular accident, 1 muscular weakness, 1 epistaxis, 1 leukopenia, 1 sarcoidosis, 1 hypotension, 1 idiopathic thrombocytopenic purpura, 1 optic ischaemic neuropathy, 1 hypersensitivity, 1 hypoparathyroidism, 1 retinopathy, 1 subdural hematoma, 1 cervix carcinoma, 1 cubital tunnel syndrome, 1 dyspnoea exertional </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 out of 520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 cholecystitis, 1 gun shot wound, 1 rash maculo‐papular, 1 diverticulitis, 1 inguinal hernia, 1 hepatic lesion, 1 polymyositis, 1 blister </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 out of 132</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0192" title="AsselahT , ZehnterE , AgarwalK , SakaiY , YatsuhashiH , WillemsB , et al. Pharmacokinetic‐response analysis of faldaprevir in patients with chronic HCV genotype‐1 infection with prior relapse. Journal of Hepatology2014;60(1 Suppl S):S458‐9. BergerK , SarrazinC , FerenciP , JensenDM , JacobsonIM , SternJO , et al. NS3 Q80K did not impact efficacy or treatment‐emergent resistance patterns in HCV genotype 1‐infected patients receiving faldaprevir+peginterferon/ribavirin in three phase III trials. Journal of Hepatology2014;60(1 Suppl S):S497. JacobsonIM , AsselahT , FerenciP , FosterGR , JensenDM , NegroF , et al. STARTVerso3: a randomized, double‐blind, placebo‐controlled phase III trial of faldaprevir in combination with pegylated interferon a lf a‐2a and ribavirin in treatment‐experienced patients with chronic hepatitis C genotype‐1 infection. Hepatology2013;48(S1):742A‐3A. JacobsonIM , FerenciP , FosterGR , JensenDM , NegroF , MantryP , et al. STARTVerso3: a randomized, double‐blind, placebo controlled phase III trial of faldaprevir in combination with pegylated interferon alpha‐2a and ribavirin in treatment experienced patients with chronic hepatitis C genotype‐1 infection. Hepatology International2014;8(1 Suppl):S213‐4. ">STARTverso‐3 2013a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faldaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 anaemia, 1 atrial fibrillation, 1 abdominal pain, 5 diarrhoea, 1 pancreatitis acute, 1 asthenia, 1 chest pain, 8 pyrexia, 2 appendicitis, 1 gastroenteritis viral, 2 pneumonia, 1 decreased appetite, 1 dehydration, 1 back pain, 1 hepatic neoplasm malignant, 2 cholelithiasis, 1 biliary colic, 2 hyperbilirubinaemia, 3 nausea, 2 vomiting, 1 thrombocytopenia, 1 cellulitis, 1 bradycardia, 2 presyncope, 2 malaise, 2 headache, 2 sepsis, 1 rash erythematous, 1 rash generalised, 1 fall, 1 multiple injuries, 1 haematochezia, 1 peritonitis bacterial, 1 congestive cardiac failure, 1 gastroenteritis, 1 hypertensive crisis, 1 hypokalaemia, 1 fatigue, 1 pancreatitis, 1 coma, 1 renal colic, 1 leukopenia, 1 cardio‐respiratory arrest, 1 anxiety, 1 psychiatric decompensation, 2 hypotension, 1 viral infection, 2 ascites, 1 hepatic failure, 1 hypoglycaemia, 1 haemolytic anaemia, 1 keratosis follicular, 1 oral lichen planus, 1 peritoneal haemorrhage, 1 salivary gland calculus, 1 hepatorenal failure, 2 jaundice, 1 streptococcal infection, 1 blood lactate dehydrogenase increased, 1 international normalised ratio abnormal, 1 metabolic acidosis, 1 fasciitis, 1 joint instability, 1 musculoskeletal discomfort, 1 haemothorax, 1 venous thrombosis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 out of 599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 depression, 1 pleural effusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0144" title="NishiguchiS , KubokiM , SakaiY , AizawaN , IwataK , IkedaN , et al. All treated Japanese genotype 1 patients with IL28B TT allele achieved SVR by 4 weeks faldaprevir and 48 weeks PegIFN/ ribavirin. Hepatology International2013;7(1 Suppl):S393. NishiguchiS , KubokiM , SakaiY , AizawaN , TakashimaT , IwataK . 100% SVR in Japanese genotype 1 patients with IL28B TT allele treated with 4 weeks faldaprevir and 48 weeks PegIFN/ribavirin. Hepatology International2013;7(1 Suppl):S372‐3. NishiguchiS , SakaiY , KubokiM , TsunematsuS , UranoY , SakamotoW , et al. Safety and efficacy of faldaprevir with pegylated interferon alfa‐2a and ribavirin in Japanese patients with chronic genotype‐1 hepatitis C infection. Liver International2014;34(1):78‐88. ">Nishiguchi 2014a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faldaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 abdominal pain upper</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0115" title="MannsMP , BourliereM , BenhamouY , PolS , BonaciniM , BergT . Safety and antiviral activity of BI201335, a new HCV NS3 protease inhibitor, in treatment‐naive patients with chronic hepatitis C genotype‐1 infection given as monotherapy and in combination with peginterferon alfa 2a (P) and ribavirin (R). Hepatology2008;48(4 Suppl):1023A. MannsMP , BourliereM , BenhamouY , PolS , BonaciniM , TrepoC , et al. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype‐1 infection. Journal of Hepatology2011;54(6):1114‐22. ">Manns 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faldaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 asthenia, 1 cataract , 1 hypoalbuminaemia, 1 metabolic disorder, 1 ascites</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 out of 88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0196" title="ShermanKE , RockstrohJK , DieterichDT , SorianoV , GirardPM , McCallisterS , et al. Telaprevir combination with peginterferon alfa‐2A/ribavirin in HCV/HIV coinfected patients: 24‐week treatment interim analysis. Hepatology2011;54(4 Suppl):1431A‐2A. SulkowskiMS , ShermanKE , DieterichDT , BsharatM , MahnkeL , RockstrohJK , et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Annals of Internal Medicine2013;159(2):86‐96. SulkowskiMS , ShermanKE , SorianoV , RockstrohJ , DieterichDT , GirardPM , et al. Telaprevir in combination with peginterferon alfa‐2a/ribavirin in HCV/HIV co‐infected patients: SVR24 final study results. Hepatology2012;56(S1):219A. ">Sulkowski 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faldeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 anaemia, 1 angina pectoris, 1 myocardial infarction, 1 diarrhoea, 1 asthenia, 1 chest pain, 1 oedema peripheral, 4 pyrexia, 1 cholecystitis, 1 pneumonia, 2 dehydration, 1 intervertebral disc protrusion, 2 syncope, 1 depression, 1 nausea, 2 vomiting, 1 thrombocytopenia, 1 upper gastrointestinal haemorrhage, 1 influenza, 1 lower respiratory tract infection, 2 photosensitivity reaction, 1 upper respiratory tract infection, 2 headache, 1 rash, 1 road traffic accident, 2 suicide attempt, 3 drug eruption, 2 rash maculo‐papular, 1 rash erythematous, 2 febrile neutropenia, 1 oral herpes, 1 pulmonary embolism, 1 pyelonephritis, 1 cataract, 1 anaemia haemolytic autoimmune, 1 lymphopenia, 1 microvascular angina, 1 prinzmetal angina, 1 anal fistula, 1 haemorrhoids, 1 mouth ulceration, 1 rectal haemorrhage, 1 chest discomfort, 1 fatigue, 1 mucosal inflammation, 1 gallbladder polyp, 1 cryoglobulinaemia, 1 anal abscess, 1 ear infection, 2 H1N1 influenza, 1 infected skin ulcer, 1 lymphangitis, 1 perirectal abscess, 1 pharyngitis, 1 subcutaneous abscess, 1 superinfection bacterial, 1 urinary tract infection, 1 diabetes mellitus, 1 ischaemic stroke, 1 acute psychosis, 1 depressed mood, 1 calculus ureteric, 1 endometrial hyperplasia, 1 dermatitis atopic, 1 eczema, 1 erythema multiforme, 1 lichen planus, 1 palmar‐plantar erythrodysaesthesia syndrome, 1 parapsoriasis, 1 pruritus allergic, 1 rash pruritic, 1 appendicectomy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 out of 641</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 headache, 1 photophobia, 1 cyst, 1 benign salivary gland neoplasm, 1 migraine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 out of 71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0083" title="JacobsonI , PockrosP , LalezariJ , LawitzE , Rodriguez‐TorresM , DeJesusE , et al. Antiviral activity of filibuvir in combination with pegylated interferon alfa‐2A and ribavirin for 28 days in treatment naive patients chronically infected with HCV genotype 1. Journal of Hepatology2009;50(Suppl 1):S382. JacobsonI , PockrosPJ , LalezariJ , LawitzE , Rodriguez‐TorresM , DeJesusE , et al. Virologic response rates following 4 weeks of filibuvir in combination with pegylated interferon alfa‐2A and ribavirin in chronically‐infected HCV genotype‐1 patients. Journal of Hepatology2010;52(Suppl 1):S464. MoriJ , HammondJL , SrinivasanS , JagannathaS , RystECC . Genotypic characterisation of filibuvir (PF‐00868554 ) resistance in patients receiving four weeks co‐administration of filibuvir with pegIFN/RBV. Hepatology2010;52(Suppl S1):722A. MoriJ , HammondJL , SrinivasanS , JagannathaS , Van derRystE . Genotypic characterisation of filibuvir (PF‐00868554) resistance in patients receiving four weeks co‐administration of filibuvir with PEGIFN/RBV (12 week analysis). Journal of Hepatology2010;52(Suppl 1):S15. ">Jacobson 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Filibuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 blood creatinine increased, 1 chronic obstructive pulmonary disease, 1 pulmonary embolism </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 out of 27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 thyroiditis, 1 gait disturbance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0179" title="Rodriguez‐TorresM , YoshidaEM , MarcellinP , SrinivasanS , PurohitVS , WangC , et al. A phase 2 study of filibuvir in combination with pegylated IFN alfa and ribavirin for chronic HCV. Annals of Hepatology2014;13(4):364‐75. ">Rodriguez‐Torres 2014b1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Filibuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 appendicitis, 1 rectal ulcer haemorrhage, 1 craniocerebral injury, 1 vertigo, 1 vestibular disorder, 1 haematochezia, 1 peritonitis bacterial, 1 lymph node tuberculosis, 1 scapula fracture, 1 blood urea nitrogen/creatinine increased, 1 gastric cancer, 1 rectal cancer, 1 abortion spontaneous, 1 cardiac necrosis, 1 pyoderma gangrenosum, 1 depression, 1 breast cancer, 1 chronic obstructive pulmonary disease, 1 lung neoplasm malignant, 1 fall, 1 loss of consciousness, 1 bacterial abscess CNS, 1 actinomyces test positive, 1 pulmonary calcification </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 out of 192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 neutropenia, 1 sepsis, 1 pulmonary embolism, 1 cerebral haemorrhage, 1 ecchymosis, 1 Appendicitis perforated </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 out of 96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0106" title="LawitzE , HillJM , MarburyTC , Rodriguez‐TorresM , DeMiccoMP , QuesadaJ , et al. Three‐day, dose‐ranging study of the HCV NS3 protease inhibitor GS‐9451. Hepatology2010;52(Suppl S1):714A. LawitzEJ , HillJM , MarburyT , DemiccoMP , DelaneyW , YangJ , et al. A phase I, randomized, placebo‐controlled, 3‐day, ascending‐dose study of GS‐9451, an NS3/4a protease inhibitor, in genotype 1 hepatitis C patients. Antiviral Therapy2013;18(3):311‐9. ">Lawitz 2013b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GS‐9451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 death, 1 heroin overdose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0070" title="GardnerS , CutrellAMY , Elko‐SimmsC , AdkisonK , HamatakeR , WalkerJ , et al. A double‐blind, randomized, placebo‐controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa‐2a and ribavirin in hepatitis C virus genotype 1‐infected treatment‐naive subjects. Liver International2014;34(6):e89‐e95. ">Gardner 2014a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GSK2336805</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 pneumonia, 1 upper lobe cavitary lesion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0092" title="LalezariJ , BoxT , O'RiordanW , MehraP , NguyenT , PoordadF , et al. IDX184 in combination with pegylated interferon‐alpha2a and ribavirin for 2 weeks in treatment‐naive patients with chronic hepatitis C. Antiviral Therapy2013;18(6):755‐64. LalezariJ , PoordadF , MehraP , NguyenT , DejesusE , GodofskyE , et al. Antiviral activity, pharmacokinetics and safety of IDX184 in combination with pegylated interferon (pegIFN) and ribavirin (RBV) in treatment‐naive HCV genotype 1‐infected subjects. Journal of Hepatology2010;52(Suppl S1):S469. LalezariJP , O'RiordanW , PoordadF , NguyenTT , PatrickGD , ChenJ , et al. A phase IIA study of IDX184 in combination with pegylated interferon (PEGIFN) and ribavirin (RBV) in treatment‐naive HCV genotype 1‐infected subjects. Hepatology2010;52(Suppl S1):337A. ">Lalezari 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IDX‐184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 pancreatitis, 1 acute cholecystitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 out of 65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0067" title="ChuT , KulkarniR , GaneEJ , RobertsSK , StedmanC , AngusP , et al. The effect of host IL28B genotype on early viral kinetics during interferon‐free treatment in patients with chronic hepatitis C (CHC). Journal of Hepatology2011;54(Suppl 1):S521‐2. GaneEJ , RobertsSK , StedmanC , AngusPW , RitchieB , ElstonR , et al. First‐in‐man demonstration of potent antiviral activity with a nucleoside polymerase (R7128) and protease (R7227/ITMN‐191) inhibitor combination in HCV: safety, pharmacokinetics, and virologic results from INFORM‐1. Journal of Hepatology2009;50(Suppl 1):S380. GaneEJ , RobertsSK , StedmanCA , AngusPW , RitchieB , ElstonR , et al. Combination therapy with a nucleoside polymerase (R7128) and protease (R7227/ITMN ‐ 191) inhibitor in HCV: safety, pharmacokinetics, and virologic results from INFORM‐1. Hepatology2009;50(4 Suppl):394A‐5A. GaneEJ , RobertsSK , StedmanCAM , AngusPW , RitchieB , ElstonROB , et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM‐1): a randomised, double‐blind, placebo‐controlled, dose‐escalation trial. Lancet2010;376(9751):1467‐75. LePogamS , YanJM , ChhabraM , IlnickaM , KangH , KosakaA , et al. Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short‐term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir. Antimicrobial Agents and Chemotherapy2012;56(11):5494‐502. LimLY , KwoPY . A glimpse at the future of hepatitis C therapy: The INFORM trial. Hepatology2011;54(1):360‐3. MorcosPN , KulkarniR , IpeD , JumbeS , TranJ , BradfordWZ , et al. Pharmacokinetics/pharmacodynamics (PK/PD) of combination R7227 and R7128 therapy from INFORM‐1 demonstrates similar early HCV viral dynamics when R7227 is combined with either PEG ‐ IFN/ribavirin (SOC) or R7128. Hepatology2009;50(4 Suppl):1041A‐2A. ">Gane 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mericitabine/danoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 multiple drug overdose, 1 ankle fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 out of 73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0050" title="FeldJJ , JacobsonIM , HezodeC , AsselahT , RuanePJ , GruenerN , et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. New England Journal of Medicine2015;373(27):2599‐607. ">Feld 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mericitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 nephrolithiasis, 1 porphyria non‐acute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 out of 102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 arthritis infective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0085" title="PockrosPJ , JensenD , TsaiN , TaylorR , RamjiA , CooperC , et al. JUMP‐C: a randomized trial of mericitabine plus pegylated interferon alpha‐2a/ribavirin for 24 weeks in treatment‐naïve HCV genotype 1/4 patients. Hepatology2013;58(2):514‐23. ">JUMP‐C 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mericitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 SAEs but not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 out of 81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 SAEs but not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 out of 85</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0039" title="DeBruijneJ , BergmannJF , ReesinkHW , WeeginkCJ , MolenkampR , SchinkelJ , et al. Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients. Hepatology2010;52(5):1590‐9. DeBruijneJ , BergmannJF , WeeginkCJ , MolenkampR , SchinkelJ , TreitelMA , et al. Narlaprevir and peginterferon alfa‐2b for 2 weeks in chronic hepatitis C genotype 1 patients, followed by peginterferon alfa‐2b and ribavirin for 24/48 weeks: final results. Journal of Hepatology2010;52:S290‐1. HothoDM , DeBruijneJ , SpaanM , TreitelMA , BoonstraA , DeKnegtRJ , et al. Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long‐term follow‐up. Journal of Viral Hepatitis2013;20(4):e78‐81. ">De Bruijne 2010a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Narlaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 pyrexia, 1 elevated CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0128" title="MuirA , PoordadF , SheikhA , ElkashabM , BrennanR , Ankoma‐SeyV , et al. SVR4 results for the combination of ACH‐3102 and Sovaprevir, with ribavirin, in patients with genotype 1 chronic hepatitis C infection. 23rd Annual Conference of APASL, Brisbane, Australia. 2014. ">Muir 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Odalasvir (ACH‐3102) and sovaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 non‐cardiac chest pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0210" title="LiuY , LarsenL , BourliereM , BaranR , JudayT . Ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin (RBV) has mild impact on health‐related quality of life (HRQoL) compared with placebo during 12‐week treatment in treatment‐experienced adults with chronic hepatitis C (CHC). Journal of Hepatology2015;62(Suppl S2):S661. ZeuzemS , JacobsonIM , BaykalT , MarinhoRT , PoordadF , BourliereM , et al. Retreatment of HCV with ABT‐450/r‐ombitasvir and dasabuvir with ribavirin. New England Journal of Medicine2014;370(17):1604‐14. ">Zeuzem 2014a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paritaprevir (ABT‐450)/r–ombitasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 pneumonia, 1 nausea, 1 vomiting, 1 bradycardia, 1 chronic obstructive pulmonary disease, 1 renal failure acute,<br/> 1 dizziness, 1 intestinal obstruction, 1 cerebrovascular accident, 1 bile duct stone, 1 calculus ureteric, 1 angioedema </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 out of 393</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 atrial fibrillation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 97</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0003" title="AndersonRT , BaranRW , EricksonP , RevickiDA , DietzB , GoochK . Psychometric evaluation of the hepatitis C virus patient‐reported outcomes (HCV‐PRO) instrument: validity, responsiveness, and identification of the minimally important difference in a phase 2 clinical trial. Quality of Life Research2014;23(3):877‐86. GaultierI , CohenDE , BhathenaA , IdlerK , LarsenLM , PodsadeckiT , et al. The effect of IL28B polymorphisms on virologic response to treatment with pegylated interferon alpha‐2A and ribavirin (SOC) added to ABT‐450/ritonavir (ABT‐450/R), ABT‐333, or ABT‐072. Journal of Hepatology2011;54(Suppl 1):S523. Pilot‐MatiasTJ , TripathiRL , DekhtyarT , MenonRM , GaultierIA , CohenDE , et al. Genotypic and phenotypic characterization of NS3 variants selected in HCV‐infected patients treated with ABT‐450. Journal of Hepatology2011;54(Suppl 1):S485‐6. ">Anderson 2014a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paritaprevir/ABT‐072/dasabuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 haemorrhoids, 1 malignant melanoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 out of 63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0049" title="FeldJJ , KowdleyKV , CoakleyE , SigalS , NelsonD , CrawfordD , et al. Sapphire I: Phase 3 placebo‐controlled study of interferon‐free, 12‐week regimen of ABT‐450/R/ABT‐267, ABT‐333, and ribavirin in 631 treatment‐naive adults with hepatitis Cvirus genotype 1. Journal of Hepatology2014;60(1 Suppl 1):S25. FeldJJ , KowdleyKV , CoakleyE , SigalS , NelsonDR , CrawfordD , et al. Treatment of HCV with ABT‐450/r‐ombitasvir and dasabuvir with ribavirin. New England Journal of Medicine2014;370(17):1594‐603. KowdleyKV , FeldJJ , CoakleyE , SigalS , NelsonDR , CrawfordD , et al. Sapphire I: Phase 3 placebo‐controlled study of interferon‐free, 12‐week regimen of ABT‐450/R/ABT‐267, ABT‐333, and ribavirin in 631 treatment‐naive adults with hepatitis C virus genotype 1. Gastroenterology2014;146(5 Suppl 1):S912‐S3. ">Feld 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paritaprevir/ombitasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 abdominal pain, 1 diarrhoea, 1 cholecystitis, 1 appendicitis, 1 overdose, 1 sinus tachycardia, 1 ventricular extrasystoles, 1 nausea, 1 vomiting, 1 chills, 1 non‐cardiac chest pain, 1 lobar pneumonia, 1 postoperative wound infection, 1 lumbar vertebral fracture, 1 non‐small cell lung cancer, 1 encephalopathy, 1 acute respiratory failure, 1 hypoxia, 1 mediastinal mass, 1 aortic stenosis, 1 biliary colic, 1 subcutaneous abscess </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 out of 630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 158</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0157" title="NelsonD , PockrosPJ , GodofskyE , Rodriguez‐TorresM , EversonG , FriedM , et al. High end‐of‐treatment response (84%) after 4 weeks of R1626, peginterferon alfa‐2A (40KD) and ribavirin followed by a further 44 weeks of peginterferon alfa‐2A and ribavirin. Journal of Hepatology2008;48(Suppl 2):S371. PockrosPJ , NelsonD , GodofskyE , Rodriguez‐TorresM , EversonGT , FriedMW , et al. R1626 plus peginterferon alfa‐2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology2008;48(2):385‐97. ">Pockros 2008a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>R1626</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 SAEs but not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 out of 84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 SAE but not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0057" title="FornsX , LawitzE , ZeuzemS , GaneE , BronowickiJP , AndreoneP , et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology2014;146(7):1669‐79. FornsX , LawitzE , ZeuzemS , GaneEJ , BronowickiJP , AndreoneP , et al. Simeprevir (TMC435) with peg‐interferon alpha‐2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon‐based therapy: efficacy and safety in patient sub‐populations in the PROMISE phase III trial. Hepatology2013;58(4 SUPPL. 1):737A‐8A. GaneEJ , FornsX , LawitzE , ZeuzemS , BronowickiJP , AndreoneP , et al. Simeprevir (TMC435) with peg‐interferon alpha‐2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon‐based therapy: efficacy in patients with genotype 1b HCV in the PROMISE phase III trial. Hepatology International2014;8(1 Suppl 1):S181. LawitzE , FornsX , ZeuzemS , GaneE , BronowickiJP , AndreoneP , et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon‐based therapy: results from PROMISE, a phase III trial. Gastroenterology2013;144(5 Suppl 1):S151. ">Forns 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 abdominal pain, 1 pyrexia, 1 appendicitis, 2 pneumonia, 1 depression, 1 dyspnoea, 1 cholelithiasis, 1 anaemia haemolytic autoimmune, 1 pancytopenia, 1 angina pectoris, 1 bradycardia, 1 myocardial ischaemia, 1 hepatitis, 1 endocarditis, 1 lower respiratory tract infection, 1 septic shock, 1 breast cancer, 1 Guillain‐Barre syndrome, 1 presyncope, 1 confusional state, 1 vaginal haemorrhage, 1 chronic obstructive pulmonary disease, 1 respiratory acidosis, 1 photosensitivity reaction </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 out of 260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 atrial fibrillation, 1 depression, 1 bronchitis, 1 hypercalcaemia, 1 head injury, 1 bacterial prostatitis, 1 pericarditis, 1 infection, 1 inguinal hernia, 1 neuropathy peripheral, 1 arthritis infective, 1 headache </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 out of 133</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0062" title="AerssensJ , FanningG , ScholliersA , LenzO , PeetersM , DeSmedtG , et al. Impact of IL28B genotype and pretreatment serum IP‐10 in treatment‐naive genotype‐1 HCV patients treated with TMC435 in combination with peginterferona‐2A and ribavirin in PILLAR study. Journal of Hepatology2011;54(Suppl S1):S5‐6. FriedMW , ButiM , DoreGJ , FerenciP , JacobsonI , MarcellinP , et al. Efficacy and safety of TMC435 in combination with peginterferon alfa‐2a and ribavirin in treatment‐naive genotype‐1 HCV patients: 24‐week interim results from the PILLAR study. Hepatology2010;52(Suppl S1):403A. FriedMW , ButiM , DoreGJ , FlisiakR , FerenciP , JacobsonI , et al. Once‐daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment‐naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology2013;58(6):1918‐29. ScottJ , GillesL , FuM , BrohanE , AmatyaR , JessnerW , et al. Patients with chronic hepatitis C virus treated with simeprevir added to peginterferon and ribavirin experienced less time with fatigue, depressive symptoms, and functional limitations: results from patients in the QUEST‐1, QUEST‐2, and promise studies. Value in Health2013;16(7):A362. ScottJ , GillesL , FuM , BrohanE , PanterC , ArbuckleR , et al. Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies. Journal of Viral Hepatitis2015;22(8):639‐50. ScottJ , RosaK , FuM , CerriK , PeetersM , Beumont‐MauvielM , et al. Improved SVR with simeprevir (TMC435) associated with reduced time with patient‐reported fatigue in treatment‐naive, HCV‐infected patients in the PILLAR phase IIb trial. Journal of Hepatology2013;58(Suppl 1):S371‐2. ">Fried 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 cholecystitis, 1 intervertebral disc protrusion, 1 depression, 1 nausea, 1 breast cancer, 1 hyperthyroidism, 1 ocular vasculitis, 1 abdominal pain upper, 1 colitis, 1 small intestinal obstruction, 1 malaise, 1 incision site cellulitis, 1 necrotising fasciitis, 1 perihepatic abscess, 1 pneumonia pneumococcal, 1 upper respiratory tract infection, 1 post‐procedural bile leak, 1 malnutrition, 1 type 1 diabetes mellitus, 1 spinal disorder, 1 parathyroid tumour benign, 1 headache, 1 haemoptysis, 1 cutaneous vasculitis, 1 hypertension </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 out of 309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 myocardial infarction, 1 myopericarditis, 1 asthenia, 1 appendicitis, 1 vomiting, 1 chronic obstructive pulmonary disease, 1 headache, 1 subcutaneous abscess, 1 vulval abscess, 1 myositis, 1 ovarian neoplasm </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 out of 77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0044" title="HayashiN , SetoC , KatoM , KomadaY , GotoS . Once‐daily simeprevir (TMC435) with peginterferon/ribavirin for treatment‐naive hepatitis C genotype 1‐infected patients in Japan: the DRAGON study. Journal of Gastroenterology2014;49(1):138‐47. ">DRAGON 2014a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 subarachnoid haemorrhage, 1 malaise, 1 cerebral infarction, 1 vulvar erosion, 1 rash, 1 incorrect dose administered </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 out of 79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0077" title="HoebenE , VibergA , PeterssonK , LeeM , VanwelkenhuysenI , WitekJ , et al. Simeprevir exposure in Asian treatment naive patients with chronic hepatitis C virus genotype 1 infection results from a population pharmacokinetic model in the phase III Tiger study. Hepatology International2015;9(1 Suppl):S71. WeiL , HanT , YangD , HeoJ , ShangJ , ChengJ . Simeprevir plus peginterferon ribavirin in treatment naive patients with chronic hepatitis C virus genotype 1 infection results from the phase III Tiger study conducted in East Asian patients living in China and Korea. Hepatology International2015;9(1 Suppl):S61. ">Hoeben 2015a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 depression, 1 non‐cardiac chest pain, 1 angina unstable, 1 nephrolithiasis, 1 ureteric stenosis, 1 colitis ischaemic, 1 incision site infection, 1 craniocerebral injury, 1 foot fracture, 1 meniscus lesion, 1 multiple injuries, 1 rib fracture, 1 tibia fracture, 1 traumatic lung injury, 1 wound, 1 cholesterosis, 1 type 2 diabetes mellitus, 1 shock haemorrhagic </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 out of 305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 decreased appetite, 1 cholelithiasis, 1 contusion, 1 supraventricular tachycardia, 1 ligament sprain, 1 pain, 1 atypical pneumonia, 1 chronic hepatitis C, 1 pulmonary tuberculosis, 1 undifferentiated connective tissue disease, 1 brain neoplasm </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 out of 152</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0146" title="MannsM , ReesinkH , BergT , DusheikoG , FlisiakR , MarcellinP , et al. Rapid viral response of once‐daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype‐1 patients: a randomized trial. Antiviral Therapy2011;16(7):1021‐33. ">OPERA 2011a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 sinus arrest, 1 erysipelas, 1 type 1 diabetes mellitus, 1 psychotic disorder, 1 drug abuse, 1 bronchitis, 1 exostosis, 1 toe deformity, 1 hyperthyroidism, 1 Bowen's disease, 1 neutropenia, 1 thrombocytopenia, 1 breast cancer, 1 sepsis, 1 cupulolithiasis, 1 pneumonia escherichia, 1 panic reaction </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 out of 88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 pneumonia, 1 sinusitis, 1 panic attack, 1 social stay hospitalisation, 1 pneumonia escherichia </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 out of 28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0120" title="MannsM , MarcellinP , PoordadF , DeAraujoESA , ButiM , HorsmansY , et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment‐naive patients with chronic hepatitis C virus genotype 1 infection (QUEST‐2): a randomised, double‐blind, placebo‐controlled phase 3 trial. Lancet2014;384(9941):414‐26. PoordadF , MannsMP , MarcellinP , AraujoESA , ButiM , HorsmansY , et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype‐1 infection in treatment‐naive patients: results from QUEST‐2, a phase III trial. Gastroenterology2013;144(5 Suppl 1):S151. ">Manns 2014a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 anaemia, 1 back pain, 1 syncope, 1 hyperthyroidism, 1 death, 1 muscle spasms, 1 colon cancer, 1 anal abscess, 1 urinary tract infection, 1 mixed deafness, 1 hyphaema, 1 visual impairment, 1 enterocutaneous fistula, 1 autoimmune hepatitis, 1 lymphadenitis bacteria, 1 fluid overload, 1 epilepsy, 1 memory impairment, 1 aggression </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 out of 257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 pancreatitis acute, 1 dehydration, 1 vomiting, 1 pancytopenia, 1 loss of consciousness, 1 angina unstable, 1 meniscus lesion, 1 pulmonary embolism, 1 cholecystitis acute, 1 drug abuse, 1 retinal ischaemia, 1 respiratory tract infection viral, 1 viral infection, 1 neuropathy peripheral, 1 thoracic outlet syndrome </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 out of 134</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0155" title="PearlmanBL , EhlebenC , PerrysM . The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C‐related Child's class A cirrhosis. Gastroenterology2015;148(4):762. ">Pearlman 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 liver decompensation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0014" title="FerenciP , FriedM , PoordadF , ZeuzemS , LenzO , Ouwerkerk‐MahadevanS , et al. Safety of simeprevir (SMV) with peg Ifnalpha‐2a/ribavirin (PR) in HCV genotype 1‐infected patients: PILLAR and ASPIRE trials. Swiss Medical Weekly2013;143(Suppl 199):15S. LenzO , FeveryB , VijgenL , VerbeeckJ , PeetersM , Beumont‐MauvielM , et al. TMC435 in patients infected with HCV genotype 1 who have failed previous pegylated interferon/ribavirin treatment: virologic analyses of the ASPIRE trial. Journal of Hepatology2012;56(Suppl S2):S5. ScottJ , RosaK , FuM , CerriK , PeetersM , BeumontM , et al. Fatigue during treatment for hepatitis C virus: results of self‐reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection. BMC Infectious Diseases2014;14:465. ScottJ , RosaK , FuM , CerriK , PeetersM , Beumont‐MauvielM , et al. Fatigue severity scale: reliability, validity and interpretation of change‐evidence from two clinical trials in patients with chronic HCV infection. Value in Health2013;16(3):A216. ScottJ , RosaK , ZeuzemS , Beumont‐MauvielM , PeetersM , Cerri , K , et al. Adding simeprevir (TMC435) to pegylated interferon/ribavirin does not increase patient reported fatigue in treatment‐experienced patients with chronic HCV infection: results from the ASPIRE trial. Journal of Hepatology2013;58(Suppl S1):S371. ZeuzemS , BergT , GaneE , FerenciP , FosterGR , FriedMW , et al. Simeprevir increases rate of sustained virologic response among treatment‐experienced patients with HCV genotype‐1 infection: a phase IIb trial. Gastroenterology2014;146(2):430‐41. ZeuzemS , FosterGR , FriedMW , HezodeC , HirschfieldGM , NikitinI , et al. The ASPIRE trial: TMC435 in treatment‐experienced patients with genotype‐1 HCV infection who have failed previous PEGIFN/RBV treatment. Journal of Hepatology2011;54(Suppl 1):S546. ">ASPIRE 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 abdominal pain, 1 diarrhoea, 1 oedema peripheral, 2 cholecystitis, 1 pneumonia, 1 overdose, 2<br/> dehydration, 1 intervertebral disc protrusion, 1 hepatic neoplasm malignant, 2 vomiting, 1 non‐cardiac chest pain, 1 neutropenia, 2 cellulitis, 1 pancytopenia, 1 headache, 1 hypertension, 1 suicide attempt, 1 drug eruption, 2 clostridium difficile colitis, 1 nephrolithiasis, 1 pulmonary embolism, 1 rectal cancer, 1 sinusitis, 3 urinary tract infection, 1 diabetes mellitus, 1 migraine, 1 coma, 1 epistaxis, 1 alcohol abuse, 1 haemorrhagic anaemia, 1 cervix carcinoma, 1 periodontal disease, 1 enteritis, 1 gastro intestinal pain, 1 gingival infection, 1 lung infection, 1 meningitis bacterial, 1 pneumonia bordetella, 1 salpingitis, 1 thermal burn, 1 neurilemmoma benign, 1 brain injury, 1 cerebral haemorrhage, 1 vii nerve paralysis, 1 metrorrhagia, 1 pelvic adhesions </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 out of 396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 sciatica, 1 nausea, 1 vomiting, 1 lower respiratory tract infection, 1 haemorrhoids, 1 weight decreased, 1 histiocytosis haematophagic, 1 tuberculosis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 out of 66</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0166" title="JacobsonIM , GordonSC , KowdleyKV , YoshidaEM , Rodriguez‐TorresM , SulkowskiMS , et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. New England Journal of Medicine2013;368(20):1867‐77. YounossiZM , StepanovaM , HenryL , GaneE , JacobsonIM , LawitzE , et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH‐C). Journal of Hepatology2014;60(4):741‐7. [PUBMED: 24333184] ">POSITRON 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sofosbuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 drug withdrawal syndrome, 1 non‐cardiac chest pain, 1 oedema peripheral, 1 pyrexia, 1 hypersensitivity, 1 abdominal abscess, 1 cellulitis, 2 overdose, 1 injury, 1 road traffic accident, 1 spinal compression fracture, 1 hypoglycaemia, 1 hepatic neoplasm malignant, 1 abnormal behaviour, 1 eczema </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 out of 207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 pancreatitis, 1 bile duct stone, 1 bronchitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 out of 71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0104" title="LawitzE , LalezariJP , HassaneinT , KowdleyKV , PoordadFF , SheikhAM , et al. Sofosbuvir in combination with peginterferon alfa‐2a and ribavirin for non‐cirrhotic, treatment‐naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double‐blind, phase 2 trial. Lancet Infectious Diseases2013;13(5):401‐8. ">Lawitz 2013a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sofosbuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 retinal vein occlusion, 1 depression, 1 suicidal ideation, 1 lymphangitis, 1 acute myocardial infarction </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 out of 95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 chest pain, 1 electrocardiogram ST segment elevation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0051" title="LawitzE , MangiaA , WylesD , Rodriguez‐TorresM , HassaneinT , Gordon StuartC , et al. Sofosbuvir for previously untreated chronic hepatitis C infection. New England Journal of Medicine2013;368(20):1878‐87. YounossiZM , StepanovaM , HenryL , GaneE , JacobsonIM , LawitzE , et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH‐C). Journal of Hepatology2014;60(4):741‐7. [PUBMED: 24333184] ">FISSION 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sofosbuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 chest pain, 1 cellulitis, 1 chronic obstructive pulmonary disease, 1 urinary tract infection, 1 allergy to anthropod sting, 1 osteomyelitis chronic , 1 toxicity to various agents </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 out of 256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 pneumothorax, 1 breast cancer, 1 infection, 1 atrioventricular shock, 1 clavicle fracture, 1 rib fracture </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 out of 243</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0174" title="Rodriguez‐TorresM , LawitzE , KowdleyKV , NelsonDR , DejesusE , McHutchisonJG , et al. Sofosbuvir (GS‐7977) plus peginterferon/ribavirin in treatment‐naïve patients with HCV genotype 1: a randomized, 28‐day, dose‐ranging trial. Journal of Hepatology2013;58(4):663‐8. ">Rodriguez‐Torres 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sofosbuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 depression, 1 peripheral ischaemia, 1 pancreatitis acute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 out of 49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0050" title="FeldJJ , JacobsonIM , HezodeC , AsselahT , RuanePJ , GruenerN , et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. New England Journal of Medicine2015;373(27):2599‐607. ">Feld 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sofosbuvir/velpatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 bronchitis, 1 cellulitis, 1 influenza, 1 chronic obstructive pulmonary disease, 1 death, 1 gastroenteritis, 1 acute myocardial infarct, 1 ligament sprain, 1 foot abscess, 1 foot necrosis, 1 recurring appendicitis, 1 epileptic seizure, 1 rotator cuff syndrome, 1 lung cancer, 1 mania, 1 palpitations, 1 small bowel obstruction, 1 upper limb fracture, 1 vestibular neuronitis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 out of 624</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 116</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0020" title="BenhamouY , MoussalliJ , RatziuV , LebrayP , DeBackerK , DeMeyerS , et al. Telaprevir activity in treatment‐naive patients infected hepatitis C virus genotype 4: a randomized trial. Journal of Infectious Diseases2013;208(6):1000‐7. BenhamouY , MoussalliJ , RatziuV , LebrayP , GysenV , deBackerK , et al. Results of a proof of concept study (C210) of telaprevir monotherapy and in combination with peginterferon ALFA‐2A and ribavirin in treatment‐naive genotype 4 HCV patients. Journal of Hepatology2009;50(Suppl 1):S6. BenhamouY , MoussalliJ , RatziuV , LebrayP , deBackerK , GhysA , et al. Activity of telaprevir monotherapy or in combination with peginterferon‐alfa‐2a and ribavirin in treatment‐naive genotype 4 hepatitis C patients: final results of study C210. Hepatology2010;52(Suppl S1):719A. DeMeyerS , GhysA , DierynckI , BeumontM , LuoD , PicchioG . Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir. Virology Journal2014;11:93. ">Benhamou 2013a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 cholelithiasis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0075" title="BronowickiJP , HezodeC , BengtssonL , PolS , BourliereM , SerfatyL , et al. 100% SVR in IL28B CC patients treated with 12 weeks of telaprevir, peginterferon and ribavirin in the PROVE2 trial. Journal of Hepatology2012;56(Suppl 2):S430‐1. DusheikoGM , HezodeC , PolS , GoeserT , BronowickiJP , BourliereM , et al. Treatment of chronic hepatitis C with telaprevir (TVR) in combination with peginterferon‐alfa‐2a with or without ribavirin: further interim analysis results of the PROVE2 study. Journal of Hepatology2008;48(Suppl 2):S26. HezodeC , FerenciP , Dusheiko GeoffreyM , TranA , GrangeJ‐D , MathurinP , et al. Prove2 Study: treatment of chronic hepatitis C with telaprevir (Tvr) in combination with peginterferon‐alfa‐2a with or without ribavirin, interim analysis results. Gastroenterology2008;134(4, Suppl. 1):A755. HezodeC , ForestierN , DusheikoG , FerenciP , PolS , GoeserT , et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. New England Journal of Medicine2009;360(18):1839‐50. MuirA , PoordadF , SheikhA , ElkashabM , BrennanR , Ankoma‐SeyV , et al. SVR4 results for the combination of ACH‐3102 and sovaprevir, with ribavirin, in subjects with genotype 1 chronic hepatitis C infection. Hepatology International2014;8(1 Suppl):s395. PawlotskyJ , KiefferT , ZhouY , ZhangE , MarcialM , ByrnR , et al. Evaluation of viral variants during a phase 2 study (PROVE2) of telaprevir with peginterferon alfa‐2A and ribavirin in treatment‐naïve HCV genotype 1‐infected patients. Hepatology2007;46(4 Suppl 1):862A. PawlotskyJM , FerenciP , DusheikoGM , AlvesK , KauffmanR , ZeuzemS . PROVE2: a phase 2b study of telaprevir combined with peginterferon‐alfa‐2a with or without ribavirin for treatment‐naive patients with chronic hepatitis C. Hepatology International2009;3(1):169. ZeuzemS , HezodeC , FerenciP , DusheikoGM , AlvesK , BengtssonL , et al. Telaprevir in combination with peginterferon‐alfa‐2a with or without ribavirin in the treatment of chronic hepatitis C: final results of the PROVE2 study. Hepatology2008;48(4 Suppl):418A‐9A. ZeuzemS , HezodeC , FerenciP , DusheikoGM , PolS , GoeserT , et al. PROVE2: phase II study of VX950 (telaprevir) in combination with peginterferon alfa2A with or without ribavirin in subjects with chronic hepatitis C; first interim analysis. Hepatology2007;46(4 Suppl 1):268A‐9A. ">Hezode 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 anaemia, 2 abdominal pain, 1 asthenia, 1 pyrexia, 1 back pain, 3 syncope, 3 depression, 2 dyspnoea, 1 nausea, 1 chills, 1 pancytopenia, 5 rash, 1 lymphadenopathy, 1 hydrocele, 1 retinal haemorrhage, 1 catheter‐related complication, 1 bacterial sepsis, 1 pneumonia, 1 herpes viral, 1 sepsis, 1 road traffic accident, 1 tendon rupture, 1 lung neoplasm malignant, 1 speech disorder, 1 disorientation, 1 emotional distress, 1 suicide attempt, 1 renal failure, 1 acute testicular swelling, 3 pruritis, 2 drug eruption, 2 rash maculo‐papular, 1 rash erythematous, 1 rash generalised, 1 toxic skin eruption, 1 urticaria, 1 splenectomy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 out of 241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 anaemia, 1 angina pectoris, 1 syncope, 1 hyperthyroidism, 1 gastroenteritis, 1 haemorrhagic anaemia, 1 alcoholic pancreatitis, 1 paranoia, 1 uterine polyp </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 out of 82</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0001" title="BroganAJ , TalbirdSE , ThompsonJR , MillerJD , RubinJ , DenizB . Cost‐effectiveness of telaprevir combination therapy for chronic hepatitis C. PLoS ONE2014;9(3):e90295. CurtisS , CureS , GavartS , DeardenL , FleischmannJ , OuwensM , et al. The cost‐effectiveness of telaprevir (TVR) in combination with pegylated interferon‐alfa and ribavirin (PR) for the treatment of genotype 1 chronic hepatitis C patients. Journal of Hepatology2012; Vol. 56, issue Suppl 2:S434. DiBisceglieAM , DusheikoGM , MuirAJ , ZeuzemS , MarcellinP , BzowejNH . Telaprevir in combination with peginterferon alfa‐2a and ribavirin: analyses of pre‐defined subpopulations in the phase 3 ADVANCE trial. Gastroenterology2011;140(5 Suppl 1):S908. DusheikoGM , BengtssonL , AddaN , KauffmanR , JacobsonIM . Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment‐naive patients: final results of phase 3 Advance study. Gut2011;60(Suppl 2):A32‐3. EversonG , DusheikoG , PolS , NelsonD , MuirA , AndreoneP , et al. Telaprevir in combination with peginterferon alfa‐2a and ribavirin increased sustained virologic response in genotype 1 chronic HCV and allowed for shorter treatment duration in treatment‐naive and prior relapser patients. American Journal of Gastroenterology2011;106(2S):S113‐4. JacobsonIM , McHutchisonJG , DusheikoG , DiBisceglieAM , ReddyKR , BzowejNH , et al. Telaprevir for previously untreated chronic hepatitis C virus infection. New England Journal of Medicine2011;364(25):2405‐16. JacobsonIM , McHutchisonJG , DusheikoGM , DiBisceglieAM , ReddyR , BzowejNH , et al. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment‐naive patients: final results of phase 3 ADVANCE study. Hepatology2010;52(Suppl S1):427A. KiefferTL , BartelsDJ , SullivanJ , AdiwijayaBS , ZhangEZ , TiggesA , et al. Clinical virology results from telaprevir phase 3 study ADVANCE. Hepatology2010;52(Suppl S1):879A. LuoD , ZeuzemS , JacobsonIM , ShermanK , AddaN , WrightCI , et al. High concordance between SVR12 and SVR24 in patients receiving telaprevir plus peginterferon and ribavirin in three phase iii clinical trials: Advance, Illuminate and Realize. Journal of Hepatology2012;56(Suppl 2):S446‐7. MarcellinP , JacobsonIM , ZeuzemS , BzowejN , MuirAJ , DusheikoG . Telaprevir in combination with peginterferon alfa‐2a and ribavirin: analyses of pre‐defined subpopulations in the phase 3 ADVANCE trial. Journal of Hepatology2011;54(Suppl 1):S183‐4. RizzettoM , AndreoneP , ColomboM , ScuteriA , CiancioA , SmedileA , et al. ADVANCE study: final results of the phase III trial with telaprevir in combination with PEG‐IFN and RBV in treatment‐naive genotype 1 HCV. Digestive and Liver Disease2011;43(Suppl 2):S69. SulkowskiMS , ReddyR , AfdhalNH , DiBisceglieAM , ZeuzemS , PoordadF , et al. Anemia had no effect on efficacy outcomes in treatment‐naive patients who received telaprevir‐based regimen in the Advance and Illuminate phase 3 studies. Journal of Hepatology2011;54(Suppl 1):S195. ">ADVANCE 2011a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 anaemia, 3 pneumonia, 3 syncope, 2 cellulitis, 5 rash, 3 psychiatric disorder, 2 musculoskeletal disorder, 2 cardiac disorder, 2 eye disorder, 3 hepatobiliary disorders, 2 vascular disorder </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 out of 727</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 anaemia, 1 cellulitis, 3 psychiatric disorder, 3 musculoskeletal disorder, 2 cardiac disorder, 4 renal and urinary disorder, 1 eye disorder, 1 vascular disorder </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 out of 361</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0125" title="EversonGT , GordonSC , JacobsonI , KauffmanRS , McNairL , MuirA , et al. PROVE 1: subgroup analysis of a phase 2 study of telaprevir with peginterferon alfa‐2a and ribavirin in treatment‐naive subjects with hepatitis C. Hepatology International2009;3:167. McHutchisonJG , EversonGT , GordonSC , JacobsonI , KauffmanR , McNairL , et al. PROVE1: results from a phase 2 study of telaprevir with peginterferon alfa‐2a and ribavirin in treatment‐naive subjects with hepatitis C. Journal of Hepatology2008;48(Suppl S2):S4. McHutchisonJG , EversonGT , GordonSC , JacobsonIM , SulkowskiM , KauffmanR , et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. New England Journal of Medicine2009;360(18):1827‐38. ">McHutchison 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 anaemia, 1 gastroenteritis viral, 1 dehydration, 2 depression, 1 non‐cardiac chest pain, 1 chronic obstructive pulmonary disease, 1 rash, 1 rash generalised, 1 furuncle, 1 colitis ischaemic, 1 acute myocardial infarction, 1 adrenal disorder, 2 scotoma, 1 retinal exudates, 1 retinal infarction, 1 bronchitis bacterial, 1 incisional hernia, 1 lumbar radiculopathy, 1 exfoliative rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 out of 175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 lobar pneumonia, 1 pancytopenia, 1 anxiety, 1 lymphadenitis bacteria, 1 deafness neurosensory </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 out of 75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0126" title="EversonGT , GordonSC , JacobsonI , KauffmanRS , McNairL , MuirA , et al. PROVE 1: subgroup analysis of a phase 2 study of telaprevir with peginterferon alfa‐2a and ribavirin in treatment‐naive subjects with hepatitis C. Hepatology International2009;3:167. MannsM , MuirA , AddaN , JacobsonI , AfdhalN , HeathcoteJ , et al. Telaprevir in hepatitis C genotype‐1‐infected patients with prior non‐response, viral breakthrough or relapse to peginterferonalfa‐2A/B and ribavirin therapy: SVR results of the PROVE3 study. Journal of Hepatology2009;50(Suppl 1):S379. McHutchinsonJG , MannsMP , MuirAJ , TerraultNA , JacobsonIM , AfdhalNH , et al. Telaprevir for previously treated chronic HCV infection. New England Journal of Medicine2010;362(14):1292‐303. McHutchinsonJG , ShiffmanML , TerraultN , MannsMP , DiBiscegliAM , JacobsonIM , et al. Interim results of PROVE 3: a randomized, controlled, phase 2b study of telaprevir (TVR) with peginterferon‐alfa‐2a (P) and/or ribavirin (R) in subjects with hepatitis C genotype 1 who failed to achieve an SVR with a prior course of PR therapy. Hepatology International2009;3(1):25. McHutchisonJG , MannsMP , MuirA , TerraultN , JacobsonIM , AfdhalNH , et al. PROVE3 final results and 1‐year durability of SVR with telaprevir‐based regimen in hepatitis C genotype 1‐infected patients with prior non‐response, viral breakthrough or relapse to peginterferon‐alfa‐2a/b and ribavirin therapy. Hepatology2009;50(4 Suppl):334A‐5A. McHutchisonJG , ShiffmanML , TerraultN , MannsMP , DiBisceglieAM , JacobsonIM , et al. A phase 2b study of telaprevir with peginterferon‐alfa‐2a and ribavirin in hepatitis C genotype 1 null and partial responders and relapsers following a prior course of peginterferon‐alfa‐2a/b and ribavirin therapy: PROVE3 interim results. Hepatology2008;48(4 Suppl):269A‐70A. ">McHutchison 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 anaemia, 1 pancreatitis acute, 1 gastroenteritis viral, 1 pneumonia, 1 dehydration, 1 back pain, 1 suicidal ideation, 2 cholelithiasis, 1 postoperative wound infection, 1 upper gastrointestinal haemorrhage, 1 confusional state, 2 small intestinal obstruction, 1 necrotising fasciitis, 1 pneumonia pneumococcal, 1 post‐procedural bile leak, 1 rash, 1 renal failure acute, 1 retinal detachment, 9 gastroenteritis, 1 cholecystitis acute, 1 sinusitis, 1 hypokalaemia, 1 eczema, 2 pancreatitis, 1 dermatitis, 1 diverticulitis, 1 alcohol abuse, 1 hypotension, 1 haemorrhagic anaemia, 1 idiopathic thrombocytopenic purpura, 1 cardiomyopathy, 1 diverticular perforation, 1 gastritis erosive, 1 abscess intestinal, 1 cholecystitis infective, 1 infected insect bite, 1 sepsis syndrome, 1 hypovolaemia, 1 B‐cell unclassifiable lymphoma low grade, 1 migraine with aura, 1 ruptured cerebral aneurysm, 1 neurogenic bladder, 1 lichenoid keratosis, 1 rash macular </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 out of 339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 pneumonia, 2 dehydration, 1 syncope, 1 depression, 1 non‐small cell lung cancer, 1 headache, 2 rash, 1 renal failure acute, 2 gastroenteritis, 1 renal tubular acidosis, 1 decubitus ulcer, 1 hematoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 out of 114</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0196" title="ShermanKE , RockstrohJK , DieterichDT , SorianoV , GirardPM , McCallisterS , et al. Telaprevir combination with peginterferon alfa‐2A/ribavirin in HCV/HIV coinfected patients: 24‐week treatment interim analysis. Hepatology2011;54(4 Suppl):1431A‐2A. SulkowskiMS , ShermanKE , DieterichDT , BsharatM , MahnkeL , RockstrohJK , et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Annals of Internal Medicine2013;159(2):86‐96. SulkowskiMS , ShermanKE , SorianoV , RockstrohJ , DieterichDT , GirardPM , et al. Telaprevir in combination with peginterferon alfa‐2a/ribavirin in HCV/HIV co‐infected patients: SVR24 final study results. Hepatology2012;56(S1):219A. ">Sulkowski 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 myocardial infarction, 1 staphylococcal infection, 1 pyelonephritis acute, 1 haemolytic anaemia, 1 groin infection, 1 cellulitis staphylococcal, 1 staphylococcal abscess, 1 hypokalaemia, 1 hyponatraemia, 1 epididymitis, 1 non‐ cardiac chest pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 out of 38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 appendicitis, 1 peritonitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 out of 22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0209" title="BergT , AndreoneP , PolS , RobertsSK , YounossiZM , DiagoM , et al. Predictors of virologic response with telaprevir‐based combination treatment in HCV genotype 1‐infected patients with prior peginterferon/ribavirin treatment failure: post‐hoc analysis of the phase III REALIZE study. Hepatology2011;54(S1):375A‐6A. DeMeyerS , DierynckI , GhysA , BeumontM , DaemsB , VanBaelenB , et al. Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial. Hepatology2012;56(6):2106‐15. FosterGR , JacobsonIM , DoreGJ , FriedM , MannsM , MarcellinP , et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment‐naive European patients in the QUEST‐1 and QUEST‐2 phase III trials. Journal of Hepatology2014;60(1 Suppl 1):S456. FosterGR , ZeuzemS , AndreoneP , PolS , LawitzEJ , DiagoM , et al. Subanalyses of the telaprevir lead‐in arm in the REALIZE study: response at week 4 is not a substitute for prior null response categorization. Journal of Hepatology2011;54(Suppl 1):S3‐S4. FosterGR , ZeuzemS , AndreoneP , PolS , LawitzEJ , DiagoM , et al. Sustained virologic response rates with telaprevir by response after 4 weeks of lead‐in therapy in patients with prior treatment failure. Journal of Hepatology2013;58(3):488‐94. PolS , AerssensJ , ZeuzemS , AndreoneP , LawitzEJ , RobertsS , et al. Similar SVR rates in IL28B CC, CT OR TT prior relapser, partial‐ or null‐responder patients treated with telaprevir/peginterferon/ribavirin: retrospective analysis of the REALIZE study. Journal of Hepatology2011;54(Suppl 1):S6‐7. PolS , RobertsSK , AndreoneP , YounossiZM , DiagoM , LawitzE , et al. Efficacy and safety of telaprevir‐based regimens in cirrhotic patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: subanalysis of the REALIZE phase III study. Hepatology2011;54(S1):374A‐5A. RobertsSK , AndreoneP , PolS , YounossiZM , DiagoM , LawitzE , et al. Impact of anemia and ribavirin dose reduction on SVR to a telaprevir‐based regimen in patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure in the phase III REALIZE study. Hepatology2011;54(4 Suppl):1007A‐8A. TuefferdM , PalescandoloE , VijgenL , ColomboM , RobertsS , WedemeyerH , et al. ITPA gene variants and anemia during telaprevir/peginterferon/ribavirin combination therapy in patients with chronic hepatitis C infection. Journal of Hepatology2014;60(1 Suppl S):S490. WitekJ . Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment‐experienced patients. Journal of Hepatology2014;60(6):1112‐7. YounossiZ , NegroF , SerfatyL , PolS , DiagoM , ZeuzemS , et al. Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial. Hepatology2013;58(6):1897‐906. ZeuzemS , AndreoneP , PolS , LawitzE , DiagoM , RobertsS , et al. Telaprevir for retreatment of HCV infection. New England Journal of Medicine2011;364(25):2417‐28. ZeuzemS , AndreoneP , PolS , LawitzEJ , DiagoM , RobertsS , et al. REALIZE trial final results: telaprevir‐based regimen for genotype 1 hepatitis C virus infection in patients with prior null response, partial response or relapse to peginterferon/ribavirin. Journal of Hepatology2011;54(Suppl S1):S3. ">Zeuzem 2011a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 anaemia, 1 febrile neutropenia, 2 pancytopenia, 1 thrombocytopenia , 3 acute myocardial infarction, 2 atrial fibrillation, 1 cardiac valve disease, 1 myocardial infarction, 1 supraventricular tachycardia, 1 sudden hearing loss, 1 Basedow's disease, 1 retinal detachment, 1 abdominal pain, 1 anal fissure, 1 caecitis, 1 gastrointestinal haemorrhage, 1 pancreatitis, 2 pancreatitis acute, 1 general physical health deterioration, 1 pyrexia, 1 appendicitis, 2 bronchitis, 1 erysipelas, 1 folliculitis, 1 Helicobacter gastritis, 1 pneumonia, 1 post‐procedural infection, 1 rectal abscess, 2 sepsis, 1 sinusitis, 1 tooth abscess, 2 urinary tract infection, 1 injection site reaction, 1 animal scratch, 1 ankle fracture, 1 femoral neck fracture, 1 multiple drug overdose, 1 blood corticotrophin decreased, 1 weight decreased, 1 anorexia, 1 diabetes mellitus, 1 bronchial carcinoma, 2 gastric cancer, 2 hepatic neoplasm malignant, 1 histiocytosis haematophagic, 1 lung neoplasm malignant, 1 lethargy, 1 subarachnoid haemorrhage, 2 syncope, 1 delirium, 1 depression, 1 insomnia, 1 substance abuse, 1 renal cyst, 1 renal failure, 1 urinary bladder polyp, 1 prostatitis, 1 pulmonary embolism, 1 dermatitis, 1 eczema , 1 erythema multiforme, 1 pruritus 1 pustular psoriasis, 1 rash, 2 toxic skin eruption, 1 orthostatic hypotension, 1 peripheral artery aneurysm </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 out of 530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 atrial fibrillation, 1 abdominal pain, 1 pneumonia, 1 colitis, 1 pyelonephritis, 1 cerebral thrombosis, 1 coma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 out of 132</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0116" title="LawitzE , SulkowskiM , JacobsonIRA , KraftWK , MaliakkalB , Al‐IbrahimM , et al. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics. Antiviral Research2013;99(3):214‐20. MannsMP , GaneE , Rodriguez‐TorresM , StoehrA , YehC‐T , MarcellinP , et al. Vaniprevir with pegylated interferon alpha‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C: a randomized phase II study. Hepatology2012;56(3):884‐93. MannsMP , GaneE , Rodriguez‐TorresM , StoehrA , YehC‐T , WiedmannR , et al. MK‐7009 significantly improves rapid viral response (RVR) in combination with pegylated interferon ALFA‐2A and ribavirin in patients with chronic hepatitis C (CHC) genotype 1 infection. Journal of Hepatology2009;50(Suppl S1):S384. MannsMP , GaneE , Rodriguez‐TorresM , StoehrA , YehCT , MarcellinP , et al. Vaniprevir with pegylated interferon alpha‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C: a randomized phase II study. Hepatology2012;56(3):884‐93. MannsMP , GaneEJ , Rodriguez‐TorresM , StoehrAD , YehC , MarcellinP , et al. Early viral response (EVR) rates in treatment ‐ naive patients with chronic hepatitis C (CHC) genotype 1 infection treated with MK‐7009, a novel NS3/4a protease inhibitor, in combination with pegylated interferon alfa‐2a and ribavirin for 28 days. Hepatology2009;50(4 Suppl):332A‐3A. MannsMP , GaneEJ , Rodriguez‐TorresM , StoehrAD , YehC , MarcellinP , et al. Sustained viral response (SVR) rates in genotype 1 treatment‐naive patients with chronic hepatitis C (CHC) infection treated with vaniprevir (MK‐7009), A NS3/4A protease inhibitor, in combination with pegylated interferon alfa‐2a and ribavirin for 28 days. Hepatology2010;52(Suppl S1):361A. ">Manns 2012a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaniprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 appendicitis, 1 lobar pneumonia, 1 septic shock, 1 confusional state, 1 gastroenteritis, 1 cholecystitis acute, 1 empyema, 1 haemoglobin decreased, 1 myopathy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 out of 75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 colon cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0107" title="BarnardR , HwangPMT , BhanjaS , CampbellH , StrizkiJ , CheneyC , et al. Resistance analysis of cirrhotic treatment‐experienced genotype 1 patients in a study of MK‐7009 in combination with pegylated interferon/ribavirin. Journal of Hepatology2013;58(Suppl S1):S487. ElbashaE , ElKhouryA , MobasheryN . Projected long‐term impact of MK‐7009 (vaniprevir) for previously treated chronic HCV genotype 1 infection. Hepatology International2013;7(1 Suppl):S354. GaoW , CaroL , AndersonM , HwangP , ZhouA , SuJ , et al. Vaniprevir (MK‐7009) demonstrates higher exposures in treatment‐experienced genotype (GT) 1 cirrhotic than non‐cirrhotic HCV‐infected patients. Hepatology2013;58(Suppl S1):739A. LawitzE , Rodriguez‐TorresM , StoehrA , GaneEJ , SerfatyL , BhanjaS , et al. A phase 2B study of MK‐7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment. Journal of Hepatology2013;59(1):11‐7. MobasheryN , WongP , ZhangS , BhanjaS , WarnerA , ShawPM , et al. Impact of IL28B genotype on virologic response in prior treatment failure patients who received MK‐7009 in combination with peginterferon and ribavirin. Journal of Hepatology2012;56(Suppl S2):S467. ">Lawitz 2013c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaniprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 pneumonia, 1 syncope, 1 upper gastrointestinal haemorrhage, 1 cellulitis, 1 confusional state, 1 dizziness, 1 nephrolithiasis, 1 malignant melanoma, 3 retinal detachment, 1 joint dislocation, 1 congestive cardiac failure, 2 gastroenteritis, 1 femur fracture, 1 hyperglycaemia, 1 dermatomyositis, 1 retinal vascular thrombosis, 1 general physical health deterioration, 1 anaphylactic reaction, 1 pyelonephritis, 1 pyelonephritis acute, 1 carbon monoxide poisoning, 1 arthralgia, 1 arthritis infective, 1 completed suicide </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 out of 229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 hypertensive crisis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 56</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>SAE: serious adverse events.</p> </div> </div> </section> <section id="CD012143-sec-0109"> <h6 class="title">Heterogeneity</h6> <p>Neither visual inspection of the funnel plots nor tests for statistical heterogeneity (I² = 0%, P = 0.99) indicated significant heterogeneity. </p> </section> <section id="CD012143-sec-0110"> <h6 class="title">Trial Sequential Analysis</h6> <p>The Trial Sequential Analysis showed that the Z‐curve crossed the trial sequential monitoring boundary for futility. Hence, there is firm evidence that DAAs versus control do not reduce the risk of serious adverse events by 20% or more (<a href="#CD012143-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD012143-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of the effects of direct‐acting antivirals on the market or under development versus placebo or no intervention on risk of serious adverse events. The analysis was based on a proportion in the control group (Pc) of 4.5%, a relative risk reduction (RRR) of 20%, and alfa of 2.5%, a beta of 20%, and a diversity of 0%. The cumulative Z‐curve enters the futility area after the randomisation of about 6000 participants." data-id="CD012143-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial Sequential Analysis of the effects of direct‐acting antivirals on the market or under development versus placebo or no intervention on risk of serious adverse events. The analysis was based on a proportion in the control group (Pc) of 4.5%, a relative risk reduction (RRR) of 20%, and alfa of 2.5%, a beta of 20%, and a diversity of 0%. The cumulative Z‐curve enters the futility area after the randomisation of about 6000 participants. </p> </div> </div> </div> </section> <section id="CD012143-sec-0111"> <h6 class="title">Bayes factor</h6> <p>Bayes factor was calculated based on a RR of 20%, and the meta‐analysis result (OR 0.93). Bayes factor was 2.41 which is above the Bayes factor threshold for significance of 0.1, supporting that there seems to be more evidence for the null hypothesis compared to the evidence for an intervention effect of 20% relative risk reduction (RRR). </p> </section> <section id="CD012143-sec-0112"> <h6 class="title">Risk of bias and sensitivity analyses</h6> <p>The risk of bias of the outcome result was assessed as high risk of bias.</p> <p>The best‐worst case meta‐analysis (OR 0.79, 95% CI 0.64 to 0.97, I²= 0%, P = 0.022) (see <a href="#CD012143-sec-0071">Dealing with missing data</a>) and worst‐best case meta‐analysis (OR 1.06, 95% CI 0.86 to 1.31, I² = 0%, P = 0.56) (see <a href="#CD012143-sec-0071">Dealing with missing data</a>) showed that incomplete outcome data may influence the results. </p> <p>Visual inspection of the funnel plots showed no clear signs of asymmetry.</p> </section> <section id="CD012143-sec-0113"> <h6 class="title">Subgroup analyses</h6> <p>The test for subgroup differences comparing the effects of each type of DAA showed no evidence of a difference (P = 0.49). The only single DAA that showed evidence of a difference when meta‐analysed separately was simeprevir (OR 0.62, 95% CI 0.45 to 0.86, P = 0.004; <a href="./references#CD012143-fig-0028" title="">Analysis 2.3</a>). However, a post hoc Trial Sequential Analysis showed that the trial sequential monitoring boundary for benefit was not crossed (<a href="#CD012143-fig-0004">Figure 4</a>). Furthermore, if just one trial with an extreme result (<a href="./references#CD012143-bbs2-0057" title="FornsX , LawitzE , ZeuzemS , GaneE , BronowickiJP , AndreoneP , et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology2014;146(7):1669‐79. FornsX , LawitzE , ZeuzemS , GaneEJ , BronowickiJP , AndreoneP , et al. Simeprevir (TMC435) with peg‐interferon alpha‐2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon‐based therapy: efficacy and safety in patient sub‐populations in the PROMISE phase III trial. Hepatology2013;58(4 SUPPL. 1):737A‐8A. GaneEJ , FornsX , LawitzE , ZeuzemS , BronowickiJP , AndreoneP , et al. Simeprevir (TMC435) with peg‐interferon alpha‐2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon‐based therapy: efficacy in patients with genotype 1b HCV in the PROMISE phase III trial. Hepatology International2014;8(1 Suppl 1):S181. LawitzE , FornsX , ZeuzemS , GaneE , BronowickiJP , AndreoneP , et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon‐based therapy: results from PROMISE, a phase III trial. Gastroenterology2013;144(5 Suppl 1):S151. ">Forns 2014</a>) was excluded from the analysis then a post hoc sensitivity meta‐analysis did not show evidence of a difference (OR 0.70, 95% CI 0.49 to 1.01, P = 0.053). The remaining P values for each DAA meta‐analysed separately were: paritaprevir P = 0.69; asunaprevir P = 0.20; alisporivir P = 0.15; daclatasvir P = 0.75; danoprevir P = 0.15; mericitabine P = 0.96; GSK2336805 P = 0.63; sofosbuvir P = 0.66; GS‐9451 P = 0.70; vaniprevir P = 0.06; GS‐9851 P = 0.83; beclabuvir P = 0.44 (<a href="./references#CD012143-fig-0028" title="">Analysis 2.3</a>). </p> <div class="figure" id="CD012143-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of the effects of simeprevir versus placebo or no intervention on risk of serious adverse events. The analysis was based on a proportion in the control group (Pc) of 8.4%, a relative risk reduction (RRR) of 20%, and alfa of 2.5%, a beta of 20%, and a diversity of 0%. The cumulative Z‐curve crosses the naive type I error level of 5%, but it does not cross the trial monitoring boundary for benefit." data-id="CD012143-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial Sequential Analysis of the effects of simeprevir versus placebo or no intervention on risk of serious adverse events. The analysis was based on a proportion in the control group (Pc) of 8.4%, a relative risk reduction (RRR) of 20%, and alfa of 2.5%, a beta of 20%, and a diversity of 0%. The cumulative Z‐curve crosses the naive type I error level of 5%, but it does not cross the trial monitoring boundary for benefit. </p> </div> </div> </div> <p>The test for subgroup differences showed no evidence of a difference in five subgroup analyses (treatment‐naive compared to treatment‐experienced, P = 0.39; IFN in both groups compared to no IFN in both groups, P = 0.277; RBV in both groups compared to no RBV in both groups, P = 0.10; viral genotype 1 compared to mixed, P = 0.09); subclasses of DAAs (P = 0.31). Because of no relevant data it was not possible to conduct any of the remaining planned subgroup analyses (<a href="./references#CD012143-fig-0028" title="">Analysis 2.3</a>; <a href="./references#CD012143-fig-0029" title="">Analysis 2.4</a>; <a href="./references#CD012143-fig-0030" title="">Analysis 2.5</a>; <a href="./references#CD012143-fig-0031" title="">Analysis 2.6</a>; <a href="./references#CD012143-fig-0032" title="">Analysis 2.7</a>; <a href="./references#CD012143-fig-0033" title="">Analysis 2.8</a>; <a href="./references#CD012143-fig-0034" title="">Analysis 2.9</a>; <a href="./references#CD012143-fig-0035" title="">Analysis 2.10</a>; <a href="./references#CD012143-fig-0036" title="">Analysis 2.11</a>; <a href="./references#CD012143-fig-0037" title="">Analysis 2.12</a>; <a href="./references#CD012143-fig-0038" title="">Analysis 2.13</a>; <a href="./references#CD012143-fig-0039" title="">Analysis 2.14</a>; <a href="./references#CD012143-fig-0040" title="">Analysis 2.15</a>; <a href="./references#CD012143-fig-0041" title="">Analysis 2.16</a>; <a href="./references#CD012143-fig-0042" title="">Analysis 2.17</a>). </p> <p>As a post hoc analysis we calculated the median dose of each assessed DAA. We then divided all trials reporting relevant data into two groups: 1. trials assessing the effects of a DAA over or at the median dose, and 2. trials assessing the effects of a DAA below the median dose. The test for subgroup differences showed no evidence of a difference (P = 0.67). </p> </section> <section id="CD012143-sec-0114"> <h6 class="title">Assessment of clinical significance</h6> <p>We did not assess the clinical significance of the results on serious adverse events because the threshold for statistical significance was not crossed. </p> </section> </section> <section id="CD012143-sec-0115"> <h5 class="title">Health‐related quality of life</h5> <p>Only one trial assessed the effects of a DAA (sofosbuvir, DAA on the market) on quality of life (SF 36 mental score and SF 36 physical score) (<a href="./references#CD012143-bbs2-0051" title="LawitzE , MangiaA , WylesD , Rodriguez‐TorresM , HassaneinT , Gordon StuartC , et al. Sofosbuvir for previously untreated chronic hepatitis C infection. New England Journal of Medicine2013;368(20):1878‐87. YounossiZM , StepanovaM , HenryL , GaneE , JacobsonIM , LawitzE , et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH‐C). Journal of Hepatology2014;60(4):741‐7. [PUBMED: 24333184] ">FISSION 2013</a>). There was no evidence of a difference between the DAA and control on either SF 36 mental score or SF 36 physical score (<a href="./references#CD012143-bbs2-0051" title="LawitzE , MangiaA , WylesD , Rodriguez‐TorresM , HassaneinT , Gordon StuartC , et al. Sofosbuvir for previously untreated chronic hepatitis C infection. New England Journal of Medicine2013;368(20):1878‐87. YounossiZM , StepanovaM , HenryL , GaneE , JacobsonIM , LawitzE , et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH‐C). Journal of Hepatology2014;60(4):741‐7. [PUBMED: 24333184] ">FISSION 2013</a>). An additional trial also assessed the effects sofosbuvir on quality of life (SF 36 mental score and SF 36 physical score) (<a href="./references#CD012143-bbs2-0166" title="JacobsonIM , GordonSC , KowdleyKV , YoshidaEM , Rodriguez‐TorresM , SulkowskiMS , et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. New England Journal of Medicine2013;368(20):1867‐77. YounossiZM , StepanovaM , HenryL , GaneE , JacobsonIM , LawitzE , et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH‐C). Journal of Hepatology2014;60(4):741‐7. [PUBMED: 24333184] ">POSITRON 2013</a>). However, this trial randomised participants to a combination of DAAs and RBV versus placebo. There was no evidence of a difference between the compared groups on either SF 36 mental score or SF 36 physical score (<a href="./references#CD012143-bbs2-0166" title="JacobsonIM , GordonSC , KowdleyKV , YoshidaEM , Rodriguez‐TorresM , SulkowskiMS , et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. New England Journal of Medicine2013;368(20):1867‐77. YounossiZM , StepanovaM , HenryL , GaneE , JacobsonIM , LawitzE , et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH‐C). Journal of Hepatology2014;60(4):741‐7. [PUBMED: 24333184] ">POSITRON 2013</a>). </p> </section> <section id="CD012143-sec-0116"> <h5 class="title">No sustained virological response</h5> <section id="CD012143-sec-0117"> <h6 class="title">Meta‐analysis</h6> <p>Thirty‐two trials with a total of 7115 participants reported results on no sustained virological response. A total of 1214/5347 (22.7%) in the DAA groups and a total of 955/1768 (54.0%) participants in the control group had no sustained virological response during the observation period. Meta‐analysis showed that DAAs seemed to decrease the risk of no sustained virological response (RR 0.44, 95% CI 0.37 to 0.52, P &lt; 0.00001, I² = 77%, 32 trials, low‐quality evidence; <a href="./references#CD012143-fig-0044" title="">Analysis 3.1</a>). </p> </section> <section id="CD012143-sec-0118"> <h6 class="title">Heterogeneity</h6> <p>Visual inspection of the funnel plots did not indicate significant statistical heterogeneity (<a href="./references#CD012143-fig-0044" title="">Analysis 3.1</a>). The tests for statistical heterogeneity (I² = 78%; P &lt; 0.00001) indicated significant heterogeneity. </p> </section> <section id="CD012143-sec-0119"> <h6 class="title">Trial Sequential Analysis</h6> <p>The Trial Sequential Analysis showed that the Z‐curve crossed the trial sequential monitoring boundary for benefit. Hence, there is evidence that DAAs versus control do reduce the risk of no sustained virological response by 20% or more (<a href="#CD012143-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD012143-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of the effects of direct‐acting antivirals on the market or under development versus placebo or no intervention on risk of no sustained virological response. The analysis was based on a proportion in the control group (Pc) of 60.2%, a RRR of 20%, and alfa of 2.5%, a beta of 20%, and a diversity of 83%. After randomisation of about 1000 participants, the cumulative Z‐curve crosses the trial sequential monitoring boundary for benefit." data-id="CD012143-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial Sequential Analysis of the effects of direct‐acting antivirals on the market or under development versus placebo or no intervention on risk of no sustained virological response. The analysis was based on a proportion in the control group (Pc) of 60.2%, a RRR of 20%, and alfa of 2.5%, a beta of 20%, and a diversity of 83%. After randomisation of about 1000 participants, the cumulative Z‐curve crosses the trial sequential monitoring boundary for benefit. </p> </div> </div> </div> </section> <section id="CD012143-sec-0120"> <h6 class="title">Bayes factor</h6> <p>Bayes factor was calculated based on a RR of 20%, and the meta‐analysis result (OR 0.44). Bayes factor of 3.29 * 10<sup>‐25</sup> was below the Bayes factor threshold for significance of 0.1, supporting that there seems to be more evidence for a 20 % RRR on risk of no sustained virological response compared to evidence for the null hypothesis. </p> </section> <section id="CD012143-sec-0121"> <h6 class="title">Risk of bias and sensitivity analyses</h6> <p>The risk of bias of the outcome result was assessed as high.</p> <p>The best‐worst (OR 0.41, 95% CI 0.34 to 0.49, <a href="./references#CD012143-fig-0061" title="">Analysis 3.18</a>) and the worst‐best (OR 0.51, 95% CI 0.43 to 0.60, <a href="./references#CD012143-fig-0062" title="">Analysis 3.19</a>) case meta‐analyses showed that incomplete outcome data bias did not seem to have any potential impact on the meta‐analysis result. </p> <p>Visual inspection of the funnel plots showed signs of asymmetry. However, the Harbord test showed no evidence of a difference (P = 0.52). </p> </section> <section id="CD012143-sec-0122"> <h6 class="title">Subgroup analyses</h6> <section id="CD012143-sec-0123"> <p><b>Types of DAA</b></p> <p>The test for subgroup differences comparing the effects of each type of DAA showed evidence of a difference between the different DAAs (P &lt; 0.001, I² = 61.1%, <a href="./references#CD012143-fig-0046" title="">Analysis 3.3</a>). When analysed separately, the following single DAAs all showed evidence of an effect when assessing no sustained virological response: asunaprevir (RR 0.49, 95% CI 0.29 to 0.85, <a href="./references#CD012143-fig-0046" title="">Analysis 3.3</a>); daclatasvir (RR 0.60, 95% CI 0.50 to 0.73, <a href="./references#CD012143-fig-0046" title="">Analysis 3.3</a>); danoprevir (RR 0.38, 95% CI 0.28 to 0.51, <a href="./references#CD012143-fig-0046" title="">Analysis 3.3</a>); GS‐9451 (RR 0.42, 95% CI 0.26 to 0.67, <a href="./references#CD012143-fig-0046" title="">Analysis 3.3</a>); simeprevir (RR 0.39, 95% CI 0.33 to 0.46, <a href="./references#CD012143-fig-0046" title="">Analysis 3.3</a>); sofosbuvir (RR 0.34, 95% CI 0.20 to 0.58, <a href="./references#CD012143-fig-0046" title="">Analysis 3.3</a>); and vaniprevir (RR 0.33, 95% CI 0.25 to 0.43, <a href="./references#CD012143-fig-0046" title="">Analysis 3.3</a>). </p> </section> <section id="CD012143-sec-0124"> <p><b>Subclass of DAA</b></p> <p>The test for subgroup differences comparing the effects of each type of DAA showed evidence of a difference between the different DAAs (P &lt; 0.00001, I² = 95%, <a href="./references#CD012143-fig-0047" title="">Analysis 3.4</a>). When analysed separately, the following subclasses of DAAs all showed evidence of an effect when assessing no sustained virological response: NS3/NS4A inhibitors (RR 0.41, 95% CI 0.36 to 0.46, <a href="./references#CD012143-fig-0047" title="">Analysis 3.4</a>); NS5B inhibitors (NPI) (RR 0.57, 95% CI 0.36 to 0.90); and NS5A inhibitors (RR 0.59, 95% CI 0.49 to 0.69, <a href="./references#CD012143-fig-0047" title="">Analysis 3.4</a>). </p> </section> <section id="CD012143-sec-0125"> <p><b>Viral genotype</b></p> <p>The test for subgroup differences comparing the effects of DAAs in different genotypes showed evidence of a difference between the subgroups (P = 0.002; I² = 73.6%, <a href="./references#CD012143-fig-0050" title="">Analysis 3.7</a>). Only trials randomising participants with HCV genotype 1 (RR 0.43, 95% CI 0.37 to 0.50, <a href="./references#CD012143-fig-0050" title="">Analysis 3.7</a>) and HCV genotype 4 (RR 0.10, 95% CI 0.02 to 0.68, <a href="./references#CD012143-fig-0050" title="">Analysis 3.7</a>) showed an evidence of a difference when analysed separately. </p> </section> <section id="CD012143-sec-0126"> <p><b>Human genotype</b></p> <p>The test for subgroup differences comparing the effects of DAAs in different human genotypes did not show evidence of a difference between the subgroups (P = 0.62; I² = 0%, <a href="./references#CD012143-fig-0051" title="">Analysis 3.8</a>). All of the subgroups showed clear evidence of differences in favour of DAAs when analysed separately (<a href="./references#CD012143-fig-0051" title="">Analysis 3.8</a>). </p> </section> <section id="CD012143-sec-0127"> <p><b>Trials conducted in an Asian region compared to trials not conducted in an Asian region</b></p> <p>The test for subgroup differences comparing the effects of DAAs in trials conducted in an Asian region compared to trials conducted outside an Asian region showed evidence of a difference between the subgroups, with larger effects in Asia: (P &lt; 0.02, I² = 70.3%, <a href="./references#CD012143-fig-0052" title="">Analysis 3.9</a>). When analysed separately, both trials randomising Asian (RR 0.34, 95% CI 0.28 to 0.42) and non‐Asian (RR 0.51, 95% CI 0.43 to 0.60) participants showed clear evidence of differences in favour of DAAs (<a href="./references#CD012143-fig-0052" title="">Analysis 3.9</a>). </p> </section> <section id="CD012143-sec-0128"> <p><b>Treatment‐experienced compared to treatment‐naive</b></p> <p>The test for subgroup differences comparing the effects of DAAs in trials randomising treatment‐experienced participants to trials randomising treatment‐naive participants, did not show evidence of a difference between the subgroups (P = 0.46; I² = 0%, <a href="./references#CD012143-fig-0055" title="">Analysis 3.12</a>). When analysed separately, both trials randomising treatment‐experienced (RR 0.50, 95% CI 0.36 to 0.69) and treatment‐naive (RR 0.48, 95% CI 0.41 to 0.56) participants showed clear evidence of differences in favour of DAAs (<a href="./references#CD012143-fig-0055" title="">Analysis 3.12</a>). </p> </section> <section id="CD012143-sec-0129"> <p><b>IFN as co‐intervention compared to no IFN as co‐intervention</b></p> <p>The test for subgroup differences comparing the effects of DAAs in trials using IFN as co‐intervention in both groups compared to trials not using IFN as co‐intervention in both groups, did not show evidence of a difference between the subgroups (P = 0.68, I² = 0%, <a href="./references#CD012143-fig-0056" title="">Analysis 3.13</a>). </p> <p>None of the remaining planned subgroup analyses were possible to conduct because of the lack of relevant trial data. </p> <p>As a post hoc analysis we calculated the median dose of each assessed DAA. We then divided all trials reporting relevant data into two groups: 1. trials assessing the effects of a DAA over or at the median dose, and 2. trials assessing the effects of a DAA below the median dose. The test for subgroup differences showed no evidence of a difference (P = 0.56; <a href="./references#CD012143-fig-0063" title="">Analysis 3.20</a>). </p> </section> </section> <section id="CD012143-sec-0130"> <h6 class="title">Assessment of clinical significance</h6> <p>A number of the analyses showed clear evidence of an effect. However, the clinical relevance of these effects on a non‐validated surrogate outcome results is unclear (see <a href="#CD012143-sec-0030">Background</a>). </p> </section> </section> <section id="CD012143-sec-0131"> <h5 class="title">Analysis of trials using RBV and IFN only in the control group</h5> <p>Analysis of trials using RBV and IFN only in the control group and not as co‐intervention in the experimental group, showed that there was no evidence of a difference between the DAAs versus RBV and IFN on risk of serious adverse events (OR 1.81, 95% CI 0.74 to 4.44, P = 0.192, I² = 0%, 3 trials, very low‐quality evidence). </p> <p>Our results are summarised in our 'Summary of findings' tables (<a href="./full#CD012143-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD012143-tbl-0002">summary of findings Table 2</a>). </p> </section> </section> <section id="CD012143-sec-0132"> <h4 class="title">Analyses of trials assessing the effects of withdrawn DAAs</h4> <section id="CD012143-sec-0133"> <h5 class="title">Hepatitis C‐related morbidity or all‐cause mortality</h5> <p>When analysing the composite outcome hepatitis C‐related morbidity or all‐cause mortality, all events were deaths only. </p> <p>Meta‐analysis showed no evidence of an effect when assessing the effects of withdrawn DAAs on hepatitis C‐related morbidity or all‐cause mortality (OR 0.64, 95% CI 0.23 to 1.79, P = 0.40, I² = 0%; 5 trials, very low‐quality evidence). Test for subgroup differences between DAAs on the market and withdrawn DAAs showed no evidence of a difference (P=0.45) (<a href="./references#CD012143-fig-0070" title="">Analysis 5.1</a>) </p> <section id="CD012143-sec-0134"> <h6 class="title">Additional analyses</h6> <p>Due to the total lack of data on hepatitis C‐related morbidity and the low number of events on all‐cause mortality, we did not perform additional analysis, including Trial Sequential Analysis, Bayes factor, funnel plots, or subgroup analysis. </p> </section> </section> <section id="CD012143-sec-0135"> <h5 class="title">Serious adverse events</h5> <p>Meta‐analysis showed that withdrawn DAAs seemed to increase the risk of serious adverse events (OR 1.45, 95% CI 1.22 to 1.73, P = 0.001, I² = 0%, 29 trials, very low‐quality evidence). A post hoc Trial Sequential Analysis confirmed this meta‐analysis result (<a href="#CD012143-fig-0006">Figure 6</a>). Test for subgroup differences between DAAs on the market and withdrawn DAAs showed evidence of a difference between the DAAs that are on the market and the withdrawn DAAs (P &lt; 0.001) (<a href="./references#CD012143-fig-0071" title="">Analysis 6.1</a>). </p> <div class="figure" id="CD012143-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of the effects of withdrawn direct‐acting antivirals versus placebo or no intervention on risk of serious adverse events. The analysis was based on a proportion in the control group (Pc) of 7.5%, a RRR of 20%, and alfa of 2.5%, a beta of 20%, and a diversity of 0%. After randomisation of about 5000 participants, the cumulative Z‐curve crosses the trial sequential monitoring boundary for harm." data-id="CD012143-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial Sequential Analysis of the effects of withdrawn direct‐acting antivirals versus placebo or no intervention on risk of serious adverse events. The analysis was based on a proportion in the control group (Pc) of 7.5%, a RRR of 20%, and alfa of 2.5%, a beta of 20%, and a diversity of 0%. After randomisation of about 5000 participants, the cumulative Z‐curve crosses the trial sequential monitoring boundary for harm. </p> </div> </div> </div> </section> <section id="CD012143-sec-0136"> <h5 class="title">No sustained virological response</h5> <p>Meta‐analysis of trials assessing the effects of withdrawn DAAs showed similar results to the meta‐analysis of trials assessing the effects of DAAs on the market or under development when assessing no sustained virological response (<a href="./references#CD012143-fig-0087" title="">Analysis 7.1</a>). </p> </section> <section id="CD012143-sec-0137"> <h5 class="title">Without significant reductions in serum ALT or AST</h5> <p>Four trials reported results on participants without significant reductions in serum ALT or AST, but all of these trials assessed the effects of withdrawn DAAs (<a href="./references#CD012143-fig-0108" title="">Analysis 12.1</a>). Meta‐analysis showed that these withdrawn DAAs seemed to decrease the risk of no significant reduction of serum ALT or AST (RR 0.79, 95% CI 0.68 to 0.92, <a href="./references#CD012143-fig-0108" title="">Analysis 12.1</a>). </p> </section> <section id="CD012143-sec-0138"> <h5 class="title">Non‐serious adverse events</h5> <p>A large number of non‐serious adverse events were reported in the included trials. Overall, 92.4% of the DAA participants experienced one or more non‐serious adverse event compared to 91.5% control participants. We have summarised these in <a href="#CD012143-tbl-0005">Table 3</a>. We plan to analyse each of these adverse events separately, in detail, in a later publication. </p> <div class="table" id="CD012143-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Non‐serious adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Experimental intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Type and number of participants with a non‐serious adverse events (experimental group)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Proportion of participants with a non‐serious adverse event (experimental group)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Type and number of participants with a non‐serious adverse events (control group)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Proportion of participants with a non‐serious adverse event (control group)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0024" title="BronowickiJP , PolS , ThuluvathP , LarreyD , MartorellCT , RustgiVK , et al. Asunaprevir (ASV; BMS‐650032), an NS3 protease inhibitor, in combination with peginterferon and ribavirin in treatment‐naive patients with genotype 1 chronic hepatitis C infection. Journal of Hepatology2012;56(Suppl 2):S431‐2. BronowickiJP , PolS , ThuluvathPJ , LarreyD , MartorellCT , RustgiVK , et al. BMS‐650032, an NS3 inhibitor, in combination with peginterferon alpha‐2a and ribavirin in treatment‐naive subjects with genotype 1 chronic hepatitis C infection. Journal of Hepatology2011;54:S472. BronowickiJP , PolS , ThuluvathPJ , LarreyD , MartorellCT , RustgiVK , et al. Randomized study of asunaprevir plus pegylated interferon‐alpha and ribavirin for previously untreated genotype 1 chronic hepatitis C. Antiviral Therapy2013;18(7):885‐93. ">Bronowicki 2013a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asunaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 diarrhoea, 13 nausea, 10 asthenia, 21 fatigue, 14 influenza‐like illness, 7 irritability, 12 decreased appetite, 4 arthralgia, 9 myalgia, 13 headache, 9 depression, 10 insomnia, 7 cough, 10 dyspnoea, 7 alopecia, 11 dry skin, 10 pruritus, 6 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 out of 36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 diarrhoea, 2 nausea, 4 asthenia, 5 fatigue, 5 influenza‐like illness, 4 irritability, 3 decreased appetite, 4 arthralgia, 1 myalgia, 6 headache, 1 depression, 1 insomnia, 3 cough, 3 dyspnoea, 3 alopecia, 1 dry skin, 2 pruritus, 3 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 out of 11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0027" title="BronowickiJ‐P , RatziuV , GadanoA , Thuluvath PaulJ , BessoneF , Martorell ClaudiaT , et al. Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C. Journal of Hepatology2014;61(6):1220‐7. BronowickiJP , PolS , ThuluvathP , LarreyD , MartorellCT , RustgiVK , et al. Asunaprevir (ASV; BMS‐650032), an NS3 protease inhibitor, in combination with peginterferon and ribavirin in treatment‐naive patients with genotype 1 chronic hepatitis C infection. Journal of Hepatology2012;56(Suppl 2):S431‐S2. BronowickiJP , RatziuV , GadanoA , ThuluvathPJ , BessoneF , MartorellCT , et al. Asunaprevir with peginterferon‐alfa and ribavirin in treatment‐naive patients with genotype‐1 or ‐4 chronic hepatitis C: SVR24 results from a randomized phase 2B study (AI447016). Journal of Hepatology2013;58:S571‐2. ">Bronowicki 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asunaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 anaemia, 63 asthenia, 62 fatigue, 37 influenza‐like illness, 43 decreased appetite, 66 headache, 41 pruritus </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173 out of 177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 anaemia, 1 asthenia, 62 fatigue, 23 influenza‐like illness, 22 decreased appetite, 26 headache, 16 pruritus </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 out of 61</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0152" title="PasquinelliC , EleyT , VillegasC , SandyK , MathiasE , WendelburgP , et al. Safety, tolerability, pharmacokinetics and antiviral activity following single and multiple‐dose administration of BMS‐650032, a novel HCV NS3 inhibitor, in subjects with chronic genotype 1 HCV infection. Hepatology International2010;4(1):184. PasquinelliC , EleyT , VillegasC , SandyK , MathiasE , WendelburgP , et al. Safety, tolerability, pharmacokinetics and antiviral activity following single‐and multiple‐dose administration of BMS‐650032, a novel HCV NS3 inhibitor, in subjects with chronic genotype 1 HCV infection. Hepatology2009;50(4 Suppl):411A‐2A. PasquinelliC , McPheeF , EleyT , VillegasC , SandyK , SheridanP , et al. Single‐ and multiple‐ascending‐dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrobial Agents and Chemotherapy2012;56(4):1838‐44. ">Pasquinelli 2012a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asunaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 nausea, 3 headache, 1 flatulence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0153" title="PasquinelliC , EleyT , VillegasC , SandyK , MathiasE , WendelburgP , et al. Safety, tolerability, pharmacokinetics and antiviral activity following single and multiple‐dose administration of BMS‐650032, a novel HCV NS3 inhibitor, in subjects with chronic genotype 1 HCV infection. Hepatology International2010;4(1):184. PasquinelliC , EleyT , VillegasC , SandyK , MathiasE , WendelburgP , et al. Safety, tolerability, pharmacokinetics and antiviral activity following single‐and multiple‐dose administration of BMS‐650032, a novel HCV NS3 inhibitor, in subjects with chronic genotype 1 HCV infection. Hepatology2009;50(4 Suppl):411A‐2A. PasquinelliC , McPheeF , EleyT , VillegasC , SandyK , SheridanP , et al. Single‐ and multiple‐ascending‐dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrobial Agents and Chemotherapy2012;56(4):1838‐44. ">Pasquinelli 2012a2</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asunaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 nausea, 3 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 nausea, 1 flatulence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0130" title="NelsonDR , ZeuzemS , AndreoneP , FerenciP , HerringR , JensenDM , et al. Balapiravir plus peginterferon alfa‐2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. Annals of Hepatology2012;11(1):15‐31. ">Nelson 2012a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Balapiravir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120 anaemia, 41 neutropenia, 115 diarrhoea, 162 nausea, 138 chills, 231 fatigue, 117 pyrexia, 100 arthralgia, 156 myalgia, 82 dizziness, 241 headache, 90 depression, 174 insomnia, 86 cough, 88 alopecia, 60 dry skin, 108 pruritus, 90 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 anaemia, 3 neutropenia, 16 diarrhoea, 25 nausea, 30 chills, 43 fatigue, 19 pyrexia, 16 arthralgia, 33 myalgia, 15 dizziness, 42 headache, 17 depression, 24 insomnia, 11 cough, 11 alopecia, 16 dry skin, 15 pruritus, 13 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 72</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0201" title="McPheeF , FalkP , FracassoP , LemmJ , LiuM , KirkM , et al. Characterization of viral escape in HCV genotype 1‐infected patients treated with BMS‐791325 and pegylated interferon‐ALFA and ribavirin. Journal of Hepatology2012;56(Suppl S2):S473. TatumH , ThuluvathP , LawitzE , MartorellCT , DemiccoM , CohenS , et al. A phase 2A study of BMS‐791325, an NS5B polymerase inhibitor, with peginterferon alfa‐2A and ribavirin in treatment‐naive patients with genotype 1 chronic hepatitis C infection. Journal of Hepatology2012;56(Suppl S2):S460. TatumH , ThuluvathPJ , LawitzE , MartorellC , DemiccoM , CohenS , et al. A randomized, placebo‐controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1. Journal of Viral Hepatitis2015;22(8):658‐64. TatumHA , ThuluvathPJ , LawitzE , MartorellC , CohenSM , RustgiVK , et al. Safety and efficacy of BMS‐791325, a non‐nucleoside NS5B polymerase inhibitor, combined with peginterferon alfa‐2a and ribavirin in treatment‐naive patients infected with hepatitis C virus genotype 1. Hepatology2013;58(S1):759A‐60A. ">Tatum 2015a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Beclabuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 anaemia, 5 neutropenia, 5 diarrhoea, 9 nausea, 3 chills, 12 fatigue, 6 influenza‐like illness, 7 irritability, 3 pyrexia, 7 decreased appetite, 4 arthralgia, 5 myalgia, 12 headache, 6 depression, 9 insomnia, 6 cough, 5 pruritus, 2 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 anaemia, 1 neutropenia, 1 diarrhoea, 2 nausea, 5 fatigue, 7 influenza‐like illness, 3 irritability, 1 pyrexia, 2 decreased appetite, 3 headache, 3 depression, 3 insomnia, 3 cough, 4 pruritus, 4 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0048" title="ErhardtA , DeterdingK , BenhamouY , ReiserM , FornsX , PolS , et al. Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment. Antiviral Therapy2009;14(1):23‐32. ">Erhardt 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BILB‐1941</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 diarrhoea, 7 nausea, 2 vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 out of 77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 out of 19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0187" title="SimsKD , LemmJ , EleyT , LiuM , BerglindA , ShermanD , et al. Randomized, placebo‐controlled, single‐ascending‐dose study of BMS‐791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection. Antimicrobial Agents and Chemotherapy2014;58(6):3496‐503. ">Sims 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BMS‐791325</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 diarrhoea, 1 nausea, 1 vomiting, 1 headache, 1 pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 out of 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 nausea, 1 vomiting, 1 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0016" title="BaconBR , BrunoS , SchiffER , KwoPY , ButiM , PediconeL , et al. Predictors of sustained virologic response (SVR) among poor interferon (IFN) responders when boceprevir (BOC) is added to peginterferon alfa‐2b/ribavirin (PR). Hepatology2011;54(S1):376A‐7A. BaconBR , GordonSC , LawitzE , MarcellinP , VierlingJM , ZeuzemS , et al. Boceprevir for previously treated chronic HCV genotype 1 infection. New England Journal of Medicine2011;364(13):1207‐17. BaconBR , GordonSC , LawitzE , MarcellinP , VierlingJM , ZeuzemS , et al. HCV RESPOND‐2 final results: high sustained virologic response among genotype 1 previous non‐responders and relapsers to peginterferon/ribavirin when re‐treated with boceprevir plus PEGINTRON (peginterferon alfa‐2b)/ribavirin. Hepatology2010;52(Suppl S1):430A. BarnardRJ , HoweJA , OgertRA , ZeuzemS , PoordadF , GordonSC , et al. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology2013;444(1‐2):329‐36. BognarFA , HuKQ , ThompsonS , PediconeL , WahlJ , LinSG . Boceprevir (BOC) plus peginterferon alfa‐2b/ ribavirin (PR) in the treatment of chronic hepatitis C virus genotype‐1 (HCV‐G1) infected Asian patients in the SPRINT‐1, SPRINT‐2 and RESPOND‐2 trials. Journal of Gastroenterology and Hepatology2012;27(Suppl 4):161. BrassC , BarnardRJO , HoweJA , OgertRA , RalstonR , BoparaiN , et al. Sustained virologic response and boceprevir resistance‐associated variants observed in patients infected with HCV genotpype Ia/Ib when treated with boceprevir plus peginterferon alfa‐2b/ribavirin. Journal of Hepatology2011;54(Suppl 1):S471‐2. BrunoS , VierlingJM , EstebanR , NybergLM , TannoH , AlbrechtJK , et al. Boceprevir in addition to standard of care enhanced SVR in hepatitis C virus (HCV) genotype‐1 with advanced fibrosis/cirrhosis: subgroup analysis of sprint‐2 and respond‐2 studies. Journal of Hepatology2011;54(Suppl 1):S4‐5. BrunoS , VierlingJM , EstebanR , NybergLM , TannoH , GoodmanZ , et al. Efficacy and safety of boceprevir plus peginterferon‐ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. Journal of Hepatology2013;58(3):479‐87. ChhatwalJ , FerranteSA , BrassC , ElKhouryAC , BurroughsM , BaconB , et al. Cost‐effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. Value in Health2013;16(6):973‐86. ChhatwalJ , FerranteSA , DasbachEJ , ElKhouryA , BurroughsM , BaconB , et al. Projecting the long‐term clinical impact of boceprevir in patients with chronic hepatitis C genotype‐1 who failed prior treatment with peginterferon/ribavirin. Journal of Hepatology2011;54:S164. ChhatwalJ , FerranteSA , DasbachEJ , KhouryA , BrassCA , BurroughsM , et al. Cost‐effectiveness of boceprevir use in patients with chronic hepatitis C genotype‐1 who failed prior treatment with peginterferon/ribavirin. Hepatology2011;54(4 (Suppl)):801A‐2A. ChhatwalJ , LundbergJ , FerranteS , ElKhourhyAC , OksanenA , ElbashaEH . Cost‐effectiveness of boceprevir in the treatment of chronic Hepatitis C genotype 1 in Sweden. Journal of Hepatology2012;56(Suppl 2):S386‐7. GordonSC , SulkowskiMS , JacobsonIM , VierlingJM , DavisGL , AfdhalNH , et al. Reasons for screen failure in 2 phase III studies of boceprevir with peginterferon/ribavirin in patients with chronic HCV genotype 1 infection (sprint‐2 and respond‐2). Hepatology2011;54(Suppl S1):848A‐9A. LenzO , FeveryB , VijgenL , VerbeeckJ , PeetersM , BeumontM , et al. TMC435 in combination with peginterferon alpha‐2A/ribavirin in treatment‐naïve patients infected with HCV genotype 1: virology analysis of the PILLAR study. Hepatology2011;54(4 (Suppl)):985A. MarcellinP , VierlingJM , AlricL , PirisiM , TranA , AlbrechtJK , et al. Efficacy among North American and European HCV genotype‐1 treatment‐naive and previous non‐responders and relapsers to peginterferon/ribavirin when treated with boceprevir plus peginterferon alfa‐2b/ribavirin. Journal of Hepatology2011;54(Suppl 1):S184. SulkowskiMS , BaconBR , GordonSC , LawitzE , MarcellinP , VierlingJM , et al. Boceprevir combined with peginterferon alfa‐2b/ribavirin for previous treatment failure patients with hepatitis C virus genotype 1: RESPOND‐2 final results. Journal of the International Association of Physicians in AIDS Care2011;10(3):198. ZeuzemS , VierlingJM , EstebanR , GibasAL , PolS , BoparaiN , et al. Predictors of sustained virologic response among genotype 1 previous non‐responders and relapsers to peginterferon/ribavirin when re‐treated with boceprevir plus peginterferon alfa‐2b/ribavirin. Journal of Hepatology2011;54(Suppl 1):S198‐9. ">Bacon 2011a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145 anaemia, 46 neutropenia, 78 diarrhoea, 140 nausea, 47 vomiting, 68 asthenia, 106 chills, 179 fatigue, 79 influenza‐like illness, 67 irritability, 93 pyrexia, 83 decreased appetite, 73 arthralgia, 81 myalgia, 52 dizziness, 142 dysgeusia, 133 headache, 46 depression, 97 insomnia, 70 cough, 69 dyspnoea, 71 alopecia, 72 dry skin, 62 pruritus, 51 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>319 out of 323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 anaemia, 8 neutropenia, 13 diarrhoea, 30 nausea, 6 vomiting, 13 asthenia, 24 chills, 40 fatigue, 20 influenza‐like illness, 10 irritability, 20 pyrexia, 13 decreased appetite, 13 arthralgia, 19 myalgia, 8 dizziness, 9 dysgeusia, 39 headache, 12 depression, 19 insomnia, 14 cough, 14 dyspnoea, 13 alopecia, 7 dry skin, 14 pruritus, 5 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77 out of 80</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0052" title="FlammS , LawitzE , JacobsonI , RubinR , BourliereM , HezodeC , et al. High sustained virologic response (SVR) among genotype 1 previous non‐responders and relapsers to peginterferon/ribavirin when re‐treated with boceprevir (BOC) plus peginterferon alfa‐2A/ribavirin. Journal of Hepatology2011;54(Suppl 1):S541‐2. FlammSL , LawitzE , JacobsonI , BourliereM , HezodeC , VierlingJM , et al. Boceprevir with peginterferon alfa‐2a‐ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clinical Gastroenterology and Hepatology2013;11(1):81‐7. HoweJA , OgertRA , BarnardRJ , HazudaD , PediconeL , BrassCA . Analysis of sustained viral response and boceprevir resistance following combination treatment with boceprevir plus peginterferon alfa‐2A/ribavirin in HCV genotype 1 prior relapsers and non‐responders. Hepatology2011;54(S1):443A. ">Flamm 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 anaemia, 41 neutropenia, 33 diarrhoea, 52 nausea, 16 vomiting, 29 asthenia, 14 chills, 67 fatigue, 35 influenza‐like illness, 29 irritability, 18 pyrexia, 27 decreased appetite, 16 arthralgia, 25 myalgia, 17 dizziness, 52 dysgeusia, 37 headache, 22 depression, 32 insomnia, 26 cough, 26 dyspnoea, 22 alopecia, 20 dry skin, 18 pruritus, 31 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133 out of 134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 anaemia, 12 neutropenia, 5 diarrhoea, 18 nausea, 12 asthenia, 8 chills, 36 fatigue, 18 influenza‐like illness, 16 irritability, 8 pyrexia, 12 decreased appetite, 12 arthralgia, 5 myalgia, 10 dizziness, 10 dysgeusia, 21 headache, 6 depression, 20 insomnia, 14 cough, 17 dyspnoea, 5 alopecia, 11 dry skin, 8 pruritus, 5 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 out of 67</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0080" title="IsakovV , NikitinI , ChulanovV , OgurtsovP , LukyanovaE , LongJ , et al. Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in Russia. World Journal of Hepatology2016;8(6):331‐9. ">Isakov 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105 anaemia, 103 leukopenia, 141 neutropenia, 16 thrombocytopenia, 22 diarrhoea, 13 dry mouth, 59 nausea, </p> <p>12 vomiting, 63 asthenia, 24 chills, 40 fatigue, 51 hyperthermia,</p> <p>356 influenza‐like illness, 9 injection site erythema, 18 irritability, 217 pyrexia, 14 body temperature increased, 33 weight decreased, 10 decreased appetite, 16 arthralgia, 33 myalgia, 9 dizziness, 69 dysgeusia, 89 headache, 2 sleep disorder, 38 cough, 7 dyspnoea, 33 alopecia, 12 dry skin, 20 pruritus, 17 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153 out of 159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 anaemia, 35 leukopenia, 45 neutropenia, 7 thrombocytopenia, 3 diarrhoea, 5 dry mouth, 15 nausea, </p> <p>2 vomiting, 23 asthenia, 2 chills, 18 fatigue, 12 hyperthermia,</p> <p>72 influenza‐like illness, 2 injection site erythema, 11 irritability,</p> <p>124 pyrexia, 2 body temperature increased, 9 weight decreased, 7 decreased appetite, 4 arthralgia, 8 myalgia, 7 dizziness, 5 dysgeusia, 51 headache, 4 sleep disorder, 14 cough, 7 dyspnoea, 16 alopecia, 3 dry skin, 6 pruritus, 2 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71 out of 78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0086" title="KwoP , LawitzE , McConeJ , SchiffE , VierlingJ , PoundD , et al. HCV Sprint‐1 final results: SVR 24 from a phase 2 study of boceprevir plus pegintron (peginterferon ALFA‐2B)/ribavirin in treatment‐naive subjects with genotype‐1 chronic hepatitis C. Journal of Hepatology2009;50(Suppl 1):S4. KwoPJ , LawitzEJ , McConeJ , SchiffER , VierlingJM , PoundD , et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa‐2b and ribavirin in treatment‐naive patients with genotype 1 hepatitis C infection (SPRINT‐1): an open‐label, randomised, multicentre phase 2 trial. Lancet2010;376(9742):705‐16. OgertRA , HoweJA , VierlingJM , KwoPY , LawitzEJ , McConeJ , et al. Resistance‐associated amino acid variants associated with boceprevir plus pegylated interferon‐alpha2b and ribavirin in patients with chronic hepatitis C in the SPRINT‐1 trial. Antiviral Therapy2013;18(3):387‐97. PoordadF , VierlingJM , EstebanR , KwoPY , LongJ , ChaudhriEI , et al. Hemogloblin decline during lead‐in phase as an early predictor of anemia after the addition of boceprevir: a retrospective analysis of HCV SPRINT‐1. Hepatology2010;52(Suppl S1):770A. VierlingJM , KwoPY , LawitzE , McConeJ , SchiffER , PoundD , et al. Frequencies of resistance‐associated amino acid variants following combination treatment with boceprevir plus PEGINTRON (peginterferon alfa‐2b)/ribavirin in patients with chronic hepatitis C (CHC), genotype 1 (G1). Hepatology2010;52(Suppl S1):702A. ">Kwo 2010a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>226 anaemia, 96 neutropenia, 109 diarrhoea, 186 nausea, 81 vomiting, 53 asthenia, 130 chills, 259 fatigue, 79 influenza‐like illness, 91 irritability, 129 pyrexia, 49 decreased appetite, 76 arthralgia, 99 myalgia, 70 dizziness, 111 dysgeusia, 190 headache, 91 depression, 146 insomnia, 76 cough, 66 dyspnoea, 131 alopecia, 60 dry skin, 80 pruritus, 27 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>413 out of 416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 anaemia, 12 neutropenia, 23 diarrhoea, 45 nausea, 5 vomiting, 14 asthenia, 35 chills, 57 fatigue, 25 influenza‐like illness, 23 irritability, 35 pyrexia, 12 decreased appetite, 21 arthralgia, 17 myalgia, 16 dizziness, 9 dysgeusia, 45 headache, 22 depression, 40 insomnia, 20 cough, 15 dyspnoea, 27 alopecia, 17 dry skin, 16 pruritus, 6 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102 out of 104</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0164" title="AlbrechtJ , VierlingJ , KwoP , LawitzE , McConeJ , SchiffE . Frequencies of resistance‐associated amino acid variants (RAV) following treatment with boceprevir (BOC) plus peginterferon alfa‐2b and ribavirin (P/R). Hepatology International2011;5(1):261‐2. BarnardRJO , PediconeLD , ChaudhriE , TongX , QiuP , BrassCA . Frequencies of resistance‐associated amino acid variants following combination treatment with boceprevir (BOC) plus Pegintron (peglnterferon alfa‐2b) and ribavirin (P/R) in patients with chronic hepatitis C (CHC), genotype 1 (G1). Journal of the International Association of Physicians in AIDS Care2011;10(3):199‐200. BronowickiJ , McConeJ , BaconBR , BrunoS , MannsMP , SulkowskiMS , et al. Response‐guided therapy (RGT) with boceprevir (BOC) + peginterferon alfa‐2b/ribavirin (P/R) for treatment‐naive patients with hepatitis C virus (HCV) genotype (G) 1 was similar to a 48‐wk fixed‐duration regimen with BOC + P/R in SPRINT‐2. Hepatology2010;52(Suppl S1):881A. CharltonM . Boceprevir (Victrelis) for HCV: V is for victory and very complex. Hepatology2011;54(5):1882‐6. MannsMP , MarkovaAA , SerranoBC , CornbergM . Phase III results of boceprevir in treatment naive patients with chronic hepatitis C genotype 1. Liver International2012;32(Suppl 1):27‐31. MannsMP , McConeJ , DavisM , ShiffmanML , RossaroL , BourliereM , et al. Safety benefits of response‐guided therapy with boceprevir (BOC) plus peginterferon alfa‐2B/ribavirin (PR) in previously untreated patients with HCV genotype 1 infection. Hepatology2011;54(4 Suppl):813A. McConeJ , JacobsonIM , BaconBR , PediconeL , GotetiVS , BurroughsM , et al. Treatment‐naive black patients treated with boceprevir combined with peginterferon alfa‐2b + ribavirin: results from HCV sprint‐2. Hepatology2011;54(4 Suppl):822A‐3A. PoordadF , McConeJ , BaconBR , BrunoS , MannsMP , SulkowskiMS , et al. Boceprevir (BOC) combined with peginterferon alfa‐2b/ribavirin (P/R) for treatment‐naive patients with hepatitis C virus (HCV) genotype (G) 1: SPRINT‐2 final results. Hepatology2010;52(Suppl S1):402A. PoordadF , McConeJ , BaconBR , BrunoS , MannsMP , SulkowskiMS , et al. Boceprevir for untreated chronic HCV genotype 1 infection. New England Journal of Medicine2011;364(13):1195‐206. ReddyKR , BrunoS , RossaroL , RavendhranN , PaulyMP , BoparaiN , et al. Predictors of sustained virologic response among treatment‐naive patients with hepatitis C virus genotype 1 when treated with boceprevir (BOC) plus peginterferon alfa‐2B/ribavirin (PR). Journal of Hepatology2011;54(Suppl 1):S190. SulkowskiMS , BaconBR , GordonSC , LawitzE , MarcellinP , VierlingJM , et al. Boceprevir combined with peginterferon alfa‐2b/ribavirin for previous treatment failure patients with hepatitis C virus genotype 1: RESPOND‐2 final results. Journal of the International Association of Physicians in AIDS Care2011;10(3):197‐8. SulkowskiMS , PoordadF , MannsMP , BronowickiJP , RajenderRK , HarrisonSA , et al. Anemia during treatment with peginterferon alfa‐2b/ribavirin and boceprevir: analysis from the serine protease inhibitor therapy 2 (SPRINT‐2) trial. Hepatology2013;57(3):974‐84. ">Poordad 2011a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>361 anaemia, 184 neutropenia, 180 diarrhoea, 334 nausea, 145 vomiting, 125 asthenia, 255 chills, 405 fatigue, 174 influenza‐like illness, 164 irritability, 240 pyrexia, 186 decreased appetite, 141 arthralgia, 170 myalgia, 146 dizziness, 293 dysgeusia, 335 headache, 151 depression, 239 insomnia, 130 cough, 152 dyspnoea, 179 alopecia, 153 dry skin, 181 pruritus, 181 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>728 out of 734</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107 anaemia, 77 neutropenia, 79 diarrhoea, 153 nausea, 57 vomiting, 70 asthenia, 102 chills, 217 fatigue, 93 influenza‐like illness, 86 irritability, 120 pyrexia, 90 decreased appetite, 66 arthralgia, 94 myalgia, 59 dizziness, 64 dysgeusia, 153 headache, 78 depression, 118 insomnia, 76 cough, 59 dyspnoea, 99 alopecia, 66 dry skin, 98 pruritus, 83 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>353 out of 363</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0196" title="ShermanKE , RockstrohJK , DieterichDT , SorianoV , GirardPM , McCallisterS , et al. Telaprevir combination with peginterferon alfa‐2A/ribavirin in HCV/HIV coinfected patients: 24‐week treatment interim analysis. Hepatology2011;54(4 Suppl):1431A‐2A. SulkowskiMS , ShermanKE , DieterichDT , BsharatM , MahnkeL , RockstrohJK , et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Annals of Internal Medicine2013;159(2):86‐96. SulkowskiMS , ShermanKE , SorianoV , RockstrohJ , DieterichDT , GirardPM , et al. Telaprevir in combination with peginterferon alfa‐2a/ribavirin in HCV/HIV co‐infected patients: SVR24 final study results. Hepatology2012;56(S1):219A. ">Sulkowski 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 anaemia, 12 neutropenia, 21 diarrhoea, 26 nausea, 18 vomiting, 22 asthenia, 5 chills, 25 fatigue, 16 influenza‐like illness, 10 irritability, 24 pyrexia, 22 decreased appetite, 7 arthralgia, 9 myalgia, 8 dizziness, 18 dysgeusia, 18 headache, 11 depression, 15 insomnia, 9 cough, 5 dyspnoea, 12 alopecia, 8 dry skin, 13 pruritus, 5 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 out of 64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 anaemia, 2 neutropenia, 6 diarrhoea, 11 nausea, 5 vomiting, 9 asthenia, 5 chills, 12 fatigue, 13 influenza‐like illness, 5 irritability, 7 pyrexia, 6 decreased appetite, 2 arthralgia, 6 myalgia, 2 dizziness, 5 dysgeusia, 6 headache, 4 depression, 9 insomnia, 6 cough, 2 dyspnoea, 6 alopecia, 3 dry skin, 3 pruritus </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 out of 34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0042" title="DoreGJ , LawitzE , HezodeC , ShafranSD , RamjiA , TatumHA , et al. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. Gastroenterology2015;148(2):355‐66. ">Dore 2015a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daclatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 anaemia, 9 neutropenia, 10 diarrhoea, 22 nausea, 4 vomiting, 13 asthenia, 4 chills, 35 fatigue, 19 influenza‐like illness, 17 irritability, 7 pyrexia, 12 decreased appetite, 11 arthralgia, 14 myalgia, 6 dizziness, 5 dysgeusia, 30 headache, 11 depression, 19 insomnia, 8 cough, 12 dyspnoea, 12 alopecia, 13 dry skin, 27 pruritus, 25 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98 out of 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 anaemia, 8 neutropenia, 3 diarrhoea, 8 nausea, 4 vomiting, 7 asthenia, 19 fatigue, 7 influenza‐like illness, 6 irritability, 2 pyrexia, 8 decreased appetite, 9 arthralgia, 11 myalgia, 6 dizziness, 3 dysgeusia, 9 headache, 9 depression, 17 insomnia, 8 cough, 6 dyspnoea, 5 alopecia, 6 dry skin, 14 pruritus, 12 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 out of 51</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0031" title="HezodeC , HirschfieldGM , GhesquiereW , SievertW , Rodriguez‐TorresM , ShafranS , et al. BMS‐790052, a NS5A replication complex inhibitor, combined with peginterferon alfa‐2a and ribavirin in treatment‐naive HCV‐genotype 1 or 4 patients: phase 2b AI444010 study interim week 12 results. Hepatology2011;54(S1):474A‐5A. HezodeC , HirschfieldGM , GhesquiereW , SievertW , Rodriguez‐TorresM , ShafranS , et al. Daclatasvir (BMS‐790052), a NS5A replication complex inhibitor, combined with peginterferon‐alfa‐2a and ribavirin in treatment‐naive HCV genotype 1 or 4 subjects: phase 2b AI444010 study interim week 24 results. Hepatology International2012;6(1):167. HezodeC , HirschfieldGM , GhesquiereW , SievertW , Rodriguez‐TorresM , ShafranSD , et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment‐naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut2015;64(6):948‐56. ">COMMAND‐1 2015a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daclatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 anaemia, 43 neutropenia, 73 diarrhoea, 109 nausea, 34 vomiting, 32 asthenia, 49 chills, 174 fatigue, 94 influenza‐like illness, 72 irritability, 48 pyrexia, 67 decreased appetite, 55 arthralgia, 88 myalgia, 46 dizziness, 25 dysgeusia, 136 headache, 45 depression, 102 insomnia, 54 cough, 58 dyspnoea, 80 alopecia, 88 dry skin, 119 pruritus, 94 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>311 out of 317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 anaemia, 9 neutropenia, 14 diarrhoea, 20 nausea, 11 vomiting, 7 asthenia, 16 chills, 46 fatigue, 16 influenza‐like illness, 22 irritability, 15 pyrexia, 17 decreased appetite, 19 arthralgia, 24 myalgia, 9 dizziness, 4 dysgeusia, 36 headache, 10 depression, 30 insomnia, 18 cough, 11 dyspnoea, 13 alopecia, 15 dry skin, 26 pruritus, 25 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 out of 78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0081" title="IzumiN , AsahinaY , YokosukaO , ImazekiF , KawadaN , TamoriA , et al. Combination therapy of treatment‐naive and nonresponder patients with HCV genotype 1 infection with BMS‐790052, an NS5A replication complex inhibitor, in combination with peginterferon alfa‐2a and ribavirin. Hepatology2011;54(S1):1439A‐40A. IzumiN , YokosukaO , KawadaN , OsakiY , YamamotoK , SataM , et al. Daclatasvir combined with peginterferon alfa‐2a and ribavirin in Japanese patients infected with hepatitis C genotype 1. Antiviral Therapy2014;19(5):501‐10. McPheeF , HernandezD , ZhouN , YuF , UelandJ , MonikowskiA , et al. Virological escape in HCV genotype‐1‐infected patients receiving daclatasvir plus ribavirin and peginterferon alfa‐2a or alfa‐2b. Antiviral Therapy2014;19(5):479‐90. SuzukiF , ChayamaK , KawakamiY , ToyotaJ , KarinoY , MochidaS , et al. BMS‐790052, AN NS5A replication complex inhibitor, in combination with peginterferon alpha‐2B and ribavirin in Japanese treatment naive and nonresponder patients with chronic HCV genotype 1 infection. Hepatology2011;54(S1):1441A. SuzukiF , ChayamaK , KawakamiY , ToyotaJ , KarinoY , MochidaS , et al. Daclatasvir (BMS‐790052), an NS5A replication complex inhibitor, in combination with peginterferon alpha‐2b and ribavirin in Japanese treatment‐naive and nonresponder patients with chronic HCV genotype 1 infection. Hepatology International2012;6(1):161‐2. SuzukiF , ToyotaJ , IkedaK , ChayamaK , MochidaS , HayashiN , et al. A randomized trial of daclatasvir with peginterferon alfa‐2b and ribavirin for HCV genotype 1 infection. Antiviral Therapy2014;19(5):491‐9. ">Izumi 2014a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daclatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 anaemia, 7 neutropenia, 2 diarrhoea, 4 nausea, 6 fatigue, 1 irritability, 11 pyrexia, 7 decreased appetite, 4 arthralgia, 1 myalgia, 1 dizziness, 4 dysgeusia, 3 headache, 7 insomnia, 4 cough, 2 dyspnoea, 8 alopecia, 1 dry skin, 6 pruritus, 7 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 out of 34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 anaemia, 4 neutropenia, 3 diarrhoea, 2 nausea, 3 vomiting, 4 chills, 4 fatigue, 2 influenza‐like illness, 5 pyrexia, 5 decreased appetite, 2 arthralgia, 2 myalgia, 1 dizziness, 1 dysgeusia, 4 headache, 2 insomnia, 1 cough, 6 alopecia, 1 dry skin, 3 pruritus, 3 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0161" title="PolS , GhalibRH , RustgiVK , MartorellC , EversonGT , TatumHA , et al. Daclatasvir for previously untreated chronic hepatitis C genotype‐1 infection: a randomised, parallel‐group, double‐blind, placebo‐controlled, dose‐finding, phase 2a trial. Lancet Infectious Diseases2012;12(9):671‐7. ">Pol 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daclatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 anaemia, 9 neutropenia, 5 diarrhoea, 13 nausea, 7 vomiting, 9 asthenia, 4 chills, 19 fatigue, 11 influenza‐like illness, 12 irritability, 7 pyrexia, 9 decreased appetite, 2 arthralgia, 8 myalgia, 5 dizziness, 2 dysgeusia, 19 headache, 7 depression, 9 insomnia, 9 cough, 6 dyspnoea, 8 alopecia, 2 dry skin, 12 pruritus, 10 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 out of 36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 anaemia, 5 neutropenia, 3 diarrhoea, 6 nausea, 1 asthenia, 2 chills, 9 fatigue, 4 influenza‐like illness, 2 irritability, 3 pyrexia, 3 decreased appetite, 3 myalgia, 1 dizziness, 1 dysgeusia, 3 headache, 3 depression, 6 insomnia, 3 cough, 2 dyspnoea, 2 alopecia, 1 dry skin, 3 pruritus, 3 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 out of 12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0137" title="NettlesRE , ChienC , ChungE , PerssonA , GaoM , BelemaM , et al. MS‐790052 is a first‐in class potent Hepatitis C Virus (HCV) NS5A inhibitor for patients with chronic HCV infection: results from a proof‐of‐concept study. Hepatology International2010;4(1):184. ">Nettles 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daclatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 diarrhoea, 1 nausea, 4 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 out of 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0138" title="NettlesR , SevinskyH , ChungE , BurtD , XiaoH , MarburyTC , et al. BMS‐790052, a first‐in class potent hepatitis C virus NS5A inhibitor, demonstrates multiple dose proof‐of‐concept in subjects with chronic GT1 HCV infection. Hepatology2010;52(Suppl S1):1214A‐5A. NettlesRE , GaoM , BifanoM , ChungE , PerssonA , MarburyTC , et al. Multiple ascending dose study of BMS‐790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology2011;54(6):1956‐65. ">Nettles 2011a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daclatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 diarrhoea, 3 fatigue, 1 arthralgia, 1 dizziness, 5 headache, 2 insomnia, 1 dry skin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 out of 24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 nausea, 1 vomiting, 2 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 out of 6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0035" title="EversonG , CooperC , HezodeC , ShiffmanML , YoshidaE , Beltran‐JaramilloT , et al. Dauphine: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha‐2a/ribavirin in HCV genotypes 1 or 4. Liver International2015;35(1):108‐19. EversonG , CooperC , HezodeC , ShiffmanML , YoshidaE , Beltran‐JaramilloT , et al. Rapid and sustained achievement of undetectable HCV RNA during treatment with ritonavir‐boosted danoprevir/peg‐ifna‐2a/RBV in HCV genotype 1 or 4 patients: dauphine week 12 interim analysis. Journal of Hepatology2012;56(Suppl 2):S466. HezodeC , ShiffmanML , CooperC , EversonGT , MarcellinP , Rodriguez‐TorresM , et al. Ritonavir‐boosted danoprevir plus peg‐IFNalpha‐2a/ribavirin (P/R) demonstrates up to 100% SVR24 with 12 or 24 weeks of total treatment in treatment‐naive patients with HCV genotype 4 infection in the DAUPHINE study. Hepatology2012;56(S1):557A. LePogamS , NavarroM , BuL , VoulgariA , IllnickaM , YanJM , et al. Low rate of on‐treatment resistance to danoprevir boosted by ritonavir (DNVR) combined with Peg‐IFNa‐2a/ribavirin: 12 week interim analysis from Dauphine study. Journal of Hepatology2012;56(Suppl 2):S472. ">Dauphine 2015a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Danoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115 diarrhoea, 106 nausea, 77 asthenia, 89 chills, 158 fatigue, 125 pyrexia, 88 decreased appetite, 72 arthralgia, 93 myalgia,158 headache, 102 insomnia, 62 cough, 54 alopecia, 83 pruritus, 78 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>364 out of 373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 diarrhoea, 13 nausea, 9 asthenia, 8 chills, 17 fatigue, 15 pyrexia, 6 decreased appetite, 9 arthralgia, 13 myalgia, 24 headache, 16 insomnia, 12 cough, 4 alopecia, 14 pruritus, 6 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 out of 44</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0054" title="ForestierN , LarreyD , GuyaderD , MarcellinP , RouzierR , PatatA , et al. Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN‐191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study. Journal of Hepatology2011;54(6):1130‐6. ForestierN , LarreyDG , GuyaderD , MarcellinP , RouzierR , PatatAA , et al. Treatment of chronic hepatitis C virus (HCV) genotype 1 patients with the NS3/4A protease inhibitor ITMN‐191 leads to rapid reductions in plasma HCV RNA: results of a phase 1b multiple ascending dose (MAD) study. Hepatology2008;48(4 (Suppl)):1132A. MoucariR , ForestierN , LarreyD , GuyaderD , CouzigouP , BenhamouY , et al. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut2010;59(12):1694‐8. ">Forestier 2011a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Danoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 diarrhoea, 3 myalgia, 5 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 out of 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 diarrhoea, 2 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 out of 10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0056" title="ForestierN , LarreyD , MarcellinP , BenhamouY , GuyaderD , BradfordW , et al. Antiviral activity and safety of ITMN‐191 in combination with peginterferon alfa‐2a and ribavirin in patients with chronic hepatitis C virus (HCV). Journal of Hepatology2009;50(Suppl 1):S35. ForestierN , LarreyD , MarcellinP , GuyaderD , PatatA , RouzierR , et al. Antiviral activity of danoprevir (ITMN‐191/RG7227) in combination with pegylated interferon alpha‐2a and ribavirin in patients with hepatitis C. Journal of Infectious Diseases2011;204(4):601‐8. ">Forestier 2011b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Danoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 neutropenia, 5 diarrhoea, 4 nausea, 3 asthenia, 5 chills, 8 fatigue, 4 influenza‐like illness, 2 pyrexia, 2 arthralgia, 17 myalgia, 6 dizziness, 23 headache, 2 depression, 6 insomnia, 3 pruritus </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 out of 47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 neutropenia, 2 diarrhoea, 1 nausea, 1 chills, 3 fatigue, 1 influenza‐like illness, 1 arthralgia, 5 myalgia, 1 dizziness, 4 headache, 1 depression, 2 insomnia </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 out of 12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0068" title="GaneE , RouzierR , StedmanC , Wiercinska‐DrapaloA , HorbanA , ChangL , et al. Ritonavir boosting of low dose RG7227/ITMN‐191, HCV NS3/4 a protease inhibitor, results in robust reduction in HCV RNA at lower exposures than provided by unboosted regimens. Journal of Hepatology2010;52(Suppl 1):S16‐7. GaneEJ , RouzierR , StedmanC , Wiercinska‐DrapaloA , HorbanA , ChangL , et al. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG‐IFN alpha‐2a/RBV in hepatitis C patients. Journal of Hepatology2011;55(5):972‐9. MorcosPN , ChangL , KulkarniR , GiraudonM , ShulmanN , BrennanBJ , et al. A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail. European Journal of Clinical Pharmacology2013;69(11):1939‐49. ">Gane 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Danoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 diarrhoea, 5 nausea, 5 fatigue, 3 influenza‐like illness, 5 irritability, 5 arthralgia, 5 myalgia, 11 headache, 4 insomnia, 6 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 out of 25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 diarrhoea, 3 nausea, 1 fatigue, 2 myalgia, 4 headache, 2 insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 out of 5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0121" title="MarcellinP , PopaS , BerlibaA , BoyerN , Streinu‐CercelA , TongM , et al. ALS‐2200, a novel once‐daily nucleotide HCV polymerase inhibitor, demonstrates potent antiviral activity in treatment naive GT1 chronic hepatitis C patients. Hepatology International2013;7(1 Suppl):S342. ">Marcellin 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Danoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 anaemia, 70 neutropenia, 56 diarrhoea, 85 nausea, 29 vomiting, 57 chills, 109 fatigue, 38 irritability, 51 pyrexia, 34 decreased appetite, 29 arthralgia, 60 myalgia, 92 headache, 42 depression, 69 insomnia, 31 alopecia, 46 pruritus, 42 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 anaemia, 11 neutropenia, 7 diarrhoea, 10 nausea, 4 vomiting, 13 chills, 14 fatigue, 7 irritability, 5 pyrexia, 4 decreased appetite, 9 arthralgia, 11 myalgia, 18 headache, 4 depression, 9 insomnia, 5 alopecia, 6 pruritus, 8 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0093" title="LarreyD , LohseA , DeLedinghenV , TrepoC , GerlachT , ZarskiJP , et al. 4 week therapy with the non‐nucleosidic polymerase inhibitor BI207127 in combination with peginterferon‐alfa2A and ribavirin in treatment naive and treatment experienced chronic HCV GT1 patients. Journal of Hepatology2010;52(Suppl S1):S466. LarreyD , LohseAW , DeLedinghenV , TrepoC , GerlachT , ZarskiJP , et al. Rapid and strong antiviral activity of the non‐nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. Journal of Hepatology2012;57(1):39‐46. ">Larrey 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deleobuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 19 diarrhoea, 19 nausea, 11 vomiting, 16 asthenia, 3 chills, 12 fatigue, 14 influenza‐like illness, 7 irritability, 6 pyrexia, 14 decreased appetite, 4 arthralgia, 4 myalgia, 6 dizziness, 4 dysgeusia, 20 headache, 15 insomnia, 6 cough, 3 dyspnoea, 1 alopecia, 6 dry skin, 5 pruritus, 8 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 out of 49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 nausea, 1 asthenia, 1 chills, 2 fatigue, 1 influenza‐like illness, 2 irritability, 1 decreased appetite, 2 headache, 1 dry skin, 1 pruritus, 2 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0190" title="AsselahT , JensenDM , FosterG , SulkowskiM , OuzanD , MoranoL , et al. Faldaprevir plus pegylated interferon/ribavirin did not increase anaemia compared with pegylated interferon/ribavirin in HCV genotype‐1, treatment‐naive patients: pooled analysis of phase III studies. Gastroenterology2014;146(5 (Suppl 1)):S‐977. AsselahT , JensenDM , FosterG , SulkowskiM , OuzanD , MoranoL , et al. Virological response in treatment‐naive patients with chronic HCV genotype‐1 infection receiving faldaprevir plus pegylated interferon alpha‐2a and ribavirin is unaffected by ribavirin dose reduction. Gastroenterology2014;146(5 (Suppl 1)):S975‐6. BergerK , SarrazinC , FerenciP , JensenDM , JacobsonIM , SternJO , et al. NS3 Q80K did not impact efficacy or treatment‐emergent resistance patterns in HCV genotype 1‐infected patients receiving faldaprevir + peginterferon/ribavirin in three phase III trials. Journal of Hepatology2014;60(1):S497. FerenciP , DieterichD , ZeuzemS , MantryP , SarrazinC , CrespoJ , et al. Early stopping rules for faldaprevir plus pegylated interferon alpha‐2a and ribavirin in treatment‐naive patients: exploratory study of pooled data from phase III trials. Journal of Hepatology2014;60(1 (Suppl 1)):S452‐3. FosterGR , CooperC , DieterichD , FerenciP , CrespoJ , DiagoM , et al. Pharmacokinetic‐response analysis of faldaprevir in treatment‐naive patients with chronic HCV genotype‐1 infection: a pooled analysis of two phase III trials. Journal of Hepatology2014;60(1 (Suppl 1)):S454‐5. JensenDM , AsselahT , DieterichDT , FosterGR , SulkowskiMS , ZeuzemS , et al. A pooled analysis of two randomized, double‐blind placebo‐controlled phase III trials (STARTVerso1&amp;2) of faldaprevir plus pegylated interferon alfa‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C genotype‐1 infection. Hepatology2013;58(Suppl 1):734A‐5A. JensenDM , FosterG , FerenciP , CooperC , DieterichDT , SulkowskiM , et al. Faldaprevir plus pegylated interferon alfa‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C genotype‐1 infection: a pooled analysis of two randomized, double‐blind placebo‐controlled phase iii trials (STARTVerso1&amp;2). Gastroenterology2014;146(5 (Suppl 1)):S974. YoshidaEM , AsselahT , MorenoC , MaevskayaMV , KaoJH , CrespoJ , et al. Subgroup analyses and baseline predictors of response with faldaprevir plus pegylated interferon alfa‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C genotype‐1 infection: a pooled analysis of STARTVerso1 and 2. Hepatology2013;58(4 Suppl):751A‐2A. ZeuzemS , JensenDM , CarvalhoA , DiagoM , FeinmanSV , KowdleyKV , et al. No effect of faldaprevir on renal function in treatment‐naive patients with chronic HCV genotype‐1 infection: pooled data from two phase III trials. Journal of Hepatology2014;60(1 (Suppl 1)):S451. ">STARTverso‐2 2014a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faldaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114 anaemia, 59 neutropenia, 160 diarrhoea, 249 nausea, 110 vomiting, 29 asthenia, 78 chills, 246 fatigue, 39 influenza‐like illness, 67 irritability, 79 pyrexia, 117 decreased appetite, 72 arthralgia, 100 myalgia, 80 dizziness, 31 dysgeusia, 165 headache, 68 depression, 137 insomnia, 89 cough, 53 dyspnoea, 96 alopecia, 67 dry skin, 164 pruritus, 298 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>513 out of 525</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 anaemia, 14 neutropenia, 23 diarrhoea, 52 nausea, 11 vomiting, 6 asthenia, 25 chills, 70 fatigue, 15 influenza‐like illness, 27 irritability, 20 pyrexia, 26 decreased appetite, 22 arthralgia, 37 myalgia, 25 dizziness, 3 dysgeusia, 45 headache, 11 depression, 38 insomnia, 21 cough, 20 dyspnoea, 22 alopecia, 15 dry skin, 37 pruritus, 41 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130 out of 132</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0188" title="AsselahT , JensenDM , FosterG , SulkowskiM , OuzanD , MoranoL , et al. Faldaprevir plus pegylated interferon/ribavirin did not increase anaemia compared with pegylated interferon/ribavirin in HCV genotype‐1, treatment‐naive patients: pooled analysis of phase III studies. Gastroenterology2014;146(5 Suppl 1):S‐977. AsselahT , JensenDM , FosterG , SulkowskiM , OuzanD , MoranoL , et al. Virological response in treatment‐naive patients with chronic HCV genotype‐1 infection receiving faldaprevir plus pegylated interferon alpha‐2a and ribavirin is unaffected by ribavirin dose reduction. Gastroenterology2014;146(5 Suppl 1):S975‐6. BergerK , SarrazinC , FerenciP , JensenDM , JacobsonIM , SternJO , et al. NS3 Q80K did not impact efficacy or treatment‐emergent resistance patterns in HCV genotype 1‐infected patients receiving faldaprevir + peginterferon/ribavirin in three phase III trials. Journal of Hepatology2014;60(1 Suppl S):S497. FerenciP , AsselahT , FosterGR , ZeuzemS , SarrazinC , MorenoC , et al. Faldaprevir plus pegylated interferon alfa‐2A and ribavirin in chronic HCV genotype‐1 treatment‐naive patients: final results from STARTVerso1, a randomised, double‐blind, placebo‐controlled phase III trial. Journal of Gastroenterology and Hepatology2013;28(Suppl 2):157‐8. FerenciP , AsselahT , FosterGR , ZeuzemS , SarrazinC , MorenoC , et al. STARTVerso1: a randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype‐1 infection. Journal of Hepatology2015;62(6):1246‐55. FerenciP , DieterichD , ZeuzemS , MantryP , SarrazinC , CrespoJ , et al. Early stopping rules for faldaprevir plus pegylated interferon alpha‐2a and ribavirin in treatment‐naive patients: exploratory study of pooled data from phase III trials. Journal of Hepatology2014;60(1 Suppl 1):S452‐S3. FosterGR , CooperC , DieterichD , FerenciP , CrespoJ , DiagoM , et al. Pharmacokinetic‐response analysis of faldaprevir in treatment‐naive patients with chronic HCV genotype‐1 infection: a pooled analysis of two phase III trials. Journal of Hepatology2014;60(1 Suppl 1):S454‐5. JensenDM , AsselahT , DieterichDT , FosterGR , SulkowskiMS , ZeuzemS , et al. A pooled analysis of two randomized, double‐blind placebo‐controlled phase III trials (STARTVerso1 &amp; 2) of faldaprevir plus pegylated interferon alfa‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C genotype‐1 infection. Hepatology2013;58(Suppl 1):734A‐5A. JensenDM , FosterG , FerenciP , CooperC , DieterichDT , SulkowskiM , et al. Faldaprevir plus pegylated interferon alfa‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C genotype‐1 infection: a pooled analysis of two randomized, double‐blind placebo‐controlled phase III trials (STARTVerso 1 &amp; 2). Gastroenterology2014;146(5 Suppl 1):S974. MorenoC , FerenciP , AsselahT , FosterG , ZeuzemS , SarrazinC , et al. Faldaprevir plus pegylated interferon alfa‐2a and ribavirin in chronic HCV genotype‐1 treatment‐naive patients: final results from STARTVerso1: a randomized, double‐blind, placebo‐controlled, phase 3 trial. American Journal of Gastroenterology2013;108(Suppl 1):S145. YoshidaEM , AsselahT , MorenoC , MaevskayaMV , KaoJH , CrespoJ , et al. Subgroup analyses and baseline predictors of response with faldaprevir plus pegylated interferon alfa‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C genotype‐1 infection: a pooled analysis of STARTVerso1 and 2. Hepatology2013;58(Suppl S1):751A‐2A. ZeuzemS , JensenDM , CarvalhoA , DiagoM , FeinmanSV , KowdleyKV , et al. No effect of faldaprevir on renal function in treatment‐naive patients with chronic HCV genotype‐1 infection: pooled data from two phase III trials. Journal of Hepatology2014;60(1 Suppl S):S451. ">STARTVerso‐1 2015a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faldaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89 anaemia, 57 neutropenia, 121 diarrhoea, 168 nausea, 79 vomiting, 96 asthenia, 143 fatigue, 92 influenza‐like illness, 37 irritability, 110 pyrexia, 87 decreased appetite, 39 arthralgia, 41 myalgia, 38 dizziness, 23 dysgeusia, 146 headache, 32 depression, 70 insomnia, 58 cough, 36 dyspnoea, 49 alopecia, 80 dry skin, 160 pruritus, 139 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>496 out of 520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 anaemia, 18 neutropenia, 17 diarrhoea, 19 nausea, 6 vomiting, 27 asthenia, 35 fatigue, 21 influenza‐like illness, 9 irritability, 32 pyrexia, 22 decreased appetite, 14 arthralgia, 20 myalgia, 13 dizziness, 5 dysgeusia, 40 headache, 8 depression, 22 insomnia, 20 cough, 16 dyspnoea, 15 alopecia, 17 dry skin, 41 pruritus, 25 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120 out of 132</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0192" title="AsselahT , ZehnterE , AgarwalK , SakaiY , YatsuhashiH , WillemsB , et al. Pharmacokinetic‐response analysis of faldaprevir in patients with chronic HCV genotype‐1 infection with prior relapse. Journal of Hepatology2014;60(1 Suppl S):S458‐9. BergerK , SarrazinC , FerenciP , JensenDM , JacobsonIM , SternJO , et al. NS3 Q80K did not impact efficacy or treatment‐emergent resistance patterns in HCV genotype 1‐infected patients receiving faldaprevir+peginterferon/ribavirin in three phase III trials. Journal of Hepatology2014;60(1 Suppl S):S497. JacobsonIM , AsselahT , FerenciP , FosterGR , JensenDM , NegroF , et al. STARTVerso3: a randomized, double‐blind, placebo‐controlled phase III trial of faldaprevir in combination with pegylated interferon a lf a‐2a and ribavirin in treatment‐experienced patients with chronic hepatitis C genotype‐1 infection. Hepatology2013;48(S1):742A‐3A. JacobsonIM , FerenciP , FosterGR , JensenDM , NegroF , MantryP , et al. STARTVerso3: a randomized, double‐blind, placebo controlled phase III trial of faldaprevir in combination with pegylated interferon alpha‐2a and ribavirin in treatment experienced patients with chronic hepatitis C genotype‐1 infection. Hepatology International2014;8(1 Suppl):S213‐4. ">STARTverso‐3 2013a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faldaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98 anaemia, 65 neutropenia, 190 diarrhoea, 318 nausea, 171 vomiting, 108 asthenia, 32 chills, 204 fatigue, 107 influenza‐like illness, 49 irritability, 113 pyrexia, 128 decreased appetite, 60 arthralgia, 72 myalgia, 37 dizziness, 39 dysgeusia, 182 headache, 52 depression, 118 insomnia, 99 cough, 47 dyspnoea, 53 alopecia, 108 dry skin, 225 pruritus, 160 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>585 out of 599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 anaemia, 12 neutropenia, 10 diarrhoea, 18 nausea, 5 vomiting, 21 asthenia, 5 chills, 16 fatigue, 15 influenza‐like illness, 11 irritability, 14 pyrexia, 10 decreased appetite, 7 arthralgia, 8 myalgia, 6 dizziness, 4 dysgeusia, 22 headache, 10 depression, 13 insomnia, 16 cough, 7 dyspnoea, 4 alopecia, 12 dry skin, 23 pruritus, 16 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74 out of 78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0115" title="MannsMP , BourliereM , BenhamouY , PolS , BonaciniM , BergT . Safety and antiviral activity of BI201335, a new HCV NS3 protease inhibitor, in treatment‐naive patients with chronic hepatitis C genotype‐1 infection given as monotherapy and in combination with peginterferon alfa 2a (P) and ribavirin (R). Hepatology2008;48(4 Suppl):1023A. MannsMP , BourliereM , BenhamouY , PolS , BonaciniM , TrepoC , et al. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype‐1 infection. Journal of Hepatology2011;54(6):1114‐22. ">Manns 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faldaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 anaemia, 1 neutropenia, 4 diarrhoea, 7 nausea, 10 asthenia, 2 chills, 2 fatigue, 4 influenza‐like illness, 4 irritability, 2 pyrexia, 1 decreased appetite, 7 myalgia, 1 dizziness, 6 headache, 2 depression, 5 insomnia, 2 cough, 1 alopecia, 5 dry skin, 3 pruritis, 1 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 out of 26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 diarrhoea, 2 nausea, 2 asthenia, 2 headache, 1 depression, 1 insomnia, 1 cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0144" title="NishiguchiS , KubokiM , SakaiY , AizawaN , IwataK , IkedaN , et al. All treated Japanese genotype 1 patients with IL28B TT allele achieved SVR by 4 weeks faldaprevir and 48 weeks PegIFN/ ribavirin. Hepatology International2013;7(1 Suppl):S393. NishiguchiS , KubokiM , SakaiY , AizawaN , TakashimaT , IwataK . 100% SVR in Japanese genotype 1 patients with IL28B TT allele treated with 4 weeks faldaprevir and 48 weeks PegIFN/ribavirin. Hepatology International2013;7(1 Suppl):S372‐3. NishiguchiS , SakaiY , KubokiM , TsunematsuS , UranoY , SakamotoW , et al. Safety and efficacy of faldaprevir with pegylated interferon alfa‐2a and ribavirin in Japanese patients with chronic genotype‐1 hepatitis C infection. Liver International2014;34(1):78‐88. ">Nishiguchi 2014a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faldaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 neutropenia, 3 diarrhoea, 3 nausea, 3 vomiting, 2 influenza‐like illness, 8 pyrexia, 2 decreased appetite, 2 arthralgia, 4 dizziness, 1 dysgeusia, 7 headache, 1 depression, 5 insomnia, 1 cough, 3 alopecia, 1 dry skin, 6 pruritus, 6 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 out of 35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 nausea, 2 vomiting, 1 influenza‐like illness, 1 pyrexia, 1 decreased appetite, 1 headache, 1 insomnia, 1 dyspnoea, 2 dry skin, 3 pruritus, 1 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0196" title="ShermanKE , RockstrohJK , DieterichDT , SorianoV , GirardPM , McCallisterS , et al. Telaprevir combination with peginterferon alfa‐2A/ribavirin in HCV/HIV coinfected patients: 24‐week treatment interim analysis. Hepatology2011;54(4 Suppl):1431A‐2A. SulkowskiMS , ShermanKE , DieterichDT , BsharatM , MahnkeL , RockstrohJK , et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Annals of Internal Medicine2013;159(2):86‐96. SulkowskiMS , ShermanKE , SorianoV , RockstrohJ , DieterichDT , GirardPM , et al. Telaprevir in combination with peginterferon alfa‐2a/ribavirin in HCV/HIV co‐infected patients: SVR24 final study results. Hepatology2012;56(S1):219A. ">Sulkowski 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faldeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 anaemia, 49 neutropenia, 188 diarrhoea, 239 nausea, 105 vomiting, 122 asthenia, 54 chills, 194 fatigue, 217 influenza‐like illness, 82 irritability, 86 pyrexia, 133 decreased appetite, 72 arthralgia, 133 myalgia, 48 dizziness, 25 dysgeusia, 243 headache, 68 depression, 107 insomnia, 100 cough, 73 dyspnoea, 106 alopecia, 122 dry skin, 227 pruritus, 163 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>620 out of 641</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 anaemia, 8 neutropenia, 13 diarrhoea, 14 nausea, 4 vomiting, 15 asthenia, 8 chills, 24 fatigue, 34 influenza‐like illness, 10 irritability, 11 pyrexia, 11 decreased appetite, 5 arthralgia, 12 myalgia, 5 dizziness, 27 headache, 7 depression, 17 insomnia, 9 cough, 11 dyspnoea, 8 alopecia, 10 dry skin, 12 pruritus, 12 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 out of 71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0083" title="JacobsonI , PockrosP , LalezariJ , LawitzE , Rodriguez‐TorresM , DeJesusE , et al. Antiviral activity of filibuvir in combination with pegylated interferon alfa‐2A and ribavirin for 28 days in treatment naive patients chronically infected with HCV genotype 1. Journal of Hepatology2009;50(Suppl 1):S382. JacobsonI , PockrosPJ , LalezariJ , LawitzE , Rodriguez‐TorresM , DeJesusE , et al. Virologic response rates following 4 weeks of filibuvir in combination with pegylated interferon alfa‐2A and ribavirin in chronically‐infected HCV genotype‐1 patients. Journal of Hepatology2010;52(Suppl 1):S464. MoriJ , HammondJL , SrinivasanS , JagannathaS , RystECC . Genotypic characterisation of filibuvir (PF‐00868554 ) resistance in patients receiving four weeks co‐administration of filibuvir with pegIFN/RBV. Hepatology2010;52(Suppl S1):722A. MoriJ , HammondJL , SrinivasanS , JagannathaS , Van derRystE . Genotypic characterisation of filibuvir (PF‐00868554) resistance in patients receiving four weeks co‐administration of filibuvir with PEGIFN/RBV (12 week analysis). Journal of Hepatology2010;52(Suppl 1):S15. ">Jacobson 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Filibuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 anaemia,4 neutropenia ,6 diarrhoea, 13 nausea, 3 vomiting, 4 chills, 13 fatigue, 3 influenza‐like illness, 2 irritability, 2 pyrexia, 3 decreased appetite, 2 arthralgia, 4 myalgia, 4 dizziness, 14 headache, 5 depression, 11 insomnia, 5 cough, 2 dyspnoea, 2 alopecia, 3 dry skin, 2 pruritus, 3 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 out of 27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 anaemia, 3 diarrhoea, 4 nausea, 1 vomiting, 1 chills, 5 fatigue, 2 influenza‐like illness, 2 decreased appetite, 2 arthralgia, 2 headache, 3 depression, 2 insomnia, 2 cough, 2 dyspnoea, 1 alopecia, 2 dry skin, 3 pruritus, 1 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0175" title="Rodriguez‐TorresM , StoehrA , GaneEJ , SerfatyL , LawitzE , ZhouA , et al. Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment‐experienced patients with chronic HCV genotype 1 infection and cirrhosis. Clinical Gastroenterology and Hepatology2014;12(6):1029‐37.e5. ">Rodriguez‐Torres 2014a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Filibuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 anaemia, 26 neutropenia, 24 diarrhoea, 55 nausea, 20 vomiting, 35 asthenia, 25 chills, 73 fatigue, 29 influenza‐like illness, 33 irritability, 28 pyrexia, 36 decreased appetite, 30 arthralgia, 37 myalgia, 20 dizziness, 40 dysgeusia, 61 headache, 32 depression, 55 insomnia, 33 cough, 18 dyspnoea, 34 alopecia, 33 dry skin, 56 pruritus, 34 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174 out of 192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>anaemia, neutropenia, diarrhoea, nausea, vomiting, asthenia, chills, fatigue, influenza‐like illness, irritability, pyrexia, decreased appetite, arthralgia, myalgia, dizziness, dysgeusia, headache, depression, insomnia, cough, dyspnoea, alopecia, dry skin, pruritus, rash. </p> <p>The authors did not report number of adverse events in the control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 out of 96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0156" title="PetryAS , FraserIP , O’MaraE , VanDyckK , NachbarRB , DeLepeleireIM , et al. Safety and antiviral activity of MK‐5172, a next generation HCV NS3/4A protease inhibitor with a broad HCV genotypic activity spectrum and potent activity against known resistance mutants, in genotype 1 and 3 HCV infected patients. Hepatology2011;54(4 Suppl):531A. ">Petry 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grazoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 diarrhoea, 2 nausea, 1 vomiting, 7 fatigue, 1 dysgeusia, 16 headache, 1 insomnia, 2 pruritis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 out of 76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 out of 15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0070" title="GardnerS , CutrellAMY , Elko‐SimmsC , AdkisonK , HamatakeR , WalkerJ , et al. A double‐blind, randomized, placebo‐controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa‐2a and ribavirin in hepatitis C virus genotype 1‐infected treatment‐naive subjects. Liver International2014;34(6):e89‐e95. ">Gardner 2014a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GSK2336805</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 anaemia, 3 neutropenia, 4 nausea, 2 vomiting, 2 chills, 5 fatigue, 2 cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 out of 11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 out of 4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0091" title="LalezariJ , AsmuthD , CasiroA , VargasH , LawrenceS , Dubuc‐PatrickG , et al. Short‐term monotherapy with IDX184, a liver‐targeted nucleotide polymerase inhibitor, in patients with chronic hepatitis C virus infection. Antimicrobial Agents and Chemotherapy2012;56(12):6372‐8. ">Lalezari 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IDX‐184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 diarrhoea, 2 fatigue, 1 dizziness, 4 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 out of 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 diarrhoea, 1 fatigue, 1 dizziness, 1 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0092" title="LalezariJ , BoxT , O'RiordanW , MehraP , NguyenT , PoordadF , et al. IDX184 in combination with pegylated interferon‐alpha2a and ribavirin for 2 weeks in treatment‐naive patients with chronic hepatitis C. Antiviral Therapy2013;18(6):755‐64. LalezariJ , PoordadF , MehraP , NguyenT , DejesusE , GodofskyE , et al. Antiviral activity, pharmacokinetics and safety of IDX184 in combination with pegylated interferon (pegIFN) and ribavirin (RBV) in treatment‐naive HCV genotype 1‐infected subjects. Journal of Hepatology2010;52(Suppl S1):S469. LalezariJP , O'RiordanW , PoordadF , NguyenTT , PatrickGD , ChenJ , et al. A phase IIA study of IDX184 in combination with pegylated interferon (PEGIFN) and ribavirin (RBV) in treatment‐naive HCV genotype 1‐infected subjects. Hepatology2010;52(Suppl S1):337A. ">Lalezari 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IDX‐184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 neutropenia, 7 diarrhoea, 22 nausea, 5 vomiting, 15 chills, 36 fatigue, 10 irritability, 9 pyrexia, 5 decreased appetite, 19 myalgia, 27 headache, 4 depression, 10 insomnia, 6 pruritus </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 out of 65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 neutropenia, 2 diarrhoea, 3 nausea, 5 chills, 9 fatigue, 4 irritability, 3 decreased appetite, 5 myalgia, 7 headache, 3 depression, 5 insomnia, 2 pruritus </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 out of 16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0039" title="DeBruijneJ , BergmannJF , ReesinkHW , WeeginkCJ , MolenkampR , SchinkelJ , et al. Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients. Hepatology2010;52(5):1590‐9. DeBruijneJ , BergmannJF , WeeginkCJ , MolenkampR , SchinkelJ , TreitelMA , et al. Narlaprevir and peginterferon alfa‐2b for 2 weeks in chronic hepatitis C genotype 1 patients, followed by peginterferon alfa‐2b and ribavirin for 24/48 weeks: final results. Journal of Hepatology2010;52:S290‐1. HothoDM , DeBruijneJ , SpaanM , TreitelMA , BoonstraA , DeKnegtRJ , et al. Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long‐term follow‐up. Journal of Viral Hepatitis2013;20(4):e78‐81. ">De Bruijne 2010a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IDX320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 diarrhoea, 1 myalgia, 4 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0102" title="LawitzEJ , GruenerD , HillJM , MarburyT , MooreheadL , MathiasA , et al. A phase 1, randomized, placebo‐controlled, 3‐day, dose‐ranging study of GS‐5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. Journal of Hepatology2012;57(1):24‐31. ">Lawitz 2012a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ledispasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 nausea, 6 headache, 2 rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 out of 59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 out of 11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0067" title="ChuT , KulkarniR , GaneEJ , RobertsSK , StedmanC , AngusP , et al. The effect of host IL28B genotype on early viral kinetics during interferon‐free treatment in patients with chronic hepatitis C (CHC). Journal of Hepatology2011;54(Suppl 1):S521‐2. GaneEJ , RobertsSK , StedmanC , AngusPW , RitchieB , ElstonR , et al. First‐in‐man demonstration of potent antiviral activity with a nucleoside polymerase (R7128) and protease (R7227/ITMN‐191) inhibitor combination in HCV: safety, pharmacokinetics, and virologic results from INFORM‐1. Journal of Hepatology2009;50(Suppl 1):S380. GaneEJ , RobertsSK , StedmanCA , AngusPW , RitchieB , ElstonR , et al. Combination therapy with a nucleoside polymerase (R7128) and protease (R7227/ITMN ‐ 191) inhibitor in HCV: safety, pharmacokinetics, and virologic results from INFORM‐1. Hepatology2009;50(4 Suppl):394A‐5A. GaneEJ , RobertsSK , StedmanCAM , AngusPW , RitchieB , ElstonROB , et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM‐1): a randomised, double‐blind, placebo‐controlled, dose‐escalation trial. Lancet2010;376(9751):1467‐75. LePogamS , YanJM , ChhabraM , IlnickaM , KangH , KosakaA , et al. Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short‐term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir. Antimicrobial Agents and Chemotherapy2012;56(11):5494‐502. LimLY , KwoPY . A glimpse at the future of hepatitis C therapy: The INFORM trial. Hepatology2011;54(1):360‐3. MorcosPN , KulkarniR , IpeD , JumbeS , TranJ , BradfordWZ , et al. Pharmacokinetics/pharmacodynamics (PK/PD) of combination R7227 and R7128 therapy from INFORM‐1 demonstrates similar early HCV viral dynamics when R7227 is combined with either PEG ‐ IFN/ribavirin (SOC) or R7128. Hepatology2009;50(4 Suppl):1041A‐2A. ">Gane 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mericitabine/danoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 diarrhoea, 9 nausea, 36 headache, 9 rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 diarrhoea, 2 nausea, 8 headache, 1 rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0050" title="FeldJJ , JacobsonIM , HezodeC , AsselahT , RuanePJ , GruenerN , et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. New England Journal of Medicine2015;373(27):2599‐607. ">Feld 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mericitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 diarrhoea, 16 nausea, 6 chills, 47 fatigue, 14 irritability, 16 pyrexia, 12 arthralgia, 19 myalgia, 43 headache, 27 insomnia, 21 cough, 15 pruritus </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 diarrhoea, 14 nausea, 12 chills, 25 fatigue, 10 irritability, 14 pyrexia, 11 arthralgia, 18 myalgia, 28 headache, 11 insomnia, 11 cough, 11 pruritus </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0085" title="PockrosPJ , JensenD , TsaiN , TaylorR , RamjiA , CooperC , et al. JUMP‐C: a randomized trial of mericitabine plus pegylated interferon alpha‐2a/ribavirin for 24 weeks in treatment‐naïve HCV genotype 1/4 patients. Hepatology2013;58(2):514‐23. ">JUMP‐C 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mericitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 diarrhoea, 33 nausea, 31 chills, 58 fatigue, 21 irritability, 20 pyrexia, 25 decreased appetite, 18 arthralgia, 24 myalgia, 19 dizziness, 42 headache, 31 insomnia, 17 cough, 14 alopecia, 15 pruritus, 17 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 diarrhoea, 34 nausea, 33 chills, 58 fatigue, 25 irritability, 27 pyrexia, 22 decreased appetite, 21 arthralgia, 24 myalgia, 20 dizziness, 38 headache, 28 insomnia, 22 cough, 17 alopecia, 28 pruritus, 28 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 85</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0040" title="DeBruijneJ , BergmannJF , ReesinkHW , WeeginkCJ , MolenkampR , SchinkelJ , et al. Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients. Hepatology2010;52(5):1590‐9. DeBruijneJ , BergmannJF , WeeginkCJ , MolenkampR , SchinkelJ , TreitelMA , et al. Narlaprevir and peginterferon alfa‐2b for 2 weeks in chronic hepatitis C genotype 1 patients, followed by peginterferon alfa‐2b and ribavirin for 24/48 weeks: final results. Journal of Hepatology2010;52:S290‐1. HothoDM , DeBruijneJ , SpaanM , TreitelMA , BoonstraA , DeKnegtRJ , et al. Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long‐term follow‐up. Journal of Viral Hepatitis2013;20(4):e78‐81. ">De Bruijne 2010a2</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Narlaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 diarrhoea, 8 nausea, 30 influenza‐like illness, 6 dizziness, 11 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 out of 32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 nausea, 6 influenza‐like illness, 1 dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0203" title="VierlingJM , PoordadFF , LawitzE , GhalibRH , LeeWM , RavendhranN , et al. Once daily narlaprevir (NVR; SCH 900518) and ritonavir (RTV) in combination with peginterferon alfa‐2B/ribavirin (PR) for 12 weeks plus 12 weeks pr in treatment‐naïve patients with HCV genotype 1 (G1): SVR results from next‐1, a phase 2 study. Hepatology2011;54(Suppl S1):1437A‐8A. ">Vierling 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Narlaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87 anaemia, 84 diarrhoea, 131 nausea, 54 vomiting, 44 chills, 123 fatigue, 106 influenza‐like illness, 58 irritability, 58 pyrexia, 61 decreased appetite, 60 arthralgia, 39 myalgia, 58 dizziness, 83 headache, 33 depression, 80 insomnia, 28 pruritus, 31 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 anaemia, 17 diarrhoea, 50 nausea, 28 vomiting, 17 chills, 56 fatigue, 44 influenza‐like illness, 28 irritability, 17 pyrexia, 44 decreased appetite, 28 arthralgia, 6 dizziness, 39 headache, 22 depression, 39 insomnia, 33 pruritus, 11 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0128" title="MuirA , PoordadF , SheikhA , ElkashabM , BrennanR , Ankoma‐SeyV , et al. SVR4 results for the combination of ACH‐3102 and Sovaprevir, with ribavirin, in patients with genotype 1 chronic hepatitis C infection. 23rd Annual Conference of APASL, Brisbane, Australia. 2014. ">Muir 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Odalasvir/sovaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 anaemia, 2 diarrhoea, 5 fatigue, 2 influenza‐like illness, 2 irritability, 1 decreased appetite, 2 arthralgia, 3 myalgia, 1 dizziness, 1 dysgeusia, 6 headache, 2 insomnia, 4 cough, 1 dyspnoea, 1 pruritus, 1 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 out of 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 diarrhoea, 4 fatigue, 1 myalgia, 1 dizziness, 1 headache, 1 cough, pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 out of 10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0199" title="SullivanGJ , Rodriques‐TorresM , LawitzE , PoordadF , KapoorM , CampbellA , et al. ABT‐267 combined with pegylated interferon alpha‐ 2a/ribavirin in genotype 1 (GT1) HCV‐infected treatment naive subjects: 12 week antiviral and safety analysis. Journal of Hepatology2012;56(Suppl S2):S480. ">Sullivan 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ombitasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 anaemia, 5 neutropenia, 4 diarrhoea, 9 nausea, 7 vomiting, 6 chills, 18 fatigue, 1 influenza‐like illness, 1 irritability, 3 pyrexia, 5 decreased appetite, 2 arthralgia, 2 myalgia, 2 dizziness, 9 headache, 4 depression, 4 insomnia, 3 cough, 2 dyspnoea, 5 dry skin, 3 pruritus, 6 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 out of 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 neutropenia, 1 diarrhoea, 3 nausea, 2 vomiting, 6 fatigue, 2 influenza‐like illness, 1 irritability, 1 decreased appetite, 1 myalgia, 2 headache, 1 depression, 2 insomnia, 1 cough, dyspnoea, 1 dry skin, 2 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 out of 9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0003" title="AndersonRT , BaranRW , EricksonP , RevickiDA , DietzB , GoochK . Psychometric evaluation of the hepatitis C virus patient‐reported outcomes (HCV‐PRO) instrument: validity, responsiveness, and identification of the minimally important difference in a phase 2 clinical trial. Quality of Life Research2014;23(3):877‐86. GaultierI , CohenDE , BhathenaA , IdlerK , LarsenLM , PodsadeckiT , et al. The effect of IL28B polymorphisms on virologic response to treatment with pegylated interferon alpha‐2A and ribavirin (SOC) added to ABT‐450/ritonavir (ABT‐450/R), ABT‐333, or ABT‐072. Journal of Hepatology2011;54(Suppl 1):S523. Pilot‐MatiasTJ , TripathiRL , DekhtyarT , MenonRM , GaultierIA , CohenDE , et al. Genotypic and phenotypic characterization of NS3 variants selected in HCV‐infected patients treated with ABT‐450. Journal of Hepatology2011;54(Suppl 1):S485‐6. ">Anderson 2014a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paritaprevir/ABT‐072/dasabuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 anaemia, 14 neutropenia, 16 diarrhoea, 15 nausea, 6 vomiting, 4 asthenia, 11 chills, 29 fatigue, 14 influenza‐like illness, 8 irritability, 12 pyrexia, 4 decreased appetite, 9 arthralgia, 14 myalgia, 9 dizziness, 6 dysgeusia, 38 headache, 15 depression, 14 insomnia, 6 cough, 6 dyspnoea, 5 alopecia, 2 dry skin, 8 pruritus, 12 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 out of 63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 2 neutropenia, 4 diarrhoea, 4 nausea, 1 vomiting, 1 asthenia, 6 fatigue, 1 influenza‐like illness, 1 irritability, 1 pyrexia, 2 decreased appetite, 1 arthralgia, 3 myalgia, 4 dizziness, 2 dysgeusia, 4 headache, 2 insomnia, 2 dyspnoea, 1 alopecia, 2 pruritus, 2 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 out of 11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0049" title="FeldJJ , KowdleyKV , CoakleyE , SigalS , NelsonD , CrawfordD , et al. Sapphire I: Phase 3 placebo‐controlled study of interferon‐free, 12‐week regimen of ABT‐450/R/ABT‐267, ABT‐333, and ribavirin in 631 treatment‐naive adults with hepatitis Cvirus genotype 1. Journal of Hepatology2014;60(1 Suppl 1):S25. FeldJJ , KowdleyKV , CoakleyE , SigalS , NelsonDR , CrawfordD , et al. Treatment of HCV with ABT‐450/r‐ombitasvir and dasabuvir with ribavirin. New England Journal of Medicine2014;370(17):1594‐603. KowdleyKV , FeldJJ , CoakleyE , SigalS , NelsonDR , CrawfordD , et al. Sapphire I: Phase 3 placebo‐controlled study of interferon‐free, 12‐week regimen of ABT‐450/R/ABT‐267, ABT‐333, and ribavirin in 631 treatment‐naive adults with hepatitis C virus genotype 1. Gastroenterology2014;146(5 Suppl 1):S912‐S3. ">Feld 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paritaprevir/ombitasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 anaemia, 65 diarrhoea, 112 nausea, 23 vomiting, 59 asthenia, 164 fatigue, 26 irritability, 37 decreased appetite, 23 arthralgia, 21 myalgia, 38 dizziness, 156 headache, 67 insomnia, 34 cough, 38 dyspnoea, 27 dry skin, 80 pruritus, 51 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>391 out of 473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 diarrhoea, 22 nausea, 6 vomiting, 6 asthenia, 45 fatigue, 4 irritability, 5 decreased appetite, 9 arthralgia, 8 myalgia, 6 dizziness, 42 headache, 12 insomnia, 8 cough, 4 dyspnoea, 2 dry skin, 7 pruritus, 9 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108 out of 158</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0210" title="LiuY , LarsenL , BourliereM , BaranR , JudayT . Ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin (RBV) has mild impact on health‐related quality of life (HRQoL) compared with placebo during 12‐week treatment in treatment‐experienced adults with chronic hepatitis C (CHC). Journal of Hepatology2015;62(Suppl S2):S661. ZeuzemS , JacobsonIM , BaykalT , MarinhoRT , PoordadF , BourliereM , et al. Retreatment of HCV with ABT‐450/r‐ombitasvir and dasabuvir with ribavirin. New England Journal of Medicine2014;370(17):1604‐14. ">Zeuzem 2014a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paritaprevir/ombitasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 anaemia, 47 diarrhoea, 72 nausea, 22 vomiting, 60 asthenia, 115 fatigue, 22 irritability, 24 decreased appetite, 21 arthralgia, 28 myalgia, 30 dizziness, 13 dysgeusia, 126 headache, 52 insomnia, 43 cough, 50 dyspnoea, 27 dry skin, 53 pruritus, 34 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>328 out of 394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 diarrhoea, 17 nausea, 11 asthenia, 22 fatigue, 8 irritability, 2 decreased appetite, 7 arthralgia, 10 myalgia, 5 dizziness, 5 dysgeusia, 34 headache, 7 insomnia, 5 cough, 10 dyspnoea, 3 dry skin, 5 pruritus, 6 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74 out of 97</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0079" title="HothoD , DeBruijneJ , O'FarrellA , BoyeaT , LiJ , WeeginkCJ , et al. Accelerated clinical trial design to assess the safety, tolerability and anti‐viral activity of PHX1766, a novel HCV NS3/4A protease inhibitor, in healthy volunteers and chronic hepatitis C patients. Hepatology2009;50(4 Suppl):1031A‐2A. Hotho DaphneM , DeBruijneJ , O'FarrellA , BoyeaT , LiJ , BrackenM , et al. Pharmacokinetics and antiviral activity of PHX1766, a novel HCV protease inhibitor, using an accelerated Phase I study design. Antiviral Therapy2012;17(2):365‐75. ">Hotho 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PHX1766</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 nausea, 2 fatigue, 1 dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0157" title="NelsonD , PockrosPJ , GodofskyE , Rodriguez‐TorresM , EversonG , FriedM , et al. High end‐of‐treatment response (84%) after 4 weeks of R1626, peginterferon alfa‐2A (40KD) and ribavirin followed by a further 44 weeks of peginterferon alfa‐2A and ribavirin. Journal of Hepatology2008;48(Suppl 2):S371. PockrosPJ , NelsonD , GodofskyE , Rodriguez‐TorresM , EversonGT , FriedMW , et al. R1626 plus peginterferon alfa‐2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology2008;48(2):385‐97. ">Pockros 2008a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>R1626</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 neutropenia, 42 diarrhoea, 49 nausea, 26 vomiting, 39 chills, 45 fatigue, 20 irritability, 29 pyrexia, 21 arthralgia, 23 myalgia, 15 dizziness, 47 headache, 27 insomnia, 15 cough, 11 pruritus, 20 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 diarrhoea, 10 nausea, 2 vomiting, 9 chills, 10 fatigue, 1 irritability, 8 pyrexia, 5 arthralgia, 11 myalgia, 3 dizziness, 11 headache, 6 insomnia, 4 cough, 6 pruritus, 2 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0205" title="VinceB , HillJM , LawitzEJ , O'RiordanW , WebsterLR , GruenerDM , et al. A randomized, double‐blind, multiple‐dose study of the pan‐genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4. Journal of Hepatology2014;60(5):920‐7. ">Vince 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Samatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 nausea, 1 decreased appetite, 6 headache, 1 insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 out of 48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 nausea, 1 decreased appetite, 1 headache, 1 insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 out of 12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0057" title="FornsX , LawitzE , ZeuzemS , GaneE , BronowickiJP , AndreoneP , et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology2014;146(7):1669‐79. FornsX , LawitzE , ZeuzemS , GaneEJ , BronowickiJP , AndreoneP , et al. Simeprevir (TMC435) with peg‐interferon alpha‐2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon‐based therapy: efficacy and safety in patient sub‐populations in the PROMISE phase III trial. Hepatology2013;58(4 SUPPL. 1):737A‐8A. GaneEJ , FornsX , LawitzE , ZeuzemS , BronowickiJP , AndreoneP , et al. Simeprevir (TMC435) with peg‐interferon alpha‐2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon‐based therapy: efficacy in patients with genotype 1b HCV in the PROMISE phase III trial. Hepatology International2014;8(1 Suppl 1):S181. LawitzE , FornsX , ZeuzemS , GaneE , BronowickiJP , AndreoneP , et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon‐based therapy: results from PROMISE, a phase III trial. Gastroenterology2013;144(5 Suppl 1):S151. ">Forns 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 anaemia, 37 neutropenia, 36 diarrhoea, 59 nausea, 18 vomiting, 57 asthenia, 17 chills, 87 fatigue, 78 influenza‐like illness, 63 pyrexia, 35 decreased appetite, 26 arthralgia, 39 myalgia, 14 dizziness, 12 dysgeusia, 87 headache, 22 depression, 49 insomnia, 34 cough, 26 dyspnoea, 26 alopecia, 24 dry skin, 16 pruritus, 33 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>245 out of 260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 anaemia, 26 neutropenia, 22 diarrhoea, 26 nausea, 9 vomiting, 25 asthenia, 11 chills, 58 fatigue, 27 influenza‐like illness, 30 pyrexia, 24 decreased appetite, 12 arthralgia, 17 myalgia, 6 dizziness, 7 dysgeusia, 48 headache, 10 depression, 33 insomnia, 21 cough, 5 dyspnoea, 17 alopecia, 18 dry skin, 37 pruritus, 19 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123 out of 133</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0062" title="AerssensJ , FanningG , ScholliersA , LenzO , PeetersM , DeSmedtG , et al. Impact of IL28B genotype and pretreatment serum IP‐10 in treatment‐naive genotype‐1 HCV patients treated with TMC435 in combination with peginterferona‐2A and ribavirin in PILLAR study. Journal of Hepatology2011;54(Suppl S1):S5‐6. FriedMW , ButiM , DoreGJ , FerenciP , JacobsonI , MarcellinP , et al. Efficacy and safety of TMC435 in combination with peginterferon alfa‐2a and ribavirin in treatment‐naive genotype‐1 HCV patients: 24‐week interim results from the PILLAR study. Hepatology2010;52(Suppl S1):403A. FriedMW , ButiM , DoreGJ , FlisiakR , FerenciP , JacobsonI , et al. Once‐daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment‐naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology2013;58(6):1918‐29. ScottJ , GillesL , FuM , BrohanE , AmatyaR , JessnerW , et al. Patients with chronic hepatitis C virus treated with simeprevir added to peginterferon and ribavirin experienced less time with fatigue, depressive symptoms, and functional limitations: results from patients in the QUEST‐1, QUEST‐2, and promise studies. Value in Health2013;16(7):A362. ScottJ , GillesL , FuM , BrohanE , PanterC , ArbuckleR , et al. Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies. Journal of Viral Hepatitis2015;22(8):639‐50. ScottJ , RosaK , FuM , CerriK , PeetersM , Beumont‐MauvielM , et al. Improved SVR with simeprevir (TMC435) associated with reduced time with patient‐reported fatigue in treatment‐naive, HCV‐infected patients in the PILLAR phase IIb trial. Journal of Hepatology2013;58(Suppl 1):S371‐2. ">Fried 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 anaemia, 75 neutropenia, 47 diarrhoea, 86 nausea, 22 vomiting, 63 asthenia, 25 chills, 107 fatigue, 98 influenza‐like illness, 11 irritability, 64 pyrexia, 17 decreased appetite, 53 arthralgia, 55 myalgia, 29 dizziness, 16 dysgeusia, 142 headache, 32 depression, 69 insomnia, 52 cough, 33 dyspnoea, 53 alopecia, 63 dry skin, 173 pruritus, 65 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>302 out of 309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 anaemia, 16 neutropenia, 12 diarrhoea, 21 nausea, 5 vomiting, 16 asthenia, 8 chills, 37 fatigue, 29 influenza‐like illness, 8 irritability, 13 pyrexia, 6 decreased appetite, 11 arthralgia, 17 myalgia, 6 dizziness, 5 dysgeusia, 40 headache, 14 depression, 23 insomnia, 15 cough, 6 dyspnoea, 16 alopecia, 14 dry skin, 35 pruritus, 18 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75 out of 77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0044" title="HayashiN , SetoC , KatoM , KomadaY , GotoS . Once‐daily simeprevir (TMC435) with peginterferon/ribavirin for treatment‐naive hepatitis C genotype 1‐infected patients in Japan: the DRAGON study. Journal of Gastroenterology2014;49(1):138‐47. ">DRAGON 2014a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 anaemia, 13 diarrhoea,13 nausea, 6 vomiting, 4 chills, 2 fatigue, 42 pyrexia, 15 decreased appetite, 27 arthralgia, 15 myalgia, 3 dizziness, 6 dysgeusia, 41 headache, 2 depression, 23 insomnia, 8 cough, 25 alopecia, 5 dry skin, 15 pruritus, 47 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79 out of 79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 anaemia, 5 diarrhoea, 2 vomiting, 7 pyrexia, 3 decreased appetite, 2 arthralgia, 2 myalgia, 8 headache, 2 insomnia, 2 cough, 6 alopecia, 6 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 out of 13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0033" title="HayashiN , IzumiN , KumadaH , OkanoueT , TsubouchiH , YatsuhashiH , et al. Simeprevir with peginterferon/ribavirin for treatment‐naive hepatitis C genotype 1 patients in Japan: CONCERTO‐1, a phase III trial. Journal of Hepatology2014;61(2):219‐27. ">CONCERTO‐1 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 anaemia, 8 neutropenia, 20 diarrhoea, 16 nausea, 6 vomiting, 13 fatigue, 75 pyrexia, 28 decreased appetite, 30 arthralgia, 9 myalgia, 4 dizziness, 20 dysgeusia, 54 headache, 27 insomnia, 11 cough, 44 alopecia, 8 dry skin, 35 pruritus, 57 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123 out of 123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 anaemia, 1 neutropenia, 20 diarrhoea, 16 nausea, 6 vomiting, 7 fatigue, 31 pyrexia, 20 decreased appetite, 14 arthralgia, 11 myalgia, 4 dizziness, 8 dysgeusia, 26 headache, 3 depression, 25 insomnia, 8 cough, 28 alopecia, 9 dry skin, 18 pruritus, 37 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 out of 60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0077" title="HoebenE , VibergA , PeterssonK , LeeM , VanwelkenhuysenI , WitekJ , et al. Simeprevir exposure in Asian treatment naive patients with chronic hepatitis C virus genotype 1 infection results from a population pharmacokinetic model in the phase III Tiger study. Hepatology International2015;9(1 Suppl):S71. WeiL , HanT , YangD , HeoJ , ShangJ , ChengJ . Simeprevir plus peginterferon ribavirin in treatment naive patients with chronic hepatitis C virus genotype 1 infection results from the phase III Tiger study conducted in East Asian patients living in China and Korea. Hepatology International2015;9(1 Suppl):S61. ">Hoeben 2015a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82 anaemia, 59 neutropenia, 14 diarrhoea, 16 nausea, 15 asthenia, 63 fatigue, 39 influenza‐like illness, 67 pyrexia, 28 decreased appetite, 13 arthralgia, 36 myalgia, 39 headache, 17 insomnia, 16 cough, 47 alopecia, 40 pruritus, 57 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>298 out of 305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 anaemia, 32 neutropenia, 7 diarrhoea, 10 nausea, 7 asthenia, 36 fatigue, 19 influenza‐like illness, 46 pyrexia, 16 decreased appetite, 4 arthralgia, 22 myalgia, 28 headache, 18 insomnia, 17 cough, 26 alopecia, 17 pruritus, 27 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>149 out of 152</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0084" title="JacobsonI , DoreGJ , FosterGR , FriedMW , RaduM , RafalskiyVV , et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype‐1 infection in treatment‐naive patients: results from QUEST‐1, a phase III trial. Journal of Hepatology2013;58(Suppl 1):S574. JacobsonIM , DoreGJ , FosterGR , FriedMW , RaduM , RafalskyVV , et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment‐naive patients with chronic hepatitis C virus genotype 1 infection (QUEST‐1): a phase 3, randomised, double‐blind, placebo‐controlled trial. Lancet2014;384(9941):403‐13. ">Jacobson 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 anaemia, 54 neutropenia, 35 diarrhoea, 65 nausea, 23 vomiting, 25 asthenia, 33 chills, 111 fatigue, 62 influenza‐like illness, 51 pyrexia, 47 decreased appetite, 34 arthralgia, 39 myalgia, 23 dizziness, 16 dysgeusia, 88 headache, 23 depression, 56 insomnia, 25 cough, 23 dyspnoea, 30 alopecia, 33 dry skin, 68 pruritus, 60 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>252 out of 264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 anaemia, 15 neutropenia, 19 diarrhoea, 32 nausea, 9 vomiting, 21 asthenia, 18 chills, 53 fatigue, 26 influenza‐like illness, 28 pyrexia, 19 decreased appetite, 21 arthralgia, 18 myalgia, 9 dizziness, 4 dysgeusia, 51 headache, 16 depression, 31 insomnia, 20 cough, 9 dyspnoea, 16 alopecia, 11 dry skin, 20 pruritus, 30 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124 out of 130</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0146" title="MannsM , ReesinkH , BergT , DusheikoG , FlisiakR , MarcellinP , et al. Rapid viral response of once‐daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype‐1 patients: a randomized trial. Antiviral Therapy2011;16(7):1021‐33. ">OPERA 2011a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 anaemia, 26 neutropenia, 20 diarrhoea, 31 nausea, 9 vomiting, 26 asthenia, 6 chills, 35 fatigue, 24 influenza‐like illness, 10 irritability, 21 pyrexia, 7 decreased appetite, 20 arthralgia, 14 myalgia, 4 dizziness, 5 dysgeusia, 42 headache, 14 depression, 12 insomnia, 19 cough, 18 dyspnoea, 16 alopecia, 19 dry skin, 18 pruritus, 9 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82 out of 83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 anaemia, 4 neutropenia, 3 diarrhoea, 4 nausea, 3 vomiting, 7 asthenia, 5 chills, 13 fatigue, 5 influenza‐like illness, 4 irritability, 4 pyrexia, 2 decreased appetite, 3 arthralgia, 8 myalgia, 3 dizziness, 3 dysgeusia, 16 headache, 2 depression, 7 insomnia, 10 cough, 4 dyspnoea, 3 alopecia, 5 dry skin, 7 pruritus, 5 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 out of 28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0120" title="MannsM , MarcellinP , PoordadF , DeAraujoESA , ButiM , HorsmansY , et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment‐naive patients with chronic hepatitis C virus genotype 1 infection (QUEST‐2): a randomised, double‐blind, placebo‐controlled phase 3 trial. Lancet2014;384(9941):414‐26. PoordadF , MannsMP , MarcellinP , AraujoESA , ButiM , HorsmansY , et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype‐1 infection in treatment‐naive patients: results from QUEST‐2, a phase III trial. Gastroenterology2013;144(5 Suppl 1):S151. ">Manns 2014a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 anaemia, 49 neutropenia, 34 diarrhoea, 63 nausea, 17 vomiting, 59 asthenia, 21 chills, 95 fatigue, 66 influenza‐like illness, 80 pyrexia, 46 decreased appetite, 32 arthralgia, 58 myalgia, 21 dizziness, 101 headache, 29 depression, 51 insomnia, 32 cough, 23 dyspnoea, 43 alopecia, 28 dry skin, 65 pruritus, 46 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>243 out of 257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 anaemia, 29 neutropenia, 12 diarrhoea, 24 nausea, 7 vomiting, 38 asthenia, 12 chills, 56 fatigue, 35 influenza‐like illness, 53 pyrexia, 21 decreased appetite, 14 arthralgia, 28 myalgia, 9 dizziness, 49 headache, 19 depression, 21 insomnia, 22 cough, 11 dyspnoea, 27 alopecia, 18 dry skin, 34 pruritus, 15 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131 out of 134</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0155" title="PearlmanBL , EhlebenC , PerrysM . The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C‐related Child's class A cirrhosis. Gastroenterology2015;148(4):762. ">Pearlman 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 diarrhoea, 6 nausea, 8 fatigue, 1 irritability, 2 myalgia, 7 headache, 3 insomnia, 6 pruritus, 10 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 out of 58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 anaemia, 5 neutropenia, 2 diarrhoea, 7 nausea, 4 asthenia, 17 fatigue, 6 influenza‐like illness, 3 irritability, 4 myalgia, 8 headache, 6 insomnia, 4 pruritus, 3 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 out of 24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0014" title="FerenciP , FriedM , PoordadF , ZeuzemS , LenzO , Ouwerkerk‐MahadevanS , et al. Safety of simeprevir (SMV) with peg Ifnalpha‐2a/ribavirin (PR) in HCV genotype 1‐infected patients: PILLAR and ASPIRE trials. Swiss Medical Weekly2013;143(Suppl 199):15S. LenzO , FeveryB , VijgenL , VerbeeckJ , PeetersM , Beumont‐MauvielM , et al. TMC435 in patients infected with HCV genotype 1 who have failed previous pegylated interferon/ribavirin treatment: virologic analyses of the ASPIRE trial. Journal of Hepatology2012;56(Suppl S2):S5. ScottJ , RosaK , FuM , CerriK , PeetersM , BeumontM , et al. Fatigue during treatment for hepatitis C virus: results of self‐reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection. BMC Infectious Diseases2014;14:465. ScottJ , RosaK , FuM , CerriK , PeetersM , Beumont‐MauvielM , et al. Fatigue severity scale: reliability, validity and interpretation of change‐evidence from two clinical trials in patients with chronic HCV infection. Value in Health2013;16(3):A216. ScottJ , RosaK , ZeuzemS , Beumont‐MauvielM , PeetersM , Cerri , K , et al. Adding simeprevir (TMC435) to pegylated interferon/ribavirin does not increase patient reported fatigue in treatment‐experienced patients with chronic HCV infection: results from the ASPIRE trial. Journal of Hepatology2013;58(Suppl S1):S371. ZeuzemS , BergT , GaneE , FerenciP , FosterGR , FriedMW , et al. Simeprevir increases rate of sustained virologic response among treatment‐experienced patients with HCV genotype‐1 infection: a phase IIb trial. Gastroenterology2014;146(2):430‐41. ZeuzemS , FosterGR , FriedMW , HezodeC , HirschfieldGM , NikitinI , et al. The ASPIRE trial: TMC435 in treatment‐experienced patients with genotype‐1 HCV infection who have failed previous PEGIFN/RBV treatment. Journal of Hepatology2011;54(Suppl 1):S546. ">ASPIRE 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 anaemia, 101 neutropenia, 59 diarrhoea, 95 nausea, 21 vomiting, 84 asthenia, 34 chills, 174 fatigue, 116 influenza‐like illness, 53 irritability, 69 pyrexia, 69 decreased appetite, 50 arthralgia, 64 myalgia, 29 dizziness, 22 dysgeusia, 138 headache, 45 depression, 79 insomnia, 76 cough, 49 dyspnoea, 31 alopecia, 72 dry skin, 135 pruritus, 61 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>380 out of 396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 anaemia, 11 neutropenia, 13 diarrhoea, 14 nausea, 5 vomiting, 7 asthenia, 6 chills, 174 fatigue, 13 influenza‐like illness, 7 irritability, 9 pyrexia, 9 decreased appetite, 9 arthralgia, 12 myalgia, 6 dizziness, 3 dysgeusia, 24 headache, 6 depression, 9 insomnia, 8 cough, 4 dyspnoea, 5 alopecia, 10 dry skin, 11 pruritus, 9 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 out of 66</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0084" title="JacobsonI , DoreGJ , FosterGR , FriedMW , RaduM , RafalskiyVV , et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype‐1 infection in treatment‐naive patients: results from QUEST‐1, a phase III trial. Journal of Hepatology2013;58(Suppl 1):S574. JacobsonIM , DoreGJ , FosterGR , FriedMW , RaduM , RafalskyVV , et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment‐naive patients with chronic hepatitis C virus genotype 1 infection (QUEST‐1): a phase 3, randomised, double‐blind, placebo‐controlled trial. Lancet2014;384(9941):403‐13. ">Jacobson 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sofosbuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 diarrhoea, 46 nausea, 12 vomiting, 91 fatigue, 19 irritability, 7 decreased appetite, 16 arthralgia, 19 dizziness, 43 headache, 15 depression, 39 insomnia, 11 cough, 19 dyspnoea, 23 pruritus, 18 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>184 out of 207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 diarrhoea, 13 nausea, 5 vomiting, 17 fatigue, 1 irritability, 7 decreased appetite, 1 arthralgia, 5 dizziness, 14 headache, 1 depression, 3 insomnia, 2 cough, 1 dyspnoea, 6 pruritus, 6 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 out of 71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0104" title="LawitzE , LalezariJP , HassaneinT , KowdleyKV , PoordadFF , SheikhAM , et al. Sofosbuvir in combination with peginterferon alfa‐2a and ribavirin for non‐cirrhotic, treatment‐naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double‐blind, phase 2 trial. Lancet Infectious Diseases2013;13(5):401‐8. ">Lawitz 2013a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sofosbuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 anaemia, 23 neutropenia, 18 diarrhoea, 38 nausea, 12 vomiting, 2 asthenia, 37 chills, 64 fatigue, 15 irritability, 22 pyrexia, 11 decreased appetite, 10 arthralgia, 17 myalgia, 11 dizziness, 9 dysgeusia, 37 headache, 12 depression, 24 insomnia, 14 cough, 11 dyspnoea, 10 alopecia, 12 dry skin, 13 pruritus, 29 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117 out of 120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 anaemia, 5 neutropenia, 2 diarrhoea, 9 nausea, 2 vomiting, 1 asthenia, 10 chills, 16 fatigue, 5 irritability, 2 pyrexia, 4 decreased appetite, 5 arthralgia, 6 myalgia, 3 dizziness, 15 headache, 3 depression, 9 insomnia, 3 cough, 4 dyspnoea, 2 alopecia, 3 dry skin, 3 pruritus, 4 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 out of 26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>)<a href="./references#CD012143-bbs2-0051" title="LawitzE , MangiaA , WylesD , Rodriguez‐TorresM , HassaneinT , Gordon StuartC , et al. Sofosbuvir for previously untreated chronic hepatitis C infection. New England Journal of Medicine2013;368(20):1878‐87. YounossiZM , StepanovaM , HenryL , GaneE , JacobsonIM , LawitzE , et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH‐C). Journal of Hepatology2014;60(4):741‐7. [PUBMED: 24333184] ">FISSION 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sofosbuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 anaemia, 23 diarrhoea, 46 nausea, 17 vomiting, 7 chills, 92 fatigue, 7 influenza‐like illness, 25 irritability, 6 pyrexia, 17 decreased appetite, 15 arthralgia, 21 myalgia, 27 dizziness, 64 headache, 14 depression, 31 insomnia, 19 cough, 18 dyspnoea, 12 alopecia, 11 dry skin, 19 pruritus, 23 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219 out of 256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 anaemia, 30 neutropenia, 45 diarrhoea, 70 nausea, 23 vomiting, 44 chills, 134 fatigue, 44 influenza‐like illness, 40 irritability, 33 pyrexia, 44 decreased appetite, 35 arthralgia, 40 myalgia, 33 dizziness, 108 headache, 34 depression, 71 insomnia, 21 cough, 20 dyspnoea, 24 alopecia, 23 dry skin, 42 pruritus, 43 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>233 out of 243</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0174" title="Rodriguez‐TorresM , LawitzE , KowdleyKV , NelsonDR , DejesusE , McHutchisonJG , et al. Sofosbuvir (GS‐7977) plus peginterferon/ribavirin in treatment‐naïve patients with HCV genotype 1: a randomized, 28‐day, dose‐ranging trial. Journal of Hepatology2013;58(4):663‐8. ">Rodriguez‐Torres 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sofosbuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 anaemia, 17 nausea, 3 vomiting, 22 fatigue, 4 pyrexia, 7 decreased appetite, 12 arthralgia, 7 myalgia, 6 dizziness, 15 headache, 4 depression, 7 insomnia, 9 pruritus </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 out of 49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 5 nausea, 2 chills, 6 fatigue, 1 pyrexia, 1 decreased appetite, 1 myalgia, 2 dizziness, 2 headache, 2 insomnia,1 pruritus </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 out of 14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0050" title="FeldJJ , JacobsonIM , HezodeC , AsselahT , RuanePJ , GruenerN , et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. New England Journal of Medicine2015;373(27):2599‐607. ">Feld 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sofosbuvir/velpatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 diarrhoea, 75 nausea, 41 asthenia, 126 fatigue, 40 arthralgia, 25 myalgia, 182 headache, 50 insomnia, 39 cough </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>485 out of 624</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 diarrhoea, 13 nausea, 9 asthenia, 23 fatigue, 9 arthralgia, 6 myalgia, 33 headache, 11 insomnia, 4 cough </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89 out of 116</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3<a href="./references#CD012143-bbs2-0020" title="BenhamouY , MoussalliJ , RatziuV , LebrayP , DeBackerK , DeMeyerS , et al. Telaprevir activity in treatment‐naive patients infected hepatitis C virus genotype 4: a randomized trial. Journal of Infectious Diseases2013;208(6):1000‐7. BenhamouY , MoussalliJ , RatziuV , LebrayP , GysenV , deBackerK , et al. Results of a proof of concept study (C210) of telaprevir monotherapy and in combination with peginterferon ALFA‐2A and ribavirin in treatment‐naive genotype 4 HCV patients. Journal of Hepatology2009;50(Suppl 1):S6. BenhamouY , MoussalliJ , RatziuV , LebrayP , deBackerK , GhysA , et al. Activity of telaprevir monotherapy or in combination with peginterferon‐alfa‐2a and ribavirin in treatment‐naive genotype 4 hepatitis C patients: final results of study C210. Hepatology2010;52(Suppl S1):719A. DeMeyerS , GhysA , DierynckI , BeumontM , LuoD , PicchioG . Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir. Virology Journal2014;11:93. ">Benhamou 2013a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 diarrhoea, 4 nausea, 1 vomiting, 6 asthenia, 4 fatigue, 10 influenza‐like illness, 3 headache, 2 insomnia, 1 dyspnoea, 1 dry skin, 3 pruritus </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 out of 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 neutropenia, 3 asthenia, 4 influenza‐like illness, 1 decreased appetite, 1 headache, 1 insomnia, 1 cough, 1 dry skin, 2 pruritus, 2 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0053" title="ForestierN , ReesinkHW , WeeginkCJ , McNairL , KiefferTL , ChuHM , et al. Antiviral activity of telaprevir (VX‐950) and peginterferon alfa‐2a in patients with hepatitis C. Hepatology2007;46(3):640‐8. ForestierN , SarrazinC , Friedrich‐RustM , WeeginkC , JansenP , ReesinkH , et al. Status of patients with chronic hepatitis C after a 14‐day pre‐treatment with Telaprevir (VX‐950) followed by an anti‐viral therapy with Peg‐interferon‐alpha‐2a (Peg‐IFN‐2a) and Ribavirin (RBV). Zeitschrift fur Gastroenterologie2007;45(8):841. ForestierN , SarrazinC , Friedrich‐RustM , ZeuzemS . Status of patients with chronic hepatitis C after a pretreatment period of 14 days with Telaprevir (VX‐950) und a following antiviral therapy with Peg‐interferon‐alfa‐2a (Peg‐IFN‐2s) and ribavirin (RBV). Zeitschrift fur Gastroenterologie2008;46(1):145. ForestierN , WeeginkCJ , PurdyS , McNairL , JansenPL , ZeuzemS , et al. Current status of subjects receiving peg‐interferon‐alfa‐2A (peg‐ifn) and ribavirin (RBV) after a 14‐day study of the hepatitis C protease inhibitor telaprevir (VX‐950), with peg‐ifn. Hepatology2006;44(4 (Suppl 1)):614A‐5A. WeeginkCJ , ForestierN , JansenPL , ZeuzemS , ReesinkHW . Final results of patients receiving peg‐interferon‐alfa‐2a (Peg‐IFN) and ribavirin (RBV) after a 14‐day study of the hepatitis C protease inhibitor telaprevir (VX‐950), with Peg‐IFN. Hepatology2007;46(4 (Suppl 1)):819A. ">Forestier 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 diarrhoea, 3 nausea, 1 chills, 5 myalgia, 2 dizziness, 5 headache, 3 dry skin, 3 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 out of 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 diarrhoea, 1 nausea, 1 asthenia, 2 chills, 2 myalgia, 1 dizziness, 2 headache, 1 dry skin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 out of 4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1<a href="./references#CD012143-bbs2-0058" title="DeMeyerS , GhysA , FosterGR , BeumontM , VanBaelenB , LinTI , et al. Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes. Journal of Viral Hepatitis2013;20(6):395‐403. DeMeyerS , GhysA , FosterGR , Beumont‐MauvielM , VanBaelenB , LinTI , et al. Analyses of genotype 2/3 HCV variants in patients treated with telaprevir in study C209 showed that the telaprevir resistance profile appears to be consistent across genotypes. Antiviral Therapy2010;15(Suppl 2):A118. FosterGR , HezodeC , BronowickiJP , CarosiG , WeilandO , VerlindenL , et al. Activity of telaprevir alone or in combination with peginterferon alfa‐2a and ribavirin in treatment‐naive genotype 2 and 3 hepatitis‐C patients: final results of STUDY C209. Journal of Hepatology2010;52(Suppl 1):S27. FosterGR , HézodeC , BronowickiJP , CarosiG , WeilandO , VerlindenL , et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology2011;141(3):881‐9. ">Foster 2011a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 4 diarrhoea, 8 nausea, 5 vomiting, 9 asthenia, 1 chills, 5 fatigue, 11 influenza‐like illness, 1 irritability, 2 pyrexia, 1 arthralgia, 4 myalgia, 3 dizziness, 5 headache, 1 depression, 2 insomnia, 1 cough, 2 dyspnoea, 1 alopecia, 3 dry skin, 11 pruritus, 5 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 out of 31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 neutropenia, 1 diarrhoea, 1 nausea, 5 asthenia, 3 chills, 2 fatigue, 7 influenza‐like illness, 5 pyrexia, 3 myalgia, 1 dysgeusia, 6 headache, 1 depression, 2 insomnia, 2 cough, 2 dyspnoea, 1 dry skin, 2 pruritus </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 out of 18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0075" title="BronowickiJP , HezodeC , BengtssonL , PolS , BourliereM , SerfatyL , et al. 100% SVR in IL28B CC patients treated with 12 weeks of telaprevir, peginterferon and ribavirin in the PROVE2 trial. Journal of Hepatology2012;56(Suppl 2):S430‐1. DusheikoGM , HezodeC , PolS , GoeserT , BronowickiJP , BourliereM , et al. Treatment of chronic hepatitis C with telaprevir (TVR) in combination with peginterferon‐alfa‐2a with or without ribavirin: further interim analysis results of the PROVE2 study. Journal of Hepatology2008;48(Suppl 2):S26. HezodeC , FerenciP , Dusheiko GeoffreyM , TranA , GrangeJ‐D , MathurinP , et al. Prove2 Study: treatment of chronic hepatitis C with telaprevir (Tvr) in combination with peginterferon‐alfa‐2a with or without ribavirin, interim analysis results. Gastroenterology2008;134(4, Suppl. 1):A755. HezodeC , ForestierN , DusheikoG , FerenciP , PolS , GoeserT , et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. New England Journal of Medicine2009;360(18):1839‐50. MuirA , PoordadF , SheikhA , ElkashabM , BrennanR , Ankoma‐SeyV , et al. SVR4 results for the combination of ACH‐3102 and sovaprevir, with ribavirin, in subjects with genotype 1 chronic hepatitis C infection. Hepatology International2014;8(1 Suppl):s395. PawlotskyJ , KiefferT , ZhouY , ZhangE , MarcialM , ByrnR , et al. Evaluation of viral variants during a phase 2 study (PROVE2) of telaprevir with peginterferon alfa‐2A and ribavirin in treatment‐naïve HCV genotype 1‐infected patients. Hepatology2007;46(4 Suppl 1):862A. PawlotskyJM , FerenciP , DusheikoGM , AlvesK , KauffmanR , ZeuzemS . PROVE2: a phase 2b study of telaprevir combined with peginterferon‐alfa‐2a with or without ribavirin for treatment‐naive patients with chronic hepatitis C. Hepatology International2009;3(1):169. ZeuzemS , HezodeC , FerenciP , DusheikoGM , AlvesK , BengtssonL , et al. Telaprevir in combination with peginterferon‐alfa‐2a with or without ribavirin in the treatment of chronic hepatitis C: final results of the PROVE2 study. Hepatology2008;48(4 Suppl):418A‐9A. ZeuzemS , HezodeC , FerenciP , DusheikoGM , PolS , GoeserT , et al. PROVE2: phase II study of VX950 (telaprevir) in combination with peginterferon alfa2A with or without ribavirin in subjects with chronic hepatitis C; first interim analysis. Hepatology2007;46(4 Suppl 1):268A‐9A. ">Hezode 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 anaemia, 11 neutropenia, 66 diarrhoea, 102 nausea, 22 vomiting, 110 asthenia, 12 chills, 70 fatigue, 92 influenza‐like illness, 22 irritability, 44 pyrexia, 30 decreased appetite, 36 arthralgia, 35 myalgia, 12 dizziness, 20 dysgeusia, 105 headache, 51 depression, 62 insomnia, 37 cough, 50 dyspnoea, 29 alopecia, 64 dry skin, 139 pruritus, 71 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240 out of 241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 anaemia, 14 neutropenia, 23 diarrhoea, 33 nausea, 12 vomiting, 26 asthenia, 10 chills, 30 fatigue, 43 influenza‐like illness, 11 irritability, 19 pyrexia, 16 decreased appetite, 14 arthralgia, 17 myalgia, 8 dizziness, 3 dysgeusia, 37 headache, 19 depression, 32 insomnia, 21 cough, 13 dyspnoea, 17 alopecia, 29 dry skin, 29 pruritus, 22 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81 out of 82</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0083" title="JacobsonI , PockrosP , LalezariJ , LawitzE , Rodriguez‐TorresM , DeJesusE , et al. Antiviral activity of filibuvir in combination with pegylated interferon alfa‐2A and ribavirin for 28 days in treatment naive patients chronically infected with HCV genotype 1. Journal of Hepatology2009;50(Suppl 1):S382. JacobsonI , PockrosPJ , LalezariJ , LawitzE , Rodriguez‐TorresM , DeJesusE , et al. Virologic response rates following 4 weeks of filibuvir in combination with pegylated interferon alfa‐2A and ribavirin in chronically‐infected HCV genotype‐1 patients. Journal of Hepatology2010;52(Suppl 1):S464. MoriJ , HammondJL , SrinivasanS , JagannathaS , RystECC . Genotypic characterisation of filibuvir (PF‐00868554 ) resistance in patients receiving four weeks co‐administration of filibuvir with pegIFN/RBV. Hepatology2010;52(Suppl S1):722A. MoriJ , HammondJL , SrinivasanS , JagannathaS , Van derRystE . Genotypic characterisation of filibuvir (PF‐00868554) resistance in patients receiving four weeks co‐administration of filibuvir with PEGIFN/RBV (12 week analysis). Journal of Hepatology2010;52(Suppl 1):S15. ">Jacobson 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>276 anaemia, 217 diarrhoea, 302 nausea, 418 fatigue, 203 pyrexia, 304 headache, 233 insomnia, 346 pruritus, 262 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>723 out of 727</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 anaemia, 80 diarrhoea, 112 nausea, 206 fatigue, 87 pyrexia, 142 headache, 111 insomnia, 131 pruritus, 88 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>354 out of 361</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0125" title="EversonGT , GordonSC , JacobsonI , KauffmanRS , McNairL , MuirA , et al. PROVE 1: subgroup analysis of a phase 2 study of telaprevir with peginterferon alfa‐2a and ribavirin in treatment‐naive subjects with hepatitis C. Hepatology International2009;3:167. McHutchisonJG , EversonGT , GordonSC , JacobsonI , KauffmanR , McNairL , et al. PROVE1: results from a phase 2 study of telaprevir with peginterferon alfa‐2a and ribavirin in treatment‐naive subjects with hepatitis C. Journal of Hepatology2008;48(Suppl S2):S4. McHutchisonJG , EversonGT , GordonSC , JacobsonIM , SulkowskiM , KauffmanR , et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. New England Journal of Medicine2009;360(18):1827‐38. ">McHutchison 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58 anaemia, 30 neutropenia, 64 diarrhoea, 93 nausea, 38 vomiting, 29 chills, 127 fatigue, 75 influenza‐like illness, 23 irritability, 33 pyrexia, 22 decreased appetite, 34 arthralgia, 27 myalgia, 41 dizziness, 16 dysgeusia, 80 headache, 34 depression, 68 insomnia, 36 cough, 25 dyspnoea, 21 alopecia, 28 dry skin, 74 pruritus, 62 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175 out of 175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 anaemia, 18 neutropenia, 21 diarrhoea, 22 nausea, 9 vomiting, 14 chills, 57 fatigue, 32 influenza‐like illness, 22 irritability, 22 pyrexia, 9 decreased appetite, 16 arthralgia, 18 myalgia, 14 dizziness, 8 dysgeusia, 45 headache, 13 depression, 29 insomnia, 14 cough, 11 dyspnoea, 8 alopecia, 19 dry skin, 17 pruritus, 20 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75 out of 75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0126" title="EversonGT , GordonSC , JacobsonI , KauffmanRS , McNairL , MuirA , et al. PROVE 1: subgroup analysis of a phase 2 study of telaprevir with peginterferon alfa‐2a and ribavirin in treatment‐naive subjects with hepatitis C. Hepatology International2009;3:167. MannsM , MuirA , AddaN , JacobsonI , AfdhalN , HeathcoteJ , et al. Telaprevir in hepatitis C genotype‐1‐infected patients with prior non‐response, viral breakthrough or relapse to peginterferonalfa‐2A/B and ribavirin therapy: SVR results of the PROVE3 study. Journal of Hepatology2009;50(Suppl 1):S379. McHutchinsonJG , MannsMP , MuirAJ , TerraultNA , JacobsonIM , AfdhalNH , et al. Telaprevir for previously treated chronic HCV infection. New England Journal of Medicine2010;362(14):1292‐303. McHutchinsonJG , ShiffmanML , TerraultN , MannsMP , DiBiscegliAM , JacobsonIM , et al. Interim results of PROVE 3: a randomized, controlled, phase 2b study of telaprevir (TVR) with peginterferon‐alfa‐2a (P) and/or ribavirin (R) in subjects with hepatitis C genotype 1 who failed to achieve an SVR with a prior course of PR therapy. Hepatology International2009;3(1):25. McHutchisonJG , MannsMP , MuirA , TerraultN , JacobsonIM , AfdhalNH , et al. PROVE3 final results and 1‐year durability of SVR with telaprevir‐based regimen in hepatitis C genotype 1‐infected patients with prior non‐response, viral breakthrough or relapse to peginterferon‐alfa‐2a/b and ribavirin therapy. Hepatology2009;50(4 Suppl):334A‐5A. McHutchisonJG , ShiffmanML , TerraultN , MannsMP , DiBisceglieAM , JacobsonIM , et al. A phase 2b study of telaprevir with peginterferon‐alfa‐2a and ribavirin in hepatitis C genotype 1 null and partial responders and relapsers following a prior course of peginterferon‐alfa‐2a/b and ribavirin therapy: PROVE3 interim results. Hepatology2008;48(4 Suppl):269A‐70A. ">McHutchison 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69 anaemia, 31 neutropenia, 115 diarrhoea, 122 nausea, 37 vomiting, 57 chills, 197 fatigue, 93 influenza‐like illness, 63 irritability, 59 pyrexia, 20 decreased appetite, 51 arthralgia, 60 myalgia, 47 dizziness, 130 headache, 43 depression, 83 insomnia, 46 cough, 27 dyspnoea, 54 alopecia, 32 dry skin, 129 pruritus, 126 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>329 out of 339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 anaemia, 7 neutropenia, 22 diarrhoea, 39 nausea, 13 vomiting, 15 chills, 64 fatigue, 36 influenza‐like illness, 25 irritability, 14 pyrexia, 12 decreased appetite, 21 arthralgia, 21 myalgia, 18 dizziness, 41 headache, 19 depression, 19 insomnia, 20 cough, 9 dyspnoea, 13 alopecia, 7 dry skin, 17 pruritus, 20 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111 out of 114</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0196" title="ShermanKE , RockstrohJK , DieterichDT , SorianoV , GirardPM , McCallisterS , et al. Telaprevir combination with peginterferon alfa‐2A/ribavirin in HCV/HIV coinfected patients: 24‐week treatment interim analysis. Hepatology2011;54(4 Suppl):1431A‐2A. SulkowskiMS , ShermanKE , DieterichDT , BsharatM , MahnkeL , RockstrohJK , et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Annals of Internal Medicine2013;159(2):86‐96. SulkowskiMS , ShermanKE , SorianoV , RockstrohJ , DieterichDT , GirardPM , et al. Telaprevir in combination with peginterferon alfa‐2a/ribavirin in HCV/HIV co‐infected patients: SVR24 final study results. Hepatology2012;56(S1):219A. ">Sulkowski 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 anaemia, 26 neutropenia, 34 diarrhoea, 44 nausea, 27 vomiting, 22 asthenia, 15 chills, 50 fatigue, 24 influenza‐like illness, 18 irritability, 34 pyrexia, 30 decreased appetite, 9 arthralgia, 20 myalgia, 19 dizziness, 18 dysgeusia, 38 headache, 11 depression, 25 insomnia, 15 cough, 5 dyspnoea, 18 alopecia, 11 dry skin, 30 pruritus, 12 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 out of 38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 anaemia, 2 neutropenia, 6 diarrhoea, 11 nausea, 5 vomiting, 9 asthenia, 5 chills, 12 fatigue, 13 influenza‐like illness, 5 irritability, 7 pyrexia, 6 decreased appetite, 2 arthralgia, 6 myalgia, 2 dizziness, 5 dysgeusia, 6 headache, 4 depression, 9 insomnia, 6 cough, 2 dyspnoea, 6 alopecia, 3 dry skin, 3 pruritus </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 out of 22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0209" title="BergT , AndreoneP , PolS , RobertsSK , YounossiZM , DiagoM , et al. Predictors of virologic response with telaprevir‐based combination treatment in HCV genotype 1‐infected patients with prior peginterferon/ribavirin treatment failure: post‐hoc analysis of the phase III REALIZE study. Hepatology2011;54(S1):375A‐6A. DeMeyerS , DierynckI , GhysA , BeumontM , DaemsB , VanBaelenB , et al. Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial. Hepatology2012;56(6):2106‐15. FosterGR , JacobsonIM , DoreGJ , FriedM , MannsM , MarcellinP , et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment‐naive European patients in the QUEST‐1 and QUEST‐2 phase III trials. Journal of Hepatology2014;60(1 Suppl 1):S456. FosterGR , ZeuzemS , AndreoneP , PolS , LawitzEJ , DiagoM , et al. Subanalyses of the telaprevir lead‐in arm in the REALIZE study: response at week 4 is not a substitute for prior null response categorization. Journal of Hepatology2011;54(Suppl 1):S3‐S4. FosterGR , ZeuzemS , AndreoneP , PolS , LawitzEJ , DiagoM , et al. Sustained virologic response rates with telaprevir by response after 4 weeks of lead‐in therapy in patients with prior treatment failure. Journal of Hepatology2013;58(3):488‐94. PolS , AerssensJ , ZeuzemS , AndreoneP , LawitzEJ , RobertsS , et al. Similar SVR rates in IL28B CC, CT OR TT prior relapser, partial‐ or null‐responder patients treated with telaprevir/peginterferon/ribavirin: retrospective analysis of the REALIZE study. Journal of Hepatology2011;54(Suppl 1):S6‐7. PolS , RobertsSK , AndreoneP , YounossiZM , DiagoM , LawitzE , et al. Efficacy and safety of telaprevir‐based regimens in cirrhotic patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: subanalysis of the REALIZE phase III study. Hepatology2011;54(S1):374A‐5A. RobertsSK , AndreoneP , PolS , YounossiZM , DiagoM , LawitzE , et al. Impact of anemia and ribavirin dose reduction on SVR to a telaprevir‐based regimen in patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure in the phase III REALIZE study. Hepatology2011;54(4 Suppl):1007A‐8A. TuefferdM , PalescandoloE , VijgenL , ColomboM , RobertsS , WedemeyerH , et al. ITPA gene variants and anemia during telaprevir/peginterferon/ribavirin combination therapy in patients with chronic hepatitis C infection. Journal of Hepatology2014;60(1 Suppl S):S490. WitekJ . Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment‐experienced patients. Journal of Hepatology2014;60(6):1112‐7. YounossiZ , NegroF , SerfatyL , PolS , DiagoM , ZeuzemS , et al. Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial. Hepatology2013;58(6):1897‐906. ZeuzemS , AndreoneP , PolS , LawitzE , DiagoM , RobertsS , et al. Telaprevir for retreatment of HCV infection. New England Journal of Medicine2011;364(25):2417‐28. ZeuzemS , AndreoneP , PolS , LawitzEJ , DiagoM , RobertsS , et al. REALIZE trial final results: telaprevir‐based regimen for genotype 1 hepatitis C virus infection in patients with prior null response, partial response or relapse to peginterferon/ribavirin. Journal of Hepatology2011;54(Suppl S1):S3. ">Zeuzem 2011a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>171 anaemia, 73 neutropenia, 135 diarrhoea, 181 nausea, 68 vomiting, 111 asthenia, 73 chills, 276 fatigue, 179 influenza‐like illness, 74 irritability, 130 pyrexia, 40 decreased appetite, 67 arthralgia, 87 myalgia, 47 dizziness, 65 dysgeusia, 221 headache, 59 depression, 152 insomnia, 128 cough, 82 dyspnoea, 78 alopecia, 97 dry skin, 270 pruritus, 194 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>517 out of 530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 anaemia, 14 neutropenia, 18 diarrhoea, 31 nausea, 11 vomiting, 38 asthenia, 73 chills, 53 fatigue, 33 influenza‐like illness, 21 irritability, 36 pyrexia, 9 decreased appetite, 20 arthralgia, 24 myalgia, 7 dizziness, 8 dysgeusia, 49 headache, 19 depression, 34 insomnia, 26 cough, 17 dyspnoea, 17 alopecia, 21 dry skin, 36 pruritus, 25 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126 out of 132</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0104" title="LawitzE , LalezariJP , HassaneinT , KowdleyKV , PoordadFF , SheikhAM , et al. Sofosbuvir in combination with peginterferon alfa‐2a and ribavirin for non‐cirrhotic, treatment‐naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double‐blind, phase 2 trial. Lancet Infectious Diseases2013;13(5):401‐8. ">Lawitz 2013a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaniprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 anaemia, 7 neutropenia, 16 diarrhoea, 26 nausea, 16 vomiting, 13 asthenia, 5 chills, 17 fatigue, 17influenza‐like illness, 4 irritability, 8 pyrexia, 13 decreased appetite, 8 arthralgia, 3 myalgia, 5 dizziness, 2 dysgeusia, 26 headache, 8 depression, 15 insomnia, 8 cough, 7 dyspnoea, 6 alopecia, 6 dry skin, 9 pruritus, 10 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71 out of 75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 anaemia, 2 neutropenia, 4 diarrhoea, 6 nausea, 4 asthenia, 2 chills, 7 fatigue, 4 influenza‐like illness, 3 irritability, 2 pyrexia, 2 decreased appetite, 2 arthralgia, 3 myalgia, 7 headache, 3 depression, 2 insomnia, 3 cough, 5 dyspnoea, 3 alopecia, 6 dry skin, 4 pruritus, 4 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 out of 19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0116" title="LawitzE , SulkowskiM , JacobsonIRA , KraftWK , MaliakkalB , Al‐IbrahimM , et al. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics. Antiviral Research2013;99(3):214‐20. MannsMP , GaneE , Rodriguez‐TorresM , StoehrA , YehC‐T , MarcellinP , et al. Vaniprevir with pegylated interferon alpha‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C: a randomized phase II study. Hepatology2012;56(3):884‐93. MannsMP , GaneE , Rodriguez‐TorresM , StoehrA , YehC‐T , WiedmannR , et al. MK‐7009 significantly improves rapid viral response (RVR) in combination with pegylated interferon ALFA‐2A and ribavirin in patients with chronic hepatitis C (CHC) genotype 1 infection. Journal of Hepatology2009;50(Suppl S1):S384. MannsMP , GaneE , Rodriguez‐TorresM , StoehrA , YehCT , MarcellinP , et al. Vaniprevir with pegylated interferon alpha‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C: a randomized phase II study. Hepatology2012;56(3):884‐93. MannsMP , GaneEJ , Rodriguez‐TorresM , StoehrAD , YehC , MarcellinP , et al. Early viral response (EVR) rates in treatment ‐ naive patients with chronic hepatitis C (CHC) genotype 1 infection treated with MK‐7009, a novel NS3/4a protease inhibitor, in combination with pegylated interferon alfa‐2a and ribavirin for 28 days. Hepatology2009;50(4 Suppl):332A‐3A. MannsMP , GaneEJ , Rodriguez‐TorresM , StoehrAD , YehC , MarcellinP , et al. Sustained viral response (SVR) rates in genotype 1 treatment‐naive patients with chronic hepatitis C (CHC) infection treated with vaniprevir (MK‐7009), A NS3/4A protease inhibitor, in combination with pegylated interferon alfa‐2a and ribavirin for 28 days. Hepatology2010;52(Suppl S1):361A. ">Manns 2012a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaniprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 anaemia, 7 neutropenia, 16 diarrhoea, 26 nausea, 16 vomiting, 13 asthenia, 5 chills, 17 fatigue, 17 influenza‐like illness, 4 irritability, 8 pyrexia, 13 decreased appetite, 8 arthralgia, 3 myalgia, 5 dizziness, 2 dysgeusia, 26 headache, 8 depression, 15 insomnia, 8 cough, 7 dyspnoea, 6 alopecia, 6 dry skin, 9 pruritus, 10 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71 out of 75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 anaemia, 2 neutropenia, 4 diarrhoea, 6 nausea, 4 asthenia, 2 chills, 7 fatigue, 4 influenza‐like illness, 3 irritability, 2 pyrexia, 2 decreased appetite, 2 arthralgia, 3 myalgia, 7 headache, 3 depression, 2 insomnia, 3 cough, 5 dyspnoea, 3 alopecia, 6 dry skin, 4 pruritus, 4 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 out of 19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0175" title="Rodriguez‐TorresM , StoehrA , GaneEJ , SerfatyL , LawitzE , ZhouA , et al. Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment‐experienced patients with chronic HCV genotype 1 infection and cirrhosis. Clinical Gastroenterology and Hepatology2014;12(6):1029‐37.e5. ">Rodriguez‐Torres 2014a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaniprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 anaemia, 34 neutropenia, 97 diarrhoea, 110 nausea, 59 vomiting, 50 asthenia, 16 chills, 92 fatigue, 54 influenza‐like illness, 24 irritability, 37 pyrexia, 40 decreased appetite, 37 arthralgia, 38 myalgia, 23 dizziness, 16 dysgeusia, 92 headache, 32 depression, 40 insomnia, 54 cough, 30 dyspnoea, 35 alopecia, 37 dry skin, 75 pruritus, 43 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225 out of 229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 anaemia, 3 neutropenia, 9 diarrhoea, 10 nausea, 3 vomiting, 11 asthenia, 1 chills, 18 fatigue, 12 influenza‐like illness, 8 irritability, 14 pyrexia, 5 decreased appetite, 11 arthralgia, 12 myalgia, 6 dizziness, 3 dysgeusia, 20 headache, 3 depression, 14 insomnia, 14 cough, 8 dyspnoea, 5 alopecia, 10 dry skin, 14 pruritus, 10 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 out of 56</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0107" title="BarnardR , HwangPMT , BhanjaS , CampbellH , StrizkiJ , CheneyC , et al. Resistance analysis of cirrhotic treatment‐experienced genotype 1 patients in a study of MK‐7009 in combination with pegylated interferon/ribavirin. Journal of Hepatology2013;58(Suppl S1):S487. ElbashaE , ElKhouryA , MobasheryN . Projected long‐term impact of MK‐7009 (vaniprevir) for previously treated chronic HCV genotype 1 infection. Hepatology International2013;7(1 Suppl):S354. GaoW , CaroL , AndersonM , HwangP , ZhouA , SuJ , et al. Vaniprevir (MK‐7009) demonstrates higher exposures in treatment‐experienced genotype (GT) 1 cirrhotic than non‐cirrhotic HCV‐infected patients. Hepatology2013;58(Suppl S1):739A. LawitzE , Rodriguez‐TorresM , StoehrA , GaneEJ , SerfatyL , BhanjaS , et al. A phase 2B study of MK‐7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment. Journal of Hepatology2013;59(1):11‐7. MobasheryN , WongP , ZhangS , BhanjaS , WarnerA , ShawPM , et al. Impact of IL28B genotype on virologic response in prior treatment failure patients who received MK‐7009 in combination with peginterferon and ribavirin. Journal of Hepatology2012;56(Suppl S2):S467. ">Lawitz 2013c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaniprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 anaemia, 34 neutropenia, 97 diarrhoea, 110 nausea, 59 vomiting, 50 asthenia, 16 chills, 92 fatigue, 54 influenza‐like illness, 24 irritability, 37 pyrexia, 40 decreased appetite, 37 arthralgia, 38 myalgia, 23 dizziness, 16 dysgeusia, 92 headache, 32 depression, 40 insomnia, 54 cough, 30 dyspnoea, 35 alopecia, 37 dry skin, 75 pruritus, 43 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225 out of 229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 anaemia, 3 neutropenia, 9 diarrhoea, 10 nausea, 3 vomiting, 11 asthenia, 1 chills, 18 fatigue, 12 influenza‐like illness, 8 irritability, 14 pyrexia, 5 decreased appetite, 11 arthralgia, 12 myalgia, 6 dizziness, 3 dysgeusia, 20 headache, 3 depression, 14 insomnia, 14 cough, 8 dyspnoea, 5 alopecia, 10 dry skin, 14 pruritus, 10 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 out of 56</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0034" title="CooperC , LawitzEJ , GhaliP , Rodriguez‐TorresM , AndersonFH , LeeSS , et al. Antiviral activity of the non‐nucleoside polymerase inhibitor, VCH‐759, in chronic hepatitis C patients: results from a randomized, double‐blind, placebo‐controlled, ascending multiple dose study. Hepatology2007;46(4 (Suppl 1)):864A. CooperC , LawitzEJ , GhaliP , Rodriguez‐TorresM , AndersonFH , LeeSS , et al. Evaluation of VCH‐759 monotherapy in hepatitis C infection. Journal of Hepatology2009;51(1):39‐46. ">Cooper 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VCH‐759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 diarrhoea, 3 nausea, 4 vomiting, 1 chills, 5 fatigue, 8 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 out of 23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 diarrhoea, 1 nausea, 2 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 out of 9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0112" title="LawitzE , FreilichB , LinkJ , GermanP , MoH , HanL , et al. A phase 1, randomized, dose‐ranging study of GS‐5816, a once‐daily NS5A inhibitor, in patients with genotype 1‐4 hepatitis C virus. Journal of Viral Hepatitis2015;22(12):1011‐9. [PUBMED: 26183611] LawitzE , GlassSJ , GruenerD , Freilich B. HillJM , LinkJO , et al. GS‐5816, a once‐daily NS5A inhibitor, demonstrates potent antiviral activity in patients with genotype 1, 2, 3, or 4 HCV infection in a 3‐day monotherapy study. Hepatology2013;58(Suppl S1):731A. ">Lawitz 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Velpatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 diarrhoea, 3 nausea, 4 vomiting, 6 headache, 2 cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 out of 70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 out of 17</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD012143-sec-0139"> <h5 class="title">Remaining outcomes</h5> <p>None of the included trials assessed the effects of DAAs on ascites; variceal bleeding; hepato‐renal syndrome; hepatic encephalopathy; liver transplantation; hepatocellular carcinoma; or histological improvement. </p> <p>Our main results on DAAs on the market or under development are summarised in <a href="./full#CD012143-tbl-0001">summary of findings Table for the main comparison</a>. Our main results on withdrawn DAAs are summarised in <a href="./full#CD012143-tbl-0002">summary of findings Table 2</a>. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012143-sec-0140" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012143-sec-0140"></div> <section id="CD012143-sec-0141"> <h3 class="title" id="CD012143-sec-0141">Summary of main results</h3> <p>We included 138 trials randomising a total of 25,232 participants. All trials and outcome results were at high risk of bias and we assessed the evidence for all outcomes as very low or low quality. There were limited data on most of our clinical outcomes, that is, we could only identify clinical trial data on all‐cause mortality and serious adverse events. Our primary results showed that when all DAAs on the market or under development were pooled in one analysis, DAAs did not seem to have any significant effects on the risk of serious adverse events. When meta‐analysed separately, simeprevir was the only DAA showing evidence of a lower risk of a serious adverse event compared with placebo. However, Trial Sequential Analysis showed that there was not enough information to confirm or reject our anticipated intervention effect. The outcome result had high risk of bias, and when one trial with an extreme result was excluded from the analysis then the meta‐analysis result showed no evidence of an effect. Withdrawn DAAs seemed to increase the risk of serious adverse events. There was not enough information to confirm or refute that DAAs have clinically relevant effects on other clinically relevant outcomes. Most of the included randomised clinical trials primarily focused on and assessed the effects of DAAs on sustained virological response. Our results confirm that DAAs seem to reduce the risk of no sustained virological response, but all the trial results were at high risk of bias. The clinical relevance of the results on sustained virological response has not been demonstrated from randomised evidence. Our main results are summarised in <a href="./full#CD012143-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> <section id="CD012143-sec-0142"> <h3 class="title" id="CD012143-sec-0142">Overall completeness and applicability of evidence</h3> <p>We searched for published and unpublished trials irrespective of publication type, publication status, publication date, and language. We also searched bibliographies of both Cochrane and non‐Cochrane reviews for any trials we missed. </p> <p>The funnel plot for SVR shows possible asymmetry arising from data missing from the bottom right of the distribution (<a href="#CD012143-fig-0007">Figure 7</a>). Although our analysis of SVR may be missing data from smaller trials (presumably showing smaller or no beneficial effects of DAAs) the impact of missing data on the results is negligible. The similar result obtained with a fixed‐effect model (RR 0.42) does not indicate that small study effects exaggerate results of the primary analysis. </p> <div class="figure" id="CD012143-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), outcome: 3.1 Without sustained virological response." data-id="CD012143-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), outcome: 3.1 Without sustained virological response. </p> </div> </div> </div> <p>Our primary analysis included all DAAs that are on the market or under development. We did not include withdrawn DAAs in the primary analysis because of the historical clinical relevance of assessing the effects of these DAAs. It might be that the different types of DAAs have different clinical effects, and we therefore also assessed each DAA separately. When analysing the effects of DAAs on risk of serious adverse events, tests for subgroup difference showed evidence of a difference, but when analysed separately, only simeprevir showed evidence of an effect. Nevertheless, the evidence of an effect depended on only one trial with an extreme result and the meta‐analysis result showed no evidence of a difference when this trial was excluded from the analysis. It might be that simeprevir has a beneficial effect on risk of serious adverse events but this effect needs to be shown in trials with low risk of bias in all domains. The remaining analyses showed that there was not enough information to confirm or refute that DAAs have beneficial or harmful effects on clinically relevant outcomes. </p> <p>Our analyses showed that most DAAs seem to decrease the risk of no sustained virological response but, as mentioned, this result is based on trials at high risk of bias and the clinical relevance of results on this non‐validated surrogate outcome is unknown. </p> </section> <section id="CD012143-sec-0143"> <h3 class="title" id="CD012143-sec-0143">Quality of the evidence</h3> <p>We have assessed the quality of the evidence for the results of three main outcomes (<a href="./full#CD012143-tbl-0001">summary of findings Table for the main comparison</a>). The GRADE assessments showed that the quality if the evidence was very low for mortality (due to risk of bias and imprecision) and serious adverse events (due to risk of bias and indirectness). Trial Sequential Analysis of serious adverse events showed that the boundary for futility was crossed. Hence, there is firm evidence that DAAs versus control do not reduce the risk of serious adverse events by 20% or more (<a href="#CD012143-fig-0003">Figure 3</a>). A post‐hoc Trial Sequential Analysis showed that the acquired information was large enough to rule out that DAAs versus control reduce the risk of serious adverse events by 15% or more. </p> <p>The quality of evidence for SVR was low due to risk of bias. We have reconsidered the issue of indirectness in relation to SVR and decided that indirectness is not applicable since we have not used it as a proxy for long‐term cure in the review. Accordingly, there is a high risk that future trials may overturn the results of this present review. Reasons for the GRADE assessments are given in the footnotes of the <a href="./full#CD012143-tbl-0001">summary of findings Table for the main comparison</a>. The boundary for benefit was crossed in the Trial Sequential Analysis of no sustained virological response showing that our analyses have sufficient sample size to indicate that DAAs reduce the risk of no sustained virological response. </p> </section> <section id="CD012143-sec-0144"> <h3 class="title" id="CD012143-sec-0144">Potential biases in the review process</h3> <section id="CD012143-sec-0145"> <h4 class="title">Strengths</h4> <p>We included trials regardless of publication type, publication status, language, and choice of outcomes. We contacted all relevant trial authors if additional information was needed. </p> <p>We used predefined up‐to‐date systematic review methodology and the methodology was not changed during the review process (<a href="./references#CD012143-bbs2-0323" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.Cochrane.org. ">Higgins 2011a</a>; <a href="./references#CD012143-bbs2-0328" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14(1):120. ">Jakobsen 2014a</a>). We used Trial Sequential Analyses and adjusted our thresholds for significance to control the risks of random errors (<a href="./references#CD012143-bbs2-0294" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>; <a href="./references#CD012143-bbs2-0328" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14(1):120. ">Jakobsen 2014a</a>), we thoroughly assessed the risks of bias of each trial to assess the risks of systematic errors ('bias') (<a href="./references#CD012143-bbs2-0324" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>; <a href="./references#CD012143-bbs2-0328" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14(1):120. ">Jakobsen 2014a</a>), and we used an eight‐step procedure to assess if the thresholds for statistical and clinical significance were crossed (<a href="./references#CD012143-bbs2-0328" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14(1):120. ">Jakobsen 2014a</a>). This adds further robustness to our results and conclusions. We also tested the robustness of our results with sensitivity analyses (best‐worst, worst‐best, etc.) (<a href="./references#CD012143-bbs2-0365" title="SterneJAC , EggerM , MoherD (editors) . Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Sterne 2011</a>; <a href="./references#CD012143-bbs2-0328" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14(1):120. ">Jakobsen 2014a</a>). </p> <p>We reported both aggregate as well as individual serious adverse events for all included trials reporting them. We also reported non‐serious adverse events for all trials reporting them. </p> </section> <section id="CD012143-sec-0146"> <h4 class="title">Limitations</h4> <p>Our systematic review has several limitations.</p> <p>Our bias risk assessment showed that all trials were at high risk of bias. It is, therefore, highly probable that our review results are also biased, that is, that there is a great risk that our results overestimate benefit and underestimate harms (<a href="./references#CD012143-bbs2-0328" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14(1):120. ">Jakobsen 2014a</a>; <a href="./references#CD012143-bbs2-0339" title="LundhA , SismondoS , LexchinJ , BusuiocOA , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2] ">Lundh 2012</a>; <a href="./references#CD012143-bbs2-0357" title="SavovićJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429‐38. ">Savović 2012a</a>; <a href="./references#CD012143-bbs2-0358" title="SavovićJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment2012;16(35):1‐82. ">Savović 2012b</a>). This is the primary limitation of our review. </p> <p>The Trial Sequential Analyses showed that, except for the primary analysis of the effects of DAAs on risk of serious adverse events, we did not have enough information to confirm or refute our anticipated clinical intervention effects. Not enough trials with a sufficient number of participants assessing clinically relevant outcomes have been conducted. It might be that limited statistical power has caused the multiple neutral meta‐analysis results and that DAAs do have beneficial or harmful effects. Furthermore, we planned multiple secondary analyses and a large number of subgroup analyses, which lead to an increased risk of type I errors (<a href="./references#CD012143-bbs2-0328" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14(1):120. ">Jakobsen 2014a</a>). Hence, the risk of random type I errors is large in this review. </p> <p>We included all types of DAAs (on the market or under development) in our primary analysis and the primary analysis of the results of the effects of DAAs on risk of serious adverse events showed that we had enough information to rule out a 20% relative risk reduction. It might be that different DAAs have different effects and that including certain DAAs in the analysis dilutes the beneficial or harmful effects of other DAAs. However, we found no signs of heterogeneity in our analyses, which indicates that all of the different DAAs seem to have no, or very limited, clinical effects on risk of serious adverse events. We chose primarily to focus on the overall pooled analysis of DAAs on the market or under development for two reasons: 1. a pooled analysis would have the largest statistical power as well as precision; and 2. it would be possible to compare the different DAAs in subgroup analysis if all types of DAA were included in this present review. </p> <p>Our review is flawed by the lack of proper assessments of serious adverse events in observational studies and our lack of assessment of non‐serious adverse events in randomised clinical trials as well as in observational studies. This gives our systematic review a significant tilt towards focusing on beneficial effects. We report the adverse events reported in the trials, but we decided post hoc to analyse the details on non‐serious adverse events (due to their large number and prevalence) in a future publication focusing on this. For future systematic reviews, there is also a need to assess serious as well as non‐serious adverse events reported in observational studies. </p> <p>A potential limitation is the use of the composite outcome 'serious adverse events'. It is obvious that according to the definition of this outcome (see <a href="#CD012143-sec-0048">Primary outcomes</a>) each component of this composite outcome will not necessarily have similar degrees of severity. This might bias the results of this outcome (<a href="./references#CD012143-bbs2-0304" title="GarattiniS , JakobsenJC , WetterslevJ , BerteleV , BanziR , RathA , et al. Evidence‐based clinical practice: overview of threats to the validity of evidence and how to minimise them. European Journal of Internal Medicine2016;32:13‐21. ">Garattini 2016</a>). For example, if certain more severe serious adverse events occur in one of the intervention groups and other less severe serious adverse events occur in the other intervention group, then there is a risk of overlooking actual severity differences between the compared groups when analysing this composite outcome (<a href="./references#CD012143-bbs2-0304" title="GarattiniS , JakobsenJC , WetterslevJ , BerteleV , BanziR , RathA , et al. Evidence‐based clinical practice: overview of threats to the validity of evidence and how to minimise them. European Journal of Internal Medicine2016;32:13‐21. ">Garattini 2016</a>). All‐cause mortality would be the optimal patient‐relevant outcome with the fewest methodological limitations (<a href="./references#CD012143-bbs2-0304" title="GarattiniS , JakobsenJC , WetterslevJ , BerteleV , BanziR , RathA , et al. Evidence‐based clinical practice: overview of threats to the validity of evidence and how to minimise them. European Journal of Internal Medicine2016;32:13‐21. ">Garattini 2016</a>). However, due to limited information sizes it is rare that conclusions can be drawn assessing all‐cause mortality and this is also the case in our present review. To obtain adequate statistical power it is often necessary to use composite outcomes; the potential limitations of using composite outcomes should always be considered when interpreting review results. </p> <p>We chose pragmatically to only assess outcomes at one assessment time point, that is, the trial's result as provided at maximum follow‐up. Most trials were only short‐term results. Hence, our results can neither confirm nor reject that DAAs have clinical long‐term effects, which is a further limitation of our present review results, especially because most of the harmful effects of hepatitis C take years to develop. </p> </section> </section> <section id="CD012143-sec-0147"> <h3 class="title" id="CD012143-sec-0147">Agreements and disagreements with other studies or reviews</h3> <p>We have identified multiple reviews assessing the effects of different DAAs for chronic HCV. Tehey primarily focus on the effects of DAAs on sustained virological response showing, like we do, that DAAs increased sustained virological response. The previous reviews generally concluded that they were ‘safe’ (except for the withdrawn first‐generation protease inhibitors). We summarise below the results of some of the identified reviews. </p> <p><a href="./references#CD012143-bbs2-0337" title="LangD , LiangHJ , LiD , WeiX , MaL , JiaZ . The efficacy and safety of telaprevir‐based regimens for treating chronic hepatitis C virus genotype 1 infection: a meta‐analysis of randomized trials. Internal Medicine2013;52(6):653‐60. ">Lang 2013</a> meta‐analysed the results of six randomised clinical trials involving a total of 2759 participants with chronic HCV genotype 1 infection. The results showed that the sustained virological response rate was significantly higher in the telaprevir‐based regimens group (withdrawn DAA) than in the control group (OR 3.81; 95% CI 2.43 to 5.96). The results also showed that the relapse rate was significantly lower in the telaprevir‐based regimens group than in the control group (RR 0.40; 95% CI 0.24 to 0.66). However, there was an increased risk of serious adverse events in the telaprevir‐based regimens group (RR 1.45; 95% CI 1.12 to 1.87). </p> <p><a href="./references#CD012143-bbs2-0281" title="BasileN . Sofosbuvir‐ribavirin duo for chronic hepatitis C. Connecticut Medicine2014;78(6):355‐6. ">Basile 2014</a> meta‐analysed the results of six trials involving 636 participants in the analyses. HCV genotype 1 participants had an overall 12‐week sustained virological response of 66% (95% CI 57% to 73%) after 12 weeks of treatment. The outcome was significantly better for treatment‐naive participants (70%) compared to treatment‐experienced (10%). However, for HCV Genotype 2 and 3, there were similar 12‐week sustained virological responses for both treatment‐naive and treatment‐experienced participants. The overall 12‐week sustained virological response after 12 weeks of treatment was 75% (95% CI 71% to 78%). </p> <p><a href="./references#CD012143-bbs2-0291" title="CocoB , CaraceniP , AghemoA , BitettoD , BrunoR , CiancioA , et al. Triple therapy with first‐generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF). Digestive and Liver Disease2014;46(1):18‐24. ">Coco 2014</a> concludes that the first‐generation protease inhibitors boceprevir (withdrawn DAA) and telaprevir (withdrawn DAA), administered with peg‐IFN and RBV, significantly improved the sustained virological response both in treatment‐naive and treatment‐experienced participants with chronic genotype 1 hepatitis C. Nevertheless, their use was offset by the high incidence of adverse reactions. </p> <p><a href="./references#CD012143-bbs2-0287" title="Childs‐KeanLM , HandEO . Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection. Clinical Therapeutics2015;37(2):243‐67. ">Childs‐Kean 2015</a> reviewed the effects of simeprevir and sofosbuvir. The review focused almost exclusively on results on sustained virological response. Simeprevir was studied with peg‐IFN and RBV in seven published phase 3 trials, with overall efficacy rates of 59% to 100% (sustained virological response). Sofosbuvir was studied with RBV and with or without peg‐IFN in six phase‐3 trials with overall efficacy rates of 50% to 93% (sustained virological response). Rates of serious adverse events and early discontinuation were low in all phase‐3 trials. The most common adverse events were fatigue, insomnia, diarrhoea, headache, and anaemia, and most were considered mild to moderate in severity. The authors concluded that sofosbuvir‐ and simeprevir‐containing regimens were highly effective in obtaining sustained virological response and appeared safe for the treatment of chronic hepatitis C infection. </p> <p>A narrative review presented an overview of the treatment of chronic HCV (<a href="./references#CD012143-bbs2-0299" title="ElbazT , Mohamed El‐KassasM , EsmatG . New era for management of chronic hepatitis C virus using direct antiviral agents: a review. Journal of Advanced Research2015;6(3):301–10. ">Elbaz 2015</a>). The authors concluded that an eradication of HCV seemed to be possible in the near future (<a href="./references#CD012143-bbs2-0299" title="ElbazT , Mohamed El‐KassasM , EsmatG . New era for management of chronic hepatitis C virus using direct antiviral agents: a review. Journal of Advanced Research2015;6(3):301–10. ">Elbaz 2015</a>). </p> <p>Another narrative review concluded that DAAs were well‐tolerated oral therapies with 'cure' rates of &gt; 90% in most patient populations (<a href="./references#CD012143-bbs2-0319" title="GötteM , FeldJJ . Direct‐acting antiviral agents for hepatitis C: structural and mechanistic insights. Nature Reviews. Gastroenterology &amp; Hepatology2016;13:338–51. ">Götte 2016</a>). The authors focused on results on sustained virologic response and on the structural and mechanistic insights of DAAs (<a href="./references#CD012143-bbs2-0319" title="GötteM , FeldJJ . Direct‐acting antiviral agents for hepatitis C: structural and mechanistic insights. Nature Reviews. Gastroenterology &amp; Hepatology2016;13:338–51. ">Götte 2016</a>). </p> <p><a href="./references#CD012143-bbs2-0293" title="ContiF , BuonfiglioliF , ScuteriA , CrespiC , BolondiL , CaraceniP , et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV‐related cirrhosis treated with direct‐acting antivirals. Journal of Hepatology2016;65(4):727‐33. ">Conti 2016</a> have recently shown in an observational study that the occurrence of liver cancer is not reduced in people who obtained sustained virological response after treatment with DAAs. In addition, people previously treated for HCC still have a high risk of tumour recurrence in the short term, despite DAA treatment (<a href="./references#CD012143-bbs2-0293" title="ContiF , BuonfiglioliF , ScuteriA , CrespiC , BolondiL , CaraceniP , et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV‐related cirrhosis treated with direct‐acting antivirals. Journal of Hepatology2016;65(4):727‐33. ">Conti 2016</a>). </p> <p>Several studies have shown that achieving sustained virologic response in hepatitis C seems to be associated with improved clinical outcomes (<a href="./references#CD012143-bbs2-0363" title="Smith‐PalmerJ , CerriK , ValentineW . Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infectious Diseases2015;15(19). ">Smith‐Palmer 2015</a>). However, as mentioned in <a href="#CD012143-sec-0031">Description of the condition</a> the results of these observational studies should be interpreted with caution. Several of these non‐randomised comparisons were between those who were treated and achieved a sustained virologic response and those who were treated but did not achieve a sustained virologic response; this study design has several major limitations with regard to making any inferences about causation. First of all, observational studies will always have confounding factors. Secondly, the two subgroups had different prognoses with regard to their baseline characteristics (since patients who develop sustained virologic response have characteristics that would predict that they are less likely to progress, such as limited fibrosis, lack of obesity, favourable IL B28 genotype, female sex, lack of HIV/alcohol, etc). Lastly, it is incorrect to attribute these different outcomes to treatment because all of the patients were treated. Comparison between those who achieved sustained virologic response and those never treated is confounded by the reason for the participants to have been, or not have been treated, and then further confounded by the problem with the differences in baseline characteristics </p> <p>Our present review results confirm that DAAs seem to work on sustained virological response. Our present review results add to the previous findings that there are still limited data on the clinical effects of DAAs and that there seem to be no significant effects of DAAs on the risk of serious adverse events. We had too few data to assess the effects of DAAs on all‐cause mortality. It must be noted that we, in this present review, have assessed the effects of DAAs on ‘serious adverse events’, and in our definition, adverse events are included in our analyses regardless of a possible causal link with the DAA. When an adverse event was ‘serious’ then we included it. Even though most of our results were short‐term results, we were not able to demonstrate the presence of major clinically beneficial or harmful effects of DAAs in people with chronic hepatitis C. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012143-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD012143-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/full#CD012143-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD012143-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/full#CD012143-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of the effects of direct‐acting antivirals on the market or under development versus placebo or no intervention on risk of serious adverse events. The analysis was based on a proportion in the control group (Pc) of 4.5%, a relative risk reduction (RRR) of 20%, and alfa of 2.5%, a beta of 20%, and a diversity of 0%. The cumulative Z‐curve enters the futility area after the randomisation of about 6000 participants." data-id="CD012143-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Trial Sequential Analysis of the effects of direct‐acting antivirals on the market or under development versus placebo or no intervention on risk of serious adverse events. The analysis was based on a proportion in the control group (Pc) of 4.5%, a relative risk reduction (RRR) of 20%, and alfa of 2.5%, a beta of 20%, and a diversity of 0%. The cumulative Z‐curve enters the futility area after the randomisation of about 6000 participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/full#CD012143-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of the effects of simeprevir versus placebo or no intervention on risk of serious adverse events. The analysis was based on a proportion in the control group (Pc) of 8.4%, a relative risk reduction (RRR) of 20%, and alfa of 2.5%, a beta of 20%, and a diversity of 0%. The cumulative Z‐curve crosses the naive type I error level of 5%, but it does not cross the trial monitoring boundary for benefit." data-id="CD012143-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Trial Sequential Analysis of the effects of simeprevir versus placebo or no intervention on risk of serious adverse events. The analysis was based on a proportion in the control group (Pc) of 8.4%, a relative risk reduction (RRR) of 20%, and alfa of 2.5%, a beta of 20%, and a diversity of 0%. The cumulative Z‐curve crosses the naive type I error level of 5%, but it does not cross the trial monitoring boundary for benefit. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/full#CD012143-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of the effects of direct‐acting antivirals on the market or under development versus placebo or no intervention on risk of no sustained virological response. The analysis was based on a proportion in the control group (Pc) of 60.2%, a RRR of 20%, and alfa of 2.5%, a beta of 20%, and a diversity of 83%. After randomisation of about 1000 participants, the cumulative Z‐curve crosses the trial sequential monitoring boundary for benefit." data-id="CD012143-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Trial Sequential Analysis of the effects of direct‐acting antivirals on the market or under development versus placebo or no intervention on risk of no sustained virological response. The analysis was based on a proportion in the control group (Pc) of 60.2%, a RRR of 20%, and alfa of 2.5%, a beta of 20%, and a diversity of 83%. After randomisation of about 1000 participants, the cumulative Z‐curve crosses the trial sequential monitoring boundary for benefit. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/full#CD012143-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of the effects of withdrawn direct‐acting antivirals versus placebo or no intervention on risk of serious adverse events. The analysis was based on a proportion in the control group (Pc) of 7.5%, a RRR of 20%, and alfa of 2.5%, a beta of 20%, and a diversity of 0%. After randomisation of about 5000 participants, the cumulative Z‐curve crosses the trial sequential monitoring boundary for harm." data-id="CD012143-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Trial Sequential Analysis of the effects of withdrawn direct‐acting antivirals versus placebo or no intervention on risk of serious adverse events. The analysis was based on a proportion in the control group (Pc) of 7.5%, a RRR of 20%, and alfa of 2.5%, a beta of 20%, and a diversity of 0%. After randomisation of about 5000 participants, the cumulative Z‐curve crosses the trial sequential monitoring boundary for harm. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/full#CD012143-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), outcome: 3.1 Without sustained virological response." data-id="CD012143-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Funnel plot of comparison: 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), outcome: 3.1 Without sustained virological response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/full#CD012143-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 1 Hepatitis C‐related morbidity or all‐cause mortality." data-id="CD012143-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 1 Hepatitis C‐related morbidity or all‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 2 Hepatitis C‐related morbidity or all‐cause mortality ‐ bias risk." data-id="CD012143-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 2 Hepatitis C‐related morbidity or all‐cause mortality ‐ bias risk. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 3 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to type of DAA." data-id="CD012143-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 3 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to type of DAA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 4 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to group of DAA." data-id="CD012143-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 4 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to group of DAA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 5 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to HIV‐infection." data-id="CD012143-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 5 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to HIV‐infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 6 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to comorbidity." data-id="CD012143-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 6 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to comorbidity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 7 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to viral genotype." data-id="CD012143-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 7 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to viral genotype. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 8 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to human genotype (IL28b)." data-id="CD012143-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 8 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to human genotype (IL28b). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 9 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to Asian‐region." data-id="CD012143-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 9 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to Asian‐region. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 10 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to specific ethnicities." data-id="CD012143-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 10 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to specific ethnicities. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 11 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to reaching planned sample size." data-id="CD012143-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 11 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to reaching planned sample size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 12 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to prior treatment." data-id="CD012143-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 12 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to prior treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 13 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to interferon." data-id="CD012143-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 13 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to interferon. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 14 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to ribavirin." data-id="CD012143-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 14 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to ribavirin. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 15 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to chronic kidney disease." data-id="CD012143-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 15 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to chronic kidney disease. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 16 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to cryoglobulinaemia." data-id="CD012143-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 16 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to cryoglobulinaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 17 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to DAA group as co‐intervention." data-id="CD012143-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 17 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to DAA group as co‐intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 18 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to median dose." data-id="CD012143-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses), Outcome 18 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to median dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 1 Serious adverse events." data-id="CD012143-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 1 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 2 Serious adverse events ‐ bias risk." data-id="CD012143-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 2 Serious adverse events ‐ bias risk. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 3 Serious adverse events ‐ according to type of DAA." data-id="CD012143-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 3 Serious adverse events ‐ according to type of DAA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 4 Serious adverse events ‐ according to group of DAA." data-id="CD012143-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 4 Serious adverse events ‐ according to group of DAA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 5 Serious adverse events ‐ according to HIV‐infection." data-id="CD012143-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 5 Serious adverse events ‐ according to HIV‐infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 6 Serious adverse events ‐ according to comorbidity." data-id="CD012143-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 6 Serious adverse events ‐ according to comorbidity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 7 Serious adverse events ‐ according to viral genotype." data-id="CD012143-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 7 Serious adverse events ‐ according to viral genotype. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 8 Serious adverse events ‐ according to human genotype (IL28b)." data-id="CD012143-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 8 Serious adverse events ‐ according to human genotype (IL28b). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 9 Serious adverse events ‐ according to Asian‐region." data-id="CD012143-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 9 Serious adverse events ‐ according to Asian‐region. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 10 Serious adverse events ‐ according to specific ethnicities." data-id="CD012143-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 10 Serious adverse events ‐ according to specific ethnicities. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 11 Serious adverse events ‐ according to reaching planned sample size." data-id="CD012143-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 11 Serious adverse events ‐ according to reaching planned sample size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 12 Serious adverse events ‐ according to prior treatment." data-id="CD012143-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 12 Serious adverse events ‐ according to prior treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 13 Serious adverse events ‐ according to interferon." data-id="CD012143-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 13 Serious adverse events ‐ according to interferon. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 14 Serious adverse events ‐ according to ribavirin." data-id="CD012143-fig-0039" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 14 Serious adverse events ‐ according to ribavirin. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 15 Serious adverse events ‐ according to chronic kidney disease." data-id="CD012143-fig-0040" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 15 Serious adverse events ‐ according to chronic kidney disease. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 16 Serious adverse events ‐ according to cryoglobulinaemia." data-id="CD012143-fig-0041" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 16 Serious adverse events ‐ according to cryoglobulinaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-002-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-002-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 17 Serious adverse events ‐ according to DAA group as co‐intervention." data-id="CD012143-fig-0042" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 17 Serious adverse events ‐ according to DAA group as co‐intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-002-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-002-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 18 Serious adverse events ‐ according to median dose." data-id="CD012143-fig-0043" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2 DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses), Outcome 18 Serious adverse events ‐ according to median dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-002-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-003-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 1 Without sustained virological response." data-id="CD012143-fig-0044" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 1 Without sustained virological response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 2 Without sustained virological response ‐ bias risk." data-id="CD012143-fig-0045" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 2 Without sustained virological response ‐ bias risk. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 3 Without sustained virological response ‐ according to type of DAA." data-id="CD012143-fig-0046" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 3 Without sustained virological response ‐ according to type of DAA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 4 Without sustained virological response ‐ according to group of DAA." data-id="CD012143-fig-0047" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 4 Without sustained virological response ‐ according to group of DAA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 5 Without sustained virological response ‐ according to HIV‐infection." data-id="CD012143-fig-0048" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 5 Without sustained virological response ‐ according to HIV‐infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 6 Without sustained virological response ‐ according to comorbidity." data-id="CD012143-fig-0049" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 6 Without sustained virological response ‐ according to comorbidity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 7 Without sustained virological response ‐ according to viral genotype." data-id="CD012143-fig-0050" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 7 Without sustained virological response ‐ according to viral genotype. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 8 Without sustained virological response ‐ according to human genotype (IL28b)." data-id="CD012143-fig-0051" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 8 Without sustained virological response ‐ according to human genotype (IL28b). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 9 Without sustained virological response ‐ according to Asian‐region." data-id="CD012143-fig-0052" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 9 Without sustained virological response ‐ according to Asian‐region. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 10 Without sustained virological response ‐ according to specific ethnicities." data-id="CD012143-fig-0053" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 10 Without sustained virological response ‐ according to specific ethnicities. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 11 Without sustained virological response ‐ according to reaching planned sample size." data-id="CD012143-fig-0054" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 11 Without sustained virological response ‐ according to reaching planned sample size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 12 Without sustained virological response ‐ according to prior treatment." data-id="CD012143-fig-0055" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 12 Without sustained virological response ‐ according to prior treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-003-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-003-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 13 Without sustained virological response ‐ according to interferon." data-id="CD012143-fig-0056" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 13 Without sustained virological response ‐ according to interferon. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-003-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-003-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 14 Without sustained virological response ‐ according to ribavirin." data-id="CD012143-fig-0057" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 14 Without sustained virological response ‐ according to ribavirin. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-003-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-003-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 15 Without sustained virological response ‐ according to chronic kidney disease." data-id="CD012143-fig-0058" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 15 Without sustained virological response ‐ according to chronic kidney disease. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-003-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-003-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 16 Without sustained virological response ‐ according to cryoglobulinaemia." data-id="CD012143-fig-0059" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.16</div> <div class="figure-caption"> <p>Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 16 Without sustained virological response ‐ according to cryoglobulinaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-003-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-003-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 17 Without sustained virological response ‐ according to DAA group as co‐intervention." data-id="CD012143-fig-0060" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.17</div> <div class="figure-caption"> <p>Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 17 Without sustained virological response ‐ according to DAA group as co‐intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-003-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-003-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 18 Without sustained virological response ‐ 'Best‐worst case' scenario." data-id="CD012143-fig-0061" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.18</div> <div class="figure-caption"> <p>Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 18 Without sustained virological response ‐ 'Best‐worst case' scenario. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-003-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-003-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 19 Without sustained virological response ‐ 'Worst‐best case' scenario." data-id="CD012143-fig-0062" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.19</div> <div class="figure-caption"> <p>Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 19 Without sustained virological response ‐ 'Worst‐best case' scenario. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-003-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-003-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 20 Without sustained virological response ‐ according to median dose." data-id="CD012143-fig-0063" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.20</div> <div class="figure-caption"> <p>Comparison 3 DAA on or on the way to the market versus placebo/no intervention (sustained virological response), Outcome 20 Without sustained virological response ‐ according to median dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-003-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Danoprevir versus placebo/no intervention, Outcome 1 Hepatitis C‐related morbidity or all‐cause mortality." data-id="CD012143-fig-0064" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Danoprevir versus placebo/no intervention, Outcome 1 Hepatitis C‐related morbidity or all‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Danoprevir versus placebo/no intervention, Outcome 2 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to dose." data-id="CD012143-fig-0065" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Danoprevir versus placebo/no intervention, Outcome 2 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Danoprevir versus placebo/no intervention, Outcome 3 Serious adverse events." data-id="CD012143-fig-0066" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Danoprevir versus placebo/no intervention, Outcome 3 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Danoprevir versus placebo/no intervention, Outcome 4 Serious adverse events ‐ according to median dose." data-id="CD012143-fig-0067" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Danoprevir versus placebo/no intervention, Outcome 4 Serious adverse events ‐ according to median dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Danoprevir versus placebo/no intervention, Outcome 5 Without sustained virological response." data-id="CD012143-fig-0068" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Danoprevir versus placebo/no intervention, Outcome 5 Without sustained virological response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Danoprevir versus placebo/no intervention, Outcome 6 Without sustained virological response ‐ according to median dose." data-id="CD012143-fig-0069" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Danoprevir versus placebo/no intervention, Outcome 6 Without sustained virological response ‐ according to median dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 All DAA versus placebo/no intervention/other medical intervention (morbidity or all‐cause mortality analyses), Outcome 1 Hepatitis C‐related morbidity or all‐cause mortality." data-id="CD012143-fig-0070" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 All DAA versus placebo/no intervention/other medical intervention (morbidity or all‐cause mortality analyses), Outcome 1 Hepatitis C‐related morbidity or all‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 All DAA versus placebo/no intervention/other medical intervention (serious adverse events analyses), Outcome 1 Serious adverse events." data-id="CD012143-fig-0071" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 All DAA versus placebo/no intervention/other medical intervention (serious adverse events analyses), Outcome 1 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 All DAA versus placebo/no intervention/other medical intervention (serious adverse events analyses), Outcome 2 Serious adverse events ‐ bias risk." data-id="CD012143-fig-0072" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 All DAA versus placebo/no intervention/other medical intervention (serious adverse events analyses), Outcome 2 Serious adverse events ‐ bias risk. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 All DAA versus placebo/no intervention/other medical intervention (serious adverse events analyses), Outcome 3 Serious adverse events ‐ according to type of DAA." data-id="CD012143-fig-0073" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 All DAA versus placebo/no intervention/other medical intervention (serious adverse events analyses), Outcome 3 Serious adverse events ‐ according to type of DAA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 All DAA versus placebo/no intervention/other medical intervention (serious adverse events analyses), Outcome 4 Serious adverse events ‐ according to group of DAA." data-id="CD012143-fig-0074" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 All DAA versus placebo/no intervention/other medical intervention (serious adverse events analyses), Outcome 4 Serious adverse events ‐ according to group of DAA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 All DAA versus placebo/no intervention/other medical intervention (serious adverse events analyses), Outcome 5 Serious adverse events ‐ according to HIV‐infection." data-id="CD012143-fig-0075" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 All DAA versus placebo/no intervention/other medical intervention (serious adverse events analyses), Outcome 5 Serious adverse events ‐ according to HIV‐infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 All DAA versus placebo/no intervention/other medical intervention (serious adverse events analyses), Outcome 6 Serious adverse events ‐ according to comorbidity." data-id="CD012143-fig-0076" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 All DAA versus placebo/no intervention/other medical intervention (serious adverse events analyses), Outcome 6 Serious adverse events ‐ according to comorbidity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-006-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-006-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 All DAA versus placebo/no intervention/other medical intervention (serious adverse events analyses), Outcome 7 Serious adverse events ‐ according to viral genotype." data-id="CD012143-fig-0077" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-006-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 All DAA versus placebo/no intervention/other medical intervention (serious adverse events analyses), Outcome 7 Serious adverse events ‐ according to viral genotype. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-006-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-006-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-006-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 All DAA versus placebo/no intervention/other medical intervention (serious adverse events analyses), Outcome 8 Serious adverse events ‐ according to human genotype (IL28b)." data-id="CD012143-fig-0078" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-006-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6 All DAA versus placebo/no intervention/other medical intervention (serious adverse events analyses), Outcome 8 Serious adverse events ‐ according to human genotype (IL28b). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-006-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-006-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-006-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 All DAA versus placebo/no intervention/other medical intervention (serious adverse events analyses), Outcome 9 Serious adverse events ‐ according to Asian‐region." data-id="CD012143-fig-0079" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-006-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6 All DAA versus placebo/no intervention/other medical intervention (serious adverse events analyses), Outcome 9 Serious adverse events ‐ according to Asian‐region. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-006-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-006-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-006-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 All DAA versus placebo/no intervention/other medical intervention (serious adverse events analyses), Outcome 10 Serious adverse events ‐ according to specific ethnicities." data-id="CD012143-fig-0080" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-006-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.10</div> <div class="figure-caption"> <p>Comparison 6 All DAA versus placebo/no intervention/other medical intervention (serious adverse events analyses), Outcome 10 Serious adverse events ‐ according to specific ethnicities. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-006-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-006-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-006-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 All DAA versus placebo/no intervention/other medical intervention (serious adverse events analyses), Outcome 12 Serious adverse events ‐ according to prior treatment." data-id="CD012143-fig-0081" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-006-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.12</div> <div class="figure-caption"> <p>Comparison 6 All DAA versus placebo/no intervention/other medical intervention (serious adverse events analyses), Outcome 12 Serious adverse events ‐ according to prior treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-006-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-006-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-006-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 All DAA versus placebo/no intervention/other medical intervention (serious adverse events analyses), Outcome 13 Serious adverse events ‐ according to interferon." data-id="CD012143-fig-0082" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-006-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.13</div> <div class="figure-caption"> <p>Comparison 6 All DAA versus placebo/no intervention/other medical intervention (serious adverse events analyses), Outcome 13 Serious adverse events ‐ according to interferon. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-006-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-006-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-006-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 All DAA versus placebo/no intervention/other medical intervention (serious adverse events analyses), Outcome 14 Serious adverse events ‐ according to ribavirin." data-id="CD012143-fig-0083" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-006-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.14</div> <div class="figure-caption"> <p>Comparison 6 All DAA versus placebo/no intervention/other medical intervention (serious adverse events analyses), Outcome 14 Serious adverse events ‐ according to ribavirin. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-006-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-006-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-006-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 All DAA versus placebo/no intervention/other medical intervention (serious adverse events analyses), Outcome 15 Serious adverse events ‐ according to chronic kidney disease." data-id="CD012143-fig-0084" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-006-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.15</div> <div class="figure-caption"> <p>Comparison 6 All DAA versus placebo/no intervention/other medical intervention (serious adverse events analyses), Outcome 15 Serious adverse events ‐ according to chronic kidney disease. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-006-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-006-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-006-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 All DAA versus placebo/no intervention/other medical intervention (serious adverse events analyses), Outcome 16 Serious adverse events ‐ according to cryoglobulinaemia." data-id="CD012143-fig-0085" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-006-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.16</div> <div class="figure-caption"> <p>Comparison 6 All DAA versus placebo/no intervention/other medical intervention (serious adverse events analyses), Outcome 16 Serious adverse events ‐ according to cryoglobulinaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-006-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-006-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-006-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 All DAA versus placebo/no intervention/other medical intervention (serious adverse events analyses), Outcome 17 Serious adverse events ‐ according to DAA group as co‐intervention." data-id="CD012143-fig-0086" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-006-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.17</div> <div class="figure-caption"> <p>Comparison 6 All DAA versus placebo/no intervention/other medical intervention (serious adverse events analyses), Outcome 17 Serious adverse events ‐ according to DAA group as co‐intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-006-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 All DAA versus placebo/no intervention/other medical intervention (sustained virological response analyses), Outcome 1 Without sustained virological response." data-id="CD012143-fig-0087" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 All DAA versus placebo/no intervention/other medical intervention (sustained virological response analyses), Outcome 1 Without sustained virological response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 All DAA versus placebo/no intervention/other medical intervention (quality of life scores), Outcome 1 SF‐36 physical score." data-id="CD012143-fig-0088" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 All DAA versus placebo/no intervention/other medical intervention (quality of life scores), Outcome 1 SF‐36 physical score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 All DAA versus placebo/no intervention/other medical intervention (quality of life scores), Outcome 2 SF‐36 mental score." data-id="CD012143-fig-0089" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 All DAA versus placebo/no intervention/other medical intervention (quality of life scores), Outcome 2 SF‐36 mental score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Daclatasvir versus placebo/no intervention, Outcome 1 Hepatitis C‐related morbidity or all‐cause mortality." data-id="CD012143-fig-0090" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Daclatasvir versus placebo/no intervention, Outcome 1 Hepatitis C‐related morbidity or all‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Daclatasvir versus placebo/no intervention, Outcome 2 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to dose." data-id="CD012143-fig-0091" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 Daclatasvir versus placebo/no intervention, Outcome 2 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-009-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-009-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Daclatasvir versus placebo/no intervention, Outcome 3 Serious adverse events." data-id="CD012143-fig-0092" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-009-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9 Daclatasvir versus placebo/no intervention, Outcome 3 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-009-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-009-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-009-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Daclatasvir versus placebo/no intervention, Outcome 4 Serious adverse events ‐ according to median dose." data-id="CD012143-fig-0093" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-009-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9 Daclatasvir versus placebo/no intervention, Outcome 4 Serious adverse events ‐ according to median dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-009-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-009-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-009-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Daclatasvir versus placebo/no intervention, Outcome 5 Without sustained virological response." data-id="CD012143-fig-0094" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-009-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.5</div> <div class="figure-caption"> <p>Comparison 9 Daclatasvir versus placebo/no intervention, Outcome 5 Without sustained virological response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-009-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-009-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-009-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Daclatasvir versus placebo/no intervention, Outcome 6 Without sustained virological response ‐ according to median dose." data-id="CD012143-fig-0095" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-009-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.6</div> <div class="figure-caption"> <p>Comparison 9 Daclatasvir versus placebo/no intervention, Outcome 6 Without sustained virological response ‐ according to median dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-009-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Simeprevir versus placebo/no intervention, Outcome 1 Hepatitis C‐related morbidity or all‐cause mortality." data-id="CD012143-fig-0096" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Simeprevir versus placebo/no intervention, Outcome 1 Hepatitis C‐related morbidity or all‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-010-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-010-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Simeprevir versus placebo/no intervention, Outcome 2 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to dose." data-id="CD012143-fig-0097" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-010-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 Simeprevir versus placebo/no intervention, Outcome 2 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-010-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-010-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-010-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Simeprevir versus placebo/no intervention, Outcome 3 Serious adverse events." data-id="CD012143-fig-0098" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-010-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10 Simeprevir versus placebo/no intervention, Outcome 3 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-010-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-010-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-010-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Simeprevir versus placebo/no intervention, Outcome 4 Serious adverse events ‐ according to median dose." data-id="CD012143-fig-0099" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-010-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10 Simeprevir versus placebo/no intervention, Outcome 4 Serious adverse events ‐ according to median dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-010-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-010-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-010-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Simeprevir versus placebo/no intervention, Outcome 5 Without sustained virological response." data-id="CD012143-fig-0100" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-010-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.5</div> <div class="figure-caption"> <p>Comparison 10 Simeprevir versus placebo/no intervention, Outcome 5 Without sustained virological response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-010-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-010-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-010-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Simeprevir versus placebo/no intervention, Outcome 6 Without sustained virological response ‐ according to median dose." data-id="CD012143-fig-0101" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-010-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.6</div> <div class="figure-caption"> <p>Comparison 10 Simeprevir versus placebo/no intervention, Outcome 6 Without sustained virological response ‐ according to median dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-010-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-011-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-011-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Vaniprevir versus placebo/no intervention, Outcome 1 Hepatitis C‐related morbidity or all‐cause mortality." data-id="CD012143-fig-0102" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-011-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 Vaniprevir versus placebo/no intervention, Outcome 1 Hepatitis C‐related morbidity or all‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-011-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-011-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-011-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Vaniprevir versus placebo/no intervention, Outcome 2 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to dose." data-id="CD012143-fig-0103" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-011-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11 Vaniprevir versus placebo/no intervention, Outcome 2 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-011-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-011-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-011-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Vaniprevir versus placebo/no intervention, Outcome 3 Serious adverse events." data-id="CD012143-fig-0104" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-011-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11 Vaniprevir versus placebo/no intervention, Outcome 3 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-011-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-011-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-011-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Vaniprevir versus placebo/no intervention, Outcome 4 Serious adverse events ‐ according to median dose." data-id="CD012143-fig-0105" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-011-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.4</div> <div class="figure-caption"> <p>Comparison 11 Vaniprevir versus placebo/no intervention, Outcome 4 Serious adverse events ‐ according to median dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-011-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-011-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-011-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Vaniprevir versus placebo/no intervention, Outcome 5 Without sustained virological response." data-id="CD012143-fig-0106" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-011-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.5</div> <div class="figure-caption"> <p>Comparison 11 Vaniprevir versus placebo/no intervention, Outcome 5 Without sustained virological response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-011-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-011-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-011-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Vaniprevir versus placebo/no intervention, Outcome 6 Without sustained virological response ‐ according to median dose." data-id="CD012143-fig-0107" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-011-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.6</div> <div class="figure-caption"> <p>Comparison 11 Vaniprevir versus placebo/no intervention, Outcome 6 Without sustained virological response ‐ according to median dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-011-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-012-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-012-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 All DAA versus placebo/no intervention, Outcome 1 Without significant reductions in ALT/AST serum levels." data-id="CD012143-fig-0108" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-012-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12 All DAA versus placebo/no intervention, Outcome 1 Without significant reductions in ALT/AST serum levels. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-012-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-012-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-012-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 All DAA versus placebo/no intervention, Outcome 2 Without significant reductions in ALT/AST serum levels ‐ according to DAA status." data-id="CD012143-fig-0109" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-012-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12 All DAA versus placebo/no intervention, Outcome 2 Without significant reductions in ALT/AST serum levels ‐ according to DAA status. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-012-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012143-fig-0110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/urn:x-wiley:14651858:media:CD012143:CD012143-CMP-012-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_t/tCD012143-CMP-012-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 All DAA versus placebo/no intervention, Outcome 3 Without significant reductions in ALT/AST serum levels ‐ according to type of drug." data-id="CD012143-fig-0110" src="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-012-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12 All DAA versus placebo/no intervention, Outcome 3 Without significant reductions in ALT/AST serum levels ‐ according to type of drug. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-fig-0110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/media/CDSR/CD012143/image_n/nCD012143-CMP-012-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012143-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Direct‐acting antivirals versus control</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Direct‐acting antivirals versus control</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with chronic hepatitis C<br/> <b>Setting:</b> any setting<br/> <b>Intervention:</b> direct‐acting antivirals on the market or under development<br/> <b>Comparison:</b> placebo or no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> <p><b>(TSA‐adjusted CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or no intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with direct‐acting antivirals</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality at maximum follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000<br/> (1 to 42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 3.72<br/> (0.53 to 26.18) </p> <p>(‐)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2996<br/> (11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It was not possible to perform Trial Sequential Analysis because of limited data and too few events </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of participants with one or more serious adverse event at maximum follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 per 1000<br/> (49 to 55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.93<br/> (0.75 to 1.15) </p> <p>(TSA CI 0.71 to 1.33)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15,817<br/> (43 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial Sequential Analysis showed that the boundary for futility was crossed. This leads us to conclude that any possible intervention effect, if any, is less than 20% </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of participants with no sustained virological response at maximum follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>541 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>238 per 1000<br/> (200 to 281) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.44<br/> (0.37 to 0.52) </p> <p>(TSA CI 0.42 to 0.55)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6886<br/> (32 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial Sequential Analysis showed that the boundary for benefit was crossed. This indicates that DAAs seem to decrease the risk of no sustained virological response by at least 20% if risk of bias and other threats to the validity can be disregarded </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the observed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>DAA</b> : direct‐acting antivirals; <b>OR:</b> odds ratio; <b>RCTs</b> : randomised clinical trials; <b>RR:</b> risk ratio; <b>TSA</b>: Trial Sequential Analysis </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded two levels because of very serious risk of bias in the included trials (see <a href="./full#CD012143-fig-0001">Figure 1</a>) and two levels due to very serious imprecision (none of the TSA boundaries are crossed, so the information size is too low).<br/> <sup>2</sup>Downgraded two levels due to very serious risk of bias in the included trials (see <a href="./full#CD012143-fig-0001">Figure 1</a>) and one level due to serious indirectness (the components of this composite outcome consisted of events with very different degrees of severity, which limits the interpretability of this outcome result).<br/> <sup>3</sup>Downgraded two levels because of very serious risk of bias in the included trials (<a href="./full#CD012143-fig-0001">Figure 1</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Direct‐acting antivirals versus control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/full#CD012143-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012143-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Direct‐acting antivirals withdrawn from the market versus control</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Direct‐acting antivirals withdrawn from the market versus control</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with chronic hepatitis C<br/> <b>Setting:</b> any setting<br/> <b>Intervention:</b> direct‐acting antivirals withdrawn from the market<br/> <b>Comparison:</b> placebo or no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> <p><b>(TSA‐adjusted CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or no intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with direct‐acting antivirals</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality</p> <p>at maximum follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000<br/> (2 to 12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.64<br/> (0.23 to 1.79) </p> <p>(‐)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3045<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It was not possible to perform Trial Sequential Analysis because of limited data and too few events </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of participants with one or more serious adverse event at maximum follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>75 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>108 per 1000<br/> (91 to 129) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.45<br/> (1.22 to 1.73) </p> <p>(TSA 1.16 to 1.82)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9229<br/> (29 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial Sequential Analysis showed that the boundary for harm was crossed. This shows that there is firm evidence that withdrawn DAAs increase the risk of a serious adverse event by at least 20% </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of participants with no sustained virological response at maximum follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>586 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>356 per 1000<br/> (322 to 404) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.61 (0.55, 0.69)</p> <p>(TSA CI 0.42 to 0.55)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9075<br/> (21 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial Sequential Analysis not performed</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the observed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>DAA</b> : direct‐acting antivirals; <b>OR:</b> odds ratio; <b>RCTs</b> : randomised clinical trials; <b>RR:</b> risk ratio; <b>TSA</b>: Trial Sequential Analysis </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded two levels because of very serious risk of bias in the included trials (see <a href="./full#CD012143-fig-0001">Figure 1</a>) and two levels due to very serious imprecision (none of the TSA boundaries are crossed so the information size is too low).<br/> <sup>2</sup>Downgraded two levels because of very serious risk of bias in the included trials (see <a href="./full#CD012143-fig-0001">Figure 1</a>) and one level due to serious indirectness (the components of this composite outcome consisted of events with very different degrees of severity which limits the interpretability of this outcome result).<br/> <sup>3</sup>Downgraded two levels because of very serious risk of bias in the included trials (<a href="./full#CD012143-fig-0001">Figure 1</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Direct‐acting antivirals withdrawn from the market versus control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/full#CD012143-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012143-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">List of direct‐acting antivirals</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b> Direct‐acting antiviral agents (DAAs)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>NS3/NS4A inhibitors</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>NS5B inhibitors</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>NS5A inhibitors</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NPI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NNPI</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACH‐2684</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALS2200/VX135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ABT‐072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACH‐2928</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asunaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BILB1941</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Beclabuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Daclatasvir</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GS0938/PSI352938</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BI201127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elbasvir</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Celuprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GS6620</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dasabuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK2336805</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Danoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GS9851(PSI7851)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Deleobuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ledipasvir</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Faldaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IDX184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Filibuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MK‐8408</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grazoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INX189/BMS986094</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK2878175/GSK175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Odalasvir</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GS9256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mericitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IDX375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ombitasvir</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GS9857</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MK‐3682</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MK‐3281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PPI461</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IDX320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sofosbuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nesbuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ravidasvir</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Narlaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VX‐135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radalbuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Samatasvir</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paritaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Setrobuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Velpatasvir</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PHX1766</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tegobuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Simperevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TMC‐647055</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sovaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VCH‐759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VCH‐916</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vaniprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VX222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vedroprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>The table presents a list of 58 direct‐acting antiviral agents (DAAs). We have listed the DAAs according to the DAA class they belong to (see <a href="#CD012143-sec-0030">Background</a> section). When a DAA has not been assigned a generic or brand name, we have presented it with its experimental compound number prefix. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">List of direct‐acting antivirals</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/full#CD012143-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012143-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Serious adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Experimental intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Type and number of serious adverse events (experimental group)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Proportion of participants with a serious adverse event (experimental group)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Type and number of serious adverse events (control group)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Proportion of participants with a serious adverse event (control group)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0024" title="BronowickiJP , PolS , ThuluvathP , LarreyD , MartorellCT , RustgiVK , et al. Asunaprevir (ASV; BMS‐650032), an NS3 protease inhibitor, in combination with peginterferon and ribavirin in treatment‐naive patients with genotype 1 chronic hepatitis C infection. Journal of Hepatology2012;56(Suppl 2):S431‐2. BronowickiJP , PolS , ThuluvathPJ , LarreyD , MartorellCT , RustgiVK , et al. BMS‐650032, an NS3 inhibitor, in combination with peginterferon alpha‐2a and ribavirin in treatment‐naive subjects with genotype 1 chronic hepatitis C infection. Journal of Hepatology2011;54:S472. BronowickiJP , PolS , ThuluvathPJ , LarreyD , MartorellCT , RustgiVK , et al. Randomized study of asunaprevir plus pegylated interferon‐alpha and ribavirin for previously untreated genotype 1 chronic hepatitis C. Antiviral Therapy2013;18(7):885‐93. ">Bronowicki 2013a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asunaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 abdominal pain, 1 lung neoplasm malignant, 1 cytolytic hepatitis, and 2 unspecified events </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 out of 36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0027" title="BronowickiJ‐P , RatziuV , GadanoA , Thuluvath PaulJ , BessoneF , Martorell ClaudiaT , et al. Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C. Journal of Hepatology2014;61(6):1220‐7. BronowickiJP , PolS , ThuluvathP , LarreyD , MartorellCT , RustgiVK , et al. Asunaprevir (ASV; BMS‐650032), an NS3 protease inhibitor, in combination with peginterferon and ribavirin in treatment‐naive patients with genotype 1 chronic hepatitis C infection. Journal of Hepatology2012;56(Suppl 2):S431‐S2. BronowickiJP , RatziuV , GadanoA , ThuluvathPJ , BessoneF , MartorellCT , et al. Asunaprevir with peginterferon‐alfa and ribavirin in treatment‐naive patients with genotype‐1 or ‐4 chronic hepatitis C: SVR24 results from a randomized phase 2B study (AI447016). Journal of Hepatology2013;58:S571‐2. ">Bronowicki 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asunaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 deaths and 14 unspecified events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 out of 177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 unspecified events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 out of 61</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0130" title="NelsonDR , ZeuzemS , AndreoneP , FerenciP , HerringR , JensenDM , et al. Balapiravir plus peginterferon alfa‐2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. Annals of Hepatology2012;11(1):15‐31. ">Nelson 2012a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Balapiravir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Many events but only a few were specified: 3 deaths, 10 haematological, 10 infection, 8 eye disorders </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 out of 432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Many events but not all were specified: 2 infections, 1 death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 out of 72</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0201" title="McPheeF , FalkP , FracassoP , LemmJ , LiuM , KirkM , et al. Characterization of viral escape in HCV genotype 1‐infected patients treated with BMS‐791325 and pegylated interferon‐ALFA and ribavirin. Journal of Hepatology2012;56(Suppl S2):S473. TatumH , ThuluvathP , LawitzE , MartorellCT , DemiccoM , CohenS , et al. A phase 2A study of BMS‐791325, an NS5B polymerase inhibitor, with peginterferon alfa‐2A and ribavirin in treatment‐naive patients with genotype 1 chronic hepatitis C infection. Journal of Hepatology2012;56(Suppl S2):S460. TatumH , ThuluvathPJ , LawitzE , MartorellC , DemiccoM , CohenS , et al. A randomized, placebo‐controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1. Journal of Viral Hepatitis2015;22(8):658‐64. TatumHA , ThuluvathPJ , LawitzE , MartorellC , CohenSM , RustgiVK , et al. Safety and efficacy of BMS‐791325, a non‐nucleoside NS5B polymerase inhibitor, combined with peginterferon alfa‐2a and ribavirin in treatment‐naive patients infected with hepatitis C virus genotype 1. Hepatology2013;58(S1):759A‐60A. ">Tatum 2015a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Beclabuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 constipation, 1 febrile neutropenia, 1 leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 serotonin syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0016" title="BaconBR , BrunoS , SchiffER , KwoPY , ButiM , PediconeL , et al. Predictors of sustained virologic response (SVR) among poor interferon (IFN) responders when boceprevir (BOC) is added to peginterferon alfa‐2b/ribavirin (PR). Hepatology2011;54(S1):376A‐7A. BaconBR , GordonSC , LawitzE , MarcellinP , VierlingJM , ZeuzemS , et al. Boceprevir for previously treated chronic HCV genotype 1 infection. New England Journal of Medicine2011;364(13):1207‐17. BaconBR , GordonSC , LawitzE , MarcellinP , VierlingJM , ZeuzemS , et al. HCV RESPOND‐2 final results: high sustained virologic response among genotype 1 previous non‐responders and relapsers to peginterferon/ribavirin when re‐treated with boceprevir plus PEGINTRON (peginterferon alfa‐2b)/ribavirin. Hepatology2010;52(Suppl S1):430A. BarnardRJ , HoweJA , OgertRA , ZeuzemS , PoordadF , GordonSC , et al. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology2013;444(1‐2):329‐36. BognarFA , HuKQ , ThompsonS , PediconeL , WahlJ , LinSG . Boceprevir (BOC) plus peginterferon alfa‐2b/ ribavirin (PR) in the treatment of chronic hepatitis C virus genotype‐1 (HCV‐G1) infected Asian patients in the SPRINT‐1, SPRINT‐2 and RESPOND‐2 trials. Journal of Gastroenterology and Hepatology2012;27(Suppl 4):161. BrassC , BarnardRJO , HoweJA , OgertRA , RalstonR , BoparaiN , et al. Sustained virologic response and boceprevir resistance‐associated variants observed in patients infected with HCV genotpype Ia/Ib when treated with boceprevir plus peginterferon alfa‐2b/ribavirin. Journal of Hepatology2011;54(Suppl 1):S471‐2. BrunoS , VierlingJM , EstebanR , NybergLM , TannoH , AlbrechtJK , et al. Boceprevir in addition to standard of care enhanced SVR in hepatitis C virus (HCV) genotype‐1 with advanced fibrosis/cirrhosis: subgroup analysis of sprint‐2 and respond‐2 studies. Journal of Hepatology2011;54(Suppl 1):S4‐5. BrunoS , VierlingJM , EstebanR , NybergLM , TannoH , GoodmanZ , et al. Efficacy and safety of boceprevir plus peginterferon‐ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. Journal of Hepatology2013;58(3):479‐87. ChhatwalJ , FerranteSA , BrassC , ElKhouryAC , BurroughsM , BaconB , et al. Cost‐effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. Value in Health2013;16(6):973‐86. ChhatwalJ , FerranteSA , DasbachEJ , ElKhouryA , BurroughsM , BaconB , et al. Projecting the long‐term clinical impact of boceprevir in patients with chronic hepatitis C genotype‐1 who failed prior treatment with peginterferon/ribavirin. Journal of Hepatology2011;54:S164. ChhatwalJ , FerranteSA , DasbachEJ , KhouryA , BrassCA , BurroughsM , et al. Cost‐effectiveness of boceprevir use in patients with chronic hepatitis C genotype‐1 who failed prior treatment with peginterferon/ribavirin. Hepatology2011;54(4 (Suppl)):801A‐2A. ChhatwalJ , LundbergJ , FerranteS , ElKhourhyAC , OksanenA , ElbashaEH . Cost‐effectiveness of boceprevir in the treatment of chronic Hepatitis C genotype 1 in Sweden. Journal of Hepatology2012;56(Suppl 2):S386‐7. GordonSC , SulkowskiMS , JacobsonIM , VierlingJM , DavisGL , AfdhalNH , et al. Reasons for screen failure in 2 phase III studies of boceprevir with peginterferon/ribavirin in patients with chronic HCV genotype 1 infection (sprint‐2 and respond‐2). Hepatology2011;54(Suppl S1):848A‐9A. LenzO , FeveryB , VijgenL , VerbeeckJ , PeetersM , BeumontM , et al. TMC435 in combination with peginterferon alpha‐2A/ribavirin in treatment‐naïve patients infected with HCV genotype 1: virology analysis of the PILLAR study. Hepatology2011;54(4 (Suppl)):985A. MarcellinP , VierlingJM , AlricL , PirisiM , TranA , AlbrechtJK , et al. Efficacy among North American and European HCV genotype‐1 treatment‐naive and previous non‐responders and relapsers to peginterferon/ribavirin when treated with boceprevir plus peginterferon alfa‐2b/ribavirin. Journal of Hepatology2011;54(Suppl 1):S184. SulkowskiMS , BaconBR , GordonSC , LawitzE , MarcellinP , VierlingJM , et al. Boceprevir combined with peginterferon alfa‐2b/ribavirin for previous treatment failure patients with hepatitis C virus genotype 1: RESPOND‐2 final results. Journal of the International Association of Physicians in AIDS Care2011;10(3):198. ZeuzemS , VierlingJM , EstebanR , GibasAL , PolS , BoparaiN , et al. Predictors of sustained virologic response among genotype 1 previous non‐responders and relapsers to peginterferon/ribavirin when re‐treated with boceprevir plus peginterferon alfa‐2b/ribavirin. Journal of Hepatology2011;54(Suppl 1):S198‐9. ">Bacon 2011a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 anaemia, 1 angina pectoris, 1 atrial fibrillation, 1 coronary artery disease, 1 myocardial infarction, 1 myopericarditis, 2 abdominal pain, 1 constipation, 1 diarrhoea, 1 gastritis, 1 irritable bowel syndrome, 1 oesophageal varices haemorrhage, 1 pancreatitis acute, 1 pancreatitis necrotising, 1 peptic ulcer, 1 asthenia, 3 chest pain, 1 oedema peripheral, 1 pyrexia, 1 cholecystitis, 3 appendicitis, 1 bronchopneumonia, 1 catheter site infection, 1 gastroenteritis viral, 1 pneumonia, 1 lower limb fracture, 1 overdose, 1 decreased appetite, 1 dehydration, 1 hyperglycaemia, 1 back pain, 2 intervertebral disc protrusion, 1 pain in extremity, 1 hepatic neoplasm malignant, 1 hepatic encephalopathy, 1 sciatica, 1 syncope, 1 bipolar disorder, 1 completed suicide, 4 depression, 2 homicidal ideation, 5 suicidal ideation, 2 dyspnoea, 1 pleuritic pain, 1 pneumothorax, 1 abdominal hernia repair, 1 deep vein thrombosis, 1 phlebitis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 out of 323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 chest pain, 1 cholelithiasis, 1 gastroenteritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 out of 80</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0052" title="FlammS , LawitzE , JacobsonI , RubinR , BourliereM , HezodeC , et al. High sustained virologic response (SVR) among genotype 1 previous non‐responders and relapsers to peginterferon/ribavirin when re‐treated with boceprevir (BOC) plus peginterferon alfa‐2A/ribavirin. Journal of Hepatology2011;54(Suppl 1):S541‐2. FlammSL , LawitzE , JacobsonI , BourliereM , HezodeC , VierlingJM , et al. Boceprevir with peginterferon alfa‐2a‐ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clinical Gastroenterology and Hepatology2013;11(1):81‐7. HoweJA , OgertRA , BarnardRJ , HazudaD , PediconeL , BrassCA . Analysis of sustained viral response and boceprevir resistance following combination treatment with boceprevir plus peginterferon alfa‐2A/ribavirin in HCV genotype 1 prior relapsers and non‐responders. Hepatology2011;54(S1):443A. ">Flamm 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 coronary artery disease, 1 diarrhoea, 1 asthenia, 1 pyrexia, 2 pneumonia, 2 syncope, 1 suicidal ideation, 1 deep vein thrombosis, 1 neutropenia, 1 thrombocytopenia, 1 cardiac failure, 1 upper gastrointestinal haemorrhage , 1 multi‐organ failure, 1 bronchitis, 1 cellulitis, 1 chlamydia infection, 1 influenza, 1 pneumonia staphylococcal, 1 staphylococcal bacteraemia, 1 staphylococcal infection, 1 urosepsis, 1 gun shot wound, 2 hyponatraemia, 1 lethargy, 1 subarachnoid haemorrhage, 1 mental status changes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 out of 134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 chest pain, 1 intervertebral disc protrusion, 1 abnormal behaviour, 1 irritability, 1 osteotomy, 1 foreign body, 1 neuralgia, 1 anxiety, 1 renal colic </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 out of 67</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0080" title="IsakovV , NikitinI , ChulanovV , OgurtsovP , LukyanovaE , LongJ , et al. Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in Russia. World Journal of Hepatology2016;8(6):331‐9. ">Isakov 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 neutropenia, 1 intestinal obstruction, 1 osteomyelitis chronic, 1 pneumonia, 1 diabetic ketoacidosis, 1 intervertebral disc protrusion, 1 transient ischaemic attack </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 out of 159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 neutropenia, 1 general disorders, 1 accidental overdose, 1 prostatitis, 2 hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 out of 78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0086" title="KwoP , LawitzE , McConeJ , SchiffE , VierlingJ , PoundD , et al. HCV Sprint‐1 final results: SVR 24 from a phase 2 study of boceprevir plus pegintron (peginterferon ALFA‐2B)/ribavirin in treatment‐naive subjects with genotype‐1 chronic hepatitis C. Journal of Hepatology2009;50(Suppl 1):S4. KwoPJ , LawitzEJ , McConeJ , SchiffER , VierlingJM , PoundD , et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa‐2b and ribavirin in treatment‐naive patients with genotype 1 hepatitis C infection (SPRINT‐1): an open‐label, randomised, multicentre phase 2 trial. Lancet2010;376(9742):705‐16. OgertRA , HoweJA , VierlingJM , KwoPY , LawitzEJ , McConeJ , et al. Resistance‐associated amino acid variants associated with boceprevir plus pegylated interferon‐alpha2b and ribavirin in patients with chronic hepatitis C in the SPRINT‐1 trial. Antiviral Therapy2013;18(3):387‐97. PoordadF , VierlingJM , EstebanR , KwoPY , LongJ , ChaudhriEI , et al. Hemogloblin decline during lead‐in phase as an early predictor of anemia after the addition of boceprevir: a retrospective analysis of HCV SPRINT‐1. Hepatology2010;52(Suppl S1):770A. VierlingJM , KwoPY , LawitzE , McConeJ , SchiffER , PoundD , et al. Frequencies of resistance‐associated amino acid variants following combination treatment with boceprevir plus PEGINTRON (peginterferon alfa‐2b)/ribavirin in patients with chronic hepatitis C (CHC), genotype 1 (G1). Hepatology2010;52(Suppl S1):702A. ">Kwo 2010a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 abdominal pain, 2 asthenia, 2 pyrexia, 2 pneumonia, 1 decreased appetite, 1 dehydration, 2 depression, 2 homicidal ideation, 3 suicidal ideation, 1 dyspnoea, 1 deep vein thrombosis, 3 nausea, 1 vomiting, 3 neutropenia, 1 multi‐organ failure, 2 cellulitis, 2 abdominal pain upper, 1 headache, 1 suicide attempt, 1 accidental overdose, 1 fall, 1 pulmonary embolism, 1 gastroenteritis, 1 erysipelas, 1 panic attack, 1 fatigue, 1 supraventricular tachycardia, 3 pancreatitis, 1 cerebrovascular accident, 1 hypoaesthesia, 1 anxiety, 1 retinal ischaemia, 1 neuropathy peripheral, 1 aggression, 1 scotoma, 1 hypovolaemia, 1 vulval abscess, 1 retinopathy, 1 inguinal hernia, 1 cervix carcinoma, 1 pericarditis, 1 paranoia, 1 neutrophil count decreased, 1 paraesthesia, 1 peritoneal haemorrhage, 1 deafness unilateral, 1 periodontal disease, 1 corneal infection, 1 pneumonia streptococcal, 1 drug toxicity, 1 blood amylase increased, 1 lipase increased, 1 basal cell carcinoma, 1 renal cell carcinoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 out of 527</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 suicidal ideation, 1 breast cancer, 1 parathyroid tumour benign, 1 muscle spasms, 1 rib fracture, 1 contusion, 1 inguinal hernia, 1 diplopia, 1 staphylococcal sepsis, 1 animal bite, 1 hand fracture, 1 third nerve paralysis, 1 alcoholism, 1 dependence </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 out of 104</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0154" title="PearlmanBL , EhlebenC . Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor. Hepatology2014;59(1):71‐7. WangAS , PfeifferRM , MorganTR , O'BrienTR . Re: Pearlman and Ehleben ‐ hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor. Hepatology2014;59(6):2423–4. ">Pearlman 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0164" title="AlbrechtJ , VierlingJ , KwoP , LawitzE , McConeJ , SchiffE . Frequencies of resistance‐associated amino acid variants (RAV) following treatment with boceprevir (BOC) plus peginterferon alfa‐2b and ribavirin (P/R). Hepatology International2011;5(1):261‐2. BarnardRJO , PediconeLD , ChaudhriE , TongX , QiuP , BrassCA . Frequencies of resistance‐associated amino acid variants following combination treatment with boceprevir (BOC) plus Pegintron (peglnterferon alfa‐2b) and ribavirin (P/R) in patients with chronic hepatitis C (CHC), genotype 1 (G1). Journal of the International Association of Physicians in AIDS Care2011;10(3):199‐200. BronowickiJ , McConeJ , BaconBR , BrunoS , MannsMP , SulkowskiMS , et al. Response‐guided therapy (RGT) with boceprevir (BOC) + peginterferon alfa‐2b/ribavirin (P/R) for treatment‐naive patients with hepatitis C virus (HCV) genotype (G) 1 was similar to a 48‐wk fixed‐duration regimen with BOC + P/R in SPRINT‐2. Hepatology2010;52(Suppl S1):881A. CharltonM . Boceprevir (Victrelis) for HCV: V is for victory and very complex. Hepatology2011;54(5):1882‐6. MannsMP , MarkovaAA , SerranoBC , CornbergM . Phase III results of boceprevir in treatment naive patients with chronic hepatitis C genotype 1. Liver International2012;32(Suppl 1):27‐31. MannsMP , McConeJ , DavisM , ShiffmanML , RossaroL , BourliereM , et al. Safety benefits of response‐guided therapy with boceprevir (BOC) plus peginterferon alfa‐2B/ribavirin (PR) in previously untreated patients with HCV genotype 1 infection. Hepatology2011;54(4 Suppl):813A. McConeJ , JacobsonIM , BaconBR , PediconeL , GotetiVS , BurroughsM , et al. Treatment‐naive black patients treated with boceprevir combined with peginterferon alfa‐2b + ribavirin: results from HCV sprint‐2. Hepatology2011;54(4 Suppl):822A‐3A. PoordadF , McConeJ , BaconBR , BrunoS , MannsMP , SulkowskiMS , et al. Boceprevir (BOC) combined with peginterferon alfa‐2b/ribavirin (P/R) for treatment‐naive patients with hepatitis C virus (HCV) genotype (G) 1: SPRINT‐2 final results. Hepatology2010;52(Suppl S1):402A. PoordadF , McConeJ , BaconBR , BrunoS , MannsMP , SulkowskiMS , et al. Boceprevir for untreated chronic HCV genotype 1 infection. New England Journal of Medicine2011;364(13):1195‐206. ReddyKR , BrunoS , RossaroL , RavendhranN , PaulyMP , BoparaiN , et al. Predictors of sustained virologic response among treatment‐naive patients with hepatitis C virus genotype 1 when treated with boceprevir (BOC) plus peginterferon alfa‐2B/ribavirin (PR). Journal of Hepatology2011;54(Suppl 1):S190. SulkowskiMS , BaconBR , GordonSC , LawitzE , MarcellinP , VierlingJM , et al. Boceprevir combined with peginterferon alfa‐2b/ribavirin for previous treatment failure patients with hepatitis C virus genotype 1: RESPOND‐2 final results. Journal of the International Association of Physicians in AIDS Care2011;10(3):197‐8. SulkowskiMS , PoordadF , MannsMP , BronowickiJP , RajenderRK , HarrisonSA , et al. Anemia during treatment with peginterferon alfa‐2b/ribavirin and boceprevir: analysis from the serine protease inhibitor therapy 2 (SPRINT‐2) trial. Hepatology2013;57(3):974‐84. ">Poordad 2011a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 anaemia, 1 atrial fibrillation, 1 coronary artery disease, 2 abdominal pain, 1 gastritis, 1 pancreatitis acute, 5 chest pain, 4 pyrexia, 1 cholecystitis, 4 pneumonia, 1 overdose, 1 dehydration, 1 back pain, 1 intervertebral disc protrusion, 5 syncope, 1 completed suicide, 2 depression, 4 suicidal ideation, 1 dyspnoea, 1 nausea, 2 vomiting, 3 neutropenia, 3 thrombocytopenia, 2 bronchitis, 3 cellulitis, 1 staphylococcal infection, 1 hyponatraemia, 1 pancytopenia, 1 breast cancer, 1 malaise, 1 pneumonia pneumococcal, 1 haemoptysis, 1 road traffic accident, 1 suicide attempt, 1 pruritus, 1 rash erythematous, 1 dizziness, 2 pulmonary embolism, 1 haemorrhoids, 4 gastroenteritis, 1 general physical health deterioration, 1 hypertensive crisis, 1 colon cancer, 1 drug abuse, 2 hypokalaemia, 2 chest discomfort, 1 fatigue, 1 perirectal abscess, 1 acute myocardial infarction, 1 gastrointestinal haemorrhage, 1 aplasia pure red cell, 2 leukopenia, 1 atrial flutter, 1 cardiac arrest, 1 hypertrophic cardiomyopathy, 1 tachycardia, 1 deafness, 1 conjunctivitis, 1 optic neuropathy, 1 papilledema, 1 abdominal pain lower, 1 colonic polyp, 1 gastroesophageal reflux disease, 1 hematemesis, 1 haemorrhoidal haemorrhage, 1 Mallory‐weiss syndrome, 1 umbilical hernia, 1 sarcoidosis, 1 abscess, 1 abscess limb, 1 bacteraemia, 1 epiglottitis, 1 infected bites, 1 injection site infection, 1 scrotal abscess, 1 tracheobronchitis, 1 post procedural complication, 1 transfusion reaction, 1 vascular pseudoaneurysm, 1 wound dehiscence, 1 flank pain, 1 groin pain, 1 musculoskeletal chest pain, 1 bladder cancer, 1 pancreatic carcinoma, 1 prostate cancer, 1 carotid artery stenosis, 1 cerebral ischaemia, 1 motor neurone disease, 1 muscle spasticity, 1 affective disorder, 1 alcohol abuse, 1 anxiety, 1 psychiatric decompensation, 1 scrotal pain, 2 cough, 1 pleural fibrosis, 1 alcohol use, 1 laryngeal operation, 1 accelerated hypertension, 1 arterial thrombosis limb, 2 hypotension </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87 out of 734</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 myocardial infarction, 1 abdominal pain, 2 pyrexia, 1 cholecystitis, 1 appendicitis, 1 pneumonia, 1 hepatic neoplasm malignant, 1 completed suicide, 1 depression, 1 suicidal ideation, 1 pneumothorax, 2 cholelithiasis, 1 nausea, 1 vomiting, 1 cellulitis, 1 breast cancer, 1 colitis, 1 upper respiratory tract infection, 1 suicide attempt, 2 death, 1 accidental overdose, 1 dizziness, 1 loss of consciousness, 1 cholecystitis acute, 1 sinusitis, 2 pancreatitis, 1 leukocytosis, 1 cardiac arrest, 1 cardio‐respiratory arrest, 1 hypothyroidism, 1 cholelithiasis obstructive, 1 atypical mycobacterial infection, 1 diverticulitis, 1 enterocolitis infectious, 1 alcohol poisoning, 1 spinal fracture, 1 white blood cell count decreased, 1 lung adenocarcinoma, 1 prostate cancer, 1 hypoaesthesia, 1 affective disorder, 1 bipolar disorder, 1 drug dependence, 1 intentional self‐injury, 1 personality disorder, 1 glomerulonephritis minimal lesion, 1 renal tubular necrosis, 1 physical assault, 1 cholecystectomy, 1 skin neoplasm excision </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 out of 363</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0184" title="SilvaMO , TreitelM , GrahamDJ , CurryS , FronteraMJ , McMonagleP , et al. Antiviral activity of boceprevir monotherapy in treatment‐naive subjects with chronic hepatitis C genotype 2/3. Journal of Hepatology2013;59(1):31‐7. ">Silva 2013a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 atrial fibrillation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0196" title="ShermanKE , RockstrohJK , DieterichDT , SorianoV , GirardPM , McCallisterS , et al. Telaprevir combination with peginterferon alfa‐2A/ribavirin in HCV/HIV coinfected patients: 24‐week treatment interim analysis. Hepatology2011;54(4 Suppl):1431A‐2A. SulkowskiMS , ShermanKE , DieterichDT , BsharatM , MahnkeL , RockstrohJK , et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Annals of Internal Medicine2013;159(2):86‐96. SulkowskiMS , ShermanKE , SorianoV , RockstrohJ , DieterichDT , GirardPM , et al. Telaprevir in combination with peginterferon alfa‐2a/ribavirin in HCV/HIV co‐infected patients: SVR24 final study results. Hepatology2012;56(S1):219A. ">Sulkowski 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 anaemia, 2 pneumonia, 1 syncope, 1 depression, 1 deep vein thrombosis, 1 lymphadenopathy, 1 renal failure acute, 2 pulmonary embolism, 1 arthralgia, 1 sinusitis, 1 urinary tract infection, 1 lung infection pseudomonal, 1 pelvic inflammatory disease, 1 pulmonary hypertension, 1 suicide attempt </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 out of 64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 anaemia, 1 overdose, 1 cholelithiasis, 1 abdominal pain upper, 1 meniscus lesion, 1 pancreatitis, 1 post procedural infection, 1 renal failure, 1 cholecystectomy, 1 vulval abscess, 1 ventricular fibrillation, 1 ligament rupture, 1 lactic acidosis, 1 respiratory failure </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 out of 34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0042" title="DoreGJ , LawitzE , HezodeC , ShafranSD , RamjiA , TatumHA , et al. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. Gastroenterology2015;148(2):355‐66. ">Dore 2015a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daclatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 hepatic neoplasm malignant, 1 rectal ulcer haemorrhage, 1 gastrointestinal inflammation, 1 adhesion, 1 biliary colic, 1 hyperbilirubinaemia, 1 appendiceal abscess, 1 tonsil cancer </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 out of 196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 abdominal pain upper, 1 epicondylitis, 1 conversion disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 out of 100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0031" title="HezodeC , HirschfieldGM , GhesquiereW , SievertW , Rodriguez‐TorresM , ShafranS , et al. BMS‐790052, a NS5A replication complex inhibitor, combined with peginterferon alfa‐2a and ribavirin in treatment‐naive HCV‐genotype 1 or 4 patients: phase 2b AI444010 study interim week 12 results. Hepatology2011;54(S1):474A‐5A. HezodeC , HirschfieldGM , GhesquiereW , SievertW , Rodriguez‐TorresM , ShafranS , et al. Daclatasvir (BMS‐790052), a NS5A replication complex inhibitor, combined with peginterferon‐alfa‐2a and ribavirin in treatment‐naive HCV genotype 1 or 4 subjects: phase 2b AI444010 study interim week 24 results. Hepatology International2012;6(1):167. HezodeC , HirschfieldGM , GhesquiereW , SievertW , Rodriguez‐TorresM , ShafranSD , et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment‐naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut2015;64(6):948‐56. ">COMMAND‐1 2015a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daclatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 abdominal pain, 1 gastritis, 1 chest pain, 2 pneumonia, 1 overdose, 1 syncope, 2 depression, 2 suicidal ideation, 1 dyspnoea, 1 bronchitis, 1 peritonitis, 1 rash generalised, 1 febrile neutropenia, 1 aplastic anaemia, 1 auricular perichondritis, 2 gastric ulcer haemorrhage, 1 death, 1 bile duct stone, 1 clostridium difficile, 1 furuncle, 1 carbuncle, 1 oral herpes, 1 accidental overdose, 2 falls, 1 bursitis, 1 rhabdomyolysis, 1 muscle spasms, 1 costochondritis, 1 dizziness, 1 loss of consciousness, 1 adjustment disorder, 1 hypomania, 1 mental disorder, 1 substance‐induced psychotic disorder, 1 schizophrenia, paranoid type </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 out of 317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 anaemia, 1 atrial fibrillation, 1 pneumonia, 1 pyelonephritis, 1 haemoglobin decreased, 1 epistaxis, 1 electrocardiogram change, 1 neutrophil count decreased, 1 myalgia, 1 aphasia, 1 paraesthesia </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 out of 78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0081" title="IzumiN , AsahinaY , YokosukaO , ImazekiF , KawadaN , TamoriA , et al. Combination therapy of treatment‐naive and nonresponder patients with HCV genotype 1 infection with BMS‐790052, an NS5A replication complex inhibitor, in combination with peginterferon alfa‐2a and ribavirin. Hepatology2011;54(S1):1439A‐40A. IzumiN , YokosukaO , KawadaN , OsakiY , YamamotoK , SataM , et al. Daclatasvir combined with peginterferon alfa‐2a and ribavirin in Japanese patients infected with hepatitis C genotype 1. Antiviral Therapy2014;19(5):501‐10. McPheeF , HernandezD , ZhouN , YuF , UelandJ , MonikowskiA , et al. Virological escape in HCV genotype‐1‐infected patients receiving daclatasvir plus ribavirin and peginterferon alfa‐2a or alfa‐2b. Antiviral Therapy2014;19(5):479‐90. SuzukiF , ChayamaK , KawakamiY , ToyotaJ , KarinoY , MochidaS , et al. BMS‐790052, AN NS5A replication complex inhibitor, in combination with peginterferon alpha‐2B and ribavirin in Japanese treatment naive and nonresponder patients with chronic HCV genotype 1 infection. Hepatology2011;54(S1):1441A. SuzukiF , ChayamaK , KawakamiY , ToyotaJ , KarinoY , MochidaS , et al. Daclatasvir (BMS‐790052), an NS5A replication complex inhibitor, in combination with peginterferon alpha‐2b and ribavirin in Japanese treatment‐naive and nonresponder patients with chronic HCV genotype 1 infection. Hepatology International2012;6(1):161‐2. SuzukiF , ToyotaJ , IkedaK , ChayamaK , MochidaS , HayashiN , et al. A randomized trial of daclatasvir with peginterferon alfa‐2b and ribavirin for HCV genotype 1 infection. Antiviral Therapy2014;19(5):491‐9. ">Izumi 2014a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daclatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 pancreatitis acute, 1 back pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 out of 34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0161" title="PolS , GhalibRH , RustgiVK , MartorellC , EversonGT , TatumHA , et al. Daclatasvir for previously untreated chronic hepatitis C genotype‐1 infection: a randomised, parallel‐group, double‐blind, placebo‐controlled, dose‐finding, phase 2a trial. Lancet Infectious Diseases2012;12(9):671‐7. ">Pol 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daclatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 chest pain, 2 syncope, 1 bronchitis, 1 epistaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 out of 36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0035" title="EversonG , CooperC , HezodeC , ShiffmanML , YoshidaE , Beltran‐JaramilloT , et al. Dauphine: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha‐2a/ribavirin in HCV genotypes 1 or 4. Liver International2015;35(1):108‐19. EversonG , CooperC , HezodeC , ShiffmanML , YoshidaE , Beltran‐JaramilloT , et al. Rapid and sustained achievement of undetectable HCV RNA during treatment with ritonavir‐boosted danoprevir/peg‐ifna‐2a/RBV in HCV genotype 1 or 4 patients: dauphine week 12 interim analysis. Journal of Hepatology2012;56(Suppl 2):S466. HezodeC , ShiffmanML , CooperC , EversonGT , MarcellinP , Rodriguez‐TorresM , et al. Ritonavir‐boosted danoprevir plus peg‐IFNalpha‐2a/ribavirin (P/R) demonstrates up to 100% SVR24 with 12 or 24 weeks of total treatment in treatment‐naive patients with HCV genotype 4 infection in the DAUPHINE study. Hepatology2012;56(S1):557A. LePogamS , NavarroM , BuL , VoulgariA , IllnickaM , YanJM , et al. Low rate of on‐treatment resistance to danoprevir boosted by ritonavir (DNVR) combined with Peg‐IFNa‐2a/ribavirin: 12 week interim analysis from Dauphine study. Journal of Hepatology2012;56(Suppl 2):S472. ">Dauphine 2015a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Danoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 unspecified SAEs and 2 deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 out of 373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 unspecified SAE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 44</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0054" title="ForestierN , LarreyD , GuyaderD , MarcellinP , RouzierR , PatatA , et al. Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN‐191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study. Journal of Hepatology2011;54(6):1130‐6. ForestierN , LarreyDG , GuyaderD , MarcellinP , RouzierR , PatatAA , et al. Treatment of chronic hepatitis C virus (HCV) genotype 1 patients with the NS3/4A protease inhibitor ITMN‐191 leads to rapid reductions in plasma HCV RNA: results of a phase 1b multiple ascending dose (MAD) study. Hepatology2008;48(4 (Suppl)):1132A. MoucariR , ForestierN , LarreyD , GuyaderD , CouzigouP , BenhamouY , et al. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut2010;59(12):1694‐8. ">Forestier 2011a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Danoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 benign paroxysmal vertigo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0056" title="ForestierN , LarreyD , MarcellinP , BenhamouY , GuyaderD , BradfordW , et al. Antiviral activity and safety of ITMN‐191 in combination with peginterferon alfa‐2a and ribavirin in patients with chronic hepatitis C virus (HCV). Journal of Hepatology2009;50(Suppl 1):S35. ForestierN , LarreyD , MarcellinP , GuyaderD , PatatA , RouzierR , et al. Antiviral activity of danoprevir (ITMN‐191/RG7227) in combination with pegylated interferon alpha‐2a and ribavirin in patients with hepatitis C. Journal of Infectious Diseases2011;204(4):601‐8. ">Forestier 2011b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Danoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 gastroenteritis viral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0068" title="GaneE , RouzierR , StedmanC , Wiercinska‐DrapaloA , HorbanA , ChangL , et al. Ritonavir boosting of low dose RG7227/ITMN‐191, HCV NS3/4 a protease inhibitor, results in robust reduction in HCV RNA at lower exposures than provided by unboosted regimens. Journal of Hepatology2010;52(Suppl 1):S16‐7. GaneEJ , RouzierR , StedmanC , Wiercinska‐DrapaloA , HorbanA , ChangL , et al. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG‐IFN alpha‐2a/RBV in hepatitis C patients. Journal of Hepatology2011;55(5):972‐9. MorcosPN , ChangL , KulkarniR , GiraudonM , ShulmanN , BrennanBJ , et al. A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail. European Journal of Clinical Pharmacology2013;69(11):1939‐49. ">Gane 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Danoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 altered mood</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0015" title="MarcellinP , CooperC , BalartL , LarreyD , BoxT , YoshidaE , et al. Randomized controlled trial of danoprevir plus peginterferon alfa‐2a and ribavirin in treatment‐naïve patients with hepatitis C virus genotype 1 infection. Gastroenterology2013;145:790‐800. MarcellinP , CooperC , BalartLA , LarreyDG , BoxTD , YoshidaE , et al. High sustained virological response rates with response‐guided danoprevir plus peginterferon alfa‐2a (40KD) and ribavirin in treatment‐naive, HCV genotype 1 patients: ATLAS study final results. Journal of Hepatology2012;56(Suppl S2):S472. TerraultN , CooperC , BalartLA , LarreyDG , BoxTD , YoshidaE , et al. High sustained virologic response (SVR24) rates with response‐guided danoprevir (DNV; RG7227) plus pegIfn alpha‐2A (40KD) and ribavirin (P/R) in treatment‐naive HCV genotype 1 (G1) patients: results from the ATLAS study. Hepatology2011;54(S1):398A‐9A. TerraultN , CooperC , BalartLA , LarreyDG , BoxTD , YoshidaEM , et al. Phase II randomised, partially‐blind, parallel‐group study of oral danoprevir (RG7227) with PegIFNα‐2a (Pegasys) plus ribavirin (Copegus) in treatment‐naive genotype 1 patients with CHC: results of planned week 12 interim analysis of the ATLAS study. Hepatology2010;52(Suppl S1):335A. ">ATLAS 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Danoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 SAEs but not specified, 1 death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 out of 194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 SAEs but not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 out of 31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0094" title="LagaceL , CartierM , LaflammeG , LawetzC , MarquisM Triki I , et al. Genotypic and phenotypic analysis of the NS5B polymerase region from viral isolates of HCV chronically infected patients treated with BI 207127 for 5‐days monotherapy. Hepatology2010;52(Suppl S1):1205A‐6A. LarreyD , LohseAW , TrepoC , BronowickiJP , ArastehK , BourliereM , et al. Antiviral effect, safety, and pharmacokinetics of five‐day oral administration of deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis C. Antimicrobial Agents and Chemotherapy2013;57(10):4727‐35. LarreyDG , BenhamouY , LohseAW , TrepoC , MoellekenC , BronowickiJ , et al. BI 207127 is a potent HCV RNA polymerase inhibitor during 5 days monotherapy in patients with chronic hepatitis C. Hepatology2009;50(4):1044A. ">Larrey 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deleobuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 drug eruption</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0093" title="LarreyD , LohseA , DeLedinghenV , TrepoC , GerlachT , ZarskiJP , et al. 4 week therapy with the non‐nucleosidic polymerase inhibitor BI207127 in combination with peginterferon‐alfa2A and ribavirin in treatment naive and treatment experienced chronic HCV GT1 patients. Journal of Hepatology2010;52(Suppl S1):S466. LarreyD , LohseAW , DeLedinghenV , TrepoC , GerlachT , ZarskiJP , et al. Rapid and strong antiviral activity of the non‐nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. Journal of Hepatology2012;57(1):39‐46. ">Larrey 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deleobuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 syncope, 1 rash maculo‐papular, 1 umbilical hernia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 out of 49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0190" title="AsselahT , JensenDM , FosterG , SulkowskiM , OuzanD , MoranoL , et al. Faldaprevir plus pegylated interferon/ribavirin did not increase anaemia compared with pegylated interferon/ribavirin in HCV genotype‐1, treatment‐naive patients: pooled analysis of phase III studies. Gastroenterology2014;146(5 (Suppl 1)):S‐977. AsselahT , JensenDM , FosterG , SulkowskiM , OuzanD , MoranoL , et al. Virological response in treatment‐naive patients with chronic HCV genotype‐1 infection receiving faldaprevir plus pegylated interferon alpha‐2a and ribavirin is unaffected by ribavirin dose reduction. Gastroenterology2014;146(5 (Suppl 1)):S975‐6. BergerK , SarrazinC , FerenciP , JensenDM , JacobsonIM , SternJO , et al. NS3 Q80K did not impact efficacy or treatment‐emergent resistance patterns in HCV genotype 1‐infected patients receiving faldaprevir + peginterferon/ribavirin in three phase III trials. Journal of Hepatology2014;60(1):S497. FerenciP , DieterichD , ZeuzemS , MantryP , SarrazinC , CrespoJ , et al. Early stopping rules for faldaprevir plus pegylated interferon alpha‐2a and ribavirin in treatment‐naive patients: exploratory study of pooled data from phase III trials. Journal of Hepatology2014;60(1 (Suppl 1)):S452‐3. FosterGR , CooperC , DieterichD , FerenciP , CrespoJ , DiagoM , et al. Pharmacokinetic‐response analysis of faldaprevir in treatment‐naive patients with chronic HCV genotype‐1 infection: a pooled analysis of two phase III trials. Journal of Hepatology2014;60(1 (Suppl 1)):S454‐5. JensenDM , AsselahT , DieterichDT , FosterGR , SulkowskiMS , ZeuzemS , et al. A pooled analysis of two randomized, double‐blind placebo‐controlled phase III trials (STARTVerso1&amp;2) of faldaprevir plus pegylated interferon alfa‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C genotype‐1 infection. Hepatology2013;58(Suppl 1):734A‐5A. JensenDM , FosterG , FerenciP , CooperC , DieterichDT , SulkowskiM , et al. Faldaprevir plus pegylated interferon alfa‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C genotype‐1 infection: a pooled analysis of two randomized, double‐blind placebo‐controlled phase iii trials (STARTVerso1&amp;2). Gastroenterology2014;146(5 (Suppl 1)):S974. YoshidaEM , AsselahT , MorenoC , MaevskayaMV , KaoJH , CrespoJ , et al. Subgroup analyses and baseline predictors of response with faldaprevir plus pegylated interferon alfa‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C genotype‐1 infection: a pooled analysis of STARTVerso1 and 2. Hepatology2013;58(4 Suppl):751A‐2A. ZeuzemS , JensenDM , CarvalhoA , DiagoM , FeinmanSV , KowdleyKV , et al. No effect of faldaprevir on renal function in treatment‐naive patients with chronic HCV genotype‐1 infection: pooled data from two phase III trials. Journal of Hepatology2014;60(1 (Suppl 1)):S451. ">STARTverso‐2 2014a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faldaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 anaemia, 1 angina pectoris, 2 diarrhoea, 1 oesophageal varices haemorrhage, 1 cholecystitis, 2 pneumonia, 1 dehydration, 1 back pain, 1 intervertebral disc protrusion, 1 bipolar disorder, 1 depression, 1 suicidal ideation, 1 dyspnoea, 2 nausea, 3 vomiting, 2 neutropenia, 1 thrombocytopenia, 1 cellulitis, 1 mental status changes, 1 pancytopenia, 1 breast cancer, 1 malaise, 2 rash, 2 sepsis, 1 suicide attempt, 1 renal failure acute, 1 rash maculo‐papular, 1 accidental overdose, 1 muscle spasm, 1 tibia fracture, 1 contusion, 1 pulmonary embolism, 2 abortion spontaneous, 1 hypokalaemia, 1 subcutaneous abscess, 1 acute myocardial infarction, 1 pancreatitis, 1 umbilical hernia, 1 diverticulitis, 1 cerebral ischaemia, 1 drug dependence, 1 personality disorder, 1 epidermolysis, 1 ascites, 1 duodenal ulcer haemorrhage, 1 large intestine perforation, 1 hepatic cirrhosis, 2 hepatic failure, 1 hypersensitivity, 1 infective chondritis, 1 vulval abscess, 1 fibula fracture, 1 jaw fracture, 1 ligament sprain, 1 hypocalcaemia, 1 hyponatraemia, 1 hepatocellular carcinoma, 1 papillary thyroid cancer </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 out of 525</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 2 depression, 1 suicidal ideation, 1 bile duct stone, 1 subcutaneous abscess, 1 optic ischaemic neuropathy, 1 laceration, 1 mental status change </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 out of 132</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0188" title="AsselahT , JensenDM , FosterG , SulkowskiM , OuzanD , MoranoL , et al. Faldaprevir plus pegylated interferon/ribavirin did not increase anaemia compared with pegylated interferon/ribavirin in HCV genotype‐1, treatment‐naive patients: pooled analysis of phase III studies. Gastroenterology2014;146(5 Suppl 1):S‐977. AsselahT , JensenDM , FosterG , SulkowskiM , OuzanD , MoranoL , et al. Virological response in treatment‐naive patients with chronic HCV genotype‐1 infection receiving faldaprevir plus pegylated interferon alpha‐2a and ribavirin is unaffected by ribavirin dose reduction. Gastroenterology2014;146(5 Suppl 1):S975‐6. BergerK , SarrazinC , FerenciP , JensenDM , JacobsonIM , SternJO , et al. NS3 Q80K did not impact efficacy or treatment‐emergent resistance patterns in HCV genotype 1‐infected patients receiving faldaprevir + peginterferon/ribavirin in three phase III trials. Journal of Hepatology2014;60(1 Suppl S):S497. FerenciP , AsselahT , FosterGR , ZeuzemS , SarrazinC , MorenoC , et al. Faldaprevir plus pegylated interferon alfa‐2A and ribavirin in chronic HCV genotype‐1 treatment‐naive patients: final results from STARTVerso1, a randomised, double‐blind, placebo‐controlled phase III trial. Journal of Gastroenterology and Hepatology2013;28(Suppl 2):157‐8. FerenciP , AsselahT , FosterGR , ZeuzemS , SarrazinC , MorenoC , et al. STARTVerso1: a randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype‐1 infection. Journal of Hepatology2015;62(6):1246‐55. FerenciP , DieterichD , ZeuzemS , MantryP , SarrazinC , CrespoJ , et al. Early stopping rules for faldaprevir plus pegylated interferon alpha‐2a and ribavirin in treatment‐naive patients: exploratory study of pooled data from phase III trials. Journal of Hepatology2014;60(1 Suppl 1):S452‐S3. FosterGR , CooperC , DieterichD , FerenciP , CrespoJ , DiagoM , et al. Pharmacokinetic‐response analysis of faldaprevir in treatment‐naive patients with chronic HCV genotype‐1 infection: a pooled analysis of two phase III trials. Journal of Hepatology2014;60(1 Suppl 1):S454‐5. JensenDM , AsselahT , DieterichDT , FosterGR , SulkowskiMS , ZeuzemS , et al. A pooled analysis of two randomized, double‐blind placebo‐controlled phase III trials (STARTVerso1 &amp; 2) of faldaprevir plus pegylated interferon alfa‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C genotype‐1 infection. Hepatology2013;58(Suppl 1):734A‐5A. JensenDM , FosterG , FerenciP , CooperC , DieterichDT , SulkowskiM , et al. Faldaprevir plus pegylated interferon alfa‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C genotype‐1 infection: a pooled analysis of two randomized, double‐blind placebo‐controlled phase III trials (STARTVerso 1 &amp; 2). Gastroenterology2014;146(5 Suppl 1):S974. MorenoC , FerenciP , AsselahT , FosterG , ZeuzemS , SarrazinC , et al. Faldaprevir plus pegylated interferon alfa‐2a and ribavirin in chronic HCV genotype‐1 treatment‐naive patients: final results from STARTVerso1: a randomized, double‐blind, placebo‐controlled, phase 3 trial. American Journal of Gastroenterology2013;108(Suppl 1):S145. YoshidaEM , AsselahT , MorenoC , MaevskayaMV , KaoJH , CrespoJ , et al. Subgroup analyses and baseline predictors of response with faldaprevir plus pegylated interferon alfa‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C genotype‐1 infection: a pooled analysis of STARTVerso1 and 2. Hepatology2013;58(Suppl S1):751A‐2A. ZeuzemS , JensenDM , CarvalhoA , DiagoM , FeinmanSV , KowdleyKV , et al. No effect of faldaprevir on renal function in treatment‐naive patients with chronic HCV genotype‐1 infection: pooled data from two phase III trials. Journal of Hepatology2014;60(1 Suppl S):S451. ">STARTVerso‐1 2015a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faldaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 anaemia, 1 atrial fibrillation, 1 myocardial infarction, 1 asthenia, 1 chest pain, 1 pyrexia, 1 bronchopneumonia, 1 pneumonia, 1 sciatica, 2 vomiting, 1 thrombocytopenia, 1 pancytopenia, 1 headache, 2 rash, 1 drug eruption, 1 dizziness, 1 haemorrhoids, 1 psychotic disorder, 1 urinary tract infection, 1 diabetes mellitus, 1 parapsoriasis, 1 pancreatitis, 1 histiocytosis haematophagic, 1 cerebrovascular accident, 1 muscular weakness, 1 epistaxis, 1 leukopenia, 1 sarcoidosis, 1 hypotension, 1 idiopathic thrombocytopenic purpura, 1 optic ischaemic neuropathy, 1 hypersensitivity, 1 hypoparathyroidism, 1 retinopathy, 1 subdural hematoma, 1 cervix carcinoma, 1 cubital tunnel syndrome, 1 dyspnoea exertional </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 out of 520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 cholecystitis, 1 gun shot wound, 1 rash maculo‐papular, 1 diverticulitis, 1 inguinal hernia, 1 hepatic lesion, 1 polymyositis, 1 blister </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 out of 132</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0192" title="AsselahT , ZehnterE , AgarwalK , SakaiY , YatsuhashiH , WillemsB , et al. Pharmacokinetic‐response analysis of faldaprevir in patients with chronic HCV genotype‐1 infection with prior relapse. Journal of Hepatology2014;60(1 Suppl S):S458‐9. BergerK , SarrazinC , FerenciP , JensenDM , JacobsonIM , SternJO , et al. NS3 Q80K did not impact efficacy or treatment‐emergent resistance patterns in HCV genotype 1‐infected patients receiving faldaprevir+peginterferon/ribavirin in three phase III trials. Journal of Hepatology2014;60(1 Suppl S):S497. JacobsonIM , AsselahT , FerenciP , FosterGR , JensenDM , NegroF , et al. STARTVerso3: a randomized, double‐blind, placebo‐controlled phase III trial of faldaprevir in combination with pegylated interferon a lf a‐2a and ribavirin in treatment‐experienced patients with chronic hepatitis C genotype‐1 infection. Hepatology2013;48(S1):742A‐3A. JacobsonIM , FerenciP , FosterGR , JensenDM , NegroF , MantryP , et al. STARTVerso3: a randomized, double‐blind, placebo controlled phase III trial of faldaprevir in combination with pegylated interferon alpha‐2a and ribavirin in treatment experienced patients with chronic hepatitis C genotype‐1 infection. Hepatology International2014;8(1 Suppl):S213‐4. ">STARTverso‐3 2013a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faldaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 anaemia, 1 atrial fibrillation, 1 abdominal pain, 5 diarrhoea, 1 pancreatitis acute, 1 asthenia, 1 chest pain, 8 pyrexia, 2 appendicitis, 1 gastroenteritis viral, 2 pneumonia, 1 decreased appetite, 1 dehydration, 1 back pain, 1 hepatic neoplasm malignant, 2 cholelithiasis, 1 biliary colic, 2 hyperbilirubinaemia, 3 nausea, 2 vomiting, 1 thrombocytopenia, 1 cellulitis, 1 bradycardia, 2 presyncope, 2 malaise, 2 headache, 2 sepsis, 1 rash erythematous, 1 rash generalised, 1 fall, 1 multiple injuries, 1 haematochezia, 1 peritonitis bacterial, 1 congestive cardiac failure, 1 gastroenteritis, 1 hypertensive crisis, 1 hypokalaemia, 1 fatigue, 1 pancreatitis, 1 coma, 1 renal colic, 1 leukopenia, 1 cardio‐respiratory arrest, 1 anxiety, 1 psychiatric decompensation, 2 hypotension, 1 viral infection, 2 ascites, 1 hepatic failure, 1 hypoglycaemia, 1 haemolytic anaemia, 1 keratosis follicular, 1 oral lichen planus, 1 peritoneal haemorrhage, 1 salivary gland calculus, 1 hepatorenal failure, 2 jaundice, 1 streptococcal infection, 1 blood lactate dehydrogenase increased, 1 international normalised ratio abnormal, 1 metabolic acidosis, 1 fasciitis, 1 joint instability, 1 musculoskeletal discomfort, 1 haemothorax, 1 venous thrombosis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 out of 599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 depression, 1 pleural effusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0144" title="NishiguchiS , KubokiM , SakaiY , AizawaN , IwataK , IkedaN , et al. All treated Japanese genotype 1 patients with IL28B TT allele achieved SVR by 4 weeks faldaprevir and 48 weeks PegIFN/ ribavirin. Hepatology International2013;7(1 Suppl):S393. NishiguchiS , KubokiM , SakaiY , AizawaN , TakashimaT , IwataK . 100% SVR in Japanese genotype 1 patients with IL28B TT allele treated with 4 weeks faldaprevir and 48 weeks PegIFN/ribavirin. Hepatology International2013;7(1 Suppl):S372‐3. NishiguchiS , SakaiY , KubokiM , TsunematsuS , UranoY , SakamotoW , et al. Safety and efficacy of faldaprevir with pegylated interferon alfa‐2a and ribavirin in Japanese patients with chronic genotype‐1 hepatitis C infection. Liver International2014;34(1):78‐88. ">Nishiguchi 2014a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faldaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 abdominal pain upper</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0115" title="MannsMP , BourliereM , BenhamouY , PolS , BonaciniM , BergT . Safety and antiviral activity of BI201335, a new HCV NS3 protease inhibitor, in treatment‐naive patients with chronic hepatitis C genotype‐1 infection given as monotherapy and in combination with peginterferon alfa 2a (P) and ribavirin (R). Hepatology2008;48(4 Suppl):1023A. MannsMP , BourliereM , BenhamouY , PolS , BonaciniM , TrepoC , et al. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype‐1 infection. Journal of Hepatology2011;54(6):1114‐22. ">Manns 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faldaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 asthenia, 1 cataract , 1 hypoalbuminaemia, 1 metabolic disorder, 1 ascites</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 out of 88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0196" title="ShermanKE , RockstrohJK , DieterichDT , SorianoV , GirardPM , McCallisterS , et al. Telaprevir combination with peginterferon alfa‐2A/ribavirin in HCV/HIV coinfected patients: 24‐week treatment interim analysis. Hepatology2011;54(4 Suppl):1431A‐2A. SulkowskiMS , ShermanKE , DieterichDT , BsharatM , MahnkeL , RockstrohJK , et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Annals of Internal Medicine2013;159(2):86‐96. SulkowskiMS , ShermanKE , SorianoV , RockstrohJ , DieterichDT , GirardPM , et al. Telaprevir in combination with peginterferon alfa‐2a/ribavirin in HCV/HIV co‐infected patients: SVR24 final study results. Hepatology2012;56(S1):219A. ">Sulkowski 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faldeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 anaemia, 1 angina pectoris, 1 myocardial infarction, 1 diarrhoea, 1 asthenia, 1 chest pain, 1 oedema peripheral, 4 pyrexia, 1 cholecystitis, 1 pneumonia, 2 dehydration, 1 intervertebral disc protrusion, 2 syncope, 1 depression, 1 nausea, 2 vomiting, 1 thrombocytopenia, 1 upper gastrointestinal haemorrhage, 1 influenza, 1 lower respiratory tract infection, 2 photosensitivity reaction, 1 upper respiratory tract infection, 2 headache, 1 rash, 1 road traffic accident, 2 suicide attempt, 3 drug eruption, 2 rash maculo‐papular, 1 rash erythematous, 2 febrile neutropenia, 1 oral herpes, 1 pulmonary embolism, 1 pyelonephritis, 1 cataract, 1 anaemia haemolytic autoimmune, 1 lymphopenia, 1 microvascular angina, 1 prinzmetal angina, 1 anal fistula, 1 haemorrhoids, 1 mouth ulceration, 1 rectal haemorrhage, 1 chest discomfort, 1 fatigue, 1 mucosal inflammation, 1 gallbladder polyp, 1 cryoglobulinaemia, 1 anal abscess, 1 ear infection, 2 H1N1 influenza, 1 infected skin ulcer, 1 lymphangitis, 1 perirectal abscess, 1 pharyngitis, 1 subcutaneous abscess, 1 superinfection bacterial, 1 urinary tract infection, 1 diabetes mellitus, 1 ischaemic stroke, 1 acute psychosis, 1 depressed mood, 1 calculus ureteric, 1 endometrial hyperplasia, 1 dermatitis atopic, 1 eczema, 1 erythema multiforme, 1 lichen planus, 1 palmar‐plantar erythrodysaesthesia syndrome, 1 parapsoriasis, 1 pruritus allergic, 1 rash pruritic, 1 appendicectomy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 out of 641</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 headache, 1 photophobia, 1 cyst, 1 benign salivary gland neoplasm, 1 migraine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 out of 71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0083" title="JacobsonI , PockrosP , LalezariJ , LawitzE , Rodriguez‐TorresM , DeJesusE , et al. Antiviral activity of filibuvir in combination with pegylated interferon alfa‐2A and ribavirin for 28 days in treatment naive patients chronically infected with HCV genotype 1. Journal of Hepatology2009;50(Suppl 1):S382. JacobsonI , PockrosPJ , LalezariJ , LawitzE , Rodriguez‐TorresM , DeJesusE , et al. Virologic response rates following 4 weeks of filibuvir in combination with pegylated interferon alfa‐2A and ribavirin in chronically‐infected HCV genotype‐1 patients. Journal of Hepatology2010;52(Suppl 1):S464. MoriJ , HammondJL , SrinivasanS , JagannathaS , RystECC . Genotypic characterisation of filibuvir (PF‐00868554 ) resistance in patients receiving four weeks co‐administration of filibuvir with pegIFN/RBV. Hepatology2010;52(Suppl S1):722A. MoriJ , HammondJL , SrinivasanS , JagannathaS , Van derRystE . Genotypic characterisation of filibuvir (PF‐00868554) resistance in patients receiving four weeks co‐administration of filibuvir with PEGIFN/RBV (12 week analysis). Journal of Hepatology2010;52(Suppl 1):S15. ">Jacobson 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Filibuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 blood creatinine increased, 1 chronic obstructive pulmonary disease, 1 pulmonary embolism </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 out of 27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 thyroiditis, 1 gait disturbance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0179" title="Rodriguez‐TorresM , YoshidaEM , MarcellinP , SrinivasanS , PurohitVS , WangC , et al. A phase 2 study of filibuvir in combination with pegylated IFN alfa and ribavirin for chronic HCV. Annals of Hepatology2014;13(4):364‐75. ">Rodriguez‐Torres 2014b1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Filibuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 appendicitis, 1 rectal ulcer haemorrhage, 1 craniocerebral injury, 1 vertigo, 1 vestibular disorder, 1 haematochezia, 1 peritonitis bacterial, 1 lymph node tuberculosis, 1 scapula fracture, 1 blood urea nitrogen/creatinine increased, 1 gastric cancer, 1 rectal cancer, 1 abortion spontaneous, 1 cardiac necrosis, 1 pyoderma gangrenosum, 1 depression, 1 breast cancer, 1 chronic obstructive pulmonary disease, 1 lung neoplasm malignant, 1 fall, 1 loss of consciousness, 1 bacterial abscess CNS, 1 actinomyces test positive, 1 pulmonary calcification </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 out of 192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 neutropenia, 1 sepsis, 1 pulmonary embolism, 1 cerebral haemorrhage, 1 ecchymosis, 1 Appendicitis perforated </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 out of 96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0106" title="LawitzE , HillJM , MarburyTC , Rodriguez‐TorresM , DeMiccoMP , QuesadaJ , et al. Three‐day, dose‐ranging study of the HCV NS3 protease inhibitor GS‐9451. Hepatology2010;52(Suppl S1):714A. LawitzEJ , HillJM , MarburyT , DemiccoMP , DelaneyW , YangJ , et al. A phase I, randomized, placebo‐controlled, 3‐day, ascending‐dose study of GS‐9451, an NS3/4a protease inhibitor, in genotype 1 hepatitis C patients. Antiviral Therapy2013;18(3):311‐9. ">Lawitz 2013b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GS‐9451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 death, 1 heroin overdose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0070" title="GardnerS , CutrellAMY , Elko‐SimmsC , AdkisonK , HamatakeR , WalkerJ , et al. A double‐blind, randomized, placebo‐controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa‐2a and ribavirin in hepatitis C virus genotype 1‐infected treatment‐naive subjects. Liver International2014;34(6):e89‐e95. ">Gardner 2014a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GSK2336805</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 pneumonia, 1 upper lobe cavitary lesion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0092" title="LalezariJ , BoxT , O'RiordanW , MehraP , NguyenT , PoordadF , et al. IDX184 in combination with pegylated interferon‐alpha2a and ribavirin for 2 weeks in treatment‐naive patients with chronic hepatitis C. Antiviral Therapy2013;18(6):755‐64. LalezariJ , PoordadF , MehraP , NguyenT , DejesusE , GodofskyE , et al. Antiviral activity, pharmacokinetics and safety of IDX184 in combination with pegylated interferon (pegIFN) and ribavirin (RBV) in treatment‐naive HCV genotype 1‐infected subjects. Journal of Hepatology2010;52(Suppl S1):S469. LalezariJP , O'RiordanW , PoordadF , NguyenTT , PatrickGD , ChenJ , et al. A phase IIA study of IDX184 in combination with pegylated interferon (PEGIFN) and ribavirin (RBV) in treatment‐naive HCV genotype 1‐infected subjects. Hepatology2010;52(Suppl S1):337A. ">Lalezari 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IDX‐184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 pancreatitis, 1 acute cholecystitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 out of 65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0067" title="ChuT , KulkarniR , GaneEJ , RobertsSK , StedmanC , AngusP , et al. The effect of host IL28B genotype on early viral kinetics during interferon‐free treatment in patients with chronic hepatitis C (CHC). Journal of Hepatology2011;54(Suppl 1):S521‐2. GaneEJ , RobertsSK , StedmanC , AngusPW , RitchieB , ElstonR , et al. First‐in‐man demonstration of potent antiviral activity with a nucleoside polymerase (R7128) and protease (R7227/ITMN‐191) inhibitor combination in HCV: safety, pharmacokinetics, and virologic results from INFORM‐1. Journal of Hepatology2009;50(Suppl 1):S380. GaneEJ , RobertsSK , StedmanCA , AngusPW , RitchieB , ElstonR , et al. Combination therapy with a nucleoside polymerase (R7128) and protease (R7227/ITMN ‐ 191) inhibitor in HCV: safety, pharmacokinetics, and virologic results from INFORM‐1. Hepatology2009;50(4 Suppl):394A‐5A. GaneEJ , RobertsSK , StedmanCAM , AngusPW , RitchieB , ElstonROB , et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM‐1): a randomised, double‐blind, placebo‐controlled, dose‐escalation trial. Lancet2010;376(9751):1467‐75. LePogamS , YanJM , ChhabraM , IlnickaM , KangH , KosakaA , et al. Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short‐term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir. Antimicrobial Agents and Chemotherapy2012;56(11):5494‐502. LimLY , KwoPY . A glimpse at the future of hepatitis C therapy: The INFORM trial. Hepatology2011;54(1):360‐3. MorcosPN , KulkarniR , IpeD , JumbeS , TranJ , BradfordWZ , et al. Pharmacokinetics/pharmacodynamics (PK/PD) of combination R7227 and R7128 therapy from INFORM‐1 demonstrates similar early HCV viral dynamics when R7227 is combined with either PEG ‐ IFN/ribavirin (SOC) or R7128. Hepatology2009;50(4 Suppl):1041A‐2A. ">Gane 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mericitabine/danoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 multiple drug overdose, 1 ankle fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 out of 73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0050" title="FeldJJ , JacobsonIM , HezodeC , AsselahT , RuanePJ , GruenerN , et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. New England Journal of Medicine2015;373(27):2599‐607. ">Feld 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mericitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 nephrolithiasis, 1 porphyria non‐acute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 out of 102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 arthritis infective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0085" title="PockrosPJ , JensenD , TsaiN , TaylorR , RamjiA , CooperC , et al. JUMP‐C: a randomized trial of mericitabine plus pegylated interferon alpha‐2a/ribavirin for 24 weeks in treatment‐naïve HCV genotype 1/4 patients. Hepatology2013;58(2):514‐23. ">JUMP‐C 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mericitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 SAEs but not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 out of 81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 SAEs but not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 out of 85</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0039" title="DeBruijneJ , BergmannJF , ReesinkHW , WeeginkCJ , MolenkampR , SchinkelJ , et al. Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients. Hepatology2010;52(5):1590‐9. DeBruijneJ , BergmannJF , WeeginkCJ , MolenkampR , SchinkelJ , TreitelMA , et al. Narlaprevir and peginterferon alfa‐2b for 2 weeks in chronic hepatitis C genotype 1 patients, followed by peginterferon alfa‐2b and ribavirin for 24/48 weeks: final results. Journal of Hepatology2010;52:S290‐1. HothoDM , DeBruijneJ , SpaanM , TreitelMA , BoonstraA , DeKnegtRJ , et al. Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long‐term follow‐up. Journal of Viral Hepatitis2013;20(4):e78‐81. ">De Bruijne 2010a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Narlaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 pyrexia, 1 elevated CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0128" title="MuirA , PoordadF , SheikhA , ElkashabM , BrennanR , Ankoma‐SeyV , et al. SVR4 results for the combination of ACH‐3102 and Sovaprevir, with ribavirin, in patients with genotype 1 chronic hepatitis C infection. 23rd Annual Conference of APASL, Brisbane, Australia. 2014. ">Muir 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Odalasvir (ACH‐3102) and sovaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 non‐cardiac chest pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0210" title="LiuY , LarsenL , BourliereM , BaranR , JudayT . Ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin (RBV) has mild impact on health‐related quality of life (HRQoL) compared with placebo during 12‐week treatment in treatment‐experienced adults with chronic hepatitis C (CHC). Journal of Hepatology2015;62(Suppl S2):S661. ZeuzemS , JacobsonIM , BaykalT , MarinhoRT , PoordadF , BourliereM , et al. Retreatment of HCV with ABT‐450/r‐ombitasvir and dasabuvir with ribavirin. New England Journal of Medicine2014;370(17):1604‐14. ">Zeuzem 2014a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paritaprevir (ABT‐450)/r–ombitasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 pneumonia, 1 nausea, 1 vomiting, 1 bradycardia, 1 chronic obstructive pulmonary disease, 1 renal failure acute,<br/> 1 dizziness, 1 intestinal obstruction, 1 cerebrovascular accident, 1 bile duct stone, 1 calculus ureteric, 1 angioedema </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 out of 393</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 atrial fibrillation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 97</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0003" title="AndersonRT , BaranRW , EricksonP , RevickiDA , DietzB , GoochK . Psychometric evaluation of the hepatitis C virus patient‐reported outcomes (HCV‐PRO) instrument: validity, responsiveness, and identification of the minimally important difference in a phase 2 clinical trial. Quality of Life Research2014;23(3):877‐86. GaultierI , CohenDE , BhathenaA , IdlerK , LarsenLM , PodsadeckiT , et al. The effect of IL28B polymorphisms on virologic response to treatment with pegylated interferon alpha‐2A and ribavirin (SOC) added to ABT‐450/ritonavir (ABT‐450/R), ABT‐333, or ABT‐072. Journal of Hepatology2011;54(Suppl 1):S523. Pilot‐MatiasTJ , TripathiRL , DekhtyarT , MenonRM , GaultierIA , CohenDE , et al. Genotypic and phenotypic characterization of NS3 variants selected in HCV‐infected patients treated with ABT‐450. Journal of Hepatology2011;54(Suppl 1):S485‐6. ">Anderson 2014a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paritaprevir/ABT‐072/dasabuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 haemorrhoids, 1 malignant melanoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 out of 63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0049" title="FeldJJ , KowdleyKV , CoakleyE , SigalS , NelsonD , CrawfordD , et al. Sapphire I: Phase 3 placebo‐controlled study of interferon‐free, 12‐week regimen of ABT‐450/R/ABT‐267, ABT‐333, and ribavirin in 631 treatment‐naive adults with hepatitis Cvirus genotype 1. Journal of Hepatology2014;60(1 Suppl 1):S25. FeldJJ , KowdleyKV , CoakleyE , SigalS , NelsonDR , CrawfordD , et al. Treatment of HCV with ABT‐450/r‐ombitasvir and dasabuvir with ribavirin. New England Journal of Medicine2014;370(17):1594‐603. KowdleyKV , FeldJJ , CoakleyE , SigalS , NelsonDR , CrawfordD , et al. Sapphire I: Phase 3 placebo‐controlled study of interferon‐free, 12‐week regimen of ABT‐450/R/ABT‐267, ABT‐333, and ribavirin in 631 treatment‐naive adults with hepatitis C virus genotype 1. Gastroenterology2014;146(5 Suppl 1):S912‐S3. ">Feld 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paritaprevir/ombitasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 abdominal pain, 1 diarrhoea, 1 cholecystitis, 1 appendicitis, 1 overdose, 1 sinus tachycardia, 1 ventricular extrasystoles, 1 nausea, 1 vomiting, 1 chills, 1 non‐cardiac chest pain, 1 lobar pneumonia, 1 postoperative wound infection, 1 lumbar vertebral fracture, 1 non‐small cell lung cancer, 1 encephalopathy, 1 acute respiratory failure, 1 hypoxia, 1 mediastinal mass, 1 aortic stenosis, 1 biliary colic, 1 subcutaneous abscess </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 out of 630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 158</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0157" title="NelsonD , PockrosPJ , GodofskyE , Rodriguez‐TorresM , EversonG , FriedM , et al. High end‐of‐treatment response (84%) after 4 weeks of R1626, peginterferon alfa‐2A (40KD) and ribavirin followed by a further 44 weeks of peginterferon alfa‐2A and ribavirin. Journal of Hepatology2008;48(Suppl 2):S371. PockrosPJ , NelsonD , GodofskyE , Rodriguez‐TorresM , EversonGT , FriedMW , et al. R1626 plus peginterferon alfa‐2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology2008;48(2):385‐97. ">Pockros 2008a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>R1626</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 SAEs but not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 out of 84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 SAE but not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0057" title="FornsX , LawitzE , ZeuzemS , GaneE , BronowickiJP , AndreoneP , et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology2014;146(7):1669‐79. FornsX , LawitzE , ZeuzemS , GaneEJ , BronowickiJP , AndreoneP , et al. Simeprevir (TMC435) with peg‐interferon alpha‐2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon‐based therapy: efficacy and safety in patient sub‐populations in the PROMISE phase III trial. Hepatology2013;58(4 SUPPL. 1):737A‐8A. GaneEJ , FornsX , LawitzE , ZeuzemS , BronowickiJP , AndreoneP , et al. Simeprevir (TMC435) with peg‐interferon alpha‐2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon‐based therapy: efficacy in patients with genotype 1b HCV in the PROMISE phase III trial. Hepatology International2014;8(1 Suppl 1):S181. LawitzE , FornsX , ZeuzemS , GaneE , BronowickiJP , AndreoneP , et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon‐based therapy: results from PROMISE, a phase III trial. Gastroenterology2013;144(5 Suppl 1):S151. ">Forns 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 abdominal pain, 1 pyrexia, 1 appendicitis, 2 pneumonia, 1 depression, 1 dyspnoea, 1 cholelithiasis, 1 anaemia haemolytic autoimmune, 1 pancytopenia, 1 angina pectoris, 1 bradycardia, 1 myocardial ischaemia, 1 hepatitis, 1 endocarditis, 1 lower respiratory tract infection, 1 septic shock, 1 breast cancer, 1 Guillain‐Barre syndrome, 1 presyncope, 1 confusional state, 1 vaginal haemorrhage, 1 chronic obstructive pulmonary disease, 1 respiratory acidosis, 1 photosensitivity reaction </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 out of 260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 atrial fibrillation, 1 depression, 1 bronchitis, 1 hypercalcaemia, 1 head injury, 1 bacterial prostatitis, 1 pericarditis, 1 infection, 1 inguinal hernia, 1 neuropathy peripheral, 1 arthritis infective, 1 headache </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 out of 133</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0062" title="AerssensJ , FanningG , ScholliersA , LenzO , PeetersM , DeSmedtG , et al. Impact of IL28B genotype and pretreatment serum IP‐10 in treatment‐naive genotype‐1 HCV patients treated with TMC435 in combination with peginterferona‐2A and ribavirin in PILLAR study. Journal of Hepatology2011;54(Suppl S1):S5‐6. FriedMW , ButiM , DoreGJ , FerenciP , JacobsonI , MarcellinP , et al. Efficacy and safety of TMC435 in combination with peginterferon alfa‐2a and ribavirin in treatment‐naive genotype‐1 HCV patients: 24‐week interim results from the PILLAR study. Hepatology2010;52(Suppl S1):403A. FriedMW , ButiM , DoreGJ , FlisiakR , FerenciP , JacobsonI , et al. Once‐daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment‐naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology2013;58(6):1918‐29. ScottJ , GillesL , FuM , BrohanE , AmatyaR , JessnerW , et al. Patients with chronic hepatitis C virus treated with simeprevir added to peginterferon and ribavirin experienced less time with fatigue, depressive symptoms, and functional limitations: results from patients in the QUEST‐1, QUEST‐2, and promise studies. Value in Health2013;16(7):A362. ScottJ , GillesL , FuM , BrohanE , PanterC , ArbuckleR , et al. Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies. Journal of Viral Hepatitis2015;22(8):639‐50. ScottJ , RosaK , FuM , CerriK , PeetersM , Beumont‐MauvielM , et al. Improved SVR with simeprevir (TMC435) associated with reduced time with patient‐reported fatigue in treatment‐naive, HCV‐infected patients in the PILLAR phase IIb trial. Journal of Hepatology2013;58(Suppl 1):S371‐2. ">Fried 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 cholecystitis, 1 intervertebral disc protrusion, 1 depression, 1 nausea, 1 breast cancer, 1 hyperthyroidism, 1 ocular vasculitis, 1 abdominal pain upper, 1 colitis, 1 small intestinal obstruction, 1 malaise, 1 incision site cellulitis, 1 necrotising fasciitis, 1 perihepatic abscess, 1 pneumonia pneumococcal, 1 upper respiratory tract infection, 1 post‐procedural bile leak, 1 malnutrition, 1 type 1 diabetes mellitus, 1 spinal disorder, 1 parathyroid tumour benign, 1 headache, 1 haemoptysis, 1 cutaneous vasculitis, 1 hypertension </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 out of 309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 myocardial infarction, 1 myopericarditis, 1 asthenia, 1 appendicitis, 1 vomiting, 1 chronic obstructive pulmonary disease, 1 headache, 1 subcutaneous abscess, 1 vulval abscess, 1 myositis, 1 ovarian neoplasm </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 out of 77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0044" title="HayashiN , SetoC , KatoM , KomadaY , GotoS . Once‐daily simeprevir (TMC435) with peginterferon/ribavirin for treatment‐naive hepatitis C genotype 1‐infected patients in Japan: the DRAGON study. Journal of Gastroenterology2014;49(1):138‐47. ">DRAGON 2014a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 subarachnoid haemorrhage, 1 malaise, 1 cerebral infarction, 1 vulvar erosion, 1 rash, 1 incorrect dose administered </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 out of 79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0077" title="HoebenE , VibergA , PeterssonK , LeeM , VanwelkenhuysenI , WitekJ , et al. Simeprevir exposure in Asian treatment naive patients with chronic hepatitis C virus genotype 1 infection results from a population pharmacokinetic model in the phase III Tiger study. Hepatology International2015;9(1 Suppl):S71. WeiL , HanT , YangD , HeoJ , ShangJ , ChengJ . Simeprevir plus peginterferon ribavirin in treatment naive patients with chronic hepatitis C virus genotype 1 infection results from the phase III Tiger study conducted in East Asian patients living in China and Korea. Hepatology International2015;9(1 Suppl):S61. ">Hoeben 2015a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 depression, 1 non‐cardiac chest pain, 1 angina unstable, 1 nephrolithiasis, 1 ureteric stenosis, 1 colitis ischaemic, 1 incision site infection, 1 craniocerebral injury, 1 foot fracture, 1 meniscus lesion, 1 multiple injuries, 1 rib fracture, 1 tibia fracture, 1 traumatic lung injury, 1 wound, 1 cholesterosis, 1 type 2 diabetes mellitus, 1 shock haemorrhagic </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 out of 305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 decreased appetite, 1 cholelithiasis, 1 contusion, 1 supraventricular tachycardia, 1 ligament sprain, 1 pain, 1 atypical pneumonia, 1 chronic hepatitis C, 1 pulmonary tuberculosis, 1 undifferentiated connective tissue disease, 1 brain neoplasm </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 out of 152</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0146" title="MannsM , ReesinkH , BergT , DusheikoG , FlisiakR , MarcellinP , et al. Rapid viral response of once‐daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype‐1 patients: a randomized trial. Antiviral Therapy2011;16(7):1021‐33. ">OPERA 2011a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 sinus arrest, 1 erysipelas, 1 type 1 diabetes mellitus, 1 psychotic disorder, 1 drug abuse, 1 bronchitis, 1 exostosis, 1 toe deformity, 1 hyperthyroidism, 1 Bowen's disease, 1 neutropenia, 1 thrombocytopenia, 1 breast cancer, 1 sepsis, 1 cupulolithiasis, 1 pneumonia escherichia, 1 panic reaction </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 out of 88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 pneumonia, 1 sinusitis, 1 panic attack, 1 social stay hospitalisation, 1 pneumonia escherichia </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 out of 28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0120" title="MannsM , MarcellinP , PoordadF , DeAraujoESA , ButiM , HorsmansY , et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment‐naive patients with chronic hepatitis C virus genotype 1 infection (QUEST‐2): a randomised, double‐blind, placebo‐controlled phase 3 trial. Lancet2014;384(9941):414‐26. PoordadF , MannsMP , MarcellinP , AraujoESA , ButiM , HorsmansY , et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype‐1 infection in treatment‐naive patients: results from QUEST‐2, a phase III trial. Gastroenterology2013;144(5 Suppl 1):S151. ">Manns 2014a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 anaemia, 1 back pain, 1 syncope, 1 hyperthyroidism, 1 death, 1 muscle spasms, 1 colon cancer, 1 anal abscess, 1 urinary tract infection, 1 mixed deafness, 1 hyphaema, 1 visual impairment, 1 enterocutaneous fistula, 1 autoimmune hepatitis, 1 lymphadenitis bacteria, 1 fluid overload, 1 epilepsy, 1 memory impairment, 1 aggression </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 out of 257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 pancreatitis acute, 1 dehydration, 1 vomiting, 1 pancytopenia, 1 loss of consciousness, 1 angina unstable, 1 meniscus lesion, 1 pulmonary embolism, 1 cholecystitis acute, 1 drug abuse, 1 retinal ischaemia, 1 respiratory tract infection viral, 1 viral infection, 1 neuropathy peripheral, 1 thoracic outlet syndrome </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 out of 134</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0155" title="PearlmanBL , EhlebenC , PerrysM . The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C‐related Child's class A cirrhosis. Gastroenterology2015;148(4):762. ">Pearlman 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 liver decompensation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0014" title="FerenciP , FriedM , PoordadF , ZeuzemS , LenzO , Ouwerkerk‐MahadevanS , et al. Safety of simeprevir (SMV) with peg Ifnalpha‐2a/ribavirin (PR) in HCV genotype 1‐infected patients: PILLAR and ASPIRE trials. Swiss Medical Weekly2013;143(Suppl 199):15S. LenzO , FeveryB , VijgenL , VerbeeckJ , PeetersM , Beumont‐MauvielM , et al. TMC435 in patients infected with HCV genotype 1 who have failed previous pegylated interferon/ribavirin treatment: virologic analyses of the ASPIRE trial. Journal of Hepatology2012;56(Suppl S2):S5. ScottJ , RosaK , FuM , CerriK , PeetersM , BeumontM , et al. Fatigue during treatment for hepatitis C virus: results of self‐reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection. BMC Infectious Diseases2014;14:465. ScottJ , RosaK , FuM , CerriK , PeetersM , Beumont‐MauvielM , et al. Fatigue severity scale: reliability, validity and interpretation of change‐evidence from two clinical trials in patients with chronic HCV infection. Value in Health2013;16(3):A216. ScottJ , RosaK , ZeuzemS , Beumont‐MauvielM , PeetersM , Cerri , K , et al. Adding simeprevir (TMC435) to pegylated interferon/ribavirin does not increase patient reported fatigue in treatment‐experienced patients with chronic HCV infection: results from the ASPIRE trial. Journal of Hepatology2013;58(Suppl S1):S371. ZeuzemS , BergT , GaneE , FerenciP , FosterGR , FriedMW , et al. Simeprevir increases rate of sustained virologic response among treatment‐experienced patients with HCV genotype‐1 infection: a phase IIb trial. Gastroenterology2014;146(2):430‐41. ZeuzemS , FosterGR , FriedMW , HezodeC , HirschfieldGM , NikitinI , et al. The ASPIRE trial: TMC435 in treatment‐experienced patients with genotype‐1 HCV infection who have failed previous PEGIFN/RBV treatment. Journal of Hepatology2011;54(Suppl 1):S546. ">ASPIRE 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 abdominal pain, 1 diarrhoea, 1 oedema peripheral, 2 cholecystitis, 1 pneumonia, 1 overdose, 2<br/> dehydration, 1 intervertebral disc protrusion, 1 hepatic neoplasm malignant, 2 vomiting, 1 non‐cardiac chest pain, 1 neutropenia, 2 cellulitis, 1 pancytopenia, 1 headache, 1 hypertension, 1 suicide attempt, 1 drug eruption, 2 clostridium difficile colitis, 1 nephrolithiasis, 1 pulmonary embolism, 1 rectal cancer, 1 sinusitis, 3 urinary tract infection, 1 diabetes mellitus, 1 migraine, 1 coma, 1 epistaxis, 1 alcohol abuse, 1 haemorrhagic anaemia, 1 cervix carcinoma, 1 periodontal disease, 1 enteritis, 1 gastro intestinal pain, 1 gingival infection, 1 lung infection, 1 meningitis bacterial, 1 pneumonia bordetella, 1 salpingitis, 1 thermal burn, 1 neurilemmoma benign, 1 brain injury, 1 cerebral haemorrhage, 1 vii nerve paralysis, 1 metrorrhagia, 1 pelvic adhesions </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 out of 396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 sciatica, 1 nausea, 1 vomiting, 1 lower respiratory tract infection, 1 haemorrhoids, 1 weight decreased, 1 histiocytosis haematophagic, 1 tuberculosis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 out of 66</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0166" title="JacobsonIM , GordonSC , KowdleyKV , YoshidaEM , Rodriguez‐TorresM , SulkowskiMS , et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. New England Journal of Medicine2013;368(20):1867‐77. YounossiZM , StepanovaM , HenryL , GaneE , JacobsonIM , LawitzE , et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH‐C). Journal of Hepatology2014;60(4):741‐7. [PUBMED: 24333184] ">POSITRON 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sofosbuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 drug withdrawal syndrome, 1 non‐cardiac chest pain, 1 oedema peripheral, 1 pyrexia, 1 hypersensitivity, 1 abdominal abscess, 1 cellulitis, 2 overdose, 1 injury, 1 road traffic accident, 1 spinal compression fracture, 1 hypoglycaemia, 1 hepatic neoplasm malignant, 1 abnormal behaviour, 1 eczema </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 out of 207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 pancreatitis, 1 bile duct stone, 1 bronchitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 out of 71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0104" title="LawitzE , LalezariJP , HassaneinT , KowdleyKV , PoordadFF , SheikhAM , et al. Sofosbuvir in combination with peginterferon alfa‐2a and ribavirin for non‐cirrhotic, treatment‐naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double‐blind, phase 2 trial. Lancet Infectious Diseases2013;13(5):401‐8. ">Lawitz 2013a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sofosbuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 retinal vein occlusion, 1 depression, 1 suicidal ideation, 1 lymphangitis, 1 acute myocardial infarction </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 out of 95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 chest pain, 1 electrocardiogram ST segment elevation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0051" title="LawitzE , MangiaA , WylesD , Rodriguez‐TorresM , HassaneinT , Gordon StuartC , et al. Sofosbuvir for previously untreated chronic hepatitis C infection. New England Journal of Medicine2013;368(20):1878‐87. YounossiZM , StepanovaM , HenryL , GaneE , JacobsonIM , LawitzE , et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH‐C). Journal of Hepatology2014;60(4):741‐7. [PUBMED: 24333184] ">FISSION 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sofosbuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 chest pain, 1 cellulitis, 1 chronic obstructive pulmonary disease, 1 urinary tract infection, 1 allergy to anthropod sting, 1 osteomyelitis chronic , 1 toxicity to various agents </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 out of 256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 pneumothorax, 1 breast cancer, 1 infection, 1 atrioventricular shock, 1 clavicle fracture, 1 rib fracture </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 out of 243</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0174" title="Rodriguez‐TorresM , LawitzE , KowdleyKV , NelsonDR , DejesusE , McHutchisonJG , et al. Sofosbuvir (GS‐7977) plus peginterferon/ribavirin in treatment‐naïve patients with HCV genotype 1: a randomized, 28‐day, dose‐ranging trial. Journal of Hepatology2013;58(4):663‐8. ">Rodriguez‐Torres 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sofosbuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 depression, 1 peripheral ischaemia, 1 pancreatitis acute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 out of 49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0050" title="FeldJJ , JacobsonIM , HezodeC , AsselahT , RuanePJ , GruenerN , et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. New England Journal of Medicine2015;373(27):2599‐607. ">Feld 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sofosbuvir/velpatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 bronchitis, 1 cellulitis, 1 influenza, 1 chronic obstructive pulmonary disease, 1 death, 1 gastroenteritis, 1 acute myocardial infarct, 1 ligament sprain, 1 foot abscess, 1 foot necrosis, 1 recurring appendicitis, 1 epileptic seizure, 1 rotator cuff syndrome, 1 lung cancer, 1 mania, 1 palpitations, 1 small bowel obstruction, 1 upper limb fracture, 1 vestibular neuronitis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 out of 624</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 116</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0020" title="BenhamouY , MoussalliJ , RatziuV , LebrayP , DeBackerK , DeMeyerS , et al. Telaprevir activity in treatment‐naive patients infected hepatitis C virus genotype 4: a randomized trial. Journal of Infectious Diseases2013;208(6):1000‐7. BenhamouY , MoussalliJ , RatziuV , LebrayP , GysenV , deBackerK , et al. Results of a proof of concept study (C210) of telaprevir monotherapy and in combination with peginterferon ALFA‐2A and ribavirin in treatment‐naive genotype 4 HCV patients. Journal of Hepatology2009;50(Suppl 1):S6. BenhamouY , MoussalliJ , RatziuV , LebrayP , deBackerK , GhysA , et al. Activity of telaprevir monotherapy or in combination with peginterferon‐alfa‐2a and ribavirin in treatment‐naive genotype 4 hepatitis C patients: final results of study C210. Hepatology2010;52(Suppl S1):719A. DeMeyerS , GhysA , DierynckI , BeumontM , LuoD , PicchioG . Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir. Virology Journal2014;11:93. ">Benhamou 2013a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 cholelithiasis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0075" title="BronowickiJP , HezodeC , BengtssonL , PolS , BourliereM , SerfatyL , et al. 100% SVR in IL28B CC patients treated with 12 weeks of telaprevir, peginterferon and ribavirin in the PROVE2 trial. Journal of Hepatology2012;56(Suppl 2):S430‐1. DusheikoGM , HezodeC , PolS , GoeserT , BronowickiJP , BourliereM , et al. Treatment of chronic hepatitis C with telaprevir (TVR) in combination with peginterferon‐alfa‐2a with or without ribavirin: further interim analysis results of the PROVE2 study. Journal of Hepatology2008;48(Suppl 2):S26. HezodeC , FerenciP , Dusheiko GeoffreyM , TranA , GrangeJ‐D , MathurinP , et al. Prove2 Study: treatment of chronic hepatitis C with telaprevir (Tvr) in combination with peginterferon‐alfa‐2a with or without ribavirin, interim analysis results. Gastroenterology2008;134(4, Suppl. 1):A755. HezodeC , ForestierN , DusheikoG , FerenciP , PolS , GoeserT , et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. New England Journal of Medicine2009;360(18):1839‐50. MuirA , PoordadF , SheikhA , ElkashabM , BrennanR , Ankoma‐SeyV , et al. SVR4 results for the combination of ACH‐3102 and sovaprevir, with ribavirin, in subjects with genotype 1 chronic hepatitis C infection. Hepatology International2014;8(1 Suppl):s395. PawlotskyJ , KiefferT , ZhouY , ZhangE , MarcialM , ByrnR , et al. Evaluation of viral variants during a phase 2 study (PROVE2) of telaprevir with peginterferon alfa‐2A and ribavirin in treatment‐naïve HCV genotype 1‐infected patients. Hepatology2007;46(4 Suppl 1):862A. PawlotskyJM , FerenciP , DusheikoGM , AlvesK , KauffmanR , ZeuzemS . PROVE2: a phase 2b study of telaprevir combined with peginterferon‐alfa‐2a with or without ribavirin for treatment‐naive patients with chronic hepatitis C. Hepatology International2009;3(1):169. ZeuzemS , HezodeC , FerenciP , DusheikoGM , AlvesK , BengtssonL , et al. Telaprevir in combination with peginterferon‐alfa‐2a with or without ribavirin in the treatment of chronic hepatitis C: final results of the PROVE2 study. Hepatology2008;48(4 Suppl):418A‐9A. ZeuzemS , HezodeC , FerenciP , DusheikoGM , PolS , GoeserT , et al. PROVE2: phase II study of VX950 (telaprevir) in combination with peginterferon alfa2A with or without ribavirin in subjects with chronic hepatitis C; first interim analysis. Hepatology2007;46(4 Suppl 1):268A‐9A. ">Hezode 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 anaemia, 2 abdominal pain, 1 asthenia, 1 pyrexia, 1 back pain, 3 syncope, 3 depression, 2 dyspnoea, 1 nausea, 1 chills, 1 pancytopenia, 5 rash, 1 lymphadenopathy, 1 hydrocele, 1 retinal haemorrhage, 1 catheter‐related complication, 1 bacterial sepsis, 1 pneumonia, 1 herpes viral, 1 sepsis, 1 road traffic accident, 1 tendon rupture, 1 lung neoplasm malignant, 1 speech disorder, 1 disorientation, 1 emotional distress, 1 suicide attempt, 1 renal failure, 1 acute testicular swelling, 3 pruritis, 2 drug eruption, 2 rash maculo‐papular, 1 rash erythematous, 1 rash generalised, 1 toxic skin eruption, 1 urticaria, 1 splenectomy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 out of 241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 anaemia, 1 angina pectoris, 1 syncope, 1 hyperthyroidism, 1 gastroenteritis, 1 haemorrhagic anaemia, 1 alcoholic pancreatitis, 1 paranoia, 1 uterine polyp </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 out of 82</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0001" title="BroganAJ , TalbirdSE , ThompsonJR , MillerJD , RubinJ , DenizB . Cost‐effectiveness of telaprevir combination therapy for chronic hepatitis C. PLoS ONE2014;9(3):e90295. CurtisS , CureS , GavartS , DeardenL , FleischmannJ , OuwensM , et al. The cost‐effectiveness of telaprevir (TVR) in combination with pegylated interferon‐alfa and ribavirin (PR) for the treatment of genotype 1 chronic hepatitis C patients. Journal of Hepatology2012; Vol. 56, issue Suppl 2:S434. DiBisceglieAM , DusheikoGM , MuirAJ , ZeuzemS , MarcellinP , BzowejNH . Telaprevir in combination with peginterferon alfa‐2a and ribavirin: analyses of pre‐defined subpopulations in the phase 3 ADVANCE trial. Gastroenterology2011;140(5 Suppl 1):S908. DusheikoGM , BengtssonL , AddaN , KauffmanR , JacobsonIM . Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment‐naive patients: final results of phase 3 Advance study. Gut2011;60(Suppl 2):A32‐3. EversonG , DusheikoG , PolS , NelsonD , MuirA , AndreoneP , et al. Telaprevir in combination with peginterferon alfa‐2a and ribavirin increased sustained virologic response in genotype 1 chronic HCV and allowed for shorter treatment duration in treatment‐naive and prior relapser patients. American Journal of Gastroenterology2011;106(2S):S113‐4. JacobsonIM , McHutchisonJG , DusheikoG , DiBisceglieAM , ReddyKR , BzowejNH , et al. Telaprevir for previously untreated chronic hepatitis C virus infection. New England Journal of Medicine2011;364(25):2405‐16. JacobsonIM , McHutchisonJG , DusheikoGM , DiBisceglieAM , ReddyR , BzowejNH , et al. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment‐naive patients: final results of phase 3 ADVANCE study. Hepatology2010;52(Suppl S1):427A. KiefferTL , BartelsDJ , SullivanJ , AdiwijayaBS , ZhangEZ , TiggesA , et al. Clinical virology results from telaprevir phase 3 study ADVANCE. Hepatology2010;52(Suppl S1):879A. LuoD , ZeuzemS , JacobsonIM , ShermanK , AddaN , WrightCI , et al. High concordance between SVR12 and SVR24 in patients receiving telaprevir plus peginterferon and ribavirin in three phase iii clinical trials: Advance, Illuminate and Realize. Journal of Hepatology2012;56(Suppl 2):S446‐7. MarcellinP , JacobsonIM , ZeuzemS , BzowejN , MuirAJ , DusheikoG . Telaprevir in combination with peginterferon alfa‐2a and ribavirin: analyses of pre‐defined subpopulations in the phase 3 ADVANCE trial. Journal of Hepatology2011;54(Suppl 1):S183‐4. RizzettoM , AndreoneP , ColomboM , ScuteriA , CiancioA , SmedileA , et al. ADVANCE study: final results of the phase III trial with telaprevir in combination with PEG‐IFN and RBV in treatment‐naive genotype 1 HCV. Digestive and Liver Disease2011;43(Suppl 2):S69. SulkowskiMS , ReddyR , AfdhalNH , DiBisceglieAM , ZeuzemS , PoordadF , et al. Anemia had no effect on efficacy outcomes in treatment‐naive patients who received telaprevir‐based regimen in the Advance and Illuminate phase 3 studies. Journal of Hepatology2011;54(Suppl 1):S195. ">ADVANCE 2011a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 anaemia, 3 pneumonia, 3 syncope, 2 cellulitis, 5 rash, 3 psychiatric disorder, 2 musculoskeletal disorder, 2 cardiac disorder, 2 eye disorder, 3 hepatobiliary disorders, 2 vascular disorder </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 out of 727</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 anaemia, 1 cellulitis, 3 psychiatric disorder, 3 musculoskeletal disorder, 2 cardiac disorder, 4 renal and urinary disorder, 1 eye disorder, 1 vascular disorder </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 out of 361</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0125" title="EversonGT , GordonSC , JacobsonI , KauffmanRS , McNairL , MuirA , et al. PROVE 1: subgroup analysis of a phase 2 study of telaprevir with peginterferon alfa‐2a and ribavirin in treatment‐naive subjects with hepatitis C. Hepatology International2009;3:167. McHutchisonJG , EversonGT , GordonSC , JacobsonI , KauffmanR , McNairL , et al. PROVE1: results from a phase 2 study of telaprevir with peginterferon alfa‐2a and ribavirin in treatment‐naive subjects with hepatitis C. Journal of Hepatology2008;48(Suppl S2):S4. McHutchisonJG , EversonGT , GordonSC , JacobsonIM , SulkowskiM , KauffmanR , et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. New England Journal of Medicine2009;360(18):1827‐38. ">McHutchison 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 anaemia, 1 gastroenteritis viral, 1 dehydration, 2 depression, 1 non‐cardiac chest pain, 1 chronic obstructive pulmonary disease, 1 rash, 1 rash generalised, 1 furuncle, 1 colitis ischaemic, 1 acute myocardial infarction, 1 adrenal disorder, 2 scotoma, 1 retinal exudates, 1 retinal infarction, 1 bronchitis bacterial, 1 incisional hernia, 1 lumbar radiculopathy, 1 exfoliative rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 out of 175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 lobar pneumonia, 1 pancytopenia, 1 anxiety, 1 lymphadenitis bacteria, 1 deafness neurosensory </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 out of 75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0126" title="EversonGT , GordonSC , JacobsonI , KauffmanRS , McNairL , MuirA , et al. PROVE 1: subgroup analysis of a phase 2 study of telaprevir with peginterferon alfa‐2a and ribavirin in treatment‐naive subjects with hepatitis C. Hepatology International2009;3:167. MannsM , MuirA , AddaN , JacobsonI , AfdhalN , HeathcoteJ , et al. Telaprevir in hepatitis C genotype‐1‐infected patients with prior non‐response, viral breakthrough or relapse to peginterferonalfa‐2A/B and ribavirin therapy: SVR results of the PROVE3 study. Journal of Hepatology2009;50(Suppl 1):S379. McHutchinsonJG , MannsMP , MuirAJ , TerraultNA , JacobsonIM , AfdhalNH , et al. Telaprevir for previously treated chronic HCV infection. New England Journal of Medicine2010;362(14):1292‐303. McHutchinsonJG , ShiffmanML , TerraultN , MannsMP , DiBiscegliAM , JacobsonIM , et al. Interim results of PROVE 3: a randomized, controlled, phase 2b study of telaprevir (TVR) with peginterferon‐alfa‐2a (P) and/or ribavirin (R) in subjects with hepatitis C genotype 1 who failed to achieve an SVR with a prior course of PR therapy. Hepatology International2009;3(1):25. McHutchisonJG , MannsMP , MuirA , TerraultN , JacobsonIM , AfdhalNH , et al. PROVE3 final results and 1‐year durability of SVR with telaprevir‐based regimen in hepatitis C genotype 1‐infected patients with prior non‐response, viral breakthrough or relapse to peginterferon‐alfa‐2a/b and ribavirin therapy. Hepatology2009;50(4 Suppl):334A‐5A. McHutchisonJG , ShiffmanML , TerraultN , MannsMP , DiBisceglieAM , JacobsonIM , et al. A phase 2b study of telaprevir with peginterferon‐alfa‐2a and ribavirin in hepatitis C genotype 1 null and partial responders and relapsers following a prior course of peginterferon‐alfa‐2a/b and ribavirin therapy: PROVE3 interim results. Hepatology2008;48(4 Suppl):269A‐70A. ">McHutchison 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 anaemia, 1 pancreatitis acute, 1 gastroenteritis viral, 1 pneumonia, 1 dehydration, 1 back pain, 1 suicidal ideation, 2 cholelithiasis, 1 postoperative wound infection, 1 upper gastrointestinal haemorrhage, 1 confusional state, 2 small intestinal obstruction, 1 necrotising fasciitis, 1 pneumonia pneumococcal, 1 post‐procedural bile leak, 1 rash, 1 renal failure acute, 1 retinal detachment, 9 gastroenteritis, 1 cholecystitis acute, 1 sinusitis, 1 hypokalaemia, 1 eczema, 2 pancreatitis, 1 dermatitis, 1 diverticulitis, 1 alcohol abuse, 1 hypotension, 1 haemorrhagic anaemia, 1 idiopathic thrombocytopenic purpura, 1 cardiomyopathy, 1 diverticular perforation, 1 gastritis erosive, 1 abscess intestinal, 1 cholecystitis infective, 1 infected insect bite, 1 sepsis syndrome, 1 hypovolaemia, 1 B‐cell unclassifiable lymphoma low grade, 1 migraine with aura, 1 ruptured cerebral aneurysm, 1 neurogenic bladder, 1 lichenoid keratosis, 1 rash macular </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 out of 339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 pneumonia, 2 dehydration, 1 syncope, 1 depression, 1 non‐small cell lung cancer, 1 headache, 2 rash, 1 renal failure acute, 2 gastroenteritis, 1 renal tubular acidosis, 1 decubitus ulcer, 1 hematoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 out of 114</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0196" title="ShermanKE , RockstrohJK , DieterichDT , SorianoV , GirardPM , McCallisterS , et al. Telaprevir combination with peginterferon alfa‐2A/ribavirin in HCV/HIV coinfected patients: 24‐week treatment interim analysis. Hepatology2011;54(4 Suppl):1431A‐2A. SulkowskiMS , ShermanKE , DieterichDT , BsharatM , MahnkeL , RockstrohJK , et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Annals of Internal Medicine2013;159(2):86‐96. SulkowskiMS , ShermanKE , SorianoV , RockstrohJ , DieterichDT , GirardPM , et al. Telaprevir in combination with peginterferon alfa‐2a/ribavirin in HCV/HIV co‐infected patients: SVR24 final study results. Hepatology2012;56(S1):219A. ">Sulkowski 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 myocardial infarction, 1 staphylococcal infection, 1 pyelonephritis acute, 1 haemolytic anaemia, 1 groin infection, 1 cellulitis staphylococcal, 1 staphylococcal abscess, 1 hypokalaemia, 1 hyponatraemia, 1 epididymitis, 1 non‐ cardiac chest pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 out of 38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 appendicitis, 1 peritonitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 out of 22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0209" title="BergT , AndreoneP , PolS , RobertsSK , YounossiZM , DiagoM , et al. Predictors of virologic response with telaprevir‐based combination treatment in HCV genotype 1‐infected patients with prior peginterferon/ribavirin treatment failure: post‐hoc analysis of the phase III REALIZE study. Hepatology2011;54(S1):375A‐6A. DeMeyerS , DierynckI , GhysA , BeumontM , DaemsB , VanBaelenB , et al. Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial. Hepatology2012;56(6):2106‐15. FosterGR , JacobsonIM , DoreGJ , FriedM , MannsM , MarcellinP , et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment‐naive European patients in the QUEST‐1 and QUEST‐2 phase III trials. Journal of Hepatology2014;60(1 Suppl 1):S456. FosterGR , ZeuzemS , AndreoneP , PolS , LawitzEJ , DiagoM , et al. Subanalyses of the telaprevir lead‐in arm in the REALIZE study: response at week 4 is not a substitute for prior null response categorization. Journal of Hepatology2011;54(Suppl 1):S3‐S4. FosterGR , ZeuzemS , AndreoneP , PolS , LawitzEJ , DiagoM , et al. Sustained virologic response rates with telaprevir by response after 4 weeks of lead‐in therapy in patients with prior treatment failure. Journal of Hepatology2013;58(3):488‐94. PolS , AerssensJ , ZeuzemS , AndreoneP , LawitzEJ , RobertsS , et al. Similar SVR rates in IL28B CC, CT OR TT prior relapser, partial‐ or null‐responder patients treated with telaprevir/peginterferon/ribavirin: retrospective analysis of the REALIZE study. Journal of Hepatology2011;54(Suppl 1):S6‐7. PolS , RobertsSK , AndreoneP , YounossiZM , DiagoM , LawitzE , et al. Efficacy and safety of telaprevir‐based regimens in cirrhotic patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: subanalysis of the REALIZE phase III study. Hepatology2011;54(S1):374A‐5A. RobertsSK , AndreoneP , PolS , YounossiZM , DiagoM , LawitzE , et al. Impact of anemia and ribavirin dose reduction on SVR to a telaprevir‐based regimen in patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure in the phase III REALIZE study. Hepatology2011;54(4 Suppl):1007A‐8A. TuefferdM , PalescandoloE , VijgenL , ColomboM , RobertsS , WedemeyerH , et al. ITPA gene variants and anemia during telaprevir/peginterferon/ribavirin combination therapy in patients with chronic hepatitis C infection. Journal of Hepatology2014;60(1 Suppl S):S490. WitekJ . Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment‐experienced patients. Journal of Hepatology2014;60(6):1112‐7. YounossiZ , NegroF , SerfatyL , PolS , DiagoM , ZeuzemS , et al. Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial. Hepatology2013;58(6):1897‐906. ZeuzemS , AndreoneP , PolS , LawitzE , DiagoM , RobertsS , et al. Telaprevir for retreatment of HCV infection. New England Journal of Medicine2011;364(25):2417‐28. ZeuzemS , AndreoneP , PolS , LawitzEJ , DiagoM , RobertsS , et al. REALIZE trial final results: telaprevir‐based regimen for genotype 1 hepatitis C virus infection in patients with prior null response, partial response or relapse to peginterferon/ribavirin. Journal of Hepatology2011;54(Suppl S1):S3. ">Zeuzem 2011a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 anaemia, 1 febrile neutropenia, 2 pancytopenia, 1 thrombocytopenia , 3 acute myocardial infarction, 2 atrial fibrillation, 1 cardiac valve disease, 1 myocardial infarction, 1 supraventricular tachycardia, 1 sudden hearing loss, 1 Basedow's disease, 1 retinal detachment, 1 abdominal pain, 1 anal fissure, 1 caecitis, 1 gastrointestinal haemorrhage, 1 pancreatitis, 2 pancreatitis acute, 1 general physical health deterioration, 1 pyrexia, 1 appendicitis, 2 bronchitis, 1 erysipelas, 1 folliculitis, 1 Helicobacter gastritis, 1 pneumonia, 1 post‐procedural infection, 1 rectal abscess, 2 sepsis, 1 sinusitis, 1 tooth abscess, 2 urinary tract infection, 1 injection site reaction, 1 animal scratch, 1 ankle fracture, 1 femoral neck fracture, 1 multiple drug overdose, 1 blood corticotrophin decreased, 1 weight decreased, 1 anorexia, 1 diabetes mellitus, 1 bronchial carcinoma, 2 gastric cancer, 2 hepatic neoplasm malignant, 1 histiocytosis haematophagic, 1 lung neoplasm malignant, 1 lethargy, 1 subarachnoid haemorrhage, 2 syncope, 1 delirium, 1 depression, 1 insomnia, 1 substance abuse, 1 renal cyst, 1 renal failure, 1 urinary bladder polyp, 1 prostatitis, 1 pulmonary embolism, 1 dermatitis, 1 eczema , 1 erythema multiforme, 1 pruritus 1 pustular psoriasis, 1 rash, 2 toxic skin eruption, 1 orthostatic hypotension, 1 peripheral artery aneurysm </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 out of 530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 atrial fibrillation, 1 abdominal pain, 1 pneumonia, 1 colitis, 1 pyelonephritis, 1 cerebral thrombosis, 1 coma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 out of 132</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0116" title="LawitzE , SulkowskiM , JacobsonIRA , KraftWK , MaliakkalB , Al‐IbrahimM , et al. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics. Antiviral Research2013;99(3):214‐20. MannsMP , GaneE , Rodriguez‐TorresM , StoehrA , YehC‐T , MarcellinP , et al. Vaniprevir with pegylated interferon alpha‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C: a randomized phase II study. Hepatology2012;56(3):884‐93. MannsMP , GaneE , Rodriguez‐TorresM , StoehrA , YehC‐T , WiedmannR , et al. MK‐7009 significantly improves rapid viral response (RVR) in combination with pegylated interferon ALFA‐2A and ribavirin in patients with chronic hepatitis C (CHC) genotype 1 infection. Journal of Hepatology2009;50(Suppl S1):S384. MannsMP , GaneE , Rodriguez‐TorresM , StoehrA , YehCT , MarcellinP , et al. Vaniprevir with pegylated interferon alpha‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C: a randomized phase II study. Hepatology2012;56(3):884‐93. MannsMP , GaneEJ , Rodriguez‐TorresM , StoehrAD , YehC , MarcellinP , et al. Early viral response (EVR) rates in treatment ‐ naive patients with chronic hepatitis C (CHC) genotype 1 infection treated with MK‐7009, a novel NS3/4a protease inhibitor, in combination with pegylated interferon alfa‐2a and ribavirin for 28 days. Hepatology2009;50(4 Suppl):332A‐3A. MannsMP , GaneEJ , Rodriguez‐TorresM , StoehrAD , YehC , MarcellinP , et al. Sustained viral response (SVR) rates in genotype 1 treatment‐naive patients with chronic hepatitis C (CHC) infection treated with vaniprevir (MK‐7009), A NS3/4A protease inhibitor, in combination with pegylated interferon alfa‐2a and ribavirin for 28 days. Hepatology2010;52(Suppl S1):361A. ">Manns 2012a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaniprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 appendicitis, 1 lobar pneumonia, 1 septic shock, 1 confusional state, 1 gastroenteritis, 1 cholecystitis acute, 1 empyema, 1 haemoglobin decreased, 1 myopathy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 out of 75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 colon cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0107" title="BarnardR , HwangPMT , BhanjaS , CampbellH , StrizkiJ , CheneyC , et al. Resistance analysis of cirrhotic treatment‐experienced genotype 1 patients in a study of MK‐7009 in combination with pegylated interferon/ribavirin. Journal of Hepatology2013;58(Suppl S1):S487. ElbashaE , ElKhouryA , MobasheryN . Projected long‐term impact of MK‐7009 (vaniprevir) for previously treated chronic HCV genotype 1 infection. Hepatology International2013;7(1 Suppl):S354. GaoW , CaroL , AndersonM , HwangP , ZhouA , SuJ , et al. Vaniprevir (MK‐7009) demonstrates higher exposures in treatment‐experienced genotype (GT) 1 cirrhotic than non‐cirrhotic HCV‐infected patients. Hepatology2013;58(Suppl S1):739A. LawitzE , Rodriguez‐TorresM , StoehrA , GaneEJ , SerfatyL , BhanjaS , et al. A phase 2B study of MK‐7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment. Journal of Hepatology2013;59(1):11‐7. MobasheryN , WongP , ZhangS , BhanjaS , WarnerA , ShawPM , et al. Impact of IL28B genotype on virologic response in prior treatment failure patients who received MK‐7009 in combination with peginterferon and ribavirin. Journal of Hepatology2012;56(Suppl S2):S467. ">Lawitz 2013c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaniprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 pneumonia, 1 syncope, 1 upper gastrointestinal haemorrhage, 1 cellulitis, 1 confusional state, 1 dizziness, 1 nephrolithiasis, 1 malignant melanoma, 3 retinal detachment, 1 joint dislocation, 1 congestive cardiac failure, 2 gastroenteritis, 1 femur fracture, 1 hyperglycaemia, 1 dermatomyositis, 1 retinal vascular thrombosis, 1 general physical health deterioration, 1 anaphylactic reaction, 1 pyelonephritis, 1 pyelonephritis acute, 1 carbon monoxide poisoning, 1 arthralgia, 1 arthritis infective, 1 completed suicide </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 out of 229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 hypertensive crisis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 56</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>SAE: serious adverse events.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/full#CD012143-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012143-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Non‐serious adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Experimental intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Type and number of participants with a non‐serious adverse events (experimental group)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Proportion of participants with a non‐serious adverse event (experimental group)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Type and number of participants with a non‐serious adverse events (control group)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Proportion of participants with a non‐serious adverse event (control group)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0024" title="BronowickiJP , PolS , ThuluvathP , LarreyD , MartorellCT , RustgiVK , et al. Asunaprevir (ASV; BMS‐650032), an NS3 protease inhibitor, in combination with peginterferon and ribavirin in treatment‐naive patients with genotype 1 chronic hepatitis C infection. Journal of Hepatology2012;56(Suppl 2):S431‐2. BronowickiJP , PolS , ThuluvathPJ , LarreyD , MartorellCT , RustgiVK , et al. BMS‐650032, an NS3 inhibitor, in combination with peginterferon alpha‐2a and ribavirin in treatment‐naive subjects with genotype 1 chronic hepatitis C infection. Journal of Hepatology2011;54:S472. BronowickiJP , PolS , ThuluvathPJ , LarreyD , MartorellCT , RustgiVK , et al. Randomized study of asunaprevir plus pegylated interferon‐alpha and ribavirin for previously untreated genotype 1 chronic hepatitis C. Antiviral Therapy2013;18(7):885‐93. ">Bronowicki 2013a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asunaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 diarrhoea, 13 nausea, 10 asthenia, 21 fatigue, 14 influenza‐like illness, 7 irritability, 12 decreased appetite, 4 arthralgia, 9 myalgia, 13 headache, 9 depression, 10 insomnia, 7 cough, 10 dyspnoea, 7 alopecia, 11 dry skin, 10 pruritus, 6 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 out of 36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 diarrhoea, 2 nausea, 4 asthenia, 5 fatigue, 5 influenza‐like illness, 4 irritability, 3 decreased appetite, 4 arthralgia, 1 myalgia, 6 headache, 1 depression, 1 insomnia, 3 cough, 3 dyspnoea, 3 alopecia, 1 dry skin, 2 pruritus, 3 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 out of 11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0027" title="BronowickiJ‐P , RatziuV , GadanoA , Thuluvath PaulJ , BessoneF , Martorell ClaudiaT , et al. Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C. Journal of Hepatology2014;61(6):1220‐7. BronowickiJP , PolS , ThuluvathP , LarreyD , MartorellCT , RustgiVK , et al. Asunaprevir (ASV; BMS‐650032), an NS3 protease inhibitor, in combination with peginterferon and ribavirin in treatment‐naive patients with genotype 1 chronic hepatitis C infection. Journal of Hepatology2012;56(Suppl 2):S431‐S2. BronowickiJP , RatziuV , GadanoA , ThuluvathPJ , BessoneF , MartorellCT , et al. Asunaprevir with peginterferon‐alfa and ribavirin in treatment‐naive patients with genotype‐1 or ‐4 chronic hepatitis C: SVR24 results from a randomized phase 2B study (AI447016). Journal of Hepatology2013;58:S571‐2. ">Bronowicki 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asunaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 anaemia, 63 asthenia, 62 fatigue, 37 influenza‐like illness, 43 decreased appetite, 66 headache, 41 pruritus </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173 out of 177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 anaemia, 1 asthenia, 62 fatigue, 23 influenza‐like illness, 22 decreased appetite, 26 headache, 16 pruritus </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 out of 61</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0152" title="PasquinelliC , EleyT , VillegasC , SandyK , MathiasE , WendelburgP , et al. Safety, tolerability, pharmacokinetics and antiviral activity following single and multiple‐dose administration of BMS‐650032, a novel HCV NS3 inhibitor, in subjects with chronic genotype 1 HCV infection. Hepatology International2010;4(1):184. PasquinelliC , EleyT , VillegasC , SandyK , MathiasE , WendelburgP , et al. Safety, tolerability, pharmacokinetics and antiviral activity following single‐and multiple‐dose administration of BMS‐650032, a novel HCV NS3 inhibitor, in subjects with chronic genotype 1 HCV infection. Hepatology2009;50(4 Suppl):411A‐2A. PasquinelliC , McPheeF , EleyT , VillegasC , SandyK , SheridanP , et al. Single‐ and multiple‐ascending‐dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrobial Agents and Chemotherapy2012;56(4):1838‐44. ">Pasquinelli 2012a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asunaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 nausea, 3 headache, 1 flatulence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0153" title="PasquinelliC , EleyT , VillegasC , SandyK , MathiasE , WendelburgP , et al. Safety, tolerability, pharmacokinetics and antiviral activity following single and multiple‐dose administration of BMS‐650032, a novel HCV NS3 inhibitor, in subjects with chronic genotype 1 HCV infection. Hepatology International2010;4(1):184. PasquinelliC , EleyT , VillegasC , SandyK , MathiasE , WendelburgP , et al. Safety, tolerability, pharmacokinetics and antiviral activity following single‐and multiple‐dose administration of BMS‐650032, a novel HCV NS3 inhibitor, in subjects with chronic genotype 1 HCV infection. Hepatology2009;50(4 Suppl):411A‐2A. PasquinelliC , McPheeF , EleyT , VillegasC , SandyK , SheridanP , et al. Single‐ and multiple‐ascending‐dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrobial Agents and Chemotherapy2012;56(4):1838‐44. ">Pasquinelli 2012a2</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asunaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 nausea, 3 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 nausea, 1 flatulence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0130" title="NelsonDR , ZeuzemS , AndreoneP , FerenciP , HerringR , JensenDM , et al. Balapiravir plus peginterferon alfa‐2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. Annals of Hepatology2012;11(1):15‐31. ">Nelson 2012a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Balapiravir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120 anaemia, 41 neutropenia, 115 diarrhoea, 162 nausea, 138 chills, 231 fatigue, 117 pyrexia, 100 arthralgia, 156 myalgia, 82 dizziness, 241 headache, 90 depression, 174 insomnia, 86 cough, 88 alopecia, 60 dry skin, 108 pruritus, 90 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 anaemia, 3 neutropenia, 16 diarrhoea, 25 nausea, 30 chills, 43 fatigue, 19 pyrexia, 16 arthralgia, 33 myalgia, 15 dizziness, 42 headache, 17 depression, 24 insomnia, 11 cough, 11 alopecia, 16 dry skin, 15 pruritus, 13 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 72</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0201" title="McPheeF , FalkP , FracassoP , LemmJ , LiuM , KirkM , et al. Characterization of viral escape in HCV genotype 1‐infected patients treated with BMS‐791325 and pegylated interferon‐ALFA and ribavirin. Journal of Hepatology2012;56(Suppl S2):S473. TatumH , ThuluvathP , LawitzE , MartorellCT , DemiccoM , CohenS , et al. A phase 2A study of BMS‐791325, an NS5B polymerase inhibitor, with peginterferon alfa‐2A and ribavirin in treatment‐naive patients with genotype 1 chronic hepatitis C infection. Journal of Hepatology2012;56(Suppl S2):S460. TatumH , ThuluvathPJ , LawitzE , MartorellC , DemiccoM , CohenS , et al. A randomized, placebo‐controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1. Journal of Viral Hepatitis2015;22(8):658‐64. TatumHA , ThuluvathPJ , LawitzE , MartorellC , CohenSM , RustgiVK , et al. Safety and efficacy of BMS‐791325, a non‐nucleoside NS5B polymerase inhibitor, combined with peginterferon alfa‐2a and ribavirin in treatment‐naive patients infected with hepatitis C virus genotype 1. Hepatology2013;58(S1):759A‐60A. ">Tatum 2015a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Beclabuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 anaemia, 5 neutropenia, 5 diarrhoea, 9 nausea, 3 chills, 12 fatigue, 6 influenza‐like illness, 7 irritability, 3 pyrexia, 7 decreased appetite, 4 arthralgia, 5 myalgia, 12 headache, 6 depression, 9 insomnia, 6 cough, 5 pruritus, 2 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 anaemia, 1 neutropenia, 1 diarrhoea, 2 nausea, 5 fatigue, 7 influenza‐like illness, 3 irritability, 1 pyrexia, 2 decreased appetite, 3 headache, 3 depression, 3 insomnia, 3 cough, 4 pruritus, 4 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0048" title="ErhardtA , DeterdingK , BenhamouY , ReiserM , FornsX , PolS , et al. Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment. Antiviral Therapy2009;14(1):23‐32. ">Erhardt 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BILB‐1941</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 diarrhoea, 7 nausea, 2 vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 out of 77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 out of 19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0187" title="SimsKD , LemmJ , EleyT , LiuM , BerglindA , ShermanD , et al. Randomized, placebo‐controlled, single‐ascending‐dose study of BMS‐791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection. Antimicrobial Agents and Chemotherapy2014;58(6):3496‐503. ">Sims 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BMS‐791325</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 diarrhoea, 1 nausea, 1 vomiting, 1 headache, 1 pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 out of 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 nausea, 1 vomiting, 1 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 out of 4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0016" title="BaconBR , BrunoS , SchiffER , KwoPY , ButiM , PediconeL , et al. Predictors of sustained virologic response (SVR) among poor interferon (IFN) responders when boceprevir (BOC) is added to peginterferon alfa‐2b/ribavirin (PR). Hepatology2011;54(S1):376A‐7A. BaconBR , GordonSC , LawitzE , MarcellinP , VierlingJM , ZeuzemS , et al. Boceprevir for previously treated chronic HCV genotype 1 infection. New England Journal of Medicine2011;364(13):1207‐17. BaconBR , GordonSC , LawitzE , MarcellinP , VierlingJM , ZeuzemS , et al. HCV RESPOND‐2 final results: high sustained virologic response among genotype 1 previous non‐responders and relapsers to peginterferon/ribavirin when re‐treated with boceprevir plus PEGINTRON (peginterferon alfa‐2b)/ribavirin. Hepatology2010;52(Suppl S1):430A. BarnardRJ , HoweJA , OgertRA , ZeuzemS , PoordadF , GordonSC , et al. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology2013;444(1‐2):329‐36. BognarFA , HuKQ , ThompsonS , PediconeL , WahlJ , LinSG . Boceprevir (BOC) plus peginterferon alfa‐2b/ ribavirin (PR) in the treatment of chronic hepatitis C virus genotype‐1 (HCV‐G1) infected Asian patients in the SPRINT‐1, SPRINT‐2 and RESPOND‐2 trials. Journal of Gastroenterology and Hepatology2012;27(Suppl 4):161. BrassC , BarnardRJO , HoweJA , OgertRA , RalstonR , BoparaiN , et al. Sustained virologic response and boceprevir resistance‐associated variants observed in patients infected with HCV genotpype Ia/Ib when treated with boceprevir plus peginterferon alfa‐2b/ribavirin. Journal of Hepatology2011;54(Suppl 1):S471‐2. BrunoS , VierlingJM , EstebanR , NybergLM , TannoH , AlbrechtJK , et al. Boceprevir in addition to standard of care enhanced SVR in hepatitis C virus (HCV) genotype‐1 with advanced fibrosis/cirrhosis: subgroup analysis of sprint‐2 and respond‐2 studies. Journal of Hepatology2011;54(Suppl 1):S4‐5. BrunoS , VierlingJM , EstebanR , NybergLM , TannoH , GoodmanZ , et al. Efficacy and safety of boceprevir plus peginterferon‐ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. Journal of Hepatology2013;58(3):479‐87. ChhatwalJ , FerranteSA , BrassC , ElKhouryAC , BurroughsM , BaconB , et al. Cost‐effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. Value in Health2013;16(6):973‐86. ChhatwalJ , FerranteSA , DasbachEJ , ElKhouryA , BurroughsM , BaconB , et al. Projecting the long‐term clinical impact of boceprevir in patients with chronic hepatitis C genotype‐1 who failed prior treatment with peginterferon/ribavirin. Journal of Hepatology2011;54:S164. ChhatwalJ , FerranteSA , DasbachEJ , KhouryA , BrassCA , BurroughsM , et al. Cost‐effectiveness of boceprevir use in patients with chronic hepatitis C genotype‐1 who failed prior treatment with peginterferon/ribavirin. Hepatology2011;54(4 (Suppl)):801A‐2A. ChhatwalJ , LundbergJ , FerranteS , ElKhourhyAC , OksanenA , ElbashaEH . Cost‐effectiveness of boceprevir in the treatment of chronic Hepatitis C genotype 1 in Sweden. Journal of Hepatology2012;56(Suppl 2):S386‐7. GordonSC , SulkowskiMS , JacobsonIM , VierlingJM , DavisGL , AfdhalNH , et al. Reasons for screen failure in 2 phase III studies of boceprevir with peginterferon/ribavirin in patients with chronic HCV genotype 1 infection (sprint‐2 and respond‐2). Hepatology2011;54(Suppl S1):848A‐9A. LenzO , FeveryB , VijgenL , VerbeeckJ , PeetersM , BeumontM , et al. TMC435 in combination with peginterferon alpha‐2A/ribavirin in treatment‐naïve patients infected with HCV genotype 1: virology analysis of the PILLAR study. Hepatology2011;54(4 (Suppl)):985A. MarcellinP , VierlingJM , AlricL , PirisiM , TranA , AlbrechtJK , et al. Efficacy among North American and European HCV genotype‐1 treatment‐naive and previous non‐responders and relapsers to peginterferon/ribavirin when treated with boceprevir plus peginterferon alfa‐2b/ribavirin. Journal of Hepatology2011;54(Suppl 1):S184. SulkowskiMS , BaconBR , GordonSC , LawitzE , MarcellinP , VierlingJM , et al. Boceprevir combined with peginterferon alfa‐2b/ribavirin for previous treatment failure patients with hepatitis C virus genotype 1: RESPOND‐2 final results. Journal of the International Association of Physicians in AIDS Care2011;10(3):198. ZeuzemS , VierlingJM , EstebanR , GibasAL , PolS , BoparaiN , et al. Predictors of sustained virologic response among genotype 1 previous non‐responders and relapsers to peginterferon/ribavirin when re‐treated with boceprevir plus peginterferon alfa‐2b/ribavirin. Journal of Hepatology2011;54(Suppl 1):S198‐9. ">Bacon 2011a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145 anaemia, 46 neutropenia, 78 diarrhoea, 140 nausea, 47 vomiting, 68 asthenia, 106 chills, 179 fatigue, 79 influenza‐like illness, 67 irritability, 93 pyrexia, 83 decreased appetite, 73 arthralgia, 81 myalgia, 52 dizziness, 142 dysgeusia, 133 headache, 46 depression, 97 insomnia, 70 cough, 69 dyspnoea, 71 alopecia, 72 dry skin, 62 pruritus, 51 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>319 out of 323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 anaemia, 8 neutropenia, 13 diarrhoea, 30 nausea, 6 vomiting, 13 asthenia, 24 chills, 40 fatigue, 20 influenza‐like illness, 10 irritability, 20 pyrexia, 13 decreased appetite, 13 arthralgia, 19 myalgia, 8 dizziness, 9 dysgeusia, 39 headache, 12 depression, 19 insomnia, 14 cough, 14 dyspnoea, 13 alopecia, 7 dry skin, 14 pruritus, 5 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77 out of 80</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0052" title="FlammS , LawitzE , JacobsonI , RubinR , BourliereM , HezodeC , et al. High sustained virologic response (SVR) among genotype 1 previous non‐responders and relapsers to peginterferon/ribavirin when re‐treated with boceprevir (BOC) plus peginterferon alfa‐2A/ribavirin. Journal of Hepatology2011;54(Suppl 1):S541‐2. FlammSL , LawitzE , JacobsonI , BourliereM , HezodeC , VierlingJM , et al. Boceprevir with peginterferon alfa‐2a‐ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clinical Gastroenterology and Hepatology2013;11(1):81‐7. HoweJA , OgertRA , BarnardRJ , HazudaD , PediconeL , BrassCA . Analysis of sustained viral response and boceprevir resistance following combination treatment with boceprevir plus peginterferon alfa‐2A/ribavirin in HCV genotype 1 prior relapsers and non‐responders. Hepatology2011;54(S1):443A. ">Flamm 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 anaemia, 41 neutropenia, 33 diarrhoea, 52 nausea, 16 vomiting, 29 asthenia, 14 chills, 67 fatigue, 35 influenza‐like illness, 29 irritability, 18 pyrexia, 27 decreased appetite, 16 arthralgia, 25 myalgia, 17 dizziness, 52 dysgeusia, 37 headache, 22 depression, 32 insomnia, 26 cough, 26 dyspnoea, 22 alopecia, 20 dry skin, 18 pruritus, 31 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133 out of 134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 anaemia, 12 neutropenia, 5 diarrhoea, 18 nausea, 12 asthenia, 8 chills, 36 fatigue, 18 influenza‐like illness, 16 irritability, 8 pyrexia, 12 decreased appetite, 12 arthralgia, 5 myalgia, 10 dizziness, 10 dysgeusia, 21 headache, 6 depression, 20 insomnia, 14 cough, 17 dyspnoea, 5 alopecia, 11 dry skin, 8 pruritus, 5 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 out of 67</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0080" title="IsakovV , NikitinI , ChulanovV , OgurtsovP , LukyanovaE , LongJ , et al. Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in Russia. World Journal of Hepatology2016;8(6):331‐9. ">Isakov 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105 anaemia, 103 leukopenia, 141 neutropenia, 16 thrombocytopenia, 22 diarrhoea, 13 dry mouth, 59 nausea, </p> <p>12 vomiting, 63 asthenia, 24 chills, 40 fatigue, 51 hyperthermia,</p> <p>356 influenza‐like illness, 9 injection site erythema, 18 irritability, 217 pyrexia, 14 body temperature increased, 33 weight decreased, 10 decreased appetite, 16 arthralgia, 33 myalgia, 9 dizziness, 69 dysgeusia, 89 headache, 2 sleep disorder, 38 cough, 7 dyspnoea, 33 alopecia, 12 dry skin, 20 pruritus, 17 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153 out of 159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 anaemia, 35 leukopenia, 45 neutropenia, 7 thrombocytopenia, 3 diarrhoea, 5 dry mouth, 15 nausea, </p> <p>2 vomiting, 23 asthenia, 2 chills, 18 fatigue, 12 hyperthermia,</p> <p>72 influenza‐like illness, 2 injection site erythema, 11 irritability,</p> <p>124 pyrexia, 2 body temperature increased, 9 weight decreased, 7 decreased appetite, 4 arthralgia, 8 myalgia, 7 dizziness, 5 dysgeusia, 51 headache, 4 sleep disorder, 14 cough, 7 dyspnoea, 16 alopecia, 3 dry skin, 6 pruritus, 2 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71 out of 78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0086" title="KwoP , LawitzE , McConeJ , SchiffE , VierlingJ , PoundD , et al. HCV Sprint‐1 final results: SVR 24 from a phase 2 study of boceprevir plus pegintron (peginterferon ALFA‐2B)/ribavirin in treatment‐naive subjects with genotype‐1 chronic hepatitis C. Journal of Hepatology2009;50(Suppl 1):S4. KwoPJ , LawitzEJ , McConeJ , SchiffER , VierlingJM , PoundD , et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa‐2b and ribavirin in treatment‐naive patients with genotype 1 hepatitis C infection (SPRINT‐1): an open‐label, randomised, multicentre phase 2 trial. Lancet2010;376(9742):705‐16. OgertRA , HoweJA , VierlingJM , KwoPY , LawitzEJ , McConeJ , et al. Resistance‐associated amino acid variants associated with boceprevir plus pegylated interferon‐alpha2b and ribavirin in patients with chronic hepatitis C in the SPRINT‐1 trial. Antiviral Therapy2013;18(3):387‐97. PoordadF , VierlingJM , EstebanR , KwoPY , LongJ , ChaudhriEI , et al. Hemogloblin decline during lead‐in phase as an early predictor of anemia after the addition of boceprevir: a retrospective analysis of HCV SPRINT‐1. Hepatology2010;52(Suppl S1):770A. VierlingJM , KwoPY , LawitzE , McConeJ , SchiffER , PoundD , et al. Frequencies of resistance‐associated amino acid variants following combination treatment with boceprevir plus PEGINTRON (peginterferon alfa‐2b)/ribavirin in patients with chronic hepatitis C (CHC), genotype 1 (G1). Hepatology2010;52(Suppl S1):702A. ">Kwo 2010a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>226 anaemia, 96 neutropenia, 109 diarrhoea, 186 nausea, 81 vomiting, 53 asthenia, 130 chills, 259 fatigue, 79 influenza‐like illness, 91 irritability, 129 pyrexia, 49 decreased appetite, 76 arthralgia, 99 myalgia, 70 dizziness, 111 dysgeusia, 190 headache, 91 depression, 146 insomnia, 76 cough, 66 dyspnoea, 131 alopecia, 60 dry skin, 80 pruritus, 27 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>413 out of 416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 anaemia, 12 neutropenia, 23 diarrhoea, 45 nausea, 5 vomiting, 14 asthenia, 35 chills, 57 fatigue, 25 influenza‐like illness, 23 irritability, 35 pyrexia, 12 decreased appetite, 21 arthralgia, 17 myalgia, 16 dizziness, 9 dysgeusia, 45 headache, 22 depression, 40 insomnia, 20 cough, 15 dyspnoea, 27 alopecia, 17 dry skin, 16 pruritus, 6 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102 out of 104</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0164" title="AlbrechtJ , VierlingJ , KwoP , LawitzE , McConeJ , SchiffE . Frequencies of resistance‐associated amino acid variants (RAV) following treatment with boceprevir (BOC) plus peginterferon alfa‐2b and ribavirin (P/R). Hepatology International2011;5(1):261‐2. BarnardRJO , PediconeLD , ChaudhriE , TongX , QiuP , BrassCA . Frequencies of resistance‐associated amino acid variants following combination treatment with boceprevir (BOC) plus Pegintron (peglnterferon alfa‐2b) and ribavirin (P/R) in patients with chronic hepatitis C (CHC), genotype 1 (G1). Journal of the International Association of Physicians in AIDS Care2011;10(3):199‐200. BronowickiJ , McConeJ , BaconBR , BrunoS , MannsMP , SulkowskiMS , et al. Response‐guided therapy (RGT) with boceprevir (BOC) + peginterferon alfa‐2b/ribavirin (P/R) for treatment‐naive patients with hepatitis C virus (HCV) genotype (G) 1 was similar to a 48‐wk fixed‐duration regimen with BOC + P/R in SPRINT‐2. Hepatology2010;52(Suppl S1):881A. CharltonM . Boceprevir (Victrelis) for HCV: V is for victory and very complex. Hepatology2011;54(5):1882‐6. MannsMP , MarkovaAA , SerranoBC , CornbergM . Phase III results of boceprevir in treatment naive patients with chronic hepatitis C genotype 1. Liver International2012;32(Suppl 1):27‐31. MannsMP , McConeJ , DavisM , ShiffmanML , RossaroL , BourliereM , et al. Safety benefits of response‐guided therapy with boceprevir (BOC) plus peginterferon alfa‐2B/ribavirin (PR) in previously untreated patients with HCV genotype 1 infection. Hepatology2011;54(4 Suppl):813A. McConeJ , JacobsonIM , BaconBR , PediconeL , GotetiVS , BurroughsM , et al. Treatment‐naive black patients treated with boceprevir combined with peginterferon alfa‐2b + ribavirin: results from HCV sprint‐2. Hepatology2011;54(4 Suppl):822A‐3A. PoordadF , McConeJ , BaconBR , BrunoS , MannsMP , SulkowskiMS , et al. Boceprevir (BOC) combined with peginterferon alfa‐2b/ribavirin (P/R) for treatment‐naive patients with hepatitis C virus (HCV) genotype (G) 1: SPRINT‐2 final results. Hepatology2010;52(Suppl S1):402A. PoordadF , McConeJ , BaconBR , BrunoS , MannsMP , SulkowskiMS , et al. Boceprevir for untreated chronic HCV genotype 1 infection. New England Journal of Medicine2011;364(13):1195‐206. ReddyKR , BrunoS , RossaroL , RavendhranN , PaulyMP , BoparaiN , et al. Predictors of sustained virologic response among treatment‐naive patients with hepatitis C virus genotype 1 when treated with boceprevir (BOC) plus peginterferon alfa‐2B/ribavirin (PR). Journal of Hepatology2011;54(Suppl 1):S190. SulkowskiMS , BaconBR , GordonSC , LawitzE , MarcellinP , VierlingJM , et al. Boceprevir combined with peginterferon alfa‐2b/ribavirin for previous treatment failure patients with hepatitis C virus genotype 1: RESPOND‐2 final results. Journal of the International Association of Physicians in AIDS Care2011;10(3):197‐8. SulkowskiMS , PoordadF , MannsMP , BronowickiJP , RajenderRK , HarrisonSA , et al. Anemia during treatment with peginterferon alfa‐2b/ribavirin and boceprevir: analysis from the serine protease inhibitor therapy 2 (SPRINT‐2) trial. Hepatology2013;57(3):974‐84. ">Poordad 2011a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>361 anaemia, 184 neutropenia, 180 diarrhoea, 334 nausea, 145 vomiting, 125 asthenia, 255 chills, 405 fatigue, 174 influenza‐like illness, 164 irritability, 240 pyrexia, 186 decreased appetite, 141 arthralgia, 170 myalgia, 146 dizziness, 293 dysgeusia, 335 headache, 151 depression, 239 insomnia, 130 cough, 152 dyspnoea, 179 alopecia, 153 dry skin, 181 pruritus, 181 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>728 out of 734</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107 anaemia, 77 neutropenia, 79 diarrhoea, 153 nausea, 57 vomiting, 70 asthenia, 102 chills, 217 fatigue, 93 influenza‐like illness, 86 irritability, 120 pyrexia, 90 decreased appetite, 66 arthralgia, 94 myalgia, 59 dizziness, 64 dysgeusia, 153 headache, 78 depression, 118 insomnia, 76 cough, 59 dyspnoea, 99 alopecia, 66 dry skin, 98 pruritus, 83 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>353 out of 363</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0196" title="ShermanKE , RockstrohJK , DieterichDT , SorianoV , GirardPM , McCallisterS , et al. Telaprevir combination with peginterferon alfa‐2A/ribavirin in HCV/HIV coinfected patients: 24‐week treatment interim analysis. Hepatology2011;54(4 Suppl):1431A‐2A. SulkowskiMS , ShermanKE , DieterichDT , BsharatM , MahnkeL , RockstrohJK , et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Annals of Internal Medicine2013;159(2):86‐96. SulkowskiMS , ShermanKE , SorianoV , RockstrohJ , DieterichDT , GirardPM , et al. Telaprevir in combination with peginterferon alfa‐2a/ribavirin in HCV/HIV co‐infected patients: SVR24 final study results. Hepatology2012;56(S1):219A. ">Sulkowski 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 anaemia, 12 neutropenia, 21 diarrhoea, 26 nausea, 18 vomiting, 22 asthenia, 5 chills, 25 fatigue, 16 influenza‐like illness, 10 irritability, 24 pyrexia, 22 decreased appetite, 7 arthralgia, 9 myalgia, 8 dizziness, 18 dysgeusia, 18 headache, 11 depression, 15 insomnia, 9 cough, 5 dyspnoea, 12 alopecia, 8 dry skin, 13 pruritus, 5 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 out of 64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 anaemia, 2 neutropenia, 6 diarrhoea, 11 nausea, 5 vomiting, 9 asthenia, 5 chills, 12 fatigue, 13 influenza‐like illness, 5 irritability, 7 pyrexia, 6 decreased appetite, 2 arthralgia, 6 myalgia, 2 dizziness, 5 dysgeusia, 6 headache, 4 depression, 9 insomnia, 6 cough, 2 dyspnoea, 6 alopecia, 3 dry skin, 3 pruritus </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 out of 34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0042" title="DoreGJ , LawitzE , HezodeC , ShafranSD , RamjiA , TatumHA , et al. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. Gastroenterology2015;148(2):355‐66. ">Dore 2015a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daclatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 anaemia, 9 neutropenia, 10 diarrhoea, 22 nausea, 4 vomiting, 13 asthenia, 4 chills, 35 fatigue, 19 influenza‐like illness, 17 irritability, 7 pyrexia, 12 decreased appetite, 11 arthralgia, 14 myalgia, 6 dizziness, 5 dysgeusia, 30 headache, 11 depression, 19 insomnia, 8 cough, 12 dyspnoea, 12 alopecia, 13 dry skin, 27 pruritus, 25 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98 out of 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 anaemia, 8 neutropenia, 3 diarrhoea, 8 nausea, 4 vomiting, 7 asthenia, 19 fatigue, 7 influenza‐like illness, 6 irritability, 2 pyrexia, 8 decreased appetite, 9 arthralgia, 11 myalgia, 6 dizziness, 3 dysgeusia, 9 headache, 9 depression, 17 insomnia, 8 cough, 6 dyspnoea, 5 alopecia, 6 dry skin, 14 pruritus, 12 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 out of 51</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0031" title="HezodeC , HirschfieldGM , GhesquiereW , SievertW , Rodriguez‐TorresM , ShafranS , et al. BMS‐790052, a NS5A replication complex inhibitor, combined with peginterferon alfa‐2a and ribavirin in treatment‐naive HCV‐genotype 1 or 4 patients: phase 2b AI444010 study interim week 12 results. Hepatology2011;54(S1):474A‐5A. HezodeC , HirschfieldGM , GhesquiereW , SievertW , Rodriguez‐TorresM , ShafranS , et al. Daclatasvir (BMS‐790052), a NS5A replication complex inhibitor, combined with peginterferon‐alfa‐2a and ribavirin in treatment‐naive HCV genotype 1 or 4 subjects: phase 2b AI444010 study interim week 24 results. Hepatology International2012;6(1):167. HezodeC , HirschfieldGM , GhesquiereW , SievertW , Rodriguez‐TorresM , ShafranSD , et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment‐naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut2015;64(6):948‐56. ">COMMAND‐1 2015a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daclatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 anaemia, 43 neutropenia, 73 diarrhoea, 109 nausea, 34 vomiting, 32 asthenia, 49 chills, 174 fatigue, 94 influenza‐like illness, 72 irritability, 48 pyrexia, 67 decreased appetite, 55 arthralgia, 88 myalgia, 46 dizziness, 25 dysgeusia, 136 headache, 45 depression, 102 insomnia, 54 cough, 58 dyspnoea, 80 alopecia, 88 dry skin, 119 pruritus, 94 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>311 out of 317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 anaemia, 9 neutropenia, 14 diarrhoea, 20 nausea, 11 vomiting, 7 asthenia, 16 chills, 46 fatigue, 16 influenza‐like illness, 22 irritability, 15 pyrexia, 17 decreased appetite, 19 arthralgia, 24 myalgia, 9 dizziness, 4 dysgeusia, 36 headache, 10 depression, 30 insomnia, 18 cough, 11 dyspnoea, 13 alopecia, 15 dry skin, 26 pruritus, 25 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 out of 78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0081" title="IzumiN , AsahinaY , YokosukaO , ImazekiF , KawadaN , TamoriA , et al. Combination therapy of treatment‐naive and nonresponder patients with HCV genotype 1 infection with BMS‐790052, an NS5A replication complex inhibitor, in combination with peginterferon alfa‐2a and ribavirin. Hepatology2011;54(S1):1439A‐40A. IzumiN , YokosukaO , KawadaN , OsakiY , YamamotoK , SataM , et al. Daclatasvir combined with peginterferon alfa‐2a and ribavirin in Japanese patients infected with hepatitis C genotype 1. Antiviral Therapy2014;19(5):501‐10. McPheeF , HernandezD , ZhouN , YuF , UelandJ , MonikowskiA , et al. Virological escape in HCV genotype‐1‐infected patients receiving daclatasvir plus ribavirin and peginterferon alfa‐2a or alfa‐2b. Antiviral Therapy2014;19(5):479‐90. SuzukiF , ChayamaK , KawakamiY , ToyotaJ , KarinoY , MochidaS , et al. BMS‐790052, AN NS5A replication complex inhibitor, in combination with peginterferon alpha‐2B and ribavirin in Japanese treatment naive and nonresponder patients with chronic HCV genotype 1 infection. Hepatology2011;54(S1):1441A. SuzukiF , ChayamaK , KawakamiY , ToyotaJ , KarinoY , MochidaS , et al. Daclatasvir (BMS‐790052), an NS5A replication complex inhibitor, in combination with peginterferon alpha‐2b and ribavirin in Japanese treatment‐naive and nonresponder patients with chronic HCV genotype 1 infection. Hepatology International2012;6(1):161‐2. SuzukiF , ToyotaJ , IkedaK , ChayamaK , MochidaS , HayashiN , et al. A randomized trial of daclatasvir with peginterferon alfa‐2b and ribavirin for HCV genotype 1 infection. Antiviral Therapy2014;19(5):491‐9. ">Izumi 2014a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daclatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 anaemia, 7 neutropenia, 2 diarrhoea, 4 nausea, 6 fatigue, 1 irritability, 11 pyrexia, 7 decreased appetite, 4 arthralgia, 1 myalgia, 1 dizziness, 4 dysgeusia, 3 headache, 7 insomnia, 4 cough, 2 dyspnoea, 8 alopecia, 1 dry skin, 6 pruritus, 7 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 out of 34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 anaemia, 4 neutropenia, 3 diarrhoea, 2 nausea, 3 vomiting, 4 chills, 4 fatigue, 2 influenza‐like illness, 5 pyrexia, 5 decreased appetite, 2 arthralgia, 2 myalgia, 1 dizziness, 1 dysgeusia, 4 headache, 2 insomnia, 1 cough, 6 alopecia, 1 dry skin, 3 pruritus, 3 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0161" title="PolS , GhalibRH , RustgiVK , MartorellC , EversonGT , TatumHA , et al. Daclatasvir for previously untreated chronic hepatitis C genotype‐1 infection: a randomised, parallel‐group, double‐blind, placebo‐controlled, dose‐finding, phase 2a trial. Lancet Infectious Diseases2012;12(9):671‐7. ">Pol 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daclatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 anaemia, 9 neutropenia, 5 diarrhoea, 13 nausea, 7 vomiting, 9 asthenia, 4 chills, 19 fatigue, 11 influenza‐like illness, 12 irritability, 7 pyrexia, 9 decreased appetite, 2 arthralgia, 8 myalgia, 5 dizziness, 2 dysgeusia, 19 headache, 7 depression, 9 insomnia, 9 cough, 6 dyspnoea, 8 alopecia, 2 dry skin, 12 pruritus, 10 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 out of 36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 anaemia, 5 neutropenia, 3 diarrhoea, 6 nausea, 1 asthenia, 2 chills, 9 fatigue, 4 influenza‐like illness, 2 irritability, 3 pyrexia, 3 decreased appetite, 3 myalgia, 1 dizziness, 1 dysgeusia, 3 headache, 3 depression, 6 insomnia, 3 cough, 2 dyspnoea, 2 alopecia, 1 dry skin, 3 pruritus, 3 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 out of 12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0137" title="NettlesRE , ChienC , ChungE , PerssonA , GaoM , BelemaM , et al. MS‐790052 is a first‐in class potent Hepatitis C Virus (HCV) NS5A inhibitor for patients with chronic HCV infection: results from a proof‐of‐concept study. Hepatology International2010;4(1):184. ">Nettles 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daclatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 diarrhoea, 1 nausea, 4 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 out of 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0138" title="NettlesR , SevinskyH , ChungE , BurtD , XiaoH , MarburyTC , et al. BMS‐790052, a first‐in class potent hepatitis C virus NS5A inhibitor, demonstrates multiple dose proof‐of‐concept in subjects with chronic GT1 HCV infection. Hepatology2010;52(Suppl S1):1214A‐5A. NettlesRE , GaoM , BifanoM , ChungE , PerssonA , MarburyTC , et al. Multiple ascending dose study of BMS‐790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology2011;54(6):1956‐65. ">Nettles 2011a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daclatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 diarrhoea, 3 fatigue, 1 arthralgia, 1 dizziness, 5 headache, 2 insomnia, 1 dry skin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 out of 24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 nausea, 1 vomiting, 2 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 out of 6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0035" title="EversonG , CooperC , HezodeC , ShiffmanML , YoshidaE , Beltran‐JaramilloT , et al. Dauphine: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha‐2a/ribavirin in HCV genotypes 1 or 4. Liver International2015;35(1):108‐19. EversonG , CooperC , HezodeC , ShiffmanML , YoshidaE , Beltran‐JaramilloT , et al. Rapid and sustained achievement of undetectable HCV RNA during treatment with ritonavir‐boosted danoprevir/peg‐ifna‐2a/RBV in HCV genotype 1 or 4 patients: dauphine week 12 interim analysis. Journal of Hepatology2012;56(Suppl 2):S466. HezodeC , ShiffmanML , CooperC , EversonGT , MarcellinP , Rodriguez‐TorresM , et al. Ritonavir‐boosted danoprevir plus peg‐IFNalpha‐2a/ribavirin (P/R) demonstrates up to 100% SVR24 with 12 or 24 weeks of total treatment in treatment‐naive patients with HCV genotype 4 infection in the DAUPHINE study. Hepatology2012;56(S1):557A. LePogamS , NavarroM , BuL , VoulgariA , IllnickaM , YanJM , et al. Low rate of on‐treatment resistance to danoprevir boosted by ritonavir (DNVR) combined with Peg‐IFNa‐2a/ribavirin: 12 week interim analysis from Dauphine study. Journal of Hepatology2012;56(Suppl 2):S472. ">Dauphine 2015a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Danoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115 diarrhoea, 106 nausea, 77 asthenia, 89 chills, 158 fatigue, 125 pyrexia, 88 decreased appetite, 72 arthralgia, 93 myalgia,158 headache, 102 insomnia, 62 cough, 54 alopecia, 83 pruritus, 78 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>364 out of 373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 diarrhoea, 13 nausea, 9 asthenia, 8 chills, 17 fatigue, 15 pyrexia, 6 decreased appetite, 9 arthralgia, 13 myalgia, 24 headache, 16 insomnia, 12 cough, 4 alopecia, 14 pruritus, 6 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 out of 44</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0054" title="ForestierN , LarreyD , GuyaderD , MarcellinP , RouzierR , PatatA , et al. Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN‐191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study. Journal of Hepatology2011;54(6):1130‐6. ForestierN , LarreyDG , GuyaderD , MarcellinP , RouzierR , PatatAA , et al. Treatment of chronic hepatitis C virus (HCV) genotype 1 patients with the NS3/4A protease inhibitor ITMN‐191 leads to rapid reductions in plasma HCV RNA: results of a phase 1b multiple ascending dose (MAD) study. Hepatology2008;48(4 (Suppl)):1132A. MoucariR , ForestierN , LarreyD , GuyaderD , CouzigouP , BenhamouY , et al. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut2010;59(12):1694‐8. ">Forestier 2011a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Danoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 diarrhoea, 3 myalgia, 5 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 out of 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 diarrhoea, 2 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 out of 10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0056" title="ForestierN , LarreyD , MarcellinP , BenhamouY , GuyaderD , BradfordW , et al. Antiviral activity and safety of ITMN‐191 in combination with peginterferon alfa‐2a and ribavirin in patients with chronic hepatitis C virus (HCV). Journal of Hepatology2009;50(Suppl 1):S35. ForestierN , LarreyD , MarcellinP , GuyaderD , PatatA , RouzierR , et al. Antiviral activity of danoprevir (ITMN‐191/RG7227) in combination with pegylated interferon alpha‐2a and ribavirin in patients with hepatitis C. Journal of Infectious Diseases2011;204(4):601‐8. ">Forestier 2011b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Danoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 neutropenia, 5 diarrhoea, 4 nausea, 3 asthenia, 5 chills, 8 fatigue, 4 influenza‐like illness, 2 pyrexia, 2 arthralgia, 17 myalgia, 6 dizziness, 23 headache, 2 depression, 6 insomnia, 3 pruritus </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 out of 47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 neutropenia, 2 diarrhoea, 1 nausea, 1 chills, 3 fatigue, 1 influenza‐like illness, 1 arthralgia, 5 myalgia, 1 dizziness, 4 headache, 1 depression, 2 insomnia </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 out of 12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0068" title="GaneE , RouzierR , StedmanC , Wiercinska‐DrapaloA , HorbanA , ChangL , et al. Ritonavir boosting of low dose RG7227/ITMN‐191, HCV NS3/4 a protease inhibitor, results in robust reduction in HCV RNA at lower exposures than provided by unboosted regimens. Journal of Hepatology2010;52(Suppl 1):S16‐7. GaneEJ , RouzierR , StedmanC , Wiercinska‐DrapaloA , HorbanA , ChangL , et al. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG‐IFN alpha‐2a/RBV in hepatitis C patients. Journal of Hepatology2011;55(5):972‐9. MorcosPN , ChangL , KulkarniR , GiraudonM , ShulmanN , BrennanBJ , et al. A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail. European Journal of Clinical Pharmacology2013;69(11):1939‐49. ">Gane 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Danoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 diarrhoea, 5 nausea, 5 fatigue, 3 influenza‐like illness, 5 irritability, 5 arthralgia, 5 myalgia, 11 headache, 4 insomnia, 6 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 out of 25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 diarrhoea, 3 nausea, 1 fatigue, 2 myalgia, 4 headache, 2 insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 out of 5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0121" title="MarcellinP , PopaS , BerlibaA , BoyerN , Streinu‐CercelA , TongM , et al. ALS‐2200, a novel once‐daily nucleotide HCV polymerase inhibitor, demonstrates potent antiviral activity in treatment naive GT1 chronic hepatitis C patients. Hepatology International2013;7(1 Suppl):S342. ">Marcellin 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Danoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 anaemia, 70 neutropenia, 56 diarrhoea, 85 nausea, 29 vomiting, 57 chills, 109 fatigue, 38 irritability, 51 pyrexia, 34 decreased appetite, 29 arthralgia, 60 myalgia, 92 headache, 42 depression, 69 insomnia, 31 alopecia, 46 pruritus, 42 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 anaemia, 11 neutropenia, 7 diarrhoea, 10 nausea, 4 vomiting, 13 chills, 14 fatigue, 7 irritability, 5 pyrexia, 4 decreased appetite, 9 arthralgia, 11 myalgia, 18 headache, 4 depression, 9 insomnia, 5 alopecia, 6 pruritus, 8 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0093" title="LarreyD , LohseA , DeLedinghenV , TrepoC , GerlachT , ZarskiJP , et al. 4 week therapy with the non‐nucleosidic polymerase inhibitor BI207127 in combination with peginterferon‐alfa2A and ribavirin in treatment naive and treatment experienced chronic HCV GT1 patients. Journal of Hepatology2010;52(Suppl S1):S466. LarreyD , LohseAW , DeLedinghenV , TrepoC , GerlachT , ZarskiJP , et al. Rapid and strong antiviral activity of the non‐nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. Journal of Hepatology2012;57(1):39‐46. ">Larrey 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deleobuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 19 diarrhoea, 19 nausea, 11 vomiting, 16 asthenia, 3 chills, 12 fatigue, 14 influenza‐like illness, 7 irritability, 6 pyrexia, 14 decreased appetite, 4 arthralgia, 4 myalgia, 6 dizziness, 4 dysgeusia, 20 headache, 15 insomnia, 6 cough, 3 dyspnoea, 1 alopecia, 6 dry skin, 5 pruritus, 8 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 out of 49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 nausea, 1 asthenia, 1 chills, 2 fatigue, 1 influenza‐like illness, 2 irritability, 1 decreased appetite, 2 headache, 1 dry skin, 1 pruritus, 2 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0190" title="AsselahT , JensenDM , FosterG , SulkowskiM , OuzanD , MoranoL , et al. Faldaprevir plus pegylated interferon/ribavirin did not increase anaemia compared with pegylated interferon/ribavirin in HCV genotype‐1, treatment‐naive patients: pooled analysis of phase III studies. Gastroenterology2014;146(5 (Suppl 1)):S‐977. AsselahT , JensenDM , FosterG , SulkowskiM , OuzanD , MoranoL , et al. Virological response in treatment‐naive patients with chronic HCV genotype‐1 infection receiving faldaprevir plus pegylated interferon alpha‐2a and ribavirin is unaffected by ribavirin dose reduction. Gastroenterology2014;146(5 (Suppl 1)):S975‐6. BergerK , SarrazinC , FerenciP , JensenDM , JacobsonIM , SternJO , et al. NS3 Q80K did not impact efficacy or treatment‐emergent resistance patterns in HCV genotype 1‐infected patients receiving faldaprevir + peginterferon/ribavirin in three phase III trials. Journal of Hepatology2014;60(1):S497. FerenciP , DieterichD , ZeuzemS , MantryP , SarrazinC , CrespoJ , et al. Early stopping rules for faldaprevir plus pegylated interferon alpha‐2a and ribavirin in treatment‐naive patients: exploratory study of pooled data from phase III trials. Journal of Hepatology2014;60(1 (Suppl 1)):S452‐3. FosterGR , CooperC , DieterichD , FerenciP , CrespoJ , DiagoM , et al. Pharmacokinetic‐response analysis of faldaprevir in treatment‐naive patients with chronic HCV genotype‐1 infection: a pooled analysis of two phase III trials. Journal of Hepatology2014;60(1 (Suppl 1)):S454‐5. JensenDM , AsselahT , DieterichDT , FosterGR , SulkowskiMS , ZeuzemS , et al. A pooled analysis of two randomized, double‐blind placebo‐controlled phase III trials (STARTVerso1&amp;2) of faldaprevir plus pegylated interferon alfa‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C genotype‐1 infection. Hepatology2013;58(Suppl 1):734A‐5A. JensenDM , FosterG , FerenciP , CooperC , DieterichDT , SulkowskiM , et al. Faldaprevir plus pegylated interferon alfa‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C genotype‐1 infection: a pooled analysis of two randomized, double‐blind placebo‐controlled phase iii trials (STARTVerso1&amp;2). Gastroenterology2014;146(5 (Suppl 1)):S974. YoshidaEM , AsselahT , MorenoC , MaevskayaMV , KaoJH , CrespoJ , et al. Subgroup analyses and baseline predictors of response with faldaprevir plus pegylated interferon alfa‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C genotype‐1 infection: a pooled analysis of STARTVerso1 and 2. Hepatology2013;58(4 Suppl):751A‐2A. ZeuzemS , JensenDM , CarvalhoA , DiagoM , FeinmanSV , KowdleyKV , et al. No effect of faldaprevir on renal function in treatment‐naive patients with chronic HCV genotype‐1 infection: pooled data from two phase III trials. Journal of Hepatology2014;60(1 (Suppl 1)):S451. ">STARTverso‐2 2014a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faldaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114 anaemia, 59 neutropenia, 160 diarrhoea, 249 nausea, 110 vomiting, 29 asthenia, 78 chills, 246 fatigue, 39 influenza‐like illness, 67 irritability, 79 pyrexia, 117 decreased appetite, 72 arthralgia, 100 myalgia, 80 dizziness, 31 dysgeusia, 165 headache, 68 depression, 137 insomnia, 89 cough, 53 dyspnoea, 96 alopecia, 67 dry skin, 164 pruritus, 298 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>513 out of 525</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 anaemia, 14 neutropenia, 23 diarrhoea, 52 nausea, 11 vomiting, 6 asthenia, 25 chills, 70 fatigue, 15 influenza‐like illness, 27 irritability, 20 pyrexia, 26 decreased appetite, 22 arthralgia, 37 myalgia, 25 dizziness, 3 dysgeusia, 45 headache, 11 depression, 38 insomnia, 21 cough, 20 dyspnoea, 22 alopecia, 15 dry skin, 37 pruritus, 41 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130 out of 132</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0188" title="AsselahT , JensenDM , FosterG , SulkowskiM , OuzanD , MoranoL , et al. Faldaprevir plus pegylated interferon/ribavirin did not increase anaemia compared with pegylated interferon/ribavirin in HCV genotype‐1, treatment‐naive patients: pooled analysis of phase III studies. Gastroenterology2014;146(5 Suppl 1):S‐977. AsselahT , JensenDM , FosterG , SulkowskiM , OuzanD , MoranoL , et al. Virological response in treatment‐naive patients with chronic HCV genotype‐1 infection receiving faldaprevir plus pegylated interferon alpha‐2a and ribavirin is unaffected by ribavirin dose reduction. Gastroenterology2014;146(5 Suppl 1):S975‐6. BergerK , SarrazinC , FerenciP , JensenDM , JacobsonIM , SternJO , et al. NS3 Q80K did not impact efficacy or treatment‐emergent resistance patterns in HCV genotype 1‐infected patients receiving faldaprevir + peginterferon/ribavirin in three phase III trials. Journal of Hepatology2014;60(1 Suppl S):S497. FerenciP , AsselahT , FosterGR , ZeuzemS , SarrazinC , MorenoC , et al. Faldaprevir plus pegylated interferon alfa‐2A and ribavirin in chronic HCV genotype‐1 treatment‐naive patients: final results from STARTVerso1, a randomised, double‐blind, placebo‐controlled phase III trial. Journal of Gastroenterology and Hepatology2013;28(Suppl 2):157‐8. FerenciP , AsselahT , FosterGR , ZeuzemS , SarrazinC , MorenoC , et al. STARTVerso1: a randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype‐1 infection. Journal of Hepatology2015;62(6):1246‐55. FerenciP , DieterichD , ZeuzemS , MantryP , SarrazinC , CrespoJ , et al. Early stopping rules for faldaprevir plus pegylated interferon alpha‐2a and ribavirin in treatment‐naive patients: exploratory study of pooled data from phase III trials. Journal of Hepatology2014;60(1 Suppl 1):S452‐S3. FosterGR , CooperC , DieterichD , FerenciP , CrespoJ , DiagoM , et al. Pharmacokinetic‐response analysis of faldaprevir in treatment‐naive patients with chronic HCV genotype‐1 infection: a pooled analysis of two phase III trials. Journal of Hepatology2014;60(1 Suppl 1):S454‐5. JensenDM , AsselahT , DieterichDT , FosterGR , SulkowskiMS , ZeuzemS , et al. A pooled analysis of two randomized, double‐blind placebo‐controlled phase III trials (STARTVerso1 &amp; 2) of faldaprevir plus pegylated interferon alfa‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C genotype‐1 infection. Hepatology2013;58(Suppl 1):734A‐5A. JensenDM , FosterG , FerenciP , CooperC , DieterichDT , SulkowskiM , et al. Faldaprevir plus pegylated interferon alfa‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C genotype‐1 infection: a pooled analysis of two randomized, double‐blind placebo‐controlled phase III trials (STARTVerso 1 &amp; 2). Gastroenterology2014;146(5 Suppl 1):S974. MorenoC , FerenciP , AsselahT , FosterG , ZeuzemS , SarrazinC , et al. Faldaprevir plus pegylated interferon alfa‐2a and ribavirin in chronic HCV genotype‐1 treatment‐naive patients: final results from STARTVerso1: a randomized, double‐blind, placebo‐controlled, phase 3 trial. American Journal of Gastroenterology2013;108(Suppl 1):S145. YoshidaEM , AsselahT , MorenoC , MaevskayaMV , KaoJH , CrespoJ , et al. Subgroup analyses and baseline predictors of response with faldaprevir plus pegylated interferon alfa‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C genotype‐1 infection: a pooled analysis of STARTVerso1 and 2. Hepatology2013;58(Suppl S1):751A‐2A. ZeuzemS , JensenDM , CarvalhoA , DiagoM , FeinmanSV , KowdleyKV , et al. No effect of faldaprevir on renal function in treatment‐naive patients with chronic HCV genotype‐1 infection: pooled data from two phase III trials. Journal of Hepatology2014;60(1 Suppl S):S451. ">STARTVerso‐1 2015a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faldaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89 anaemia, 57 neutropenia, 121 diarrhoea, 168 nausea, 79 vomiting, 96 asthenia, 143 fatigue, 92 influenza‐like illness, 37 irritability, 110 pyrexia, 87 decreased appetite, 39 arthralgia, 41 myalgia, 38 dizziness, 23 dysgeusia, 146 headache, 32 depression, 70 insomnia, 58 cough, 36 dyspnoea, 49 alopecia, 80 dry skin, 160 pruritus, 139 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>496 out of 520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 anaemia, 18 neutropenia, 17 diarrhoea, 19 nausea, 6 vomiting, 27 asthenia, 35 fatigue, 21 influenza‐like illness, 9 irritability, 32 pyrexia, 22 decreased appetite, 14 arthralgia, 20 myalgia, 13 dizziness, 5 dysgeusia, 40 headache, 8 depression, 22 insomnia, 20 cough, 16 dyspnoea, 15 alopecia, 17 dry skin, 41 pruritus, 25 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120 out of 132</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0192" title="AsselahT , ZehnterE , AgarwalK , SakaiY , YatsuhashiH , WillemsB , et al. Pharmacokinetic‐response analysis of faldaprevir in patients with chronic HCV genotype‐1 infection with prior relapse. Journal of Hepatology2014;60(1 Suppl S):S458‐9. BergerK , SarrazinC , FerenciP , JensenDM , JacobsonIM , SternJO , et al. NS3 Q80K did not impact efficacy or treatment‐emergent resistance patterns in HCV genotype 1‐infected patients receiving faldaprevir+peginterferon/ribavirin in three phase III trials. Journal of Hepatology2014;60(1 Suppl S):S497. JacobsonIM , AsselahT , FerenciP , FosterGR , JensenDM , NegroF , et al. STARTVerso3: a randomized, double‐blind, placebo‐controlled phase III trial of faldaprevir in combination with pegylated interferon a lf a‐2a and ribavirin in treatment‐experienced patients with chronic hepatitis C genotype‐1 infection. Hepatology2013;48(S1):742A‐3A. JacobsonIM , FerenciP , FosterGR , JensenDM , NegroF , MantryP , et al. STARTVerso3: a randomized, double‐blind, placebo controlled phase III trial of faldaprevir in combination with pegylated interferon alpha‐2a and ribavirin in treatment experienced patients with chronic hepatitis C genotype‐1 infection. Hepatology International2014;8(1 Suppl):S213‐4. ">STARTverso‐3 2013a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faldaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98 anaemia, 65 neutropenia, 190 diarrhoea, 318 nausea, 171 vomiting, 108 asthenia, 32 chills, 204 fatigue, 107 influenza‐like illness, 49 irritability, 113 pyrexia, 128 decreased appetite, 60 arthralgia, 72 myalgia, 37 dizziness, 39 dysgeusia, 182 headache, 52 depression, 118 insomnia, 99 cough, 47 dyspnoea, 53 alopecia, 108 dry skin, 225 pruritus, 160 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>585 out of 599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 anaemia, 12 neutropenia, 10 diarrhoea, 18 nausea, 5 vomiting, 21 asthenia, 5 chills, 16 fatigue, 15 influenza‐like illness, 11 irritability, 14 pyrexia, 10 decreased appetite, 7 arthralgia, 8 myalgia, 6 dizziness, 4 dysgeusia, 22 headache, 10 depression, 13 insomnia, 16 cough, 7 dyspnoea, 4 alopecia, 12 dry skin, 23 pruritus, 16 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74 out of 78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0115" title="MannsMP , BourliereM , BenhamouY , PolS , BonaciniM , BergT . Safety and antiviral activity of BI201335, a new HCV NS3 protease inhibitor, in treatment‐naive patients with chronic hepatitis C genotype‐1 infection given as monotherapy and in combination with peginterferon alfa 2a (P) and ribavirin (R). Hepatology2008;48(4 Suppl):1023A. MannsMP , BourliereM , BenhamouY , PolS , BonaciniM , TrepoC , et al. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype‐1 infection. Journal of Hepatology2011;54(6):1114‐22. ">Manns 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faldaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 anaemia, 1 neutropenia, 4 diarrhoea, 7 nausea, 10 asthenia, 2 chills, 2 fatigue, 4 influenza‐like illness, 4 irritability, 2 pyrexia, 1 decreased appetite, 7 myalgia, 1 dizziness, 6 headache, 2 depression, 5 insomnia, 2 cough, 1 alopecia, 5 dry skin, 3 pruritis, 1 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 out of 26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 diarrhoea, 2 nausea, 2 asthenia, 2 headache, 1 depression, 1 insomnia, 1 cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0144" title="NishiguchiS , KubokiM , SakaiY , AizawaN , IwataK , IkedaN , et al. All treated Japanese genotype 1 patients with IL28B TT allele achieved SVR by 4 weeks faldaprevir and 48 weeks PegIFN/ ribavirin. Hepatology International2013;7(1 Suppl):S393. NishiguchiS , KubokiM , SakaiY , AizawaN , TakashimaT , IwataK . 100% SVR in Japanese genotype 1 patients with IL28B TT allele treated with 4 weeks faldaprevir and 48 weeks PegIFN/ribavirin. Hepatology International2013;7(1 Suppl):S372‐3. NishiguchiS , SakaiY , KubokiM , TsunematsuS , UranoY , SakamotoW , et al. Safety and efficacy of faldaprevir with pegylated interferon alfa‐2a and ribavirin in Japanese patients with chronic genotype‐1 hepatitis C infection. Liver International2014;34(1):78‐88. ">Nishiguchi 2014a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faldaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 neutropenia, 3 diarrhoea, 3 nausea, 3 vomiting, 2 influenza‐like illness, 8 pyrexia, 2 decreased appetite, 2 arthralgia, 4 dizziness, 1 dysgeusia, 7 headache, 1 depression, 5 insomnia, 1 cough, 3 alopecia, 1 dry skin, 6 pruritus, 6 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 out of 35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 nausea, 2 vomiting, 1 influenza‐like illness, 1 pyrexia, 1 decreased appetite, 1 headache, 1 insomnia, 1 dyspnoea, 2 dry skin, 3 pruritus, 1 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0196" title="ShermanKE , RockstrohJK , DieterichDT , SorianoV , GirardPM , McCallisterS , et al. Telaprevir combination with peginterferon alfa‐2A/ribavirin in HCV/HIV coinfected patients: 24‐week treatment interim analysis. Hepatology2011;54(4 Suppl):1431A‐2A. SulkowskiMS , ShermanKE , DieterichDT , BsharatM , MahnkeL , RockstrohJK , et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Annals of Internal Medicine2013;159(2):86‐96. SulkowskiMS , ShermanKE , SorianoV , RockstrohJ , DieterichDT , GirardPM , et al. Telaprevir in combination with peginterferon alfa‐2a/ribavirin in HCV/HIV co‐infected patients: SVR24 final study results. Hepatology2012;56(S1):219A. ">Sulkowski 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faldeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 anaemia, 49 neutropenia, 188 diarrhoea, 239 nausea, 105 vomiting, 122 asthenia, 54 chills, 194 fatigue, 217 influenza‐like illness, 82 irritability, 86 pyrexia, 133 decreased appetite, 72 arthralgia, 133 myalgia, 48 dizziness, 25 dysgeusia, 243 headache, 68 depression, 107 insomnia, 100 cough, 73 dyspnoea, 106 alopecia, 122 dry skin, 227 pruritus, 163 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>620 out of 641</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 anaemia, 8 neutropenia, 13 diarrhoea, 14 nausea, 4 vomiting, 15 asthenia, 8 chills, 24 fatigue, 34 influenza‐like illness, 10 irritability, 11 pyrexia, 11 decreased appetite, 5 arthralgia, 12 myalgia, 5 dizziness, 27 headache, 7 depression, 17 insomnia, 9 cough, 11 dyspnoea, 8 alopecia, 10 dry skin, 12 pruritus, 12 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 out of 71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0083" title="JacobsonI , PockrosP , LalezariJ , LawitzE , Rodriguez‐TorresM , DeJesusE , et al. Antiviral activity of filibuvir in combination with pegylated interferon alfa‐2A and ribavirin for 28 days in treatment naive patients chronically infected with HCV genotype 1. Journal of Hepatology2009;50(Suppl 1):S382. JacobsonI , PockrosPJ , LalezariJ , LawitzE , Rodriguez‐TorresM , DeJesusE , et al. Virologic response rates following 4 weeks of filibuvir in combination with pegylated interferon alfa‐2A and ribavirin in chronically‐infected HCV genotype‐1 patients. Journal of Hepatology2010;52(Suppl 1):S464. MoriJ , HammondJL , SrinivasanS , JagannathaS , RystECC . Genotypic characterisation of filibuvir (PF‐00868554 ) resistance in patients receiving four weeks co‐administration of filibuvir with pegIFN/RBV. Hepatology2010;52(Suppl S1):722A. MoriJ , HammondJL , SrinivasanS , JagannathaS , Van derRystE . Genotypic characterisation of filibuvir (PF‐00868554) resistance in patients receiving four weeks co‐administration of filibuvir with PEGIFN/RBV (12 week analysis). Journal of Hepatology2010;52(Suppl 1):S15. ">Jacobson 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Filibuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 anaemia,4 neutropenia ,6 diarrhoea, 13 nausea, 3 vomiting, 4 chills, 13 fatigue, 3 influenza‐like illness, 2 irritability, 2 pyrexia, 3 decreased appetite, 2 arthralgia, 4 myalgia, 4 dizziness, 14 headache, 5 depression, 11 insomnia, 5 cough, 2 dyspnoea, 2 alopecia, 3 dry skin, 2 pruritus, 3 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 out of 27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 anaemia, 3 diarrhoea, 4 nausea, 1 vomiting, 1 chills, 5 fatigue, 2 influenza‐like illness, 2 decreased appetite, 2 arthralgia, 2 headache, 3 depression, 2 insomnia, 2 cough, 2 dyspnoea, 1 alopecia, 2 dry skin, 3 pruritus, 1 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0175" title="Rodriguez‐TorresM , StoehrA , GaneEJ , SerfatyL , LawitzE , ZhouA , et al. Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment‐experienced patients with chronic HCV genotype 1 infection and cirrhosis. Clinical Gastroenterology and Hepatology2014;12(6):1029‐37.e5. ">Rodriguez‐Torres 2014a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Filibuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 anaemia, 26 neutropenia, 24 diarrhoea, 55 nausea, 20 vomiting, 35 asthenia, 25 chills, 73 fatigue, 29 influenza‐like illness, 33 irritability, 28 pyrexia, 36 decreased appetite, 30 arthralgia, 37 myalgia, 20 dizziness, 40 dysgeusia, 61 headache, 32 depression, 55 insomnia, 33 cough, 18 dyspnoea, 34 alopecia, 33 dry skin, 56 pruritus, 34 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174 out of 192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>anaemia, neutropenia, diarrhoea, nausea, vomiting, asthenia, chills, fatigue, influenza‐like illness, irritability, pyrexia, decreased appetite, arthralgia, myalgia, dizziness, dysgeusia, headache, depression, insomnia, cough, dyspnoea, alopecia, dry skin, pruritus, rash. </p> <p>The authors did not report number of adverse events in the control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 out of 96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0156" title="PetryAS , FraserIP , O’MaraE , VanDyckK , NachbarRB , DeLepeleireIM , et al. Safety and antiviral activity of MK‐5172, a next generation HCV NS3/4A protease inhibitor with a broad HCV genotypic activity spectrum and potent activity against known resistance mutants, in genotype 1 and 3 HCV infected patients. Hepatology2011;54(4 Suppl):531A. ">Petry 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grazoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 diarrhoea, 2 nausea, 1 vomiting, 7 fatigue, 1 dysgeusia, 16 headache, 1 insomnia, 2 pruritis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 out of 76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 out of 15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0070" title="GardnerS , CutrellAMY , Elko‐SimmsC , AdkisonK , HamatakeR , WalkerJ , et al. A double‐blind, randomized, placebo‐controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa‐2a and ribavirin in hepatitis C virus genotype 1‐infected treatment‐naive subjects. Liver International2014;34(6):e89‐e95. ">Gardner 2014a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GSK2336805</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 anaemia, 3 neutropenia, 4 nausea, 2 vomiting, 2 chills, 5 fatigue, 2 cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 out of 11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 out of 4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0091" title="LalezariJ , AsmuthD , CasiroA , VargasH , LawrenceS , Dubuc‐PatrickG , et al. Short‐term monotherapy with IDX184, a liver‐targeted nucleotide polymerase inhibitor, in patients with chronic hepatitis C virus infection. Antimicrobial Agents and Chemotherapy2012;56(12):6372‐8. ">Lalezari 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IDX‐184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 diarrhoea, 2 fatigue, 1 dizziness, 4 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 out of 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 diarrhoea, 1 fatigue, 1 dizziness, 1 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0092" title="LalezariJ , BoxT , O'RiordanW , MehraP , NguyenT , PoordadF , et al. IDX184 in combination with pegylated interferon‐alpha2a and ribavirin for 2 weeks in treatment‐naive patients with chronic hepatitis C. Antiviral Therapy2013;18(6):755‐64. LalezariJ , PoordadF , MehraP , NguyenT , DejesusE , GodofskyE , et al. Antiviral activity, pharmacokinetics and safety of IDX184 in combination with pegylated interferon (pegIFN) and ribavirin (RBV) in treatment‐naive HCV genotype 1‐infected subjects. Journal of Hepatology2010;52(Suppl S1):S469. LalezariJP , O'RiordanW , PoordadF , NguyenTT , PatrickGD , ChenJ , et al. A phase IIA study of IDX184 in combination with pegylated interferon (PEGIFN) and ribavirin (RBV) in treatment‐naive HCV genotype 1‐infected subjects. Hepatology2010;52(Suppl S1):337A. ">Lalezari 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IDX‐184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 neutropenia, 7 diarrhoea, 22 nausea, 5 vomiting, 15 chills, 36 fatigue, 10 irritability, 9 pyrexia, 5 decreased appetite, 19 myalgia, 27 headache, 4 depression, 10 insomnia, 6 pruritus </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 out of 65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 neutropenia, 2 diarrhoea, 3 nausea, 5 chills, 9 fatigue, 4 irritability, 3 decreased appetite, 5 myalgia, 7 headache, 3 depression, 5 insomnia, 2 pruritus </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 out of 16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0039" title="DeBruijneJ , BergmannJF , ReesinkHW , WeeginkCJ , MolenkampR , SchinkelJ , et al. Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients. Hepatology2010;52(5):1590‐9. DeBruijneJ , BergmannJF , WeeginkCJ , MolenkampR , SchinkelJ , TreitelMA , et al. Narlaprevir and peginterferon alfa‐2b for 2 weeks in chronic hepatitis C genotype 1 patients, followed by peginterferon alfa‐2b and ribavirin for 24/48 weeks: final results. Journal of Hepatology2010;52:S290‐1. HothoDM , DeBruijneJ , SpaanM , TreitelMA , BoonstraA , DeKnegtRJ , et al. Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long‐term follow‐up. Journal of Viral Hepatitis2013;20(4):e78‐81. ">De Bruijne 2010a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IDX320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 diarrhoea, 1 myalgia, 4 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0102" title="LawitzEJ , GruenerD , HillJM , MarburyT , MooreheadL , MathiasA , et al. A phase 1, randomized, placebo‐controlled, 3‐day, dose‐ranging study of GS‐5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. Journal of Hepatology2012;57(1):24‐31. ">Lawitz 2012a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ledispasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 nausea, 6 headache, 2 rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 out of 59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 out of 11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0067" title="ChuT , KulkarniR , GaneEJ , RobertsSK , StedmanC , AngusP , et al. The effect of host IL28B genotype on early viral kinetics during interferon‐free treatment in patients with chronic hepatitis C (CHC). Journal of Hepatology2011;54(Suppl 1):S521‐2. GaneEJ , RobertsSK , StedmanC , AngusPW , RitchieB , ElstonR , et al. First‐in‐man demonstration of potent antiviral activity with a nucleoside polymerase (R7128) and protease (R7227/ITMN‐191) inhibitor combination in HCV: safety, pharmacokinetics, and virologic results from INFORM‐1. Journal of Hepatology2009;50(Suppl 1):S380. GaneEJ , RobertsSK , StedmanCA , AngusPW , RitchieB , ElstonR , et al. Combination therapy with a nucleoside polymerase (R7128) and protease (R7227/ITMN ‐ 191) inhibitor in HCV: safety, pharmacokinetics, and virologic results from INFORM‐1. Hepatology2009;50(4 Suppl):394A‐5A. GaneEJ , RobertsSK , StedmanCAM , AngusPW , RitchieB , ElstonROB , et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM‐1): a randomised, double‐blind, placebo‐controlled, dose‐escalation trial. Lancet2010;376(9751):1467‐75. LePogamS , YanJM , ChhabraM , IlnickaM , KangH , KosakaA , et al. Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short‐term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir. Antimicrobial Agents and Chemotherapy2012;56(11):5494‐502. LimLY , KwoPY . A glimpse at the future of hepatitis C therapy: The INFORM trial. Hepatology2011;54(1):360‐3. MorcosPN , KulkarniR , IpeD , JumbeS , TranJ , BradfordWZ , et al. Pharmacokinetics/pharmacodynamics (PK/PD) of combination R7227 and R7128 therapy from INFORM‐1 demonstrates similar early HCV viral dynamics when R7227 is combined with either PEG ‐ IFN/ribavirin (SOC) or R7128. Hepatology2009;50(4 Suppl):1041A‐2A. ">Gane 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mericitabine/danoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 diarrhoea, 9 nausea, 36 headache, 9 rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 diarrhoea, 2 nausea, 8 headache, 1 rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0050" title="FeldJJ , JacobsonIM , HezodeC , AsselahT , RuanePJ , GruenerN , et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. New England Journal of Medicine2015;373(27):2599‐607. ">Feld 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mericitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 diarrhoea, 16 nausea, 6 chills, 47 fatigue, 14 irritability, 16 pyrexia, 12 arthralgia, 19 myalgia, 43 headache, 27 insomnia, 21 cough, 15 pruritus </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 diarrhoea, 14 nausea, 12 chills, 25 fatigue, 10 irritability, 14 pyrexia, 11 arthralgia, 18 myalgia, 28 headache, 11 insomnia, 11 cough, 11 pruritus </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0085" title="PockrosPJ , JensenD , TsaiN , TaylorR , RamjiA , CooperC , et al. JUMP‐C: a randomized trial of mericitabine plus pegylated interferon alpha‐2a/ribavirin for 24 weeks in treatment‐naïve HCV genotype 1/4 patients. Hepatology2013;58(2):514‐23. ">JUMP‐C 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mericitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 diarrhoea, 33 nausea, 31 chills, 58 fatigue, 21 irritability, 20 pyrexia, 25 decreased appetite, 18 arthralgia, 24 myalgia, 19 dizziness, 42 headache, 31 insomnia, 17 cough, 14 alopecia, 15 pruritus, 17 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 diarrhoea, 34 nausea, 33 chills, 58 fatigue, 25 irritability, 27 pyrexia, 22 decreased appetite, 21 arthralgia, 24 myalgia, 20 dizziness, 38 headache, 28 insomnia, 22 cough, 17 alopecia, 28 pruritus, 28 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 85</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0040" title="DeBruijneJ , BergmannJF , ReesinkHW , WeeginkCJ , MolenkampR , SchinkelJ , et al. Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients. Hepatology2010;52(5):1590‐9. DeBruijneJ , BergmannJF , WeeginkCJ , MolenkampR , SchinkelJ , TreitelMA , et al. Narlaprevir and peginterferon alfa‐2b for 2 weeks in chronic hepatitis C genotype 1 patients, followed by peginterferon alfa‐2b and ribavirin for 24/48 weeks: final results. Journal of Hepatology2010;52:S290‐1. HothoDM , DeBruijneJ , SpaanM , TreitelMA , BoonstraA , DeKnegtRJ , et al. Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long‐term follow‐up. Journal of Viral Hepatitis2013;20(4):e78‐81. ">De Bruijne 2010a2</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Narlaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 diarrhoea, 8 nausea, 30 influenza‐like illness, 6 dizziness, 11 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 out of 32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 nausea, 6 influenza‐like illness, 1 dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0203" title="VierlingJM , PoordadFF , LawitzE , GhalibRH , LeeWM , RavendhranN , et al. Once daily narlaprevir (NVR; SCH 900518) and ritonavir (RTV) in combination with peginterferon alfa‐2B/ribavirin (PR) for 12 weeks plus 12 weeks pr in treatment‐naïve patients with HCV genotype 1 (G1): SVR results from next‐1, a phase 2 study. Hepatology2011;54(Suppl S1):1437A‐8A. ">Vierling 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Narlaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87 anaemia, 84 diarrhoea, 131 nausea, 54 vomiting, 44 chills, 123 fatigue, 106 influenza‐like illness, 58 irritability, 58 pyrexia, 61 decreased appetite, 60 arthralgia, 39 myalgia, 58 dizziness, 83 headache, 33 depression, 80 insomnia, 28 pruritus, 31 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 anaemia, 17 diarrhoea, 50 nausea, 28 vomiting, 17 chills, 56 fatigue, 44 influenza‐like illness, 28 irritability, 17 pyrexia, 44 decreased appetite, 28 arthralgia, 6 dizziness, 39 headache, 22 depression, 39 insomnia, 33 pruritus, 11 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0128" title="MuirA , PoordadF , SheikhA , ElkashabM , BrennanR , Ankoma‐SeyV , et al. SVR4 results for the combination of ACH‐3102 and Sovaprevir, with ribavirin, in patients with genotype 1 chronic hepatitis C infection. 23rd Annual Conference of APASL, Brisbane, Australia. 2014. ">Muir 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Odalasvir/sovaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 anaemia, 2 diarrhoea, 5 fatigue, 2 influenza‐like illness, 2 irritability, 1 decreased appetite, 2 arthralgia, 3 myalgia, 1 dizziness, 1 dysgeusia, 6 headache, 2 insomnia, 4 cough, 1 dyspnoea, 1 pruritus, 1 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 out of 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 diarrhoea, 4 fatigue, 1 myalgia, 1 dizziness, 1 headache, 1 cough, pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 out of 10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0199" title="SullivanGJ , Rodriques‐TorresM , LawitzE , PoordadF , KapoorM , CampbellA , et al. ABT‐267 combined with pegylated interferon alpha‐ 2a/ribavirin in genotype 1 (GT1) HCV‐infected treatment naive subjects: 12 week antiviral and safety analysis. Journal of Hepatology2012;56(Suppl S2):S480. ">Sullivan 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ombitasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 anaemia, 5 neutropenia, 4 diarrhoea, 9 nausea, 7 vomiting, 6 chills, 18 fatigue, 1 influenza‐like illness, 1 irritability, 3 pyrexia, 5 decreased appetite, 2 arthralgia, 2 myalgia, 2 dizziness, 9 headache, 4 depression, 4 insomnia, 3 cough, 2 dyspnoea, 5 dry skin, 3 pruritus, 6 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 out of 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 neutropenia, 1 diarrhoea, 3 nausea, 2 vomiting, 6 fatigue, 2 influenza‐like illness, 1 irritability, 1 decreased appetite, 1 myalgia, 2 headache, 1 depression, 2 insomnia, 1 cough, dyspnoea, 1 dry skin, 2 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 out of 9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0003" title="AndersonRT , BaranRW , EricksonP , RevickiDA , DietzB , GoochK . Psychometric evaluation of the hepatitis C virus patient‐reported outcomes (HCV‐PRO) instrument: validity, responsiveness, and identification of the minimally important difference in a phase 2 clinical trial. Quality of Life Research2014;23(3):877‐86. GaultierI , CohenDE , BhathenaA , IdlerK , LarsenLM , PodsadeckiT , et al. The effect of IL28B polymorphisms on virologic response to treatment with pegylated interferon alpha‐2A and ribavirin (SOC) added to ABT‐450/ritonavir (ABT‐450/R), ABT‐333, or ABT‐072. Journal of Hepatology2011;54(Suppl 1):S523. Pilot‐MatiasTJ , TripathiRL , DekhtyarT , MenonRM , GaultierIA , CohenDE , et al. Genotypic and phenotypic characterization of NS3 variants selected in HCV‐infected patients treated with ABT‐450. Journal of Hepatology2011;54(Suppl 1):S485‐6. ">Anderson 2014a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paritaprevir/ABT‐072/dasabuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 anaemia, 14 neutropenia, 16 diarrhoea, 15 nausea, 6 vomiting, 4 asthenia, 11 chills, 29 fatigue, 14 influenza‐like illness, 8 irritability, 12 pyrexia, 4 decreased appetite, 9 arthralgia, 14 myalgia, 9 dizziness, 6 dysgeusia, 38 headache, 15 depression, 14 insomnia, 6 cough, 6 dyspnoea, 5 alopecia, 2 dry skin, 8 pruritus, 12 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 out of 63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 2 neutropenia, 4 diarrhoea, 4 nausea, 1 vomiting, 1 asthenia, 6 fatigue, 1 influenza‐like illness, 1 irritability, 1 pyrexia, 2 decreased appetite, 1 arthralgia, 3 myalgia, 4 dizziness, 2 dysgeusia, 4 headache, 2 insomnia, 2 dyspnoea, 1 alopecia, 2 pruritus, 2 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 out of 11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0049" title="FeldJJ , KowdleyKV , CoakleyE , SigalS , NelsonD , CrawfordD , et al. Sapphire I: Phase 3 placebo‐controlled study of interferon‐free, 12‐week regimen of ABT‐450/R/ABT‐267, ABT‐333, and ribavirin in 631 treatment‐naive adults with hepatitis Cvirus genotype 1. Journal of Hepatology2014;60(1 Suppl 1):S25. FeldJJ , KowdleyKV , CoakleyE , SigalS , NelsonDR , CrawfordD , et al. Treatment of HCV with ABT‐450/r‐ombitasvir and dasabuvir with ribavirin. New England Journal of Medicine2014;370(17):1594‐603. KowdleyKV , FeldJJ , CoakleyE , SigalS , NelsonDR , CrawfordD , et al. Sapphire I: Phase 3 placebo‐controlled study of interferon‐free, 12‐week regimen of ABT‐450/R/ABT‐267, ABT‐333, and ribavirin in 631 treatment‐naive adults with hepatitis C virus genotype 1. Gastroenterology2014;146(5 Suppl 1):S912‐S3. ">Feld 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paritaprevir/ombitasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 anaemia, 65 diarrhoea, 112 nausea, 23 vomiting, 59 asthenia, 164 fatigue, 26 irritability, 37 decreased appetite, 23 arthralgia, 21 myalgia, 38 dizziness, 156 headache, 67 insomnia, 34 cough, 38 dyspnoea, 27 dry skin, 80 pruritus, 51 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>391 out of 473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 diarrhoea, 22 nausea, 6 vomiting, 6 asthenia, 45 fatigue, 4 irritability, 5 decreased appetite, 9 arthralgia, 8 myalgia, 6 dizziness, 42 headache, 12 insomnia, 8 cough, 4 dyspnoea, 2 dry skin, 7 pruritus, 9 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108 out of 158</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0210" title="LiuY , LarsenL , BourliereM , BaranR , JudayT . Ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin (RBV) has mild impact on health‐related quality of life (HRQoL) compared with placebo during 12‐week treatment in treatment‐experienced adults with chronic hepatitis C (CHC). Journal of Hepatology2015;62(Suppl S2):S661. ZeuzemS , JacobsonIM , BaykalT , MarinhoRT , PoordadF , BourliereM , et al. Retreatment of HCV with ABT‐450/r‐ombitasvir and dasabuvir with ribavirin. New England Journal of Medicine2014;370(17):1604‐14. ">Zeuzem 2014a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paritaprevir/ombitasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 anaemia, 47 diarrhoea, 72 nausea, 22 vomiting, 60 asthenia, 115 fatigue, 22 irritability, 24 decreased appetite, 21 arthralgia, 28 myalgia, 30 dizziness, 13 dysgeusia, 126 headache, 52 insomnia, 43 cough, 50 dyspnoea, 27 dry skin, 53 pruritus, 34 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>328 out of 394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 diarrhoea, 17 nausea, 11 asthenia, 22 fatigue, 8 irritability, 2 decreased appetite, 7 arthralgia, 10 myalgia, 5 dizziness, 5 dysgeusia, 34 headache, 7 insomnia, 5 cough, 10 dyspnoea, 3 dry skin, 5 pruritus, 6 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74 out of 97</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0079" title="HothoD , DeBruijneJ , O'FarrellA , BoyeaT , LiJ , WeeginkCJ , et al. Accelerated clinical trial design to assess the safety, tolerability and anti‐viral activity of PHX1766, a novel HCV NS3/4A protease inhibitor, in healthy volunteers and chronic hepatitis C patients. Hepatology2009;50(4 Suppl):1031A‐2A. Hotho DaphneM , DeBruijneJ , O'FarrellA , BoyeaT , LiJ , BrackenM , et al. Pharmacokinetics and antiviral activity of PHX1766, a novel HCV protease inhibitor, using an accelerated Phase I study design. Antiviral Therapy2012;17(2):365‐75. ">Hotho 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PHX1766</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 nausea, 2 fatigue, 1 dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0157" title="NelsonD , PockrosPJ , GodofskyE , Rodriguez‐TorresM , EversonG , FriedM , et al. High end‐of‐treatment response (84%) after 4 weeks of R1626, peginterferon alfa‐2A (40KD) and ribavirin followed by a further 44 weeks of peginterferon alfa‐2A and ribavirin. Journal of Hepatology2008;48(Suppl 2):S371. PockrosPJ , NelsonD , GodofskyE , Rodriguez‐TorresM , EversonGT , FriedMW , et al. R1626 plus peginterferon alfa‐2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology2008;48(2):385‐97. ">Pockros 2008a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>R1626</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 neutropenia, 42 diarrhoea, 49 nausea, 26 vomiting, 39 chills, 45 fatigue, 20 irritability, 29 pyrexia, 21 arthralgia, 23 myalgia, 15 dizziness, 47 headache, 27 insomnia, 15 cough, 11 pruritus, 20 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 diarrhoea, 10 nausea, 2 vomiting, 9 chills, 10 fatigue, 1 irritability, 8 pyrexia, 5 arthralgia, 11 myalgia, 3 dizziness, 11 headache, 6 insomnia, 4 cough, 6 pruritus, 2 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified out of 20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0205" title="VinceB , HillJM , LawitzEJ , O'RiordanW , WebsterLR , GruenerDM , et al. A randomized, double‐blind, multiple‐dose study of the pan‐genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4. Journal of Hepatology2014;60(5):920‐7. ">Vince 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Samatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 nausea, 1 decreased appetite, 6 headache, 1 insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 out of 48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 nausea, 1 decreased appetite, 1 headache, 1 insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 out of 12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0057" title="FornsX , LawitzE , ZeuzemS , GaneE , BronowickiJP , AndreoneP , et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology2014;146(7):1669‐79. FornsX , LawitzE , ZeuzemS , GaneEJ , BronowickiJP , AndreoneP , et al. Simeprevir (TMC435) with peg‐interferon alpha‐2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon‐based therapy: efficacy and safety in patient sub‐populations in the PROMISE phase III trial. Hepatology2013;58(4 SUPPL. 1):737A‐8A. GaneEJ , FornsX , LawitzE , ZeuzemS , BronowickiJP , AndreoneP , et al. Simeprevir (TMC435) with peg‐interferon alpha‐2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon‐based therapy: efficacy in patients with genotype 1b HCV in the PROMISE phase III trial. Hepatology International2014;8(1 Suppl 1):S181. LawitzE , FornsX , ZeuzemS , GaneE , BronowickiJP , AndreoneP , et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon‐based therapy: results from PROMISE, a phase III trial. Gastroenterology2013;144(5 Suppl 1):S151. ">Forns 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 anaemia, 37 neutropenia, 36 diarrhoea, 59 nausea, 18 vomiting, 57 asthenia, 17 chills, 87 fatigue, 78 influenza‐like illness, 63 pyrexia, 35 decreased appetite, 26 arthralgia, 39 myalgia, 14 dizziness, 12 dysgeusia, 87 headache, 22 depression, 49 insomnia, 34 cough, 26 dyspnoea, 26 alopecia, 24 dry skin, 16 pruritus, 33 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>245 out of 260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 anaemia, 26 neutropenia, 22 diarrhoea, 26 nausea, 9 vomiting, 25 asthenia, 11 chills, 58 fatigue, 27 influenza‐like illness, 30 pyrexia, 24 decreased appetite, 12 arthralgia, 17 myalgia, 6 dizziness, 7 dysgeusia, 48 headache, 10 depression, 33 insomnia, 21 cough, 5 dyspnoea, 17 alopecia, 18 dry skin, 37 pruritus, 19 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123 out of 133</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0062" title="AerssensJ , FanningG , ScholliersA , LenzO , PeetersM , DeSmedtG , et al. Impact of IL28B genotype and pretreatment serum IP‐10 in treatment‐naive genotype‐1 HCV patients treated with TMC435 in combination with peginterferona‐2A and ribavirin in PILLAR study. Journal of Hepatology2011;54(Suppl S1):S5‐6. FriedMW , ButiM , DoreGJ , FerenciP , JacobsonI , MarcellinP , et al. Efficacy and safety of TMC435 in combination with peginterferon alfa‐2a and ribavirin in treatment‐naive genotype‐1 HCV patients: 24‐week interim results from the PILLAR study. Hepatology2010;52(Suppl S1):403A. FriedMW , ButiM , DoreGJ , FlisiakR , FerenciP , JacobsonI , et al. Once‐daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment‐naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology2013;58(6):1918‐29. ScottJ , GillesL , FuM , BrohanE , AmatyaR , JessnerW , et al. Patients with chronic hepatitis C virus treated with simeprevir added to peginterferon and ribavirin experienced less time with fatigue, depressive symptoms, and functional limitations: results from patients in the QUEST‐1, QUEST‐2, and promise studies. Value in Health2013;16(7):A362. ScottJ , GillesL , FuM , BrohanE , PanterC , ArbuckleR , et al. Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies. Journal of Viral Hepatitis2015;22(8):639‐50. ScottJ , RosaK , FuM , CerriK , PeetersM , Beumont‐MauvielM , et al. Improved SVR with simeprevir (TMC435) associated with reduced time with patient‐reported fatigue in treatment‐naive, HCV‐infected patients in the PILLAR phase IIb trial. Journal of Hepatology2013;58(Suppl 1):S371‐2. ">Fried 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 anaemia, 75 neutropenia, 47 diarrhoea, 86 nausea, 22 vomiting, 63 asthenia, 25 chills, 107 fatigue, 98 influenza‐like illness, 11 irritability, 64 pyrexia, 17 decreased appetite, 53 arthralgia, 55 myalgia, 29 dizziness, 16 dysgeusia, 142 headache, 32 depression, 69 insomnia, 52 cough, 33 dyspnoea, 53 alopecia, 63 dry skin, 173 pruritus, 65 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>302 out of 309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 anaemia, 16 neutropenia, 12 diarrhoea, 21 nausea, 5 vomiting, 16 asthenia, 8 chills, 37 fatigue, 29 influenza‐like illness, 8 irritability, 13 pyrexia, 6 decreased appetite, 11 arthralgia, 17 myalgia, 6 dizziness, 5 dysgeusia, 40 headache, 14 depression, 23 insomnia, 15 cough, 6 dyspnoea, 16 alopecia, 14 dry skin, 35 pruritus, 18 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75 out of 77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0044" title="HayashiN , SetoC , KatoM , KomadaY , GotoS . Once‐daily simeprevir (TMC435) with peginterferon/ribavirin for treatment‐naive hepatitis C genotype 1‐infected patients in Japan: the DRAGON study. Journal of Gastroenterology2014;49(1):138‐47. ">DRAGON 2014a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 anaemia, 13 diarrhoea,13 nausea, 6 vomiting, 4 chills, 2 fatigue, 42 pyrexia, 15 decreased appetite, 27 arthralgia, 15 myalgia, 3 dizziness, 6 dysgeusia, 41 headache, 2 depression, 23 insomnia, 8 cough, 25 alopecia, 5 dry skin, 15 pruritus, 47 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79 out of 79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 anaemia, 5 diarrhoea, 2 vomiting, 7 pyrexia, 3 decreased appetite, 2 arthralgia, 2 myalgia, 8 headache, 2 insomnia, 2 cough, 6 alopecia, 6 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 out of 13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0033" title="HayashiN , IzumiN , KumadaH , OkanoueT , TsubouchiH , YatsuhashiH , et al. Simeprevir with peginterferon/ribavirin for treatment‐naive hepatitis C genotype 1 patients in Japan: CONCERTO‐1, a phase III trial. Journal of Hepatology2014;61(2):219‐27. ">CONCERTO‐1 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 anaemia, 8 neutropenia, 20 diarrhoea, 16 nausea, 6 vomiting, 13 fatigue, 75 pyrexia, 28 decreased appetite, 30 arthralgia, 9 myalgia, 4 dizziness, 20 dysgeusia, 54 headache, 27 insomnia, 11 cough, 44 alopecia, 8 dry skin, 35 pruritus, 57 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123 out of 123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 anaemia, 1 neutropenia, 20 diarrhoea, 16 nausea, 6 vomiting, 7 fatigue, 31 pyrexia, 20 decreased appetite, 14 arthralgia, 11 myalgia, 4 dizziness, 8 dysgeusia, 26 headache, 3 depression, 25 insomnia, 8 cough, 28 alopecia, 9 dry skin, 18 pruritus, 37 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 out of 60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0077" title="HoebenE , VibergA , PeterssonK , LeeM , VanwelkenhuysenI , WitekJ , et al. Simeprevir exposure in Asian treatment naive patients with chronic hepatitis C virus genotype 1 infection results from a population pharmacokinetic model in the phase III Tiger study. Hepatology International2015;9(1 Suppl):S71. WeiL , HanT , YangD , HeoJ , ShangJ , ChengJ . Simeprevir plus peginterferon ribavirin in treatment naive patients with chronic hepatitis C virus genotype 1 infection results from the phase III Tiger study conducted in East Asian patients living in China and Korea. Hepatology International2015;9(1 Suppl):S61. ">Hoeben 2015a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82 anaemia, 59 neutropenia, 14 diarrhoea, 16 nausea, 15 asthenia, 63 fatigue, 39 influenza‐like illness, 67 pyrexia, 28 decreased appetite, 13 arthralgia, 36 myalgia, 39 headache, 17 insomnia, 16 cough, 47 alopecia, 40 pruritus, 57 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>298 out of 305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 anaemia, 32 neutropenia, 7 diarrhoea, 10 nausea, 7 asthenia, 36 fatigue, 19 influenza‐like illness, 46 pyrexia, 16 decreased appetite, 4 arthralgia, 22 myalgia, 28 headache, 18 insomnia, 17 cough, 26 alopecia, 17 pruritus, 27 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>149 out of 152</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0084" title="JacobsonI , DoreGJ , FosterGR , FriedMW , RaduM , RafalskiyVV , et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype‐1 infection in treatment‐naive patients: results from QUEST‐1, a phase III trial. Journal of Hepatology2013;58(Suppl 1):S574. JacobsonIM , DoreGJ , FosterGR , FriedMW , RaduM , RafalskyVV , et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment‐naive patients with chronic hepatitis C virus genotype 1 infection (QUEST‐1): a phase 3, randomised, double‐blind, placebo‐controlled trial. Lancet2014;384(9941):403‐13. ">Jacobson 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 anaemia, 54 neutropenia, 35 diarrhoea, 65 nausea, 23 vomiting, 25 asthenia, 33 chills, 111 fatigue, 62 influenza‐like illness, 51 pyrexia, 47 decreased appetite, 34 arthralgia, 39 myalgia, 23 dizziness, 16 dysgeusia, 88 headache, 23 depression, 56 insomnia, 25 cough, 23 dyspnoea, 30 alopecia, 33 dry skin, 68 pruritus, 60 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>252 out of 264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 anaemia, 15 neutropenia, 19 diarrhoea, 32 nausea, 9 vomiting, 21 asthenia, 18 chills, 53 fatigue, 26 influenza‐like illness, 28 pyrexia, 19 decreased appetite, 21 arthralgia, 18 myalgia, 9 dizziness, 4 dysgeusia, 51 headache, 16 depression, 31 insomnia, 20 cough, 9 dyspnoea, 16 alopecia, 11 dry skin, 20 pruritus, 30 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124 out of 130</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0146" title="MannsM , ReesinkH , BergT , DusheikoG , FlisiakR , MarcellinP , et al. Rapid viral response of once‐daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype‐1 patients: a randomized trial. Antiviral Therapy2011;16(7):1021‐33. ">OPERA 2011a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 anaemia, 26 neutropenia, 20 diarrhoea, 31 nausea, 9 vomiting, 26 asthenia, 6 chills, 35 fatigue, 24 influenza‐like illness, 10 irritability, 21 pyrexia, 7 decreased appetite, 20 arthralgia, 14 myalgia, 4 dizziness, 5 dysgeusia, 42 headache, 14 depression, 12 insomnia, 19 cough, 18 dyspnoea, 16 alopecia, 19 dry skin, 18 pruritus, 9 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82 out of 83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 anaemia, 4 neutropenia, 3 diarrhoea, 4 nausea, 3 vomiting, 7 asthenia, 5 chills, 13 fatigue, 5 influenza‐like illness, 4 irritability, 4 pyrexia, 2 decreased appetite, 3 arthralgia, 8 myalgia, 3 dizziness, 3 dysgeusia, 16 headache, 2 depression, 7 insomnia, 10 cough, 4 dyspnoea, 3 alopecia, 5 dry skin, 7 pruritus, 5 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 out of 28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0120" title="MannsM , MarcellinP , PoordadF , DeAraujoESA , ButiM , HorsmansY , et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment‐naive patients with chronic hepatitis C virus genotype 1 infection (QUEST‐2): a randomised, double‐blind, placebo‐controlled phase 3 trial. Lancet2014;384(9941):414‐26. PoordadF , MannsMP , MarcellinP , AraujoESA , ButiM , HorsmansY , et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype‐1 infection in treatment‐naive patients: results from QUEST‐2, a phase III trial. Gastroenterology2013;144(5 Suppl 1):S151. ">Manns 2014a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 anaemia, 49 neutropenia, 34 diarrhoea, 63 nausea, 17 vomiting, 59 asthenia, 21 chills, 95 fatigue, 66 influenza‐like illness, 80 pyrexia, 46 decreased appetite, 32 arthralgia, 58 myalgia, 21 dizziness, 101 headache, 29 depression, 51 insomnia, 32 cough, 23 dyspnoea, 43 alopecia, 28 dry skin, 65 pruritus, 46 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>243 out of 257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 anaemia, 29 neutropenia, 12 diarrhoea, 24 nausea, 7 vomiting, 38 asthenia, 12 chills, 56 fatigue, 35 influenza‐like illness, 53 pyrexia, 21 decreased appetite, 14 arthralgia, 28 myalgia, 9 dizziness, 49 headache, 19 depression, 21 insomnia, 22 cough, 11 dyspnoea, 27 alopecia, 18 dry skin, 34 pruritus, 15 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131 out of 134</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0155" title="PearlmanBL , EhlebenC , PerrysM . The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C‐related Child's class A cirrhosis. Gastroenterology2015;148(4):762. ">Pearlman 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 diarrhoea, 6 nausea, 8 fatigue, 1 irritability, 2 myalgia, 7 headache, 3 insomnia, 6 pruritus, 10 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 out of 58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 anaemia, 5 neutropenia, 2 diarrhoea, 7 nausea, 4 asthenia, 17 fatigue, 6 influenza‐like illness, 3 irritability, 4 myalgia, 8 headache, 6 insomnia, 4 pruritus, 3 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 out of 24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0014" title="FerenciP , FriedM , PoordadF , ZeuzemS , LenzO , Ouwerkerk‐MahadevanS , et al. Safety of simeprevir (SMV) with peg Ifnalpha‐2a/ribavirin (PR) in HCV genotype 1‐infected patients: PILLAR and ASPIRE trials. Swiss Medical Weekly2013;143(Suppl 199):15S. LenzO , FeveryB , VijgenL , VerbeeckJ , PeetersM , Beumont‐MauvielM , et al. TMC435 in patients infected with HCV genotype 1 who have failed previous pegylated interferon/ribavirin treatment: virologic analyses of the ASPIRE trial. Journal of Hepatology2012;56(Suppl S2):S5. ScottJ , RosaK , FuM , CerriK , PeetersM , BeumontM , et al. Fatigue during treatment for hepatitis C virus: results of self‐reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection. BMC Infectious Diseases2014;14:465. ScottJ , RosaK , FuM , CerriK , PeetersM , Beumont‐MauvielM , et al. Fatigue severity scale: reliability, validity and interpretation of change‐evidence from two clinical trials in patients with chronic HCV infection. Value in Health2013;16(3):A216. ScottJ , RosaK , ZeuzemS , Beumont‐MauvielM , PeetersM , Cerri , K , et al. Adding simeprevir (TMC435) to pegylated interferon/ribavirin does not increase patient reported fatigue in treatment‐experienced patients with chronic HCV infection: results from the ASPIRE trial. Journal of Hepatology2013;58(Suppl S1):S371. ZeuzemS , BergT , GaneE , FerenciP , FosterGR , FriedMW , et al. Simeprevir increases rate of sustained virologic response among treatment‐experienced patients with HCV genotype‐1 infection: a phase IIb trial. Gastroenterology2014;146(2):430‐41. ZeuzemS , FosterGR , FriedMW , HezodeC , HirschfieldGM , NikitinI , et al. The ASPIRE trial: TMC435 in treatment‐experienced patients with genotype‐1 HCV infection who have failed previous PEGIFN/RBV treatment. Journal of Hepatology2011;54(Suppl 1):S546. ">ASPIRE 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 anaemia, 101 neutropenia, 59 diarrhoea, 95 nausea, 21 vomiting, 84 asthenia, 34 chills, 174 fatigue, 116 influenza‐like illness, 53 irritability, 69 pyrexia, 69 decreased appetite, 50 arthralgia, 64 myalgia, 29 dizziness, 22 dysgeusia, 138 headache, 45 depression, 79 insomnia, 76 cough, 49 dyspnoea, 31 alopecia, 72 dry skin, 135 pruritus, 61 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>380 out of 396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 anaemia, 11 neutropenia, 13 diarrhoea, 14 nausea, 5 vomiting, 7 asthenia, 6 chills, 174 fatigue, 13 influenza‐like illness, 7 irritability, 9 pyrexia, 9 decreased appetite, 9 arthralgia, 12 myalgia, 6 dizziness, 3 dysgeusia, 24 headache, 6 depression, 9 insomnia, 8 cough, 4 dyspnoea, 5 alopecia, 10 dry skin, 11 pruritus, 9 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 out of 66</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0084" title="JacobsonI , DoreGJ , FosterGR , FriedMW , RaduM , RafalskiyVV , et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype‐1 infection in treatment‐naive patients: results from QUEST‐1, a phase III trial. Journal of Hepatology2013;58(Suppl 1):S574. JacobsonIM , DoreGJ , FosterGR , FriedMW , RaduM , RafalskyVV , et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment‐naive patients with chronic hepatitis C virus genotype 1 infection (QUEST‐1): a phase 3, randomised, double‐blind, placebo‐controlled trial. Lancet2014;384(9941):403‐13. ">Jacobson 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sofosbuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 diarrhoea, 46 nausea, 12 vomiting, 91 fatigue, 19 irritability, 7 decreased appetite, 16 arthralgia, 19 dizziness, 43 headache, 15 depression, 39 insomnia, 11 cough, 19 dyspnoea, 23 pruritus, 18 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>184 out of 207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 diarrhoea, 13 nausea, 5 vomiting, 17 fatigue, 1 irritability, 7 decreased appetite, 1 arthralgia, 5 dizziness, 14 headache, 1 depression, 3 insomnia, 2 cough, 1 dyspnoea, 6 pruritus, 6 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 out of 71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0104" title="LawitzE , LalezariJP , HassaneinT , KowdleyKV , PoordadFF , SheikhAM , et al. Sofosbuvir in combination with peginterferon alfa‐2a and ribavirin for non‐cirrhotic, treatment‐naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double‐blind, phase 2 trial. Lancet Infectious Diseases2013;13(5):401‐8. ">Lawitz 2013a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sofosbuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 anaemia, 23 neutropenia, 18 diarrhoea, 38 nausea, 12 vomiting, 2 asthenia, 37 chills, 64 fatigue, 15 irritability, 22 pyrexia, 11 decreased appetite, 10 arthralgia, 17 myalgia, 11 dizziness, 9 dysgeusia, 37 headache, 12 depression, 24 insomnia, 14 cough, 11 dyspnoea, 10 alopecia, 12 dry skin, 13 pruritus, 29 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117 out of 120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 anaemia, 5 neutropenia, 2 diarrhoea, 9 nausea, 2 vomiting, 1 asthenia, 10 chills, 16 fatigue, 5 irritability, 2 pyrexia, 4 decreased appetite, 5 arthralgia, 6 myalgia, 3 dizziness, 15 headache, 3 depression, 9 insomnia, 3 cough, 4 dyspnoea, 2 alopecia, 3 dry skin, 3 pruritus, 4 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 out of 26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>)<a href="./references#CD012143-bbs2-0051" title="LawitzE , MangiaA , WylesD , Rodriguez‐TorresM , HassaneinT , Gordon StuartC , et al. Sofosbuvir for previously untreated chronic hepatitis C infection. New England Journal of Medicine2013;368(20):1878‐87. YounossiZM , StepanovaM , HenryL , GaneE , JacobsonIM , LawitzE , et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH‐C). Journal of Hepatology2014;60(4):741‐7. [PUBMED: 24333184] ">FISSION 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sofosbuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 anaemia, 23 diarrhoea, 46 nausea, 17 vomiting, 7 chills, 92 fatigue, 7 influenza‐like illness, 25 irritability, 6 pyrexia, 17 decreased appetite, 15 arthralgia, 21 myalgia, 27 dizziness, 64 headache, 14 depression, 31 insomnia, 19 cough, 18 dyspnoea, 12 alopecia, 11 dry skin, 19 pruritus, 23 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219 out of 256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 anaemia, 30 neutropenia, 45 diarrhoea, 70 nausea, 23 vomiting, 44 chills, 134 fatigue, 44 influenza‐like illness, 40 irritability, 33 pyrexia, 44 decreased appetite, 35 arthralgia, 40 myalgia, 33 dizziness, 108 headache, 34 depression, 71 insomnia, 21 cough, 20 dyspnoea, 24 alopecia, 23 dry skin, 42 pruritus, 43 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>233 out of 243</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0174" title="Rodriguez‐TorresM , LawitzE , KowdleyKV , NelsonDR , DejesusE , McHutchisonJG , et al. Sofosbuvir (GS‐7977) plus peginterferon/ribavirin in treatment‐naïve patients with HCV genotype 1: a randomized, 28‐day, dose‐ranging trial. Journal of Hepatology2013;58(4):663‐8. ">Rodriguez‐Torres 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sofosbuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 anaemia, 17 nausea, 3 vomiting, 22 fatigue, 4 pyrexia, 7 decreased appetite, 12 arthralgia, 7 myalgia, 6 dizziness, 15 headache, 4 depression, 7 insomnia, 9 pruritus </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 out of 49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 5 nausea, 2 chills, 6 fatigue, 1 pyrexia, 1 decreased appetite, 1 myalgia, 2 dizziness, 2 headache, 2 insomnia,1 pruritus </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 out of 14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0050" title="FeldJJ , JacobsonIM , HezodeC , AsselahT , RuanePJ , GruenerN , et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. New England Journal of Medicine2015;373(27):2599‐607. ">Feld 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sofosbuvir/velpatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 diarrhoea, 75 nausea, 41 asthenia, 126 fatigue, 40 arthralgia, 25 myalgia, 182 headache, 50 insomnia, 39 cough </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>485 out of 624</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 diarrhoea, 13 nausea, 9 asthenia, 23 fatigue, 9 arthralgia, 6 myalgia, 33 headache, 11 insomnia, 4 cough </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89 out of 116</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3<a href="./references#CD012143-bbs2-0020" title="BenhamouY , MoussalliJ , RatziuV , LebrayP , DeBackerK , DeMeyerS , et al. Telaprevir activity in treatment‐naive patients infected hepatitis C virus genotype 4: a randomized trial. Journal of Infectious Diseases2013;208(6):1000‐7. BenhamouY , MoussalliJ , RatziuV , LebrayP , GysenV , deBackerK , et al. Results of a proof of concept study (C210) of telaprevir monotherapy and in combination with peginterferon ALFA‐2A and ribavirin in treatment‐naive genotype 4 HCV patients. Journal of Hepatology2009;50(Suppl 1):S6. BenhamouY , MoussalliJ , RatziuV , LebrayP , deBackerK , GhysA , et al. Activity of telaprevir monotherapy or in combination with peginterferon‐alfa‐2a and ribavirin in treatment‐naive genotype 4 hepatitis C patients: final results of study C210. Hepatology2010;52(Suppl S1):719A. DeMeyerS , GhysA , DierynckI , BeumontM , LuoD , PicchioG . Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir. Virology Journal2014;11:93. ">Benhamou 2013a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 diarrhoea, 4 nausea, 1 vomiting, 6 asthenia, 4 fatigue, 10 influenza‐like illness, 3 headache, 2 insomnia, 1 dyspnoea, 1 dry skin, 3 pruritus </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 out of 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 1 neutropenia, 3 asthenia, 4 influenza‐like illness, 1 decreased appetite, 1 headache, 1 insomnia, 1 cough, 1 dry skin, 2 pruritus, 2 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 out of 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0053" title="ForestierN , ReesinkHW , WeeginkCJ , McNairL , KiefferTL , ChuHM , et al. Antiviral activity of telaprevir (VX‐950) and peginterferon alfa‐2a in patients with hepatitis C. Hepatology2007;46(3):640‐8. ForestierN , SarrazinC , Friedrich‐RustM , WeeginkC , JansenP , ReesinkH , et al. Status of patients with chronic hepatitis C after a 14‐day pre‐treatment with Telaprevir (VX‐950) followed by an anti‐viral therapy with Peg‐interferon‐alpha‐2a (Peg‐IFN‐2a) and Ribavirin (RBV). Zeitschrift fur Gastroenterologie2007;45(8):841. ForestierN , SarrazinC , Friedrich‐RustM , ZeuzemS . Status of patients with chronic hepatitis C after a pretreatment period of 14 days with Telaprevir (VX‐950) und a following antiviral therapy with Peg‐interferon‐alfa‐2a (Peg‐IFN‐2s) and ribavirin (RBV). Zeitschrift fur Gastroenterologie2008;46(1):145. ForestierN , WeeginkCJ , PurdyS , McNairL , JansenPL , ZeuzemS , et al. Current status of subjects receiving peg‐interferon‐alfa‐2A (peg‐ifn) and ribavirin (RBV) after a 14‐day study of the hepatitis C protease inhibitor telaprevir (VX‐950), with peg‐ifn. Hepatology2006;44(4 (Suppl 1)):614A‐5A. WeeginkCJ , ForestierN , JansenPL , ZeuzemS , ReesinkHW . Final results of patients receiving peg‐interferon‐alfa‐2a (Peg‐IFN) and ribavirin (RBV) after a 14‐day study of the hepatitis C protease inhibitor telaprevir (VX‐950), with Peg‐IFN. Hepatology2007;46(4 (Suppl 1)):819A. ">Forestier 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 diarrhoea, 3 nausea, 1 chills, 5 myalgia, 2 dizziness, 5 headache, 3 dry skin, 3 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 out of 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 diarrhoea, 1 nausea, 1 asthenia, 2 chills, 2 myalgia, 1 dizziness, 2 headache, 1 dry skin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 out of 4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1<a href="./references#CD012143-bbs2-0058" title="DeMeyerS , GhysA , FosterGR , BeumontM , VanBaelenB , LinTI , et al. Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes. Journal of Viral Hepatitis2013;20(6):395‐403. DeMeyerS , GhysA , FosterGR , Beumont‐MauvielM , VanBaelenB , LinTI , et al. Analyses of genotype 2/3 HCV variants in patients treated with telaprevir in study C209 showed that the telaprevir resistance profile appears to be consistent across genotypes. Antiviral Therapy2010;15(Suppl 2):A118. FosterGR , HezodeC , BronowickiJP , CarosiG , WeilandO , VerlindenL , et al. Activity of telaprevir alone or in combination with peginterferon alfa‐2a and ribavirin in treatment‐naive genotype 2 and 3 hepatitis‐C patients: final results of STUDY C209. Journal of Hepatology2010;52(Suppl 1):S27. FosterGR , HézodeC , BronowickiJP , CarosiG , WeilandO , VerlindenL , et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology2011;141(3):881‐9. ">Foster 2011a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 anaemia, 4 diarrhoea, 8 nausea, 5 vomiting, 9 asthenia, 1 chills, 5 fatigue, 11 influenza‐like illness, 1 irritability, 2 pyrexia, 1 arthralgia, 4 myalgia, 3 dizziness, 5 headache, 1 depression, 2 insomnia, 1 cough, 2 dyspnoea, 1 alopecia, 3 dry skin, 11 pruritus, 5 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 out of 31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 neutropenia, 1 diarrhoea, 1 nausea, 5 asthenia, 3 chills, 2 fatigue, 7 influenza‐like illness, 5 pyrexia, 3 myalgia, 1 dysgeusia, 6 headache, 1 depression, 2 insomnia, 2 cough, 2 dyspnoea, 1 dry skin, 2 pruritus </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 out of 18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0075" title="BronowickiJP , HezodeC , BengtssonL , PolS , BourliereM , SerfatyL , et al. 100% SVR in IL28B CC patients treated with 12 weeks of telaprevir, peginterferon and ribavirin in the PROVE2 trial. Journal of Hepatology2012;56(Suppl 2):S430‐1. DusheikoGM , HezodeC , PolS , GoeserT , BronowickiJP , BourliereM , et al. Treatment of chronic hepatitis C with telaprevir (TVR) in combination with peginterferon‐alfa‐2a with or without ribavirin: further interim analysis results of the PROVE2 study. Journal of Hepatology2008;48(Suppl 2):S26. HezodeC , FerenciP , Dusheiko GeoffreyM , TranA , GrangeJ‐D , MathurinP , et al. Prove2 Study: treatment of chronic hepatitis C with telaprevir (Tvr) in combination with peginterferon‐alfa‐2a with or without ribavirin, interim analysis results. Gastroenterology2008;134(4, Suppl. 1):A755. HezodeC , ForestierN , DusheikoG , FerenciP , PolS , GoeserT , et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. New England Journal of Medicine2009;360(18):1839‐50. MuirA , PoordadF , SheikhA , ElkashabM , BrennanR , Ankoma‐SeyV , et al. SVR4 results for the combination of ACH‐3102 and sovaprevir, with ribavirin, in subjects with genotype 1 chronic hepatitis C infection. Hepatology International2014;8(1 Suppl):s395. PawlotskyJ , KiefferT , ZhouY , ZhangE , MarcialM , ByrnR , et al. Evaluation of viral variants during a phase 2 study (PROVE2) of telaprevir with peginterferon alfa‐2A and ribavirin in treatment‐naïve HCV genotype 1‐infected patients. Hepatology2007;46(4 Suppl 1):862A. PawlotskyJM , FerenciP , DusheikoGM , AlvesK , KauffmanR , ZeuzemS . PROVE2: a phase 2b study of telaprevir combined with peginterferon‐alfa‐2a with or without ribavirin for treatment‐naive patients with chronic hepatitis C. Hepatology International2009;3(1):169. ZeuzemS , HezodeC , FerenciP , DusheikoGM , AlvesK , BengtssonL , et al. Telaprevir in combination with peginterferon‐alfa‐2a with or without ribavirin in the treatment of chronic hepatitis C: final results of the PROVE2 study. Hepatology2008;48(4 Suppl):418A‐9A. ZeuzemS , HezodeC , FerenciP , DusheikoGM , PolS , GoeserT , et al. PROVE2: phase II study of VX950 (telaprevir) in combination with peginterferon alfa2A with or without ribavirin in subjects with chronic hepatitis C; first interim analysis. Hepatology2007;46(4 Suppl 1):268A‐9A. ">Hezode 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 anaemia, 11 neutropenia, 66 diarrhoea, 102 nausea, 22 vomiting, 110 asthenia, 12 chills, 70 fatigue, 92 influenza‐like illness, 22 irritability, 44 pyrexia, 30 decreased appetite, 36 arthralgia, 35 myalgia, 12 dizziness, 20 dysgeusia, 105 headache, 51 depression, 62 insomnia, 37 cough, 50 dyspnoea, 29 alopecia, 64 dry skin, 139 pruritus, 71 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240 out of 241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 anaemia, 14 neutropenia, 23 diarrhoea, 33 nausea, 12 vomiting, 26 asthenia, 10 chills, 30 fatigue, 43 influenza‐like illness, 11 irritability, 19 pyrexia, 16 decreased appetite, 14 arthralgia, 17 myalgia, 8 dizziness, 3 dysgeusia, 37 headache, 19 depression, 32 insomnia, 21 cough, 13 dyspnoea, 17 alopecia, 29 dry skin, 29 pruritus, 22 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81 out of 82</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0083" title="JacobsonI , PockrosP , LalezariJ , LawitzE , Rodriguez‐TorresM , DeJesusE , et al. Antiviral activity of filibuvir in combination with pegylated interferon alfa‐2A and ribavirin for 28 days in treatment naive patients chronically infected with HCV genotype 1. Journal of Hepatology2009;50(Suppl 1):S382. JacobsonI , PockrosPJ , LalezariJ , LawitzE , Rodriguez‐TorresM , DeJesusE , et al. Virologic response rates following 4 weeks of filibuvir in combination with pegylated interferon alfa‐2A and ribavirin in chronically‐infected HCV genotype‐1 patients. Journal of Hepatology2010;52(Suppl 1):S464. MoriJ , HammondJL , SrinivasanS , JagannathaS , RystECC . Genotypic characterisation of filibuvir (PF‐00868554 ) resistance in patients receiving four weeks co‐administration of filibuvir with pegIFN/RBV. Hepatology2010;52(Suppl S1):722A. MoriJ , HammondJL , SrinivasanS , JagannathaS , Van derRystE . Genotypic characterisation of filibuvir (PF‐00868554) resistance in patients receiving four weeks co‐administration of filibuvir with PEGIFN/RBV (12 week analysis). Journal of Hepatology2010;52(Suppl 1):S15. ">Jacobson 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>276 anaemia, 217 diarrhoea, 302 nausea, 418 fatigue, 203 pyrexia, 304 headache, 233 insomnia, 346 pruritus, 262 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>723 out of 727</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 anaemia, 80 diarrhoea, 112 nausea, 206 fatigue, 87 pyrexia, 142 headache, 111 insomnia, 131 pruritus, 88 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>354 out of 361</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0125" title="EversonGT , GordonSC , JacobsonI , KauffmanRS , McNairL , MuirA , et al. PROVE 1: subgroup analysis of a phase 2 study of telaprevir with peginterferon alfa‐2a and ribavirin in treatment‐naive subjects with hepatitis C. Hepatology International2009;3:167. McHutchisonJG , EversonGT , GordonSC , JacobsonI , KauffmanR , McNairL , et al. PROVE1: results from a phase 2 study of telaprevir with peginterferon alfa‐2a and ribavirin in treatment‐naive subjects with hepatitis C. Journal of Hepatology2008;48(Suppl S2):S4. McHutchisonJG , EversonGT , GordonSC , JacobsonIM , SulkowskiM , KauffmanR , et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. New England Journal of Medicine2009;360(18):1827‐38. ">McHutchison 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58 anaemia, 30 neutropenia, 64 diarrhoea, 93 nausea, 38 vomiting, 29 chills, 127 fatigue, 75 influenza‐like illness, 23 irritability, 33 pyrexia, 22 decreased appetite, 34 arthralgia, 27 myalgia, 41 dizziness, 16 dysgeusia, 80 headache, 34 depression, 68 insomnia, 36 cough, 25 dyspnoea, 21 alopecia, 28 dry skin, 74 pruritus, 62 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175 out of 175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 anaemia, 18 neutropenia, 21 diarrhoea, 22 nausea, 9 vomiting, 14 chills, 57 fatigue, 32 influenza‐like illness, 22 irritability, 22 pyrexia, 9 decreased appetite, 16 arthralgia, 18 myalgia, 14 dizziness, 8 dysgeusia, 45 headache, 13 depression, 29 insomnia, 14 cough, 11 dyspnoea, 8 alopecia, 19 dry skin, 17 pruritus, 20 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75 out of 75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0126" title="EversonGT , GordonSC , JacobsonI , KauffmanRS , McNairL , MuirA , et al. PROVE 1: subgroup analysis of a phase 2 study of telaprevir with peginterferon alfa‐2a and ribavirin in treatment‐naive subjects with hepatitis C. Hepatology International2009;3:167. MannsM , MuirA , AddaN , JacobsonI , AfdhalN , HeathcoteJ , et al. Telaprevir in hepatitis C genotype‐1‐infected patients with prior non‐response, viral breakthrough or relapse to peginterferonalfa‐2A/B and ribavirin therapy: SVR results of the PROVE3 study. Journal of Hepatology2009;50(Suppl 1):S379. McHutchinsonJG , MannsMP , MuirAJ , TerraultNA , JacobsonIM , AfdhalNH , et al. Telaprevir for previously treated chronic HCV infection. New England Journal of Medicine2010;362(14):1292‐303. McHutchinsonJG , ShiffmanML , TerraultN , MannsMP , DiBiscegliAM , JacobsonIM , et al. Interim results of PROVE 3: a randomized, controlled, phase 2b study of telaprevir (TVR) with peginterferon‐alfa‐2a (P) and/or ribavirin (R) in subjects with hepatitis C genotype 1 who failed to achieve an SVR with a prior course of PR therapy. Hepatology International2009;3(1):25. McHutchisonJG , MannsMP , MuirA , TerraultN , JacobsonIM , AfdhalNH , et al. PROVE3 final results and 1‐year durability of SVR with telaprevir‐based regimen in hepatitis C genotype 1‐infected patients with prior non‐response, viral breakthrough or relapse to peginterferon‐alfa‐2a/b and ribavirin therapy. Hepatology2009;50(4 Suppl):334A‐5A. McHutchisonJG , ShiffmanML , TerraultN , MannsMP , DiBisceglieAM , JacobsonIM , et al. A phase 2b study of telaprevir with peginterferon‐alfa‐2a and ribavirin in hepatitis C genotype 1 null and partial responders and relapsers following a prior course of peginterferon‐alfa‐2a/b and ribavirin therapy: PROVE3 interim results. Hepatology2008;48(4 Suppl):269A‐70A. ">McHutchison 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69 anaemia, 31 neutropenia, 115 diarrhoea, 122 nausea, 37 vomiting, 57 chills, 197 fatigue, 93 influenza‐like illness, 63 irritability, 59 pyrexia, 20 decreased appetite, 51 arthralgia, 60 myalgia, 47 dizziness, 130 headache, 43 depression, 83 insomnia, 46 cough, 27 dyspnoea, 54 alopecia, 32 dry skin, 129 pruritus, 126 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>329 out of 339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 anaemia, 7 neutropenia, 22 diarrhoea, 39 nausea, 13 vomiting, 15 chills, 64 fatigue, 36 influenza‐like illness, 25 irritability, 14 pyrexia, 12 decreased appetite, 21 arthralgia, 21 myalgia, 18 dizziness, 41 headache, 19 depression, 19 insomnia, 20 cough, 9 dyspnoea, 13 alopecia, 7 dry skin, 17 pruritus, 20 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111 out of 114</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0196" title="ShermanKE , RockstrohJK , DieterichDT , SorianoV , GirardPM , McCallisterS , et al. Telaprevir combination with peginterferon alfa‐2A/ribavirin in HCV/HIV coinfected patients: 24‐week treatment interim analysis. Hepatology2011;54(4 Suppl):1431A‐2A. SulkowskiMS , ShermanKE , DieterichDT , BsharatM , MahnkeL , RockstrohJK , et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Annals of Internal Medicine2013;159(2):86‐96. SulkowskiMS , ShermanKE , SorianoV , RockstrohJ , DieterichDT , GirardPM , et al. Telaprevir in combination with peginterferon alfa‐2a/ribavirin in HCV/HIV co‐infected patients: SVR24 final study results. Hepatology2012;56(S1):219A. ">Sulkowski 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 anaemia, 26 neutropenia, 34 diarrhoea, 44 nausea, 27 vomiting, 22 asthenia, 15 chills, 50 fatigue, 24 influenza‐like illness, 18 irritability, 34 pyrexia, 30 decreased appetite, 9 arthralgia, 20 myalgia, 19 dizziness, 18 dysgeusia, 38 headache, 11 depression, 25 insomnia, 15 cough, 5 dyspnoea, 18 alopecia, 11 dry skin, 30 pruritus, 12 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 out of 38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 anaemia, 2 neutropenia, 6 diarrhoea, 11 nausea, 5 vomiting, 9 asthenia, 5 chills, 12 fatigue, 13 influenza‐like illness, 5 irritability, 7 pyrexia, 6 decreased appetite, 2 arthralgia, 6 myalgia, 2 dizziness, 5 dysgeusia, 6 headache, 4 depression, 9 insomnia, 6 cough, 2 dyspnoea, 6 alopecia, 3 dry skin, 3 pruritus </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 out of 22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0209" title="BergT , AndreoneP , PolS , RobertsSK , YounossiZM , DiagoM , et al. Predictors of virologic response with telaprevir‐based combination treatment in HCV genotype 1‐infected patients with prior peginterferon/ribavirin treatment failure: post‐hoc analysis of the phase III REALIZE study. Hepatology2011;54(S1):375A‐6A. DeMeyerS , DierynckI , GhysA , BeumontM , DaemsB , VanBaelenB , et al. Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial. Hepatology2012;56(6):2106‐15. FosterGR , JacobsonIM , DoreGJ , FriedM , MannsM , MarcellinP , et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment‐naive European patients in the QUEST‐1 and QUEST‐2 phase III trials. Journal of Hepatology2014;60(1 Suppl 1):S456. FosterGR , ZeuzemS , AndreoneP , PolS , LawitzEJ , DiagoM , et al. Subanalyses of the telaprevir lead‐in arm in the REALIZE study: response at week 4 is not a substitute for prior null response categorization. Journal of Hepatology2011;54(Suppl 1):S3‐S4. FosterGR , ZeuzemS , AndreoneP , PolS , LawitzEJ , DiagoM , et al. Sustained virologic response rates with telaprevir by response after 4 weeks of lead‐in therapy in patients with prior treatment failure. Journal of Hepatology2013;58(3):488‐94. PolS , AerssensJ , ZeuzemS , AndreoneP , LawitzEJ , RobertsS , et al. Similar SVR rates in IL28B CC, CT OR TT prior relapser, partial‐ or null‐responder patients treated with telaprevir/peginterferon/ribavirin: retrospective analysis of the REALIZE study. Journal of Hepatology2011;54(Suppl 1):S6‐7. PolS , RobertsSK , AndreoneP , YounossiZM , DiagoM , LawitzE , et al. Efficacy and safety of telaprevir‐based regimens in cirrhotic patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: subanalysis of the REALIZE phase III study. Hepatology2011;54(S1):374A‐5A. RobertsSK , AndreoneP , PolS , YounossiZM , DiagoM , LawitzE , et al. Impact of anemia and ribavirin dose reduction on SVR to a telaprevir‐based regimen in patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure in the phase III REALIZE study. Hepatology2011;54(4 Suppl):1007A‐8A. TuefferdM , PalescandoloE , VijgenL , ColomboM , RobertsS , WedemeyerH , et al. ITPA gene variants and anemia during telaprevir/peginterferon/ribavirin combination therapy in patients with chronic hepatitis C infection. Journal of Hepatology2014;60(1 Suppl S):S490. WitekJ . Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment‐experienced patients. Journal of Hepatology2014;60(6):1112‐7. YounossiZ , NegroF , SerfatyL , PolS , DiagoM , ZeuzemS , et al. Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial. Hepatology2013;58(6):1897‐906. ZeuzemS , AndreoneP , PolS , LawitzE , DiagoM , RobertsS , et al. Telaprevir for retreatment of HCV infection. New England Journal of Medicine2011;364(25):2417‐28. ZeuzemS , AndreoneP , PolS , LawitzEJ , DiagoM , RobertsS , et al. REALIZE trial final results: telaprevir‐based regimen for genotype 1 hepatitis C virus infection in patients with prior null response, partial response or relapse to peginterferon/ribavirin. Journal of Hepatology2011;54(Suppl S1):S3. ">Zeuzem 2011a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>171 anaemia, 73 neutropenia, 135 diarrhoea, 181 nausea, 68 vomiting, 111 asthenia, 73 chills, 276 fatigue, 179 influenza‐like illness, 74 irritability, 130 pyrexia, 40 decreased appetite, 67 arthralgia, 87 myalgia, 47 dizziness, 65 dysgeusia, 221 headache, 59 depression, 152 insomnia, 128 cough, 82 dyspnoea, 78 alopecia, 97 dry skin, 270 pruritus, 194 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>517 out of 530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 anaemia, 14 neutropenia, 18 diarrhoea, 31 nausea, 11 vomiting, 38 asthenia, 73 chills, 53 fatigue, 33 influenza‐like illness, 21 irritability, 36 pyrexia, 9 decreased appetite, 20 arthralgia, 24 myalgia, 7 dizziness, 8 dysgeusia, 49 headache, 19 depression, 34 insomnia, 26 cough, 17 dyspnoea, 17 alopecia, 21 dry skin, 36 pruritus, 25 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126 out of 132</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0104" title="LawitzE , LalezariJP , HassaneinT , KowdleyKV , PoordadFF , SheikhAM , et al. Sofosbuvir in combination with peginterferon alfa‐2a and ribavirin for non‐cirrhotic, treatment‐naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double‐blind, phase 2 trial. Lancet Infectious Diseases2013;13(5):401‐8. ">Lawitz 2013a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaniprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 anaemia, 7 neutropenia, 16 diarrhoea, 26 nausea, 16 vomiting, 13 asthenia, 5 chills, 17 fatigue, 17influenza‐like illness, 4 irritability, 8 pyrexia, 13 decreased appetite, 8 arthralgia, 3 myalgia, 5 dizziness, 2 dysgeusia, 26 headache, 8 depression, 15 insomnia, 8 cough, 7 dyspnoea, 6 alopecia, 6 dry skin, 9 pruritus, 10 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71 out of 75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 anaemia, 2 neutropenia, 4 diarrhoea, 6 nausea, 4 asthenia, 2 chills, 7 fatigue, 4 influenza‐like illness, 3 irritability, 2 pyrexia, 2 decreased appetite, 2 arthralgia, 3 myalgia, 7 headache, 3 depression, 2 insomnia, 3 cough, 5 dyspnoea, 3 alopecia, 6 dry skin, 4 pruritus, 4 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 out of 19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0116" title="LawitzE , SulkowskiM , JacobsonIRA , KraftWK , MaliakkalB , Al‐IbrahimM , et al. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics. Antiviral Research2013;99(3):214‐20. MannsMP , GaneE , Rodriguez‐TorresM , StoehrA , YehC‐T , MarcellinP , et al. Vaniprevir with pegylated interferon alpha‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C: a randomized phase II study. Hepatology2012;56(3):884‐93. MannsMP , GaneE , Rodriguez‐TorresM , StoehrA , YehC‐T , WiedmannR , et al. MK‐7009 significantly improves rapid viral response (RVR) in combination with pegylated interferon ALFA‐2A and ribavirin in patients with chronic hepatitis C (CHC) genotype 1 infection. Journal of Hepatology2009;50(Suppl S1):S384. MannsMP , GaneE , Rodriguez‐TorresM , StoehrA , YehCT , MarcellinP , et al. Vaniprevir with pegylated interferon alpha‐2a and ribavirin in treatment‐naive patients with chronic hepatitis C: a randomized phase II study. Hepatology2012;56(3):884‐93. MannsMP , GaneEJ , Rodriguez‐TorresM , StoehrAD , YehC , MarcellinP , et al. Early viral response (EVR) rates in treatment ‐ naive patients with chronic hepatitis C (CHC) genotype 1 infection treated with MK‐7009, a novel NS3/4a protease inhibitor, in combination with pegylated interferon alfa‐2a and ribavirin for 28 days. Hepatology2009;50(4 Suppl):332A‐3A. MannsMP , GaneEJ , Rodriguez‐TorresM , StoehrAD , YehC , MarcellinP , et al. Sustained viral response (SVR) rates in genotype 1 treatment‐naive patients with chronic hepatitis C (CHC) infection treated with vaniprevir (MK‐7009), A NS3/4A protease inhibitor, in combination with pegylated interferon alfa‐2a and ribavirin for 28 days. Hepatology2010;52(Suppl S1):361A. ">Manns 2012a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaniprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 anaemia, 7 neutropenia, 16 diarrhoea, 26 nausea, 16 vomiting, 13 asthenia, 5 chills, 17 fatigue, 17 influenza‐like illness, 4 irritability, 8 pyrexia, 13 decreased appetite, 8 arthralgia, 3 myalgia, 5 dizziness, 2 dysgeusia, 26 headache, 8 depression, 15 insomnia, 8 cough, 7 dyspnoea, 6 alopecia, 6 dry skin, 9 pruritus, 10 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71 out of 75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 anaemia, 2 neutropenia, 4 diarrhoea, 6 nausea, 4 asthenia, 2 chills, 7 fatigue, 4 influenza‐like illness, 3 irritability, 2 pyrexia, 2 decreased appetite, 2 arthralgia, 3 myalgia, 7 headache, 3 depression, 2 insomnia, 3 cough, 5 dyspnoea, 3 alopecia, 6 dry skin, 4 pruritus, 4 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 out of 19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0175" title="Rodriguez‐TorresM , StoehrA , GaneEJ , SerfatyL , LawitzE , ZhouA , et al. Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment‐experienced patients with chronic HCV genotype 1 infection and cirrhosis. Clinical Gastroenterology and Hepatology2014;12(6):1029‐37.e5. ">Rodriguez‐Torres 2014a1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaniprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 anaemia, 34 neutropenia, 97 diarrhoea, 110 nausea, 59 vomiting, 50 asthenia, 16 chills, 92 fatigue, 54 influenza‐like illness, 24 irritability, 37 pyrexia, 40 decreased appetite, 37 arthralgia, 38 myalgia, 23 dizziness, 16 dysgeusia, 92 headache, 32 depression, 40 insomnia, 54 cough, 30 dyspnoea, 35 alopecia, 37 dry skin, 75 pruritus, 43 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225 out of 229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 anaemia, 3 neutropenia, 9 diarrhoea, 10 nausea, 3 vomiting, 11 asthenia, 1 chills, 18 fatigue, 12 influenza‐like illness, 8 irritability, 14 pyrexia, 5 decreased appetite, 11 arthralgia, 12 myalgia, 6 dizziness, 3 dysgeusia, 20 headache, 3 depression, 14 insomnia, 14 cough, 8 dyspnoea, 5 alopecia, 10 dry skin, 14 pruritus, 10 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 out of 56</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0107" title="BarnardR , HwangPMT , BhanjaS , CampbellH , StrizkiJ , CheneyC , et al. Resistance analysis of cirrhotic treatment‐experienced genotype 1 patients in a study of MK‐7009 in combination with pegylated interferon/ribavirin. Journal of Hepatology2013;58(Suppl S1):S487. ElbashaE , ElKhouryA , MobasheryN . Projected long‐term impact of MK‐7009 (vaniprevir) for previously treated chronic HCV genotype 1 infection. Hepatology International2013;7(1 Suppl):S354. GaoW , CaroL , AndersonM , HwangP , ZhouA , SuJ , et al. Vaniprevir (MK‐7009) demonstrates higher exposures in treatment‐experienced genotype (GT) 1 cirrhotic than non‐cirrhotic HCV‐infected patients. Hepatology2013;58(Suppl S1):739A. LawitzE , Rodriguez‐TorresM , StoehrA , GaneEJ , SerfatyL , BhanjaS , et al. A phase 2B study of MK‐7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment. Journal of Hepatology2013;59(1):11‐7. MobasheryN , WongP , ZhangS , BhanjaS , WarnerA , ShawPM , et al. Impact of IL28B genotype on virologic response in prior treatment failure patients who received MK‐7009 in combination with peginterferon and ribavirin. Journal of Hepatology2012;56(Suppl S2):S467. ">Lawitz 2013c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaniprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 anaemia, 34 neutropenia, 97 diarrhoea, 110 nausea, 59 vomiting, 50 asthenia, 16 chills, 92 fatigue, 54 influenza‐like illness, 24 irritability, 37 pyrexia, 40 decreased appetite, 37 arthralgia, 38 myalgia, 23 dizziness, 16 dysgeusia, 92 headache, 32 depression, 40 insomnia, 54 cough, 30 dyspnoea, 35 alopecia, 37 dry skin, 75 pruritus, 43 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225 out of 229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 anaemia, 3 neutropenia, 9 diarrhoea, 10 nausea, 3 vomiting, 11 asthenia, 1 chills, 18 fatigue, 12 influenza‐like illness, 8 irritability, 14 pyrexia, 5 decreased appetite, 11 arthralgia, 12 myalgia, 6 dizziness, 3 dysgeusia, 20 headache, 3 depression, 14 insomnia, 14 cough, 8 dyspnoea, 5 alopecia, 10 dry skin, 14 pruritus, 10 rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 out of 56</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0034" title="CooperC , LawitzEJ , GhaliP , Rodriguez‐TorresM , AndersonFH , LeeSS , et al. Antiviral activity of the non‐nucleoside polymerase inhibitor, VCH‐759, in chronic hepatitis C patients: results from a randomized, double‐blind, placebo‐controlled, ascending multiple dose study. Hepatology2007;46(4 (Suppl 1)):864A. CooperC , LawitzEJ , GhaliP , Rodriguez‐TorresM , AndersonFH , LeeSS , et al. Evaluation of VCH‐759 monotherapy in hepatitis C infection. Journal of Hepatology2009;51(1):39‐46. ">Cooper 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VCH‐759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 diarrhoea, 3 nausea, 4 vomiting, 1 chills, 5 fatigue, 8 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 out of 23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 diarrhoea, 1 nausea, 2 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 out of 9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012143-bbs2-0112" title="LawitzE , FreilichB , LinkJ , GermanP , MoH , HanL , et al. A phase 1, randomized, dose‐ranging study of GS‐5816, a once‐daily NS5A inhibitor, in patients with genotype 1‐4 hepatitis C virus. Journal of Viral Hepatitis2015;22(12):1011‐9. [PUBMED: 26183611] LawitzE , GlassSJ , GruenerD , Freilich B. HillJM , LinkJO , et al. GS‐5816, a once‐daily NS5A inhibitor, demonstrates potent antiviral activity in patients with genotype 1, 2, 3, or 4 HCV infection in a 3‐day monotherapy study. Hepatology2013;58(Suppl S1):731A. ">Lawitz 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Velpatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 diarrhoea, 3 nausea, 4 vomiting, 6 headache, 2 cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 out of 70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 out of 17</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Non‐serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/full#CD012143-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012143-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Hepatitis C‐related morbidity or all‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Hepatitis C‐related morbidity or all‐cause mortality ‐ bias risk <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Trials at high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Trials at low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to type of DAA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 ABT‐072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 ACH‐2684</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Alisporivir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 ALS‐2200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Asunaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Balapiravir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7 Beclabuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8 BILB‐1941</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9 BIT‐225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10 Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11 Ciluprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12 Daclatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13 Danoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14 Dasabuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15 Deleobuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.16 Faldaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.17 Filibuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.18 Grazoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.19 GS‐6620</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.20 GS‐9256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.21 GS‐9451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.22 GS‐9669</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.23 GS‐9851</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.24 GS‐9857</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.25 GSK2336805</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.26 GSK2878175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.27 IDX‐184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.28 INX‐08189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.29 Ledispasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.30 Mericitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.31 Narlaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.32 Nesbuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.33 Odalasavir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.34 Ombitasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.35 Paritaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.36 PHX1766</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.37 PPI‐461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.38 PSI‐352938</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.39 Samatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.40 Setrobuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.41 Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.42 Sofosbuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.43 Sovaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.44 Tegobuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.45 Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.46 Valopicitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.47 Vaniprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.48 VCH‐759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.49 VCH‐916</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.50 Velpatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.51 VX‐222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.52 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to group of DAA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Cyclophilin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 NS3/NS4A inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 NS5B inhibitors (NPI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 NS5B inhibitors (NNPI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 NS5A inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 VPU‐ion channel inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to HIV‐infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 With HIV‐infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Without HIV‐infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Mixed (with and without HIV‐infection)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to comorbidity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 With comorbidity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Without comorbidity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to viral genotype <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Genotype 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Genotype 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Genotype 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Genotype 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to human genotype (IL28b) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 IL28b (CC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 IL28B (CT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 IL28B (TT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 IL28B (CT + TT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to Asian‐region <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 From Asian region</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Not from Asian region</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to specific ethnicities <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 White</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Black</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Hispanic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to reaching planned sample size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Trials reaching planned sample size</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Trials not reaching planned sample size</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to prior treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Treatment‐naive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Treatment‐experienced</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to interferon <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Trials where both groups received interferon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Trials where neither group received interferon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to ribavirin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Trials where both groups received ribavirin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Trials where neither group received ribavirin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to chronic kidney disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 With chronic kidney disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Without chronic kidney disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to cryoglobulinaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 With cryoglobulinaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Without cryoglobulinaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to DAA group as co‐intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Trials where DAA were used as co‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Trials where DAA were not a co‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to median dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Over or equal to median dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 Under median dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 Not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">DAA on or on the way to the market versus placebo/no intervention (morbidity or all cause mortality analyses)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012143-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious adverse events ‐ bias risk <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Trials at high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Trials at low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serious adverse events ‐ according to type of DAA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 ABT‐072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 ACH‐2684</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Alisporivir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 ALS‐2200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Asunaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Balapiravir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7 Beclabuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8 BILB‐1941</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9 BIT‐225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10 Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11 Ciluprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12 Daclatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13 Danoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14 Dasabuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15 Deleobuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.16 Faldaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.17 Filibuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.18 Grazoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.19 GS‐6620</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.20 GS‐9256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.21 GS‐9451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.22 GS‐9669</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.23 GS‐9851</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.24 GS‐9857</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.25 GSK2336805</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.26 GSK2878175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.27 IDX‐184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.28 INX‐08189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.29 Ledispasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.30 Mericitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.31 Narlaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.32 Nesbuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.33 Odalasavir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.34 Ombitasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.35 Paritaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.36 PHX1766</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.37 PPI‐461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.38 PSI‐352938</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.39 Samatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.40 Setrobuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.41 Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.42 Sofosbuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.43 Sovaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.44 Tegobuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.45 Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.46 Valopicitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.47 Vaniprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.48 VCH‐759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.49 VCH‐916</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.50 Velpatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.51 VX‐222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.52 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serious adverse events ‐ according to group of DAA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Cyclophilin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 NS3/NS4A inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 NS5B inhibitors (NPI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 NS5B inhibitors (NNPI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 NS5A inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 VPU‐ion channel inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serious adverse events ‐ according to HIV‐infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 With HIV‐infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Without HIV‐infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Mixed (with and without HIV‐infection)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Serious adverse events ‐ according to comorbidity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 With comorbidity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Without comorbidity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Serious adverse events ‐ according to viral genotype <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Genotype 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Genotype 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Genotype 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Genotype 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Serious adverse events ‐ according to human genotype (IL28b) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 IL28b (CC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 IL28B (CT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 IL28B (TT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 IL28B (CT + TT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Serious adverse events ‐ according to Asian‐region <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 From Asian region</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Not from Asian region</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Serious adverse events ‐ according to specific ethnicities <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 White</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Black</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Hispanic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Serious adverse events ‐ according to reaching planned sample size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Trials reaching planned sample size</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Trials not reaching planned sample size</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Serious adverse events ‐ according to prior treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Treatment‐naive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Treatment‐experienced</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Serious adverse events ‐ according to interferon <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Trials where both groups received interferon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Trials where neither group received interferon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Serious adverse events ‐ according to ribavirin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Trials where both groups received ribavirin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Trials where neither group received ribavirin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Serious adverse events ‐ according to chronic kidney disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 With chronic kidney disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Without chronic kidney disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Serious adverse events ‐ according to cryoglobulinaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 With cryoglobulinaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Without cryoglobulinaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Serious adverse events ‐ according to DAA group as co‐intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Trials where DAA were used as co‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Trials where DAA were not a co‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Serious adverse events ‐ according to median dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Over or equal to median dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 Under median dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 Not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">DAA on or on the way to the market versus placebo/no intervention (serious adverse events analyses)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012143-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">DAA on or on the way to the market versus placebo/no intervention (sustained virological response)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Without sustained virological response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.37, 0.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Without sustained virological response ‐ bias risk <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.22, 0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Trials at high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.22, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Trials at low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Without sustained virological response ‐ according to type of DAA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.37, 0.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 ABT‐072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 ACH‐2684</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Alisporivir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 ALS‐2200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Asunaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.29, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Balapiravir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7 Beclabuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.43, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8 BILB‐1941</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9 BIT‐225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.03, 2.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10 Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.29, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11 Ciluprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12 Daclatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.50, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13 Danoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.28, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14 Dasabuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15 Deleobuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.16 Faldaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.17 Filibuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.18 Grazoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.19 GS‐6620</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.20 GS‐9256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.21 GS‐9451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.26, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.22 GS‐9669</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.23 GS‐9851</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.24 GS‐9857</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.25 GSK2336805</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.26 GSK2878175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.27 IDX‐184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.28 INX‐08189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.29 Ledispasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.30 Mericitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>725</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.49, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.31 Narlaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.43, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.32 Nesbuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.33 Odalasavir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.34 Ombitasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.39, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.35 Paritaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.36 PHX1766</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.37 PPI‐461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.38 PSI‐352938</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.39 Samatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.40 Setrobuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.41 Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2898</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.33, 0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.42 Sofosbuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.20, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.43 Sovaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.44 Tegobuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.45 Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.46 Valopicitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.47 Vaniprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.25, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.48 VCH‐759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.49 VCH‐916</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.50 Velpatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.51 VX‐222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.52 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>735</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.00, 7.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Without sustained virological response ‐ according to group of DAA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.37, 0.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Cyclophilin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 NS3/NS4A inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4756</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.36, 0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 NS5B inhibitors (NPI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>906</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.36, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 NS5B inhibitors (NNPI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.43, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 NS5A inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>686</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.49, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 VPU‐ion channel inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.03, 2.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>705</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [0.00, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Without sustained virological response ‐ according to HIV‐infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.37, 0.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 With HIV‐infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Without HIV‐infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.37, 0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Mixed (with and without HIV‐infection)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>389</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.35, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Without sustained virological response ‐ according to comorbidity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.22, 0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 With comorbidity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Without comorbidity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.22, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Without sustained virological response ‐ according to viral genotype <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7098</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.36, 0.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Genotype 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.37, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Genotype 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 3.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Genotype 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.43, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Genotype 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.02, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 Genotype 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [0.00, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>574</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.52, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Without sustained virological response ‐ according to human genotype (IL28b) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.40, 0.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 IL28b (CC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.29, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 IL28B (CT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.42, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 IL28B (TT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.44, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 IL28B (CT + TT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.23, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.33, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.40, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Without sustained virological response ‐ according to Asian‐region <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.37, 0.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 From Asian region</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.28, 0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Not from Asian region</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4910</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.43, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.03, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.35, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Without sustained virological response ‐ according to specific ethnicities <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.22, 0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 White</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>412</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.15, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Black</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Hispanic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.20, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>862</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.20, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.6 Asian</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.23, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Without sustained virological response ‐ according to reaching planned sample size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.22, 0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Trials reaching planned sample size</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.18, 0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Trials not reaching planned sample size</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4044</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.23, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Without sustained virological response ‐ according to prior treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.37, 0.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Treatment‐naive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4777</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.41, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Treatment‐experienced</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.36, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1064</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.02, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Without sustained virological response ‐ according to interferon <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.37, 0.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Trials where both groups received interferon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.41, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Trials where neither group received interferon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>735</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.00, 7.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 Trials where only the experimental group received interferon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 Trials where only the control group received interferon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.5 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.15, 2.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Without sustained virological response ‐ according to ribavirin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.37, 0.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Trials where both groups received ribavirin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6410</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.41, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Trials where neither group received ribavirin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>705</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [0.00, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 Trials where only the experimental group received ribavirin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4 Trials where only the control group received ribavirin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Without sustained virological response ‐ according to chronic kidney disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.22, 0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 With chronic kidney disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Without chronic kidney disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.22, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Without sustained virological response ‐ according to cryoglobulinaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.22, 0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 With cryoglobulinaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Without cryoglobulinaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.22, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Without sustained virological response ‐ according to DAA group as co‐intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.22, 0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Trials where DAA were used as co‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.27, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Trials where DAA were not a co‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.21, 0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Without sustained virological response ‐ 'Best‐worst case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.34, 0.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Without sustained virological response ‐ 'Worst‐best case' scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.43, 0.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Without sustained virological response ‐ according to median dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.37, 0.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 Over or equal to median dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.32, 0.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 Under median dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2086</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.39, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.3 Not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>875</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.26, 1.47]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">DAA on or on the way to the market versus placebo/no intervention (sustained virological response)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012143-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Danoprevir versus placebo/no intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Hepatitis C‐related morbidity or all‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>781</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.06, 5.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>781</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.06, 5.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Over or equal to median dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.06, 5.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Under median dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serious adverse events ‐ according to median dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Over or equal to median dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Under median dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Without sustained virological response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.12, 0.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Without sustained virological response ‐ according to median dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.12, 0.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Over or equal to median dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>537</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.11, 0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Under median dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.07, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Danoprevir versus placebo/no intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012143-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">All DAA versus placebo/no intervention/other medical intervention (morbidity or all‐cause mortality analyses)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Hepatitis C‐related morbidity or all‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Trials assessing DAAs on or on the way to the market</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Trials assessing DAAs withdrawn from market</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Trials using other medical intervention as control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Trials using other medical intervention as experimental group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2 Hepatitis C‐related morbidity or all‐cause mortality ‐ drugs not discontinued</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Trials assessing discontinued drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Trials assessing drugs still used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3 Hepatitis C‐related morbidity or all‐cause mortality ‐ bias risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Trials with a high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Trials with a low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to type of DAA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 ABT‐072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 ACH‐2684</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Alisporivir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 ALS‐2200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Asunaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Balapiravir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 Beclabuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8 BILB‐1941</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9 BIT‐225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.10 Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.11 Ciluprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.12 Daclatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.13 Danoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.14 Dasabuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15 Deleobuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.16 Faldaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.17 Filibuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.18 Grazoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.19 GS‐6620</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.20 GS‐9256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.21 GS‐9451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.22 GS‐9669</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.23 GS‐9851</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.24 GS‐9857</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.25 GSK2336805</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.26 GSK2878175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.27 IDX‐184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.28 INX‐08189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.29 Ledispasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.30 Mericitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.31 Narlaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.32 Nesbuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.33 Odalasavir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.34 Ombitasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.35 Paritaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.36 PHX1766</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.37 PPI‐461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.38 PSI‐352938</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.39 Samatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.40 Setrobuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.41 Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.42 Sofosbuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.43 Sovaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.44 Tegobuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.45 Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.46 Valopicitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.47 Vaniprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.48 VCH‐759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.49 VCH‐916</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.50 Velpatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.51 VX‐222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.52 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to group of DAA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Cyclophilin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 NS3/NS4A inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 NS5B inhibitors (NPI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 NS5B inhibitors (NNPI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 NS5A inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 VPU‐ion channel inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to HIV‐infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 With HIV‐infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Without HIV‐infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Mixed (with and without HIV‐infection)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to comorbidity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 With comorbidity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Without comorbidity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to viral genotype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Genotype 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Genotype 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Genotype 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Genotype 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to human genotype (IL28b) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 IL28b (CC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 IL28B (CT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 IL28B (TT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 IL28B (CT + TT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to Asian‐region</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 From Asian region</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Not from Asian region</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to specific ethnicities</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 White</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Black</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Hispanic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to reaching planned sample size </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Trials reaching planned sample size</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Trials not reaching planned sample size</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to prior treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Treatment‐naive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Treatment‐experienced</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to interferon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Trials where both groups received interferon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Trials where neither group received interferon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 Trials where only the experimental group received interferon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4 Trials where only the control group received interferon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to ribavirin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Trials where both groups received ribavirin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Trials where neither group received ribavirin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 Trials where only the experimental group received ribavirin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4 Trials where only the control group received ribavirin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to chronic kidney disease </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 With chronic kidney disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Without chronic kidney disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to cryoglobulinaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 With cryoglobulinaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Without cryoglobulinaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to DAA group as co‐intervention </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Trials where DAA were used as co‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 Trials where DAA were not a co‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">All DAA versus placebo/no intervention/other medical intervention (morbidity or all‐cause mortality analyses)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012143-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">All DAA versus placebo/no intervention/other medical intervention (serious adverse events analyses)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Trials assessing DAAs on or on the way to the market</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Trials assessing DAAs withdrawn from market</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Trials using other medical intervention as control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Trials using other medical intervention as experimental group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious adverse events ‐ bias risk <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Trials with a high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Trials with a low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serious adverse events ‐ according to type of DAA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 ABT‐072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 ACH‐2684</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Alisporivir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 ALS‐2200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Asunaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Balapiravir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7 Beclabuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8 BILB‐1941</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9 BIT‐225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10 Boceprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11 Ciluprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12 Daclatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13 Danoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14 Dasabuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15 Deleobuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.16 Faldaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.17 Filibuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.18 Grazoprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.19 GS‐6620</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.20 GS‐9256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.21 GS‐9451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.22 GS‐9669</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.23 GS‐9851</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.24 GS‐9857</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.25 GSK2336805</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.26 GSK2878175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.27 IDX‐184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.28 INX‐08189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.29 Ledispasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.30 Mericitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.31 Narlaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.32 Nesbuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.33 Odalasavir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.34 Ombitasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.35 Paritaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.36 PHX1766</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.37 PPI‐461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.38 PSI‐352938</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.39 Samatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.40 Setrobuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.41 Simeprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.42 Sofosbuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.43 Sovaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.44 Tegobuvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.45 Telaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.46 Valopicitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.47 Vaniprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.48 VCH‐759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.49 VCH‐916</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.50 Velpatasvir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.51 VX‐222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.52 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serious adverse events ‐ according to group of DAA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Cyclophilin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 NS3/NS4A inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 NS5B inhibitors (NPI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 NS5B inhibitors (NNPI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 NS5A inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 VPU‐ion channel inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serious adverse events ‐ according to HIV‐infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 With HIV‐infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Without HIV‐infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Mixed (with and without HIV‐infection)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Serious adverse events ‐ according to comorbidity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 With comorbidity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Without comorbidity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Serious adverse events ‐ according to viral genotype <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Genotype 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Genotype 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Genotype 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Genotype 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Serious adverse events ‐ according to human genotype (IL28b) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 IL28b (CC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 IL28B (CT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 IL28B (TT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 IL28B (CT + TT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6 Mixed IL28b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Serious adverse events ‐ according to Asian‐region <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 From Asian region</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Not from Asian region</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Serious adverse events ‐ according to specific ethnicities <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 White</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Black</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Hispanic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11 Serious adverse events ‐ according to reaching planned sample size</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Trials reaching planned sample size</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Trials not reaching planned sample size</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Serious adverse events ‐ according to prior treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Treatment‐naive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Treatment‐experienced</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Serious adverse events ‐ according to interferon <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Trials where both groups received interferon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Trials where neither group received interferon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 Trials where only the experimental group received interferon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 Trials where only the control group received interferon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Serious adverse events ‐ according to ribavirin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Trials where both groups received ribavirin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Trials where neither group received ribavirin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 Trials where only the experimental group received ribavirin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4 Trials where only the control group received ribavirin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Serious adverse events ‐ according to chronic kidney disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 With chronic kidney disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Without chronic kidney disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Serious adverse events ‐ according to cryoglobulinaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 With cryoglobulinaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Without cryoglobulinaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Serious adverse events ‐ according to DAA group as co‐intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Trials where DAA were used as co‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Trials where DAA were not a co‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">All DAA versus placebo/no intervention/other medical intervention (serious adverse events analyses)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012143-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">All DAA versus placebo/no intervention/other medical intervention (sustained virological response analyses)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Without sustained virological response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.48, 0.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Trials assessing DAAs on or on the way to the market</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6886</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.37, 0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Trials assessing DAAs withdrawn from market</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9075</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.55, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Trials using other medical intervention as control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>862</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.36, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Trials using other medical intervention as experimental group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>278</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.17, 0.29]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">All DAA versus placebo/no intervention/other medical intervention (sustained virological response analyses)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012143-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">All DAA versus placebo/no intervention/other medical intervention (quality of life scores)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 SF‐36 physical score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.17 [‐3.65, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 SF‐36 mental score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [‐1.53, 4.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">All DAA versus placebo/no intervention/other medical intervention (quality of life scores)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012143-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Daclatasvir versus placebo/no intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Hepatitis C‐related morbidity or all‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.06, 26.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.06, 26.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Over or equal to median dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Under median dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.06, 26.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serious adverse events ‐ according to median dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Over or equal to median dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Under median dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Without sustained virological response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.27, 0.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Without sustained virological response ‐ according to median dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.27, 0.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Over or equal to median dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.26, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Under median dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.19, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Daclatasvir versus placebo/no intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012143-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Simeprevir versus placebo/no intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Hepatitis C‐related morbidity or all‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1589</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.08, 2.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1589</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.08, 2.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Over or equal to median dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.03, 8.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Under median dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>705</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.01, 12.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>443</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.02, 13.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serious adverse events ‐ according to median dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Over or equal to median dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Under median dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Without sustained virological response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2898</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.19, 0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Without sustained virological response ‐ according to median dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2898</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.19, 0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Over or equal to median dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1765</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.20, 0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Under median dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.13, 0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>437</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.07, 0.24]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Simeprevir versus placebo/no intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012143-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Vaniprevir versus placebo/no intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Hepatitis C‐related morbidity or all‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.03, 18.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.03, 18.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Over or equal to median dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.03, 18.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Under median dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serious adverse events ‐ according to median dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Over or equal to median dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Under median dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Without sustained virological response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.06, 0.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Without sustained virological response ‐ according to median dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.06, 0.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Over or equal to median dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.05, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Under median dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.06, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Vaniprevir versus placebo/no intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012143-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">All DAA versus placebo/no intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Without significant reductions in ALT/AST serum levels <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2099</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.68, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Without significant reductions in ALT/AST serum levels ‐ according to DAA status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2099</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.68, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Trials assessing DAAs on or on the way to the market</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Trials assessing DAAs withdrawn from market</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2099</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.68, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Without significant reductions in ALT/AST serum levels ‐ according to type of drug <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2099</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.68, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Faldaprevir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.69, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Balaparavir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.41, 0.92]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">All DAA versus placebo/no intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012143.pub3/references#CD012143-tbl-0017">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012143.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012143-note-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012143-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012143-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012143-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD012143-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD012143-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012143-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012143\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012143\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012143\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012143\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012143\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012143\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012143\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012143\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012143\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012143\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012143\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012143\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012143\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012143\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012143\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012143\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012143\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012143\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=k5rEBE5b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012143.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012143.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012143.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012143.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012143.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740711445345"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012143.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740711445349"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012143.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d258d9fa59377',t:'MTc0MDcxMTQ0Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 